IL323195A - Bifunctional compounds capable of degrading androgen receptors - Google Patents

Bifunctional compounds capable of degrading androgen receptors

Info

Publication number
IL323195A
IL323195A IL323195A IL32319525A IL323195A IL 323195 A IL323195 A IL 323195A IL 323195 A IL323195 A IL 323195A IL 32319525 A IL32319525 A IL 32319525A IL 323195 A IL323195 A IL 323195A
Authority
IL
Israel
Prior art keywords
piperidin
chloro
carbonitrile
dioxopiperidin
dihydro
Prior art date
Application number
IL323195A
Other languages
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL323195A publication Critical patent/IL323195A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

WO 2024/189488 PCT/IB2024/052251 BIFUNCTIONAL COMPOUNDS CAPABLE OF DEGRADING ANDROGEN RECEPTORS RELATED APPLICATIONS This application claims priority from US Provisional Patent Application No. 63/489,528 filed March 10, 2023, the disclosure of which is incorporated herein in its entirety.
FIELD This specification relates to certain Proteolysis Targeting Chimera (PROTAC) compounds and, as a minimum, their ability to degrade the Androgen Receptor (AR) and therefore their use for the treatment of diseases or disorders dependent on the androgen receptor in mammals. Degradation of androgen receptors may provide, for example, an anti-tumour effect and accordingly this specification relates in part to the use of such compounds for the treatment of cancer and to pharmaceutical compositions containing them. It also relates to intermediate compounds that may be useful in the preparation of such PROTACs.
BACKGROUND Traditional small molecule drugs reversibly (or sometimes irreversibly) bind to a target protein as a means of modulating a given biological activity. In contrast, PROTACs bind to their target proteins, but then bring about the target protein’s degradation. Having achieved this effect, the PROTAC is in theory able to repeat this process with another target protein. Accordingly, unlike with "traditional small molecule" inhibitors, the PROTAC-driven degradation mechanism can in theory operate in a sub-stoichiometric manner - meaning that more modest exposures of a PROTAC compound could still achieve a desired level of efficacy in vivo. In practice this can mean that the degradation power (DC50 and Dmax) of a PROTAC can have an improved effect than that reflected only by its binding affinity.At a simplistic level, PROTAC molecules are often described as having three parts - (1) a part that is capable of binding to the target protein to be degraded, (2) a second part that is capable of binding to an Eubiquitin ligase, and finally, a linker that connects (1) and (2) together.In use, the PROTAC binds to both the target protein and E3 ubiquitin ligase simultaneously to form a ternary complex. The E3 ligase then recruits an E2 conjugating enzyme to the ternary complex, which ubiquitinates the target protein. This has the effect of labelling the target protein for degradation by the cell’s proteasome machinery. A PROTAC can then dissociate from the target protein and initiate another cycle of this process in a catalytic manner. Meanwhile, the ubiquitinated target proteins are recognized and degraded by the cell’s proteasome machinery.This PROT AC-mediated approach may be valuable as a method of treating certain diseases where the targeted degradation of specific bodily proteins may be beneficial, for example in the treatment of cancer. One such cancer-related target is the androgen receptor.The androgen receptor (AR) belongs to the steroid hormone group of nuclear receptors and is a ligand-dependent transcription factor which controls the expression of a range of genes involved in growth and WO 2024/189488 PCT/IB2024/052251 survival of prostate cells. AR is composed of four distinct domains: the N-terminal domain (NTD), DNA binding domain (DBD), a hinge region which allows the N- and C-termini to interact and a C-terminal ligand binding domain (LBD). Androgens such as testosterone and its derivative dihydrotestosterone (DHT) bind to the AR ligand binding domain which releases AR chaperone proteins allowing AR to dimerise and translocate from the cytoplasm into the nucleus. Within the nucleus receptor dimers bind to androgen response elements (AREs) in the promoters of androgen responsive genes such as PSA and FKBP5. The AR signalling pathway plays a role in normal prostate development and male sexual differentiation fails to occur in the absence of androgens or without a functioning AR.The relationship between androgens and prostate cancer was first discovered in a seminal study by Huggins and Hodges in 1941 and subsequent work has shown that androgen deprivation therapy is highly effective in the treatment of recurrent prostate cancer. However, despite good responses initially most tumour cells adapt to low androgen levels and patients relapse within a few years developing a disease state known as castrate resistant prostate cancer (CRPC). Several second generation antiandrogens have been approved by the US FDA for the treatment of CRPC. These include enzalutamide, apalutamide and darolutamide, which all compete with androgens for binding to the ligand binding domain. As well as antagonising the AR, preventing its activation, they also inhibit nuclear translocation and DNA binding thus effectively shutting down AR signalling. In contrast abiraterone acetate is an androgen biosynthesis inhibitor which targets cytochrome p4enzyme 17R-hydroxlase-17,20-lyase (CYP17). Testosterone is processed in the testes and adrenal glands by CYP17 and therefore inhibition of this enzyme inhibits prostate tumour growth by decreasing circulating androgen levels.Whilst the above-mentioned drugs significantly prolong survival of patients with late stage prostate cancer they are not curative and resistance inevitably occurs. However, it is clear that the AR remains central to the progression of CRPC meaning there is still a need to develop alternative AR inhibitors. Several resistance mechanisms have been identified including AR amplification, mutation or the generation of splice variants that lack the ligand binding domain. Mutations in the ligand binding domain, for example F877L or L702H, can convert antagonists into agonists or allow the receptor to utilise alternative steroid hormones such as glucocorticoids or progesterone. Agents that degrade AR, removing it from the cell could therefore help tackle these forms of resistance. As such, AR PROTACs, which bind the ligand binding domain of the androgen receptor and simultaneously recruit an E3 ligase such as cereblon leading to ubiquitination and degradation of AR via the proteasome, could offer therapeutic benefit to patients with prostate cancer, particularly metastatic CRPC. AR PROTACs may also be useful against AR+ breast cancer.Given that the above-mentioned resistance mutations that can occur in the ligand binding domain and may limit the effectiveness of known CRPC treatments, it would be beneficial to develop AR degrading PROTACs that do not just target the "wild-type" AR, but which are also effective in degrading clinically relevant mutated forms of AR too.Whichever target protein binding unit (1) is used at one end of a PROTAC’s linker unit, a fundamental element that must always be present at the other end of a PROTAC molecule is a unit (2) that helps to direct the tagging of the target protein for degradation, for example an E3 ubiquitin ligase cereblon binder unit. Scientific endeavours have already provided a number of such E3 ubiquitin ligase cereblon binder units and further examples are demonstrated hereinafter by the present researchers.
WO 2024/189488 PCT/IB2024/052251 WO2018/071606 describes certain PROTAC compounds said to be AR degraders.As with "traditional small molecule" binders and PROTACs alike, there is always the issue of "off- target" activity in vivo which can be important to avoid in the development of safe and effective drug treatments. In other words, a given binding unit may be very potent against the intended target, but if it is inadvertently potent against other unintended biological targets in the human body, it may cause unacceptable toxicities, side effects and so on.It is therefore an ongoing challenge to develop potent molecules for pharmaceutical use that are also suitably selective - i.e. avoiding inhibition/binding/degradation of unintended biological targets in vivo.For example, the present researchers have surprisingly found that certain compounds of this specification show beneficial selectivity that is expected to avoid or reduce the risk of mitotoxicity in vivo.As part of developing current and future PROTAC drag treatments for medicinal use (e.g. cancer), there is still a need to develop androgen receptor PROTAC compounds that have a combination of beneficial/improved properties. As mentioned above, development of PROTACs that target both wild-type AR and one or more clinically relevant mutated forms of AR is an example of such a combination effect.Furthermore, there is a need to develop androgen receptor binder units that can be incorporated into a PROTAC, regardless of which an E3 ubiquitin ligase cereblon binder unit is selected for use at the other end of the molecule.Other properties of interest during pharmaceutical discovery and development of such PROTACs may relate to selectivity profile, absorption/bioavailability, distribution, metabolism, elimination, toxicity and side-effect profile, stability, manufacturability and so on.
SUMMARY The compounds of this specification provide, as a minimum, potent AR binding units suitable for incorporation into PROTAC compounds, and to PROTAC compounds containing such AR binding units together with an E3 ubiquitin ligase cereblon binder unit at the other end of the PROTAC molecule. Certain AR binding units are advantageously configured to degrade not only the wild-type AR, but also one or more clinically relevant mutant forms of AR too, for example L702H. Certain PROTAC compounds of this specification also have a surprisingly beneficial combination of properties, e.g. relating to AR degradation and selectivity/safety profile in combination.This specification relates to the above-mentioned AR-binding units and to PROTAC compounds (and pharmaceutically acceptable salts thereof) that incorporate such AR binding units together with an Eubiquitin ligase cereblon binder unit (the two units being linked by a linker).This specification also relates to pharmaceutical compositions containing such PROTACs (and pharmaceutically acceptable salts thereof) and their use in methods of treatment in the human or animal body, for example in the treatment or prevention of cancer. This specification also relates to processes and intermediate compounds (and salts thereof) involved in the preparation of said PROTACs.According to the first aspect of this specification there is provided a compound of Formula (1): WO 2024/189488 PCT/IB2024/052251 (1) or a pharmaceutically acceptable salt thereof, wherein: X1 is CH or N; p where:is 0, 1 or 2; each R1 is a substituent on any C atom and is independently selected from F, Cl, Ci.galkyl and C!.3alkoxy, wherein said C!.3alkyl and C!.3alkoxy may be independently optionally substituted by one or more F; RN is selected from H and Me; n is 0, 1 or 2; m is 0 or 1;Q1 is CH or N;when n & mare both other than 0, Q2 is CH or N;when n & mare both 0, Q2 iswhen n is 0 or 1 Q3 is CH;when n is 2 and Q2 is N, Qwhen n is 2 and Q2 is CH, Q3 is R2a and R2b CH; is CH;CHorO;are substituents on the same or different C atoms other than at Q1 or Q2, each independently selected from H, F and C!.3alkyl, or R2a & R2b together form a -(CH2)r- group where r is 1, 2 or 3;Q4R4is a single bond or -NR4C(=O);is H or Me;0, 1 or 2 of Y1, Y2, Y3, Y4 & Yeach R3is/are N, and are otherwise C;is a substituent on any C atom at Y1, Y2, Y3, Y4 & Y5, and is/are independently selected from F, Cl, CN, C!.3alkyl and C!.3alkoxy, wherein said C!.3alkyl and C!.3alkoxy may be independently optionally substituted by one or more F;qis 0, 1 or 2;wherein Linkeris attached at any available C atom at Y4 & Y5; Linker is a saturated or a partially or fully unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and ‘b’ and a minimum length of from 5 to 26 WO 2024/189488 PCT/IB2024/052251 atoms between ‘a’ and ‘b’; wherein said framework may include one or more straight and/or branched chains and/or rings and is optionally substituted on any available C atom(s) by one or more F; and W is an E3 ubiquitin ligase cereblon binder unit.
This specification also describes, in part, a pharmaceutical composition which comprises a compound of Formula (I),or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient.This specification also describes, in part, a compound of Formula (I),or a pharmaceutically acceptable salt thereof, for use in therapy.This specification also describes, in part, a compound of Formula (I),or a pharmaceutically acceptable salt thereof, for use in the treatment of cancer.This specification also describes, in part, a method for treating cancer in a warm-blooded animal in need of such treatment, which comprises administering to the warm-blooded animal a therapeutically effective amount of a compound of Formula (I),or a pharmaceutically acceptable salt thereof.As shown in the experimental section hereinafter, the present researchers have not just developed a range of beneficial AR binding units, but gained an understanding about where such binding units can incorporate a linker (leading to an E3 ubiquitin ligase cereblon binder unit) without it interfering with their AR binding capability. Accordingly the present researchers understand that when incorporating their AR binding units into a PROTAC, the linker of said PROTAC should not attach at the left or central rings in Formula (I) shown hereinabove, but may suitably attach at the specified position on the right-hand ring in the compound of Formula (I)as shown herein.Therefore, in a further aspect of this specification there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la): (la) where R1, p, X1, RN, n, m, R2a , R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qmay take any of the values defined herein for each of these integers respectively. >cFor avoidance of doubt in Formula (la)indicates a point of connection via a singlecovalent bond to the remainder of the PROTAC compound.
WO 2024/189488 PCT/IB2024/052251 In one embodiment there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit linked to an AR binding unit of Formula (la) as described herein.As described herein, the link between an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la)as shown hereinabove may have a length corresponding to the length of a linear chain of from 5 to 26 atoms, said atoms being linked by single covalent bonds and each selected from carbon or a heteroatom (i.e. O, N or S).As described herein, the link between an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la)as shown hereinabove may have a length corresponding to the length of a linear chain of from 5 to 14 atoms, said atoms being linked by single covalent bonds and each selected from carbon or a heteroatom (i.e. O, N or S).In one embodiment, the link between an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la)as shown hereinabove may have a length corresponding to the length of a linear chain of from 5 to 26 atoms, said atoms being linked by single covalent bonds and each selected from C, N or O.In one embodiment, the link between an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la)as shown hereinabove may have a length corresponding to the length of a linear chain of from 5 to 14 atoms, said atoms being linked by single covalent bonds and each selected from C, N or O.It is to be understood that although a link length "corresponding to the length of [certain atoms in a chain]" it is not to be interpreted that this limits said link to said atoms, and for example sulfur atom(s) may also be present in the link even if S atoms are not included in the length descriptor.In a further aspect of the specification there is provided an androgen receptor binding unit of Formula (la),as described herein, for use in a PROTAC compound (or pharmaceutically acceptable salt thereof) that also contains an E3 ubiquitin ligase cereblon binder unit.In a further aspect of the specification there is provided an androgen receptor binding unit of Formula (la),as described herein, for use in a PROTAC compound (or pharmaceutically acceptable salt thereof) that is linked to an E3 ubiquitin ligase cereblon binder unit.Accordingly, there is provided an androgen receptor binding unit of Formula (la),as described herein, for use in a PROTAC compound (or pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit.Accordingly, there is provided an androgen receptor binding unit of Formula (la),as described herein, for use in a PROTAC compound (or pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit that is linked to said androgen receptor binding unit.Accordingly, there is provided an androgen receptor binding unit of Formula (la),as described herein, for incorporation into a PROTAC compound (or pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit.Accordingly, there is provided an androgen receptor binding unit of Formula (la),as described herein, for incorporation into a PROTAC compound (or pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit that is linked to said androgen receptor binding unit.
WO 2024/189488 PCT/IB2024/052251 Therefore, there is provided an androgen receptor binding unit of Formula (la),as described herein, contained within a PROTAC compound (or a pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit.Therefore, there is provided an androgen receptor binding unit of Formula (la),as described herein, contained within a PROTAC compound (or a pharmaceutically acceptable salt thereof) where said PROTAC compound also contains an E3 ubiquitin ligase cereblon binder unit that is linked to said androgen receptor binding unit.In one embodiment the link between androgen receptor binding unit of Formula (la)[as described above] and an E3 ubiquitin ligase cereblon binder unit is a Linkeras defined according to any embodiment or claim herein, where the point of attachment shown in Formula (la)above connects to the ‘a’ point of connection on any Linkeras defined herein.
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS Many embodiments of this disclosure are detailed throughout the specification and will be apparent to a reader skilled in the art.A pharmaceutically acceptable salt of a compound of Formula (I)or PROTAC compound described herein may be, for example, an acid-addition salt when said compound contains a basic functional group, such as an amine. An acid-addition salt may be formed using an inorganic acid or an organic acid. A pharmaceutically acceptable salt of said compound may be, for example, a base-addition salt when said compound contains an acidic functional group, such as a carboxylic acid. An acid-addition salt may be formed using an inorganic base or an organic base. "Pharmaceutically acceptable salt" is used to specify that the salt is suitable for use in the human or animal body. An example list of pharmaceutically acceptable salts can be found in the Handbook of Pharmaceutical Salts: Properties, Selection and Use, P. H. Stahl and C. G. Wermuth, editors, Weinheim/Zurich: Wiley-VCH/VHCA, 2002. A pharmaceutically acceptable salt of a compound of Formula (I)or PROTAC compound includes such salts that may be formed within the human or animal body after administration of said compound to said human or animal body.As used herein the term "alkyl" includes straight chain, branched chain and cyclic alkyl groups and combinations thereof having the specified number of carbon atoms. Therefore, C!.3alkyl includes methyl, ethyl, n-propyl, isopropyl and cyclopropyl; and C!.9alkyl would include (4-isopropylcyclohexyl)methyl. The same principles apply to the term "alkoxy". Similarly, as used herein the term "alkoxy" includes straight chain, branched chain and/or cyclic alkoxy groups having the specified number of carbon atoms. Therefore, Ci.galkoxy includes methoxy, ethoxy, n-propoxy, isopropoxy and cyclopropoxy.In this specification chemical abbreviations familiar to the skilled person may be used including for example "Me" = methyl, "Et" = ethyl, "Pr" = propyl, "Bu" = butyl and "Ph" = phenyl.Where the term "optionally" is used, it is intended that the subsequent feature may occur or may not occur. As such, use of the term "optionally" includes instances where the feature is present, and also instances where the feature is not present. For example, "methyl optionally substituted by one or more F" includes -CH3, -CH2F, -CHF2 and -CF3.
WO 2024/189488 PCT/IB2024/052251 The term "substituted" means that one or more hydrogens on the designated atom or group is replaced by the indicated substituent(s) provided that any atom(s) bearing such substituent(s) maintains its permitted valency where the skilled person understands that the standard valencies of carbon, nitrogen and oxygen are 4, and 2 respectively. Therefore, "substituted on any available C atom(s)" is to be understood to mean that the substituent(s) is/are limited in their positioning (and/or potentially in their number) according to whether there are any hydrogen atoms remaining on the designated atom or group which could be replaced by said substituent(s).The dashed bonds included in Z, " ", indicate the possibility that the bond may in each case be asingle covalent bond or a double covalent bond - in accordance with the atom (or group of atoms) present at each of the XE, XF, XG, XHand XJpositions. The skilled person understands that the standard valencies of carbon, nitrogen and oxygen are as mentioned above, and as such they can understand whether each dashed bond should be interpreted as a single bond or a double bond in any given Z group in the compound of Formula (I).The same applies to the XE2, XE2, XG2, XH2and XJ2positions in ZA.The term "adjacent" or "adjacent position" - for example in reference to XG, XHand XJof Zrefers to the next closest position in the molecular chain/ring system. Accordingly, in the context of Z: XGand XHare adjacent each other, XHand XJare also adjacent each other, but XGis not adjacent XJ. The term "saturated" means that the atoms of the specified framework or group are linked only by single covalent bonds. Accordingly, the term "unsaturated" means that the specified framework or group contains double and/or triple covalent bonds. Examples of unsaturated molecular fragments that may be present within a partly or fully unsaturated group or framework are C=C, C=N, C=0, N=N, C=C or C=N in cases where nitrogen and oxygen heteroatoms are permitted/present, and may also include S=O in cases where sulfur heteroatoms are also permitted/present.It is to be understood that "heteroatom" may represent an oxygen, nitrogen or sulfur atom unless explicitly further limited in a given context.The term "minimum length of [...] atoms between ‘a’ and ‘b’" refers to the shortest chain of atoms in the chain between ‘a’ and ‘b’. Therefore, if the chain consisted of -CH2CH2CH2-, the number of atoms in the chain is 3 (the hydrogen atoms are regarded as not being in the chain). Alternatively if the chain consisted of 1,3-phenylene, where the shorter route around the phenyl ring contains 3 C atoms and the long route around the phenyl ring contains 5 C atoms, the minimum length of such a chain would be counted as 3 atoms.It is to be understood that the points of attachment ‘a’ and ‘b’ each represent single covalent bonds to the relevant adjacent groups/atoms.It is to be understood that "direct bond" is interchangeable with "single bond".It is to be understood that in this specification "rings" or "heterocyclic groups" may include single rings, fused rings, spirocyclic rings and bridged rings.In reference to the Linker,as described herein, it is to be understood that the branching, where present may be present on a chain (even a chain of 1 atom length) and/or on a ring. The skilled person would generally interpret in this manner, but for the avoidance of doubt, it is to be understood that the "branching" that occurs inherently in order to form a ring is not considered "branching" in the context of the Linkerembodiments described herein. It is to be understood that said branches may occur on the same or different atoms of the Linkerframework. For example it is possible to have two "=O" branches on a sulfur heteroatom in order to WO 2024/189488 PCT/IB2024/052251 form a SO2 group within the Linkerframework. Linker#22 described hereinafter is an example where there is one branch (-Me) coming from a chain within the Linker. It is further to be understood that ‘branches’ (and definitions for branches provided herein) refer to branches that branch off the main chain of atoms between ‘a’ and ‘b‘, leading to a ‘dead end’ in the molecular structure.In this specification it is to be understood that the point of attachment of a given group to some other group (via a single covalent bond) may be represented by a line meeting a bond substantially at right angles to said bond, for example as shown on the far right-hand side of Formula (la)herein, and for example at either end of Linkers1 to 46 depicted hereinafter.In this specification when "0, 1 or 2 of XA, XB, Xc , XD, XE & XFis/are N where XE & XEare not both N, and are otherwise C" - certain of the C atoms are to be understood to implicitly possess a hydrogen atom where necessary in order to satisfy the standard valency (4) for carbon atoms. The skilled person will understand that such H atom cannot be present on a C at XEor XEor on a C at XA, XB, Xcor XDwhen a substituent or Linkeris attached to said carbon. The same principle applies in respect of X1, X2, X3, X4(and with X5, X6, X7 & Xswhere present), and also with Y1, Y2, Y3 & Y4.The same applies to XA2, XB2, Xc2 , XD2, XE2, XE2, XG2, XH2 & XJ2. In this specification a reference to a secondary or tertiary amine is intended to have the normal meaning in the art and therefore a nitrogen atom that is part of an amide group or a sulphonamide group, for example, is not to be regarded as a secondary or tertiary amine.In this specification a saturated heterocyclic group refers to at least one ring of atoms (including bridged rings, spiro rings, fused rings, and single rings) containing carbon atoms and at least one heteroatom, where the heteroatom(s) is/are each independently selected from N, O and S, and where each atom in the ring is linked to its adjacent atoms by single covalent bonds. Therefore, an example of a heterocyclic group is a spiro heterocyclic group having two rings and a total of one heteroatom such as 9-azasprio[5.5]undecane. Typically, a saturated heterocyclic group will have at least two carbon atoms separating each of the heteroatom(s) present in said group to ensure a suitable level of chemical stability for use in a pharmaceutical context. Where reference is made to a "nitrogen-containing saturated (or partially unsaturated) heterocyclic group" this requires the presence of at least one nitrogen heteroatom but does not limit the possibility of one or more non-nitrogen heteroatoms (i.e. S, O) being present in addition. In this specification a partially unsaturated heterocyclic group refers to at least one ring of atoms (including bridged rings, spiro rings, fused rings, and single rings) containing carbon atoms and at least one heteroatom, where the heteroatom(s) is/are each independently selected from N, O and S, and where at least two atoms within the heterocyclic group are connected to each other via a double covalent bond. As the skilled person would understand, partially unsaturated does not include fully unsaturated heterocyclic groups - i.e. where the group contains the maximum possible number of double bonds for the atomic framework in question.Where reference is made to a cyclic group (e.g. a heterocyclic group) having a specified number of ring atoms, this includes the atoms making up the ring (including atoms involved in the bridge of a bridged ring, and all atoms of a fused or spiro ring) but does not include any hydrogen atoms or other substituent atoms attached to the ring atoms. Therefore, for example, a cyclic group which is 1,4-piperazin-1,4-diyl has 6 ring atoms (4C and 2N).
WO 2024/189488 PCT/IB2024/052251 In this specification an alkylene group (for example a C!.5alkylene) is a saturated group consisting only of carbon and hydrogen atoms with two points of attachment to adjacent atoms/groups. They may include straight chain(s), branched chain(s) and/or ring(s). Accordingly Cialkylene represents -CH2-, a C2alkylene can represent -CH2CH2- or -CH(Me)-, C!.5alkylene includes for example -CH2(cyclobut-1,3-diyl)-. A "straight chain Cu1-U2alkylene" corresponds to -(CH2)U- where u is an integer from ul to u2.In this specification a hydrocarbyl group means any group consisting only of C and H atoms. For example, C!.7hydrocarbyl includes methyl, phenyl and p-tolyl.The term "therapy" is intended to have its normal meaning of dealing with a disease in order to entirely or partially relieve one, some or all of its symptoms, or to correct or compensate for the underlying pathology. The terms "therapeutic" and "therapeutically" should be interpreted in a corresponding manner.The term "treatment" is used synonymously with "therapy". Similarly the term "treat" can be regarded as "applying therapy" where "therapy" is as defined herein.Some values of variable groups are as follows. One, two or more of such values, may be used in any combination with any other definitions, claims, aspects or embodiments herein (unless the context doesn’t permit) to provide further embodiments/claims of the specification.
In one embodiment X1is CH.In one embodiment X1is N.In one embodiment RNis H.In one embodiment RNis Me.In one embodiment X1is CH and RNis H.In one embodiment X1is CH and RNis Me.In one embodiment X1is N and RNis H.In one embodiment X1is N and RNis Me.In one embodiment pis 0.In one embodiment p is 0 or 1.In one embodiment p is 1 or 2.In one embodiment pis 1.In one embodiment pis 2.When pis 1, R1may be bound para to Q1. When pis 2, one R1may be bound para to Q1,and the other R1may be ortho or meta to Q1. In one embodiment each R1 is selected from F, Cl, methyl, CF3, methoxy and OCF3.In one embodiment each R1 is selected from F, Cl and methyl.In one embodiment pis 1 and R1is selected from F, Cl and methyl.In one embodiment pis 1 and R1is selected from F and Cl.In one embodiment nis 0.In one embodiment nis 1.In one embodiment nis 2.In one embodiment mis 0.In one embodiment mis 1.
WO 2024/189488 PCT/IB2024/052251 In one embodiment nis 0 and mis 1.In one embodiment nis 1 and mis 1.In one embodiment nis 2 and mis 0.In one embodiment nis 0, mis 1, Q1 is N and Q2 is CH.In one embodiment nis 1, mis 1, Q1 is CH and Q2 is CH.In one embodiment nis 1, mis 1, Q1is N and Q2is CH orN.In one embodiment nis 2, mis 0, Q1 is N and Q2 is CH.In one embodiment nis 2, mis 0, Q1 is N, Q2 is CH and Q3 is CH.In one embodiment nis 2, mis 0, Q1 is N, Q2 is CH and Q3 is O.In one embodiment Q1is N, Q2is CH and Q3is CH.In one embodiment Q1is N, Q2is CH and Q3is CH, and nand mare 1 and 1 or 2 and 0 respectively.In one embodiment R2ais H and R2bis H.In one embodiment nis 1, mis 0, R2ais H and R2bis C!.3alkyl attached to a C atom other than at Q1and Q2, where said C atom has an (/?)-stereochemical configuration.In one embodiment nis 1, mis 0, R2ais H and R2bis C!.3alkyl attached to a C atom other than at Q1and Q2, where said C atom has an (S)-stereochemical configuration.In one embodiment nis 1, mis 1, R2ais H and R2bis C!.3alkyl attached to a C atom other than at Q1and Q2, where said C atom has an (/?)-stereochemical configuration.In one embodiment nis 1, mis 1, R2ais H and R2bis C!.3alkyl attached to a C atom other than at Q1and Q2, where said C atom has an (S)-stereochemical configuration.In one embodiment Q1 is CH with an (/?)-stereochemical configuration at said C atom.In one embodiment Q1 is CH with an (S)-stereochemical configuration at said C atom.In one embodiment nis 2; mis 0; R2a & R2bare both H; Q1 is CH and Q2 is N.In one embodiment nis 2; mis 0; R2a & R2bare both H; Q2is N and Q1is CH with an (/?)-stereochemical configuration at said C atom.In one embodiment nis 2; mis 0; R2a & R2bare both H; Q2is N and Q1is CH with an (S)-stereochemical configuration at said C atom.
In one embodiment Q2 is CH with an (/?)-stereochemical configuration at said C atom.In one embodiment Q2 is CH with an (S)-stereochemical configuration at said C atom.In one embodiment nis 2; mis 0; R2a & R2bare both H; Q1 is N and Q2 is CH.In one embodiment nis 2; mis 0; R2a & R2bare both H; Q1is N and Q2is CH with an (/?)-stereochemical configuration at said C atom.In one embodiment nis 2; mis 0; R2a & R2bare both H; Q1is N and Q2is CH with an (S)-stereochemical configuration at said C atom.In one embodiment R2aand R2bare substituents on the same or different C atoms other than at Q,each independently selected from H and C!.3alkyl.In one embodiment R2aand R2bare substituents on the same or different C atoms other than at Q,each independently selected from H and Me.
WO 2024/189488 PCT/IB2024/052251 In one embodiment R2a and R2b are substituents on the same or different C atoms adjacent Q and are otherwise as defined herein.In one embodiment R2a and R2b are substituents on the same or different C atoms adjacent Q, each independently selected from H and C!.3alkyl (for example Me).In one embodiment R2a and R2b are substituents on the same or different C atoms and are both H.In one embodiment R2a and R2b are substituents on the same or different C atoms other than at Q, each independently selected from H, F and C!.3alkyl.In one embodiment R2a and R2b are substituents on the same or different C atoms other than at Q, each independently selected from H and C!.3alkyl, or R2a & R2b together form a -(CH2)r- group where r is 1, or 3.In one embodiment R2a and R2b are substituents on the same or different C atoms other than at Q, where R2a is Me and R2b is H.In one embodiment R2a and R2b are substituents on the same C atom other than at Q, where R2a and R2b are both Me.In one embodiment R2a and R2b are substituents on the same C atom adjacent Q, where R2a and R2b are both Me.In one embodiment Q4 is a single bond.In one embodiment Q4 is a NR4C(=O) and R4 is H.In one embodiment Q4 is a NR4C(=O) and R4 is methyl.In one embodiment Q4 is a NR4C(=O), R4 is H and Q2 is CH.In one embodiment Q4 is a NR4C(=O), R4 is methyl and Q2 is CH.In one embodiment Y1, Y2, Y3, Y4 & Y5 are respectively selected from (C, C, C, C, C), (N, C, C, C, C), (C, N, C, C, C), (N, C, C, N, C), (N, N, C, C, C), (N, C, N, C, C), (C, N, C, N, C) and (C, N, N, C, C).In one embodiment Y1, Y2, Y3, Y4 & Y5 are respectively selected from (C, C, C, C, C), (N, C, C, C, C) and (N, N, C, C, C).In one embodiment 0 or 1 of Y1, Y2, Y3, Y4 & Y5 is N and are otherwise C.In one embodiment 1 or 2 of Y1, Y2, Y3, Y4 & Y5 is/are N and are otherwise C.In one embodiment 1 of Y1, Y2, Y3, Y4 & Y5 is N and are otherwise C.In one embodiment Y1 is N; and Y2, Y3, Y4 & Y5 are all C.In one embodiment Y2 is N; and Y2, Y3, Y4 & Y5 are all C.In one embodiment 2 of Y2, Y3, Y4 & Y5 are N and are otherwise C.In one embodiment Y1 & Y3 are N; and Y2, Y4 and Y5 are C.In one embodiment Y1 & Y2 are N; and Y3, Y4 and Y5 are C.In one embodiment Y1 & Y4 are N; and Y2, Y3 and Y5 are C.In one embodiment Y2 & Y3 are N; and Y1, Y4 and Y5 are C.In one embodiment Y2 & Y4 are N; and Y1, Y3 and Y5 are C.In one embodiment Y1, Y2, Y3, Y4 & Y5 are all C.In one embodiment q is 0 or 1.In one embodiment q is 0.In one embodiment q is 1.
WO 2024/189488 PCT/IB2024/052251 In one embodiment qis 2.In one embodiment q is 0, 1 or 2 and R3(when present) is a substituent on any C atom at Y1, Y2, Y3, Y4 & Y5 selected from F, CN and C!.3alkyl.In one embodiment q is 0, 1 or 2 and R3(when present) is a substituent on any C atom at Y1, Y2, Y3, Y4 & Y5 selected from F, CN and methyl.In one embodiment q is 0 or 1 and R3(when present) is a substituent on any C atom at Y1, Y2, Y3, Y4 & Y5 which is F.In one embodiment R3 (when present) is C!.3alkyl.In one embodiment R3 (when present) is Me.In one embodiment R3 (when present) is F.In one embodiment R3 (when present) is CN.In one embodiment q is 1 and R3is attached to C at Y1. In one embodiment q is 1 and R3is attached to C at Y1,and R3 is selected from F, CN and Me.In one embodiment q is 1 and R3is attached to C at Y2,and R3 is selected from CN and Me.In one embodiment q is 2 and both R3groups are F or one group is F and the other group is Me.In one embodiment qis 2 and the R3groups are attached to C at Y1and Y3. In one embodiment qis 2 and each R3group is F, which are attached to C at Y1and Y3. In one embodiment qis 2, one R3group is F, which is attached to C at Y1and one R3group is Me, which is attached to C at Y3. In one embodiment, Linkeris attached at Y5. In one embodiment, Linkeris attached at Y4. In one embodiment, the group of Formula (la)is of Formula (la-1): (la-1) where R1and Q1are as defined above. Q1is CH or N.In one embodiment, the group of Formula (la)is of Formula (la-2): WO 2024/189488 PCT/IB2024/052251 (la-2) where R1, Q1, Q2and Q3are as defined above. Q1is CH or N; Q2is CH or N; when Q2is N, Q3is CH; when Q2is CH, Q3is CH or O.In one embodiment, the group of Formula (la)is of Formula (la-3): In one embodiment Linkeris a saturated or a partially or fully unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and ‘b’ and a minimum length of from 5 to 26 atoms between ‘a’ and ‘b’; wherein said framework may include one or more straight and/or branched chains and/or rings and is optionally substituted on any available C atom(s) by one or more F.In one embodiment the framework of the Linkeris a saturated or partially unsaturated framework.In one embodiment the framework of the Linkeris a saturated framework.In one embodiment the framework of the Linkercomprises C and H atoms and at least two heteroatoms.In one embodiment the framework of the Linkercomprises C and H atoms and at least two heteroatoms selected from O and N.In one embodiment the framework of the Linkercomprises C and H atoms and at least one nitrogen heteroatom.In one embodiment the framework of the Linkercomprises C and H atoms and at least two heteroatoms including at least one nitrogen heteroatom.
WO 2024/189488 PCT/IB2024/052251 In one embodiment the framework of the Linkercomprises C and H atoms and at least one nitrogen heteroatom in the form of a secondary or tertiary amine.In one embodiment the framework of the Linkercomprises C and H atoms and at least one nitrogen heteroatom in the form of a tertiary amine.In one embodiment the framework of the Linkercomprises C and H atoms and at least two heteroatoms including at least one nitrogen heteroatom in the form of a secondary or tertiary amine.In one embodiment the framework of the Linkercomprises C and H atoms and at least two heteroatoms including at least one nitrogen heteroatom in the form of a tertiary amine.In one embodiment the Linkerhas a minimum length of from 5 to 20 atoms between ‘a’ and ‘b‘.In one embodiment the Linkerhas a minimum length of from 5 to 15 atoms between ‘a’ and ‘b‘.In one embodiment the Linkerhas a minimum length of from 5 to 14 atoms between ‘a’ and ‘b‘.In one embodiment the total number of C and hetero atoms in the Linkerframework is from 6 to 26.In one embodiment the total number of C and hetero atoms in the Linkerframework is from 7 to 24.In one embodiment the total number of C and hetero atoms in the Linkerframework is from 7 to 22.In one embodiment the total number of C and hetero atoms in the Linkerframework is from 7 to 20.In one embodiment the total number of C and hetero atoms in the Linkerframework is from 7 to 18.In one embodiment when Wis -Z-RA,the Linkeris attached at any available C atom at XBor Xcof Z. In one embodiment the framework of the Linkermay include one or more straight chains and/or rings and is optionally substituted on any available C atom(s) by one or more F.In one embodiment the framework of the Linkerconsists of one or more straight chains and/or rings that are optionally substituted on any available C atom(s) by one or more F.In one embodiment the framework of the Linkermay include (or consist of) one or more straight and/or branched chains and/or rings (wherein the total number of branches is from 0 to 5) that are optionally substituted on any available C atom(s) by one or more F.In one embodiment the framework of the Linkermay include (or consist of) one or more straight and/or branched chains and/or rings (wherein the total number of branches is from 0 to 3) that are optionally substituted on any available C atom(s) by one or more F.In one embodiment the framework of the Linkermay include (or consist of) one or more straight and/or branched chains and/or rings (wherein the total number of branches is 0 or 1) that are optionally substituted on any available C atom(s) by one or more F.In one embodiment the total number of branches is 0.In one embodiment the total number of branches is 1.In one embodiment the total number of branches is 2.In one embodiment the total number of branches is 3.In one embodiment any/each branch in the framework of a Linkerhas from 1 to 5 C and/or hetero atoms.In one embodiment any/each branch in the framework of a Linkerhas 1 or 2 C and/or hetero atoms.In one embodiment any/each branch in the framework of a Linkerhas 1 C and/or hetero atom.In one embodiment any/each branch in the framework of a Linkerhas 1 C atom.In one embodiment the total number of C and/or heteroatoms in the branch(es) (where present) of the framework of the Linkeris from 1 to 5.
WO 2024/189488 PCT/IB2024/052251 In one embodiment the total number of C and/or heteroatoms in the branch(es) (where present) of the framework of the Linkeris from 1 to 3.In one embodiment the total number of C and/or heteroatoms in the branch(es) (where present) of the framework of the Linkeris 1.In one embodiment the framework of the Linkeris either unbranched or has one branch that is Me.In one embodiment the framework of the Linkeris unbranched.In one embodiment the framework of the Linkeris optionally substituted on any available C atom(s) by 1 or F (for example by 2 F, for example where said 2 F are substituted on the same carbon atom).In one embodiment the framework of the Linkeris not substituted by any F.In one embodiment the Linkeris a saturated or a partially unsaturated framework comprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and ‘b’ and: a minimum length of from 5 to 14 atoms between ‘a’ and ‘b’;wherein the total number of C and hetero atoms in the Linkerframework is from 7 to 18;where said framework comprises one or more straight and/or rings that are optionally substituted on any available C atom(s) by 1 or 2 F (for example by 2 F).In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group (e.g. having from 4 to 12 ring atoms) or a A1-CH2-CH2-A2 unit where A1 and A2 are each independently selected from N and O.In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated heterocyclic group (e.g. having from 4 to 12 ring atoms) or a A1-CH2-CH2-A2unit where A1and A2are each independently selected from N and O.In one embodiment the framework of the Linkerincludes a A1-CH2-CH2-A2unit where A1and A2are each independently selected from N and O.In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group (e.g. having from 4 to 12 ring atoms) or a A1-CH2-CH2-A2 unit where one of A1 & A2 is N and the other of A1 & A2 is selected from N or O.In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated heterocyclic group (e.g. having from 4 to 12 ring atoms) or a A1-CH2-CH2-A2 unit where one of A1 & A2 is N and the other of A1 & A2 is selected from N or O.In one embodiment the framework of the Linkerincludes a A1-CH2-CH2-A2unit where one of A1 & A2is N and the other of A1 & A2is selected from N or O.In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group (e.g. having from 4 to 12 ring atoms) or a A1-CH2-CH2-A2 unit where one of A1 & A2 is N in the form of a secondary or tertiary amine, and the other of A1 & A2 is selected from N or O.In one embodiment the framework of the Linkerincludes a A1-CH2-CH2-A2unit where one of A1 & A2is N in the form of a secondary or tertiary amine, and the other of A1 & A2is selected from N or O.In one embodiment the framework of the Linkerincludes at least one saturated or partially unsaturated heterocyclic group.In one embodiment the framework of the Linkerincludes at least one saturated heterocyclic group.
WO 2024/189488 PCT/IB2024/052251 In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group.In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated heterocyclic group.In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group having from 4 to 12 ring atoms.In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated heterocyclic group having from 4 to 12 ring atoms.In one embodiment the framework of the Linkerincludes:(1) a A1-CH2-CH2-A2 unit where A1 and A2 are each independently selected from N and 0; and/or(2) at least one nitrogen-containing saturated or partially unsaturated heterocyclic group selected from piperazine, azetidine, piperidine, 1,4-diazepane, 12-oxa-3,9-diazaspiro[5.6]dodecane, pyrrolidine, 3,9- diazaspiro-[5.5]undecane, 2,5-diazabicyclo[2.2. !]heptane, 1,2,3,3a,4,5,6,6a- octahydropyrrolo[3,4-c]pyrrole, 1,2,3,6-tetrahydropyridine, morpholine, 2-azaspiro[3.5]nonane and 9- azaspiro[5.5]undecane.In one embodiment the framework of the Linkerincludes:(1) a A1-CH2-CH2-A2 unit where one of A1 & A2 is N in the form of a secondary or tertiary amine, and the other of A1 & A2 is selected from N or 0; and/or(2) at least one nitrogen-containing saturated or partially unsaturated heterocyclic group selected from piperazine, azetidine, piperidine, 1,4-diazepane, 12-oxa-3,9-diazaspiro[5.6]dodecane, pyrrolidine, 3,9- diazaspiro-[5.5]undecane, 2,5-diazabicyclo[2.2. !]heptane, l,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4- c]pyrrole, 1,2,3,6-tetrahydropyridine, morpholine, 2-azaspiro[3.5]nonane and 9-azaspiro[5.5]undecane.In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group selected from piperazine, azetidine, piperidine, 1,4-diazepane, 12-oxa-3,9-diazaspiro[5.6]dodecane, pyrrolidine, 3,9-diazaspiro[5.5]undecane, 2,5- diazabicyclo[2.2. !]heptane, l,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4-c]pyrrole, !,2,3,6- tetrahydropyridine, morpholine, 2-azaspiro[3.5]nonane and 9-azaspiro[5.5]undecane.In one embodiment the framework of the Linkerincludes an O-CH2-CH2-N unit.In one embodiment the framework of the Linkerincludes an O-CHCH2-O-CHCH2-N unit.In one embodiment the framework of the Linkerincludes a piperazine group.In one embodiment the framework of the Linkerincludes an azetidine group.In one embodiment the framework of the Linkerincludes a piperidine group.In one embodiment the framework of the Linkerincludes a 1,4-diazepane group.In one embodiment the framework of the Linkerincludes a 12-oxa-3,9-diazaspiro[5.6]dodecane group.In one embodiment the framework of the Linkerincludes a pyrrolidine group.In one embodiment the framework of the Linkerincludes a 3,9-diazaspiro[5.5]undecane group.In one embodiment the framework of the Linkerincludes a 2,5-diazabicyclo[2.2.1]heptane group.In one embodiment the framework of the Linkerincludes a l,2,3,3a,4,5,6,6a-octahydropyrrolo[3,4-c]pyrrole group.In one embodiment the framework of the Linkerincludes a 1,2,3,6-tetrahydropyridine group.
WO 2024/189488 PCT/IB2024/052251 In one embodiment the framework of the Linkerincludes a morpholine group.In one embodiment the framework of the Linkerincludes a 2-azaspiro [3.5]nonane group.In one embodiment the framework of the Linkerincludes a 9-azaspiro[5.5]undecane group.In one embodiment the framework of the Linkerincludes at least two nitrogen-containing saturated or partially unsaturated heterocyclic groups.In one embodiment the framework of the Linkerincludes at least two nitrogen-containing saturated heterocyclic groups.In one embodiment the framework of the Linkerincludes a C, N or O atom at the ‘a’ point of attachment.In one embodiment the framework of the Linkerincludes an N or O atom at the ‘a’ point of attachment.In one embodiment the framework of the Linkerincludes an N or O atom at the ‘b’ point of attachment.In one embodiment the framework of the Linkerincludes a C atom at the ‘a’ point of attachment.In one embodiment the framework of the Linkerincludes an N atom at the ‘a’ point of attachment.In one embodiment the framework of the Linkerincludes a C or N atom at the ‘b’ point of attachment.In one embodiment the framework of the Linkerincludes an N atom at the ‘b’ point of attachment.In one embodiment the framework of the Linkerincludes a C atom at the ‘b’ point of attachment.In one embodiment the framework of the Linkerincludes an O atom at the ‘a’ point of attachment.In one embodiment the framework of the Linkerincludes an O atom at the ‘b’ point of attachment.In one embodiment the framework of the Linkerincludes an N or O atom at both the ‘a’ and ‘b’ points of attachment.In one embodiment the framework of the Linkerincludes a C, N or O atom at the ‘a’ point of attachment and a C or N atom at the ‘b’ point of attachment.In one embodiment the framework of the Linkerincludes:(1) a A1-CH2-CH2-A2 unit where one of A1 & A2 is N in the form of a secondary or tertiary amine, and the other of A1 & A2 is selected from N or 0; and/or(2) at least one nitrogen-containing saturated or partially saturated heterocyclic group selected from piperazin-1,4-diyl, azetidin-1,3 -diyl, piperidin- 1,4-diyl, 1,4-diazepan-1,4-diyl, 12-oxa-3,9- diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin-1,3 -diyl, 3,9-diazaspiro[5.5]undecan-3,9-diyl, 2,5- diazabicyclo[2.2.1]heptan-2,5-diyl, l,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3,6-dihydro- 2H-pyridin-1,4-diyl, morpholin-2,3-diyl, 2-azaspiro[3.5]nonan-2,7-diyl and 9-azaspiro[5.5]undecan- 3,9-diyl.In one embodiment the framework of the Linkerincludes at least one nitrogen-containing saturated or partially saturated heterocyclic group selected from piperazin-1,4-diyl, azetidin-1,3-diyl, piperidin-1,4- diyl, 1,4-diazepan- 1,4-diyl, 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin-1,3-diyl, 3,9- diazaspiro[5.5]undecan-3,9-diyl, 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl, 1,3,3a,4,6,6a- hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3.6-dihydro-2//-pyridin- 1,4-diyl, morpholin-2,3-diyl, 2- azaspiro[3.5]nonan-2,7-diyl and 9-azaspiro[5.5]undecan-3,9-diyl.In one embodiment the framework of the Linkerincludes a piperazin-1,4-diyl group.In one embodiment the framework of the Linkerincludes an azetidin-1,3-diyl group.In one embodiment the framework of the Linkerincludes a piperidin-1,4-diyl group.In one embodiment the framework of the Linkerincludes a 1,4-diazepan-1,4-diyl group.
WO 2024/189488 PCT/IB2024/052251 In one embodiment the framework of the Linkerincludes a 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl group.In one embodiment the framework of the Linkerincludes a py nolidin-1,3-diyl group.In one embodiment the framework of the Linkerincludes a 3,9-diazaspiro[5.5]undecan-3,9-diyl group.In one embodiment the framework of the Linkerincludes a 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl group.In one embodiment the framework of the Linkerincludes a l,3,3a,4,6,6a-hexahydropynolo[3,4-c]pynol-2,5- diyl group.In one embodiment the framework of the Linkerincludes a 3.6-dihydro-2//-pyridin-1.4-diyl group.In one embodiment the framework of the Linkerincludes a morpholin-2,3-diyl group.In one embodiment the framework of the Linkerincludes a 2-azaspiro[3.5]nonan-2,7-diyl group.In one embodiment the framework of the Linkerincludes a 9-azaspiro[5.5]undecan-3,9-diyl group.In one embodiment the Linkerhas the Formula: a’ -Q*-Q*-QCb’wherein: a ’and ‘b’represent the end points of attachment;QA is -G-QH- or -G-(C1.5alkylene)-; QBis a direct bond, -QB1-QB2-QB3-or C1-3alkylene optionally substituted by one or more F (forexample 1 or 2 F, for example 2 F); where: QB1 & QB3each independently represent a direct bond or C!.2alkylene; q62 ؛s qh -0-CHCH-o- -0- or -N(RJ)- where RJ is H or C1-3alkyl;Qc is -QH-G- or -(C1.5alkylene)-G-;each G is independently a direct bond, -CH2-, -0-, -C(=O)- or -N(RG)- where each RG is independently H or C!.3alkyl;each QH is independently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;where the values of QA, QBand Qcare selected so that the Linkerdoes not contain any N-N or N-O bonds.In one embodiment the Linkerhas the Formula: a’ -QA-QB-QC-‘b’wherein: a ’and ‘b’represent the end points of attachment;QA is -G-QH- or -G-(C1.5alkylene)-;QB is a direct bond, -QB1-QB2-QB3- or C!.3alkylene optionally substituted by one or more F (e.g. 1 or 2); where:QB1 & QB3 each independently represent a direct bond or C!.2alkylene;QB2 is QH, -0-CHCH-0- or -N(RJ)- where RJ is C1-3alkyl;Qc is -QH-G- or-(C1.5alkylene)-G-;each G is independently a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)- where each RG is independently H or C1-3alkyl; WO 2024/189488 PCT/IB2024/052251 each QH is independently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;where the values of QA, QBand Qcare selected so that the Linkerdoes not contain any N-N or N-O bonds.In one embodiment the Linkerhas the Formula: a’ -Q*-Q*-QCb’wherein: a ’and ‘b’represent the end points of attachment;QA is -GA-QHA- or -GA-(C1-5alkylene)-; where GA is a direct bond, -CH2-, -C(=O)-, -0-, -NH- or - N(Me)-;Q"A is a 4 to 11-membered nitrogen-containing saturated heterocyclic group;QB is a direct bond, -QB1-QB2-QB3- or 0ן.י,alkylene optionally substituted by one or more F (e.g. 1 or 2); where:QB1 & QB3 each independently represent a direct bond or C!.2alkylene;QB2 is piperazin- 1,4-diyl, -O-CH2CH2-O- or -N(RJ)- where RJ is C!.3alkyl;Qc is -QHC-GC- or -(C1-2alkylene)-Gc-; where Gc is a direct bond, -0- or -NH-;QHC is a 6 to 12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;where the values of QA, QBand Qcare selected so that the Linkerdoes not contain any N-N or N-O bonds.In one embodiment QA is -GA-QHA- or -GA-(C1-5alkylene)- where:GA is selected from a direct bond, -CH2-, -C(=O)-, -0- or -N(RG)-;each RG is independently H or C!.3alkyl; andQ"A is a 4 to 11-membered nitrogen-containing saturated heterocyclic group.In one embodiment QA is -GA-QHA- or -GA-(C1-5alkylene)- where:GA is selected from a direct bond, -CH2-, -C(=O)-, -0- or -N(RG)-;each RG is independently H or C!.3alkyl; andQI,A is selected from azetidin-1,3-diyl, morpholin-2,3-diyl, pyrrolidin-1,3 -diyl, piperidin-1,4-diyl, piperazin-1,4-diyl, 3,9-diazaspiro[5.5]undecan-3,9-diyl, 2-azaspiro[3.5]nonan-2,7-diyl and 9- azaspiro [5.5]undecan-3,9-diyl.In one embodiment QA is -GA-QI,A- or -GA-(C1-5alkylene)- where:GA is selected from a direct bond, -CH2-, -C(=O)-, -O-or -NH- or -N(Me)-; Q"Ais selected from azetidin-1,3-diyl, pyrrolidin-1,3-diyl, piperidin-1,4-diyl, piperazin-1,4-diyl, 3,9- diazaspiro[5.5]undecan-3,9-diyl and 9-azaspiro[5.5]undecan-3,9-diyl; and the C1-5alkylene within said -GA-(C1-5alkylene)- is selected from -(CH2)f- where fis an integer from to 5, cyclobut-l,3-diyl and -CH2(cyclobut-1,3-diyl)-.In one embodiment QA is selected from azetidin-1,3-diyl, pyrrolidin-1,3 -diyl, piperidin-1,4-diyl, -O(piperidin-1,4-diyl)-, -C(O)-piperidin-l,4-diyl, -CH2(piperidin-l,4-diyl)-, piperazin-1,4-diyl, 3,9-diazaspiro[5.5]undecan-3,9-diyl, morpholin-2,3-diyl, 2-azaspiro[3.5]nonan-2,7-diyl, -0(9- WO 2024/189488 PCT/IB2024/052251 azaspiro[5.5]undecan-3,9-diyl)-, -O(cyclobut-l,3-diyl)-, -OCH2(cyclobut-1,3-diyl)-, -(CH2)f-, -0- (CH2)f-, -NH-(CH2)f- and -N(Me)-(CH2)f-, where fis an integer from 1 to 5.In one embodiment QA is azetidin-1,3 -diyl.In one embodiment QA is pyrrolidin-1,3 -diyl.In one embodiment QA is piperidin- 1,4-diyl.In one embodiment QA is -C(O)-piperidin-1,4-diyl.In one embodiment QA is -O(piperidin-1,4-diyl)-.In one embodiment QA is -CH2(piperidin-1,4-diyl)-.In one embodiment QA is piperazin-1,4-diyl.In one embodiment QA is -CH2(piperazin-1,4-diyl)-.In one embodiment QA is morpholin-2,3-diyl.In one embodiment QA is 2-azaspiro[3.5]nonan-2,7-diyl.In one embodiment QA is 3,9-diazaspiro[5.5]undecan-3,9-diyl.In one embodiment QA is -O(9-azaspiro[5.5]undecan-3,9-diyl)-.In one embodiment QA is -G-(C1-5alkylene)-.In one embodiment QA is selected from -O(cyclobut-1,3-diyl)-, -OCH2(cyclobut-l,3-diyl)-, -(CH2)f-, -O(CH2)f-, -NH-(CH2)f- and -N(Me)-(CH2)f-, where f is an integer from 1 to 5.In one embodiment QA is -O(cyclobut-1,3-diyl)-.In one embodiment QA is -OCH2(cyclobut-l,3-diyl)-.In one embodiment QA is -(CH2)f- where fis an integer from 1 to 4 (for example, fis 4)In one embodiment QA is -O-(CH2)f- where fis an integer from 1 to 5 (for example, fis 4).In one embodiment QA is -NH-(CH2)f- where f is an integer from 1 to 5.In one embodiment QA is -N(Me)-(CH2)f-, where fis an integer from 1 to 4.In one embodiment QB is a direct bond, .QB1.qB2.qB3. or a straight chain C!.3alkylene optionally substitutedby one or more F (for example 1 or 2 F, for example by 2 F).In one embodiment QB is a direct bond.In one embodiment QB is -QB1-QB2-QB3-.In one embodiment QB is C!.3alkylene optionally substituted by one or more F.In one embodiment QB is C!.3alkylene optionally substituted by one or two F (for example by 2 F).In one embodiment QB is a straight chain C!.3alkylene optionally substituted by 1 or 2 F (for example by 2 F).In one embodiment QB is C!.3alkylene.In one embodiment QB is a straight chain C!.3alkylene.In one embodiment QB is -CF2-CH2-CH2- or -(CH2)W- where wis 1 to 3.In one embodiment QB1 and QB3 each independently represent a direct bond, -CH2- or -CH2CH2-.In one embodiment QB1 is a direct bond or -CH2-.In one embodiment QB1 is a direct bond.In one embodiment QB1 is -CH2-.In one embodiment QB3 is a direct bond, -CH2- or -CH2CH2-.In one embodiment QB3 is a direct bond.In one embodiment QB3 is -CH2-.
WO 2024/189488 PCT/IB2024/052251 In one embodiment QB3 is -CHCH-In one embodiment QB2 is QH, -O-CHCH-0- or -N(RJ)- where RJ is C1.3alkyl.In one embodiment QB2 is QH, -0-CHCH-0- or -N(Me)-.In one embodiment QB2 is piperazin-1,4-diyl, azetidin-1,3 -diyl, -O-CH2CH2-O- or -N(Me)-.In one embodiment QB2 is piperazin-1,4-diyl, -O-CH2CH2-O- or -N(Me)-.In one embodiment QB2 is QH.In one embodiment QB2 is piperazin-1,4-diyl.In one embodiment QB2 is azetidin-1,3-diyl.In one embodiment QB2 is -O-CH2CH2-O-.In one embodiment QB2 is -N(RJ)- where RJ is C!.3alkyl.In one embodiment QB2 is -N(Me)-.In one embodiment QC is -Q"-G- or -(C1-4alkylene)-G-.In one embodiment qc is -Q"-G- or -(C1.3alkylene)-G-.In one embodiment qc is -Q"-G- or -(C1.2alkylene)-G-.In one embodiment qc is _qhc _g c_ or -(C1-5alkylene)-Gc- where:Gc is selected from a direct bond, -0- or -NH-; andQHC is a 6 to 12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group.In one embodiment qc is _qhc _g c_ or -(C1.2alkylene)-Gc- where:Gc is selected from a direct bond, -0- or -NH-; andQHC is a 6 to 12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group.In one embodiment qc is _qhc _g c_ or -(C1.2alkylene)-Gc- where:Gc is selected from a direct bond, -0- or -NH-; andQHC is selected from piperazin-1,4-diyl, piperidin-1,4-diyl, 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl, 1,4- diazepan-1,4-diyl, 3,9-diazaspiro[5.5]undecan-3,9-diyl, 12-oxa-3,9-diazaspiro[5.6]-dodecan-3,9-diyl, 1,3,3a,4,6,6a-hexahydropyrrolo [3,4-c]pyrrol-2,5-diyl and 3.6-di hydro-2//-py ridin-1,4-diyl.In one embodiment Qc is selected from piperazin-1,4-diyl, piperidin-1,4-diyl, -(piperidin-1,4-diy 1)0-, 2,5- diazabicyclo[2.2. l]heptan-2,5-diyl, 1,4-diazepan-1,4-diyl, 3,9-diazaspiro[5.5]undecan-3,9-diyl, 12-oxa- 3,9-diazaspiro[5.6]-dodecan-3,9-diyl, l,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3.6-dihydro-2//-pyridin-1.4-diyl. and -CH2CH2-NH- and -(CH2)g-O- where g is an integer from 1 to 4.In one embodiment Qc is piperazin-1,4-diyl.In one embodiment Qc is piperidin-1,4-diyl.In one embodiment Qc is -(piperidin-1,4-diyl)O-.In one embodiment Qc is 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl.In one embodiment Qc is 1,4-diazepan-1,4-diyl.In one embodiment Qc is 3,9-diazaspiro[5.5]undecan-3,9-diyl.In one embodiment Qc is 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl.In one embodiment Qc is l,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl.In one embodiment Qc is 3.6-di hydro-2//-py ridin- 1,4-diyl.In one embodiment Qc is -(C1-5alkylene)-G- [for example, -(CH2)g-O- where g is an integer from 1 to 5].In one embodiment Qc is -(C1-4alkylene)-G- [for example, -(CH2)g-O- where g is an integer from 1 to 4].
WO 2024/189488 PCT/IB2024/052251 In one embodiment Qc is -(C1-3alkylene)-G- [for example, -(CH2)g-O- where g is 1, 2 or 3].In one embodiment Qc is -(C1.2alkylene)-G- [for example, -(CH2)g-O- where g is 1 or 2].In one embodiment Qc is -(CH2)g-Gc- where g is an integer from 1 to 5 and Gc is -0- or -NH-In one embodiment Qc is -(CH2)g-Gc- where g is 1 or 2 and Gc is -0- or -NH-In one embodiment Qc is -CH2CH2NH-.In one embodiment Qc is -CH2-.In one embodiment each QH is independently selected from piperazin-1,4-diyl, azetidin-1,3 -diyl, piperidin- 1,4-diyl, 1,4-diazepan-1,4-diyl, 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin-1,3 -diyl, 3,9- diazaspiro[5.5]undecan-3,9-diyl, 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl, 1,3,3a,4,6,6a- hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3.6-dihydro-2//-pyridin- 1,4-diyl and 9-azaspiro[5.5]undecan- 3,9-diyl.In one embodiment each QH is independently selected from piperazin-1,4-diyl, azetidin-1,3-diyl, piperidin- 1,4-diyl, 1,4-diazepan- 1,4-diyl, 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin-1,3-diyl, 3,9- diazaspiro[5.5]undecan-3,9-diyl, morpholin-2,3-diyl, 2-azaspiro[3.5]nonan-2,7-diyl, 2,5- diazabicyclo[2.2.1]heptan-2,5-diyl, l,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl and 9- azaspiro [5.5]undecan-3,9-diyl.In one embodiment QH is piperazin-1,4-diyl.In one embodiment QH is azetidin-1,3-diyl.In one embodiment QH is piperidin-1,4-diyl.In one embodiment QH is 1,4-diazepan-1,4-diyl.In one embodiment QH is 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl.In one embodiment QH is pyrrolidin-1,3 -diyl.In one embodiment QH is 3,9-diazaspiro[5.5]undecan-3,9-diyl.In one embodiment QH is 2,5-diazabicyclo[2.2. l]heptan-2,5-diyl.In one embodiment QH is l,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl.In one embodiment QH is 3.6-dihydro-2//-py ridin- 1,4-diyl.In one embodiment QH is 9-azaspiro[5.5]undecan-3,9-diyl.In one embodiment QH is 2-azaspiro[3.5]nonan-2,7-diyl.In one embodiment QH is morpholin-2,3-diyl.In one embodiment RJ is C!.3alkyl.In one embodiment RJis Me.In one embodiment RG is C!.3alkyl.In one embodiment RGis H or Me.In one embodiment RGis Me.In one embodiment RGis H.In one embodiment the Linker(for example ‘a’ -QA-QB-QC-‘b‘) is selected from any of Linkers1 to shown below: WO 2024/189488 PCT/IB2024/052251 24 WO 2024/189488 PCT/IB2024/052251 WO 2024/189488 PCT/IB2024/052251 43 44 45 WO 2024/189488 PCT/IB2024/052251 58 57 WO 2024/189488 PCT/IB2024/052251 In one embodiment the Linker(for example ‘a’ -QA-QB-QC-‘b‘) is selected from any of Linkers1, 3, 6, 9, 19, 28, 45, 47, 49, 50, 51, 52, 53, 54, 55, 56, 57 and 58.In some embodiments Linker54 is 54a: 54a In one embodiment Wis an E3 ubiquitin ligase cereblon binder unit attached to the ‘b’ end of the Linkervia an available C atom within said E3 ubiquitin ligase cereblon binder unit.In one embodiment Wis W1which is: -Z-(R')h where Z is: wherein: represents a single covalent bond or a double covalent bond;0, 1 or 2 of XA, XB, Xc, XD, XE & XF0fXG, XH&XJ0fXG, XH&XJ0fXG, XH&XJ is/are N, where XE & XE are not both N, and are otherwise C;is C(O);is N-(2,6-dioxopiperidin-3-yl) (Y); andis selected from C(RT)2, -CH2CH2-, C(O), N(C!.3alkyl), -0- and -N=, wherein each RT is selected from H, F, Me or together with the carbon of C(RT)2 forms a cycloprop-1,1-diyl group; where XG, XH & XJ are selected such that there are not two C(O) groups present at adjacent positions, and that the N-(2,6-dioxopiperidin-3-yl) is not at an adjacent position to either N(C!.3alkyl) or 0;each Ra is independently a substituent on any available C atom at XA, XB, Xc or XD selected from F, Cl, C!.3alkyl, C1-3alkoxy wherein said C!.3alkyl and C1-3alkoxy is independently optionally substituted by one or more F;h is 0, 1 or 2; andwherein the Linker is attached to any C atom at XA, XB, Xc or XD.
Y is: WO 2024/189488 PCT/IB2024/052251 O In one embodiment 0 or 1 of XA, XB, Xc, XD, XE & XF is N and are otherwise C.In one embodiment 1 or 2 of XA, XB, Xc, XD, XE & XE is/are N and are otherwise C.In one embodiment XA, XB, Xc, XD, XE & XE are all C.In one embodiment 1 of XA, XB, Xc, XD, XE & XE is N and are otherwise C.In one embodiment 2 of XA, XB, Xc, XD, XE & XE are N where XE & XE are not both N, and are otherwise C.In one embodiment XB, XD & XE are all C, and 0, 1 or 2 of XA, Xc & XE is/are N, and are otherwise C.In one embodiment XB, XD & XE are all C, and 0, 1 or 2 of XA, Xc & XE is/are N, and are otherwise C; where the Linker is attached to XB or to XA when XA is C.In one embodiment XB, XD & XE are all C, and 0, 1 or 2 of XA, Xc & XE is/are N, and are otherwise C; where the Linker is attached to XB.In one embodiment XG-XH-XJ is:(i) Xg -NY-C(O) where XG is -CH2-, -CH2CH2-, =N- or C(O);(ii) XG-C(O)-NY where XG is -0- or N(C!.3alkyl) [for example N(Me)]; or(iii) C(O)-NY-CH2.In one embodiment the Linker is attached to a C atom at XA or XB and XG-XH-XJ is:(i) XG-NY-C(O) where XG is -CH2-, -CH2CH2-, =N- or C(O);(ii) XG-C(O)-NY where XG is -0- or N(C!.3alkyl) [for example N(Me)]; or(iii) C(O)-NY-CH2.In one embodiment the Linker is attached to a C atom at XB and XG-XH-XJ is:(i) XG-NY-C(O) where XG is -CH2-, -CH2CH2-, =N- or C(O);(ii) Xg -C(O)-NY where XG is -0- or N(C!.3alkyl) [for example N(Me)]; or(iii) C(O)-NY-CH2.In one embodiment XG-XH-XJ is CH2-NY-C(O).In one embodiment XG-XH-XJ is CH2CH2-NY-C(O).In one embodiment XG-XH-XJ is =N-NY-C(O).In one embodiment XG-XH-XJ is C(O)-NY-C(O).In one embodiment XG-XH-XJ is O-C(O)-NY.In one embodiment XG-XH-XJ is N(C!.3alkyl)-C(O)-NY [for example N(Me)-C(O)-NY].In one embodiment XG-XH-XJ is C(O)-NY-CH2.In one embodiment each RA is a substituent on any available C at XA, XB, Xc or XD selected from F, CI and C!.3alkoxy optionally substituted by one or more F.In one embodiment each RA is a substituent on any available C at XA, XB, Xc or XD selected from F, Cl, OMe and-OCHF2.
WO 2024/189488 PCT/IB2024/052251 In one embodiment his 0.In one embodiment his 1.In one embodiment his 2.In one embodiment the Linkeris attached to Xc ,where Xcis C; and XAis C attached to RAwhere RAis OMe where said methyl is optionally substituted by one or more F (e.g. -OCHF2).In one embodiment the Linkeris attached to Xc ,where Xcis C; and XAis C attached to RAwhere RAis OMe or -OCHF2.In one embodiment -Z-(RA)htogether represent any one of groups 1, 4, 16, 17 and 19 (referring to the specific -Z-(RA)hgroups 1 to 21 whose structures are drawn out below).In one embodiment his I and RAis C!.3alkoxy [for example OMe].In one embodiment his 1 or 2, one RAis OMe and the other RA(when present, i.e. when his 2) is Cl.In one embodiment his 1 or 2, one RAis Cl and the other RA(when present, i.e. when his 2) is OMe.In one embodiment his I and RAis F.In one embodiment his I and RAis Cl.In one embodiment his 1 and RAis -OCHF2.In one embodiment the Linkeris attached to a C at XAor XB,and his 0.In one embodiment the Linkeris attached to a C at XAor XB, his I and RAis a substituent on Xcwhere Xcis C and Ra is F.In one embodiment the Linkeris attached to a C at XAor XB, his I and RAis a substituent on XDwhere XDis C and Ra is OMe or -OCHF2.In one embodiment the Linkeris attached to a C at XB, his 0, 1 or 2; the first RA(when present, i.e. when his or 2) is a substituent on an available C at XDand the second RA(when present, i.e. when his 2) is on an available C at XA. In one embodiment the Linkeris attached to a C at XB, his 0, 1 or 2; the first RA(when present, i.e. when his or 2) is a substituent on an available C at XDselected from Cl, OMe and -OCHF2; and the second RA (when present, i.e. when his 2) is on an available C at XAand is selected from Cl and OMe.In one embodiment -Z-(RA)htogether represent any of the groups 1 to 21, 27 and 32 shown below: WO 2024/189488 PCT/IB2024/052251 21 WO 2024/189488 PCT/IB2024/052251 In one embodiment Wis W2which isZAis: wherein:represents a single covalent bond or a double covalent bond;of XA2, XB2, Xc2 & XD20, 1 or 2 of XA2, XB2, Xc2, XD2, XE2 & XF20r2 0fXG2, XH2&XJ2each Raa is C and covalently bound to YN;is/are N (where XE2 & XE2 are not both N) and are otherwise C;is/are N; and are otherwise C;is a substituent on any available C or N atom of Z - in each case independently selected from RAAI optionally substituted by one or more RM2; where RAA is further selected from RAA2 when RAA is a substituent on an available C atom of ZA;each RAA1 is independently C!.4alkyl, C2-3alkenyl, C2-3alkynyl, C1-3alkoxyC1-3alkyl, carboxyC1-3alkyl, C5-7carbocyclyl or a 4-membered heterocyclyl;each raa2 is independently selected from F, Cl, Br, CN, NH2, C!.3alkyl, O(C!.3alkyl), NH(C!.3alkyl) and N(C!-3alkyl)2; wherein said C!.3alkyls are optionally substituted by one or more F; V is 0, 1 or 2; yN is 2,4-dioxohexahydropyrimidin-1 -yl.
YNis: WO 2024/189488 PCT/IB2024/052251 In one embodiment ZA is: wherein: 1 0fXA2&XB2 0 or 1 of Xc2 & XD20fXG2&XJ2XH2, XE2 & XF2 represents a single covalent bond or a double covalent bond;is C and covalently bound to YN and the other of XA2 & XB2 is C;is N and is/are otherwise C;is N and the other of XG2 & XJ2 is C; andare all C.In one embodiment -ZA-YN together represent any one or more of the groups Al to A5 shown below, where in each case said ZA group is optionally substituted on available C and/or N atom(s) by -[RAA]v as further defined herein.
A4 A5 WO 2024/189488 PCT/IB2024/052251 In one embodiment each RM is a substituent on any available C or N atom of ZA - in each case independently selected from RAAI optionally substituted by one or more RM2; where RAA is further selected from RAA2 when RAA is a substituent on an available C atom of Z; wherein each RAAI is independently C!. 4alkyl or a 4-6 membered heterocyclyl; and each RAA2 is independently selected from F, Cl, CN and C!. alkyl.In one embodiment each RAA is a substituent on any available C or N atom of ZA - in each case independently selected from RAAI optionally substituted by one or more RAA2: where RAA is further selected from RAA2 when RAA is a substituent on an available C atom of ZA; wherein each RAA1 is independently methyl, isopropyl, cyclopropyl, pyridinyl or pyrazolyl; and each RAA2 is independently F, Cl, CN or methyl.In one embodiment each RAA is a substituent on an available C atom of ZA, each independently selected from methyl, isopropyl, cyclopropyl, pyridin-2-yl, l-methylpyrazol-4-yl, -CH2CN, F, Cl, CN; and/or a methyl substituent on an available N atom of ZA.In one embodiment v is 0.In one embodiment v is 1.In one embodiment v is 2.In one embodiment v is 1 or 2.In one embodiment v is 0 or 1.In one embodiment v is 1; XA1 is a C atom; and RAA is a substituent on XA1.In one embodiment v is 1; XA1 is a C atom; and RAA is a C!.4alkyl substituent on XA1.In one embodiment v is 1; XB1 is a C atom; and RAA is a substituent on XB1.In one embodiment v is 1; XB1 is a C atom; and RAA is a C!.4alkyl (e.g. methyl) substituent on XB1.In one embodiment v is 1; XC1 is a C atom; and RAA is a substituent on Xc1.In one embodiment v is 1; XC1 is a C atom; and RAA is a C!.4alkyl (e.g. methyl) substituent on Xc1.In one embodiment v is 1; XD1 is a C atom; and RAA is a substituent on XD1.In one embodiment v is 1; XD1 is a C atom; and RAA is a C!.4alkyl (e.g. methyl) or F substituent on XD1.In one embodiment v is 1; XG1 is a C atom; and RAA is a substituent on XG1.In one embodiment v is 1; XG1 is a C atom; and RAA is a substituent on XG1; where RAA is selected from RAAoptionally substituted by one or more RAA2: or RAA is selected from RAA2; wherein RAA1 is C!.4alkyl or a 4-6 membered heterocyclyl; and RAA2 is selected from F, Cl, CN and C1-3alkyl.In one embodiment v is 1; XG1 is a C atom; and RAA is a substituent on XG1; where RAA is selected from methyl, isopropyl, cyclopropyl, pyridine-2-yl, l-methylpyrazol-4-yl, -CH2CN, F, CI and CN.In one embodiment v is 1 or 2; XG1 is a C atom; and one/the RAA is a substituent on XG1; where RAA is selected from RAAI optionally substituted by one or more RM2; or RAA is selected from RM2; wherein RAA1 is C!.4alkyl or a 4-6 membered heterocyclyl; and RAA2 is selected from F, Cl, CN and C!.3alkyl; and when v is 2, the additional RAA is a fluoro substituted on an available C atom of ZA.In one embodiment v is 1; XG1 is a N atom; and RAA is a substituent on XG1.In one embodiment v is 1; XG1 is a N atom; and RAA is a C!.4alkyl (e.g. methyl) substituent on XG1.In one embodiment v is 1; XH1 is a C atom; and RAA is a substituent on XH1.
WO 2024/189488 PCT/IB2024/052251 In one embodiment v is 1; XH1 is a C atom; and RM is a substituent on XH1 that is CN or C!.4alkyl (e.g. methyl).In one embodiment v is 1 or 2; XH1 and XG1 are both C atoms, one or both of which are substituted by RAA where each RAA is independently selected from CN or C!.4alkyl (e.g. methyl).In one embodiment the group: together represents one or more of the groups Al to A9, shown below: A1 A8 10In some of these embodiments Wis W2-1 WO 2024/189488 PCT/IB2024/052251 wherein:XK and XLrespectively;0fXMandX°or 1 of XM and XNXNthe remainder of XN, XM and X0Xp are either N-linker and CH, N-linker and CMe, or NMe and C-linker is C-2,4-dioxohexahydropyrimidin-l-yl (YN);is C-F;may be N if XM is not C-F;are CH;is CH or CMe.
In one embodiment Wrepresents any of the groups 22 to 26, 29 and 31 shown below: where ZB is: XE3 is selected from C(=0) and CRE1RE2, where RE1 and RE2 areindependendently selected from the group consisting of H and WO 2024/189488 PCT/IB2024/052251 C1-3 alkyl, or RE1 and RE2 taken together with the carbons to be they are attached form a C3-6 cycloalkane ring; Y is N-(2,6-dioxopiperidin-3-yl);all of XA3, XB3, Xc3and XD3 are C;one pair of XA3and XB3, XB3and Xc3and Xc3and XD3form a five or six membered fully unsaturated or partially unsaturated N containg heterocylic ring, which is attached to the ‘b’ end of the Linkervia a N atom;the others of XA3, XB3, Xc3and XD3bear a group RB,where each RBis selected from H, F, Cl, C!.alkyl and C1-3 alkoxy.
In one embodiment XE3is C(=O).In one embodiment XE3 is CRE1RE2, where RE1 and RE2 are independendently selected from the group consisting of H and C1-3 alkyl, or RE1 and RE2 taken together with the carbons to be they are attached form a C3-6 cycloalkane ring.In one embodiment XE3 is CRE1RE2, where RE1 and RE2 are independendently selected from the group consisting of H and C1-3 alkyl, such as methyl.In one embodiment XA3and XB3form a five or six membered fully unsaturated or partially unsaturated N containg heterocylic ring, which is attached to the ‘b’ end of the Linkervia a N atom.In one embodiment XB3and Xc3form a five or six membered fully unsaturated or partially unsaturated N containg heterocylic ring, which is attached to the ‘b’ end of the Linkervia a N atom.In one embodiment Xc3and XD3form a five or six membered fully unsaturated or partially unsaturated N containg heterocylic ring, which is attached to the ‘b’ end of the Linkervia a N atom.In one embodiment, the five or six membered fully unsaturated or partially unsaturated N containg heterocylic ring is a five membered ring, where there is no additional unsatauration.In one embodiment, each RB is selected from H, F, Cl, methyl and methoxy.In one embodiment, each RBis H.In one embodiment, Wis the group 28: 0 In one embodiment Wis W4which is: -Zc where Zcis: WO 2024/189488 PCT/IB2024/052251 One of XB4and Xc4 One of XA4, XB4, Xc4 , XD4 and XE4 One or two of XA4, XB4, Xc4 , XD4 and XE4 is C-C(=O)-NH-Y;may be C-F; or may be N;the remainder of XA4, XB4, Xc4, XD4 andXE4are CH.
In one embodiment one of XA4, XB4, Xc4 , XD4 and XE4is C-F.In one embodiment XB4 is C-F.In one embodiment one of XB4 is C-F and Xc4 is C-C(=O)-NH-Y.In one embodiment two of XA4, XB4, Xc4 , XD4 and XE4are N.In one embodiment one of XA4, XB4, Xc4 , XD4 and XE4is N.In one embodiment none of XA4, XB4, Xc4 , XD4 and XE4are N.In one embodiment none of XA4, XB4, Xc4 , XD4 and XE4are N, and one of XA4, XB4, Xc4 , XD4 and XE4is C-F.In one embodiment XB4is C-F, Xc4is C-C(=O)-NH-Y and XA4, XD4 and XE4are CH.In one embodiment Wis the group 30: In a further aspect of the specification Formula (la)is selected from any one or more of the following groups (1) to (43):(1) 4-[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]phenyl;(2) 4-[ 1 -(3 -cyano-4-fluoro- lH-indol-7-yl)-4-piperidy!]phenyl;(3) 4-[l-(3-cyano-4-methyl-lH-indol-7-yl)-4-piperidyl]phenyl;(4) 4-[l-(4-chloro-3-cyano-lH-indazol-7-yl)-3-piperidyl]phenyl;(5) 4-[l-(4-chloro-3-cyano-lH-indol-7-yl)-3-piperidyl]phenyl;(6) 4-[ 1 -(3 -cyano-4-fluoro- lH-indol-7-yl)-3 -piperidy!]phenyl;(7) 4-[ 1 -(3 -cyano-4-methyl- lH-indol-7-yl)-4-piperidyl] -3 -fluoro-phenyl;(8) 4-[l-(3-cyano-lH-indol-7-yl)-4-piperidyl]phenyl;(9) 6-[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]-3-pyridyl;(!0) 5-[l-(4-chloro-3-cyano-!H-indol-7-yl)-4-piperidyl]pyrazin-2-yl; WO 2024/189488 PCT/IB2024/052251 (11) 4-[3-(3-cyano-4-methyl-lH-indol-7-yl)-l-piperidyl]phenyl;(12) 3 -[3-(3 -cy ano-4-methy 1- lH-indol-7-y 1)-1 -piperidy!]phenyl;(13) 4-[3-(4-chloro-3-cyano-lH-indol-7-yl)-l-piperidyl]phenyl;(14) 4-[4-(3 -cyano-4-methyl- lH-indol-7-y!)piperazin-1 -yl]phenyl;(15) 5-[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]-2-pyridyl;(16) 4-[l-(4-chloro-3-cyano-l-methyl-indol-7-yl)-4-piperidyl]phenyl;(17) 3-[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]phenyl;(18) 5-[l-(4-chloro-3-cyano-lH-indol-7-yl)-3-piperidyl]-2-pyridyl;(19) 4-[4-(4-chloro-3-cyano-lH-indol-7-yl)morpholin-2-yl]phenyl;(20) 4-[4-(4-chloro-3-cyano-lH-indazol-7-yl)morpholin-2-yl]phenyl;(21) 6-[l-(4-chloro-3-cyano-lH-indol-7-yl)-3-piperidyl]pyridazin-3-yl;(22) 4-[l-(3-cyano-4-fluoro-lH-indazol-7-yl)-3-piperidyl]phenyl;(23) 4-[l-(4-chloro-3-cyano-lH-indazol-7-yl)-4-piperidyl]phenyl;(24) 4-[l-(3-cyano-4-fluoro-lH-indazol-7-yl)-4-piperidyl]phenyl;(25) 4-[l-(3-cyano-4-methyl-lH-indazol-7-yl)-4-piperidyl]phenyl;(26) 4-[l-(3-cyano-4-methyl-lH-indol-7-yl)pyrrolidin-3-yl]phenyl;(27) 4-[[l-(4-chloro-3-cyano-lH-indazol-7-yl)-4-piperidyl]carbamoyl]-3-fluoro-phenyl;(28) 4-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]-3-fluoro-phenyl;(29) 4-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]-3-cyano-phenyl;(30) 4-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]-3-fluoro-5-methyl-phenyl;(31) 4-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]-2-methyl-phenyl;(32) 4-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]-2-cyano-phenyl;(33) 6-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]-3-pyridyl;(34) 6-[[l-(4-chloro-3-cyano-lH-indazol-7-yl)-4-piperidyl]carbamoyl]-3-pyridyl;(35) 6-[[l-(3-cyano-4-methyl-lH-indol-7-yl)-4-piperidyl]carbamoyl]-3-pyridyl;(36) 4-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]phenyl;(37) 4-[[4-(4-chloro-3-cyano-lH-indol-7-yl)cyclohexyl]carbamoyl]-3-fluoro-phenyl;(38) 4-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]-3,5-difluoro-phenyl;(39) 5-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]pyrazin-2-yl;(40) 2-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]pyrimidin-5-yl;(41) 4-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]-3-methyl-phenyl;(42) 6-[[l-(4-chloro-3-cyano-lH-indol-7-yl)-4-piperidyl]carbamoyl]pyridazin-3-yl;(43) 6-[[(3R)-l-(4-chloro-3-cyano-lH-indol-7-yl)-3-piperidyl]carbamoyl]-3-pyridyl.
In a further aspect of the specification there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la)or Formula (lb): WO 2024/189488 PCT/IB2024/052251 where: QA is -G-QH- or -G-(C1.5alkylene)-;G is a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)- where each RG is independently H or C1-3alkyl;QH is a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;and where R1, p, X1, RN, n, m, R2a, R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3 and q may take any of the values defined herein for each of these groups/variables respectively.In one embodiment QH is a 4-12-membered nitrogen-containing saturated heterocyclic group. >cFor avoidance of doubt in Formula (lb)indicates a point of connection via a single covalentbond to the remainder of the PROTAC compound.In a further aspect of the specification there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit linked to an AR binding unit of Formula (la)of Formula (Ib),as defined herein.In further embodiments of this specification Formula (1b)may be: where Lxmay be any of the groups (1) to (43) listed hereinabove in connection with Formula (la);and where QAmay take any value(s) disclosed herein for QA. In a further aspect of the specification there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la)of Formula (Ic): (ic) WO 2024/189488 PCT/IB2024/052251 where:QA is -G-QH- or -G-(C1.5alkylene)-;G is a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)- where RG is H or C!.3alkyl;QB is a direct bond, -QB1-QB2-QB3- or Ci.galkylene optionally substituted by one or more F (e.g. 1 or 2); where:QB1 & QB3 each independently represent a direct bond or C!.2alkylene; q62 ؛s qh -0-CHCH-o- -0- or -N(RJ)- where RJ is H or C!.3alkyl;and each QH is indepdendently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;where the values of QA and QB are selected so that Formula (Ic)does not contain any N-N or N-O bonds; and where R1, p, X1, RN, n, m, R2a , R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qmay otherwise take any of the values defined herein for each of these groups/variables respectively.In one embodiment QH is a 4-12-membered nitrogen-containing saturated heterocyclic group. For avoidance >cof doubt in Formula (Ic)indicates a point of connection via a single covalent bond to theremainder of the PROTAC compound.In a further aspect of the specification there is provided a PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit linked to an AR binding unit of Formula (la)or Formula (Ic),as defined herein.In further embodiments of this specification Formula (1b)may be: where Lxmay be any of the groups (1) to (43) listed hereinabove in connection with Formula (la);and where QAand QBmay take any value(s) disclosed herein for QAand QB. In further embodiments there is/are provided compound(s) or pharmaceutically acceptable salt thereof wherein said compound(s) is/are selected from one or more of the "Examples "listed hereinafter. Thus, these embodiments include one or more specific Examples(for instance one Example,or two or three specific Examples)selected from the group consisting of Examples1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, !46, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 153, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180 and 181.It is to be understood that the compound of an Examplelisted hereinafter relates to the title compound name, and is not limited in any way by the method of preparation nor whether a given compound was isolated in the form of a salt rather than as a neutral molecule.
WO 2024/189488 PCT/IB2024/052251 In some embodiments there is provided a compound of Formula (VI): (VI) or a pharmaceutically acceptable salt thereof,wherein: X11 is CH or N; R11 is F, Cl or Me; Q11and Q12 are either N and CH or CH and N respectively; nand m are either 1 and 1 or 2 and 0 respectively; Q14 is a single bond or -NHC(=O); Y11and Y12 are selected from CH and CH, CF and CH, N and CH, and N and Nrespectively; Linker is selected from linkers 3, 47, 49, 54 and 58: WO 2024/189488 PCT/IB2024/052251 In some embodiments there is provided a compound of Formula (VI-1): (VI-1) or a pharmaceutically acceptable salt thereof,wherein: X21 R21 nand m Linker is CH or N;F and Cl;are either 1 and 1 or 2 and 0 respectively;is selected from linkers 3 and 47: WO 2024/189488 PCT/IB2024/052251 In some embodiments there is provided a compound of Formula (VI-2): (VI-2) or a pharmaceutically acceptable salt thereof, wherein: X31 R31 nand m Q31and Q32 Q34 Y31and Y32 Linker is CH or N;F, Cl and methyl;are either 1 and 1 or 2 and 0 respectively;are either N and CH or CH and N respectively;is a single bond or -NHC(=O);are selected from CH and CH, CF and CH, N and CH, and N and N respectively;is selected from linkers 3, 47, 49, 54 and 58: WO 2024/189488 PCT/IB2024/052251 , where Y is 2,6-dioxopiperidin-3-yl and YN is 2,4-dioxohexahydropyrimidin-1-yl.
WO 2024/189488 PCT/IB2024/052251 In some embodiments there is provided a compound of Formula (VII): Linker —W b (VII) or a pharmaceutically acceptable salt thereof, wherein: Linker is a saturated or a partially or fully unsaturated framework comprising Cand H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and ‘b’ and a minimum length of from 5 to atoms between ‘a’ and ‘b’; wherein said framework may include one or more straight and/or branched chains and/or rings and is optionallysubstituted on any available C atom(s) by one or more F; and W is an E3 ubiquitin ligase cereblon binder unit.
In some embodiments there is provided a compound of Formula (VII-I): Linker —W (VIII) b or a pharmaceutically acceptable salt thereof,wherein: Linker is selected from linkers 3, 47, 49, 54 and 58: WO 2024/189488 PCT/IB2024/052251 , where Y is 2,6-dioxopiperidin-3-yl and YN is 2,4-dioxohexahydropyrimidin-1-yl.
WO 2024/189488 PCT/IB2024/052251 In some embodiments there is provided a compound of Formula (VII-II): (VII-II) or a pharmaceutically acceptable salt thereof, wherein: Linker is selected from linkers 3 and 47: In some embodiments there is provided a compound of Formula (VII-III): WO 2024/189488 PCT/IB2024/052251 Linker —W b (VIMII) or a pharmaceutically acceptable salt thereof, wherein: Linker is selected from linkers 3, 47, 49, 54 and 58: WO 2024/189488 PCT/IB2024/052251 In some embodiments there is provided a compound of Formula (VIII): NC (VIII) or a pharmaceutically acceptable salt thereof, wherein: W is an E3 ubiquitin ligase cereblon binder unit.
In some embodiments there is provided a compound of Formula (VIII-I): WO 2024/189488 PCT/IB2024/052251 NC (VIII-I) or a pharmaceutically acceptable salt thereof, wherein: WO 2024/189488 PCT/IB2024/052251 , where Y is 2,6-dioxopiperidin-3-yl and YN is 2,4-dioxohexahydropyrimidin-1-yl.
In some embodiments there is provided a compound of Formula (VIII-II): NC (VIII-II) or a pharmaceutically acceptable salt thereof, wherein: Specific compounds of this specification include:4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/f-isoindol-5-yl]piperazin--yl}methy !)piperidin-1 -y !]phenyl }piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/f-isoindol-5-yl]piperazin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro-1 //-indolc-3-carbonitrilc: WO 2024/189488 PCT/IB2024/052251 7-[(3S)-3-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/f-indol-l-yl]piperidin-l-yl}methyl)piperidin- -yl]phenyl}piperidin-1 -yl] -4-fluoro-1 //-indolc-3 -carbonitrile;7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -4-fluoro-1 //-indo lc-3-carbo nitrile: 4-Chloro-7-[(37?)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indazolc-3 -carbonitrile;4-Chloro-7-[(37?)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indolc-3 -carbonitrile;7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-177-isoindol-5- yl|pipcrazin-l-y !]butoxy )pheny l|pipcridin-l-yl]-4-mcthyl-l//-indolc-3-carbonitrilc:7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lH-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-lH-indole-3-carbonitrile;7-{4-[4-(4-{4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l- yl]butoxy)phcnyl|pipcridin-l-yl]-4-1ncthyl-l//-indolc-3-carbonitrilc:7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177-pynolo[3,4-c]pyridin- 6-yl Ipipcrazin-l-yl]mcthyl)pipcridin-l-yl|phcnyl]pipcridin-l-yl)-4-mcthyl-l//-indolc-3-carbonitrilc:7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177-pynolo[3,4-c]pyridin- 6-y l Ipipcrazin-1-yl] butoxy )pheny l|pipcridin-l-yl]-4-mcthy 1-1//-indolc-3-carbonitrilc:4-Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-17/-pyrrolo[3,4- c]pyridin-6-y !]piperazin-1 -yl}butoxy )pheny !]piperidin-1 -yl}-1 //-i ndolc-3 -carbonitrile;7-{4-[4-(4-{4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l- yl}butoxy)phenyl]piperidin-l-yl}-4-fluoro-177-indole-3-carbonitrile;4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177-pynolo[3,4- c]pyridin-6-y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-[4-(4-{4-[(4-{2-[(37?*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-177- py nolo [3,4-c]py ridin-6-y 1 }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 - carbonitrile;4-Chloro-7-[4-(4-{4-[(4-{2-[(3S'*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-177- py nolo [3,4-c]py ridin-6-y 1 }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 - carbonitrile;7-(4-2.6)-2|-4 -)؛ 4 -| 4 ؛ -Dioxopipcridin-3-yl)-4-mcthoxy-3-oxo-2.3-dihydro-l//-pyrrolo|3.4-c|py ridin- 6-yl Ipipcrazin-l-yl]mcthyl)pipcridin-l-yl|phcnyl]pipcridin-l-yl)-4-nuoro-l//-indolc-3-carbonitrilc:4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pynolo [3,4-c]pyridin-6-y !]piperazin-1 -yl}methyl)piperidin-l -yl]phenyl}piperidin-1 -yl] -1 //-i ndolc-3- carbonitrile;4-Chloro-7-[(3S)-3-(4-{4-[(4-{2-[(37?*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-177- pynolo [3,4-c]py ridin-6-y 1 }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 - carbonitrile; WO 2024/189488 PCT/IB2024/052251 - 177-4 - Chloro-7-[(3S)-3-(4-{4-[(4-{2-[(3S'*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro- 3 - pynolo [3,4-c]pyridin-6-y 1 }piperazin-1 -y!)methyl]piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc carbonitrile ;- 5-7 (- 4 {- 4 [- 4 {(- 4 [- 2 (- 2,6 - Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-177-isoindoly !]piperazin-1 -yl}methy !)piperidin-1 -yl] -2-fluorophenyl}piperidin-1 -y l)-4-mcthy 1-1 //-i ndolc-3 -carbonitrile ; (- 4 {- 4 [- 4 {(- 4 [- 4 (- 2,4 - Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methyl)piperidin-l -yl] -2-fluorophenyl}piperidin-1 -yl)-4-methyl-1 //-i ndolc-3 -carbonitrile ;- 5-7 (- 4 {- 4 [- 4 {(- 4 [- 2 (- 2,6 - Dioxopiperidin-3-yl)-7-methoxy-l,3-dioxo-2,3-dihydro-177-isoindoly !]piperazin-1 -yl}methy !)piperidin-1 -yl] -2-fluorophenyl}piperidin-1 -y l)-4-mcthy 1-1 //-i ndolc-3 -carbonitrile ;{- 4 [- 4 (- 4 {- 4 [- 2 (- 2,6 - Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l -yl}butoxy)phenyl]piperidin-l-yl}-4-fluoro-177-indole-3-carbonitrile ;- Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin -- yl}butoxy)phenyl]piperidin-1 -yl}-1 //-indo lc-3 -carbonitrile ;|- 4 (- 2.4 - dioxo-1.3-diazinan-l-yl)-l//-indol-l-yl|pipcridin-l -؛- 4 -) 4 -| 4 -؛ 7 - 4 - Chloroy 1 }butoxy )pheny !]piperidin-1 -y 1} -1 //-i ndo lc-3 -carbonitrile ;- 177-4 - Chloro-7-[(37?)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro- 3 - pyrrolo [3,4-c]pyridin-6-y !]piperazin-1 -yl}methyl)piperidin-l -y !]pheny !}piperidin-1 -yl] -1 //-i ndolc carbonitrile ;- 5-7 - * 4 |- 4 (- 4 *- 4 |- 2 (- 2.6 - Dioxopipcridin-3-yl)-7-mcthoxy-1.3-dioxo-2.3-dihydro-l//-isoindolyl|pipc razin-l-yl] butoxy )pheny l|pipcridin-l-yl]-4-mcthyl-l//-indolc-3-carbonitrilc :- Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l,3-dioxo-2,3-dihydro-177-isoindol -- yl]piperazin-l -yl}methyl)piperidin-l -yl]phenyl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile ;- 5-7 - * 4 |- 4 (- 4 *- 4 |- 2 (- 2.6 - Dioxopipcridin-3-yl)-6-nuoro-1.3-dioxo-2.3-dihydro-l//-isoindolyl|pipc razin-l-yl] butoxy )pheny l|pipcridin-l-yl]-4-mcthyl-l//-indolc-3-carbonitrilc :- 5-4 - Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-177-isoindoly !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 //-i ndolc-3 -carbonitrile ;- 5-7 (- 4 ]- 4 |- 4 ](- 4 |- 2 (- 2.6 - Dioxopipcridin-3-yl)-6-nuoro-1.3-dioxo-2.3-dihydro-l//-isoindoly !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-4-fluoro-1 //-indo lc-3 -carbonitrile ;- 177-4 - Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydroisoindol-5 -y !]piperazin-1 -y 1 }methy !)piperidin-1 -y !]pheny 1 }piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile ;- 177-4 - Chloro-7-[(37?)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydroisoindol-5 -y !]piperazin-1 -y 1 }methy !)piperidin-1 -y !]pheny 1 }piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile ;- 5-4 - Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l,3-dioxo-2,3-dihydro-177-isoindoly !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 //-i ndolc-3 -carbonitrile ;;- 4 |- 4 (- 4 ]- 4 |- 2 (- 2.6 - Dioxopipcridin-3-yl)-1.3-dioxo-2.3-dihydro-l//-isoindol-5-yl|pipcrazin-l -yl]butoxy)phcnyl|pipcridin-l-yl]-4-mcthyl-l//-indolc-3-carbonitrilc :{- 4 [- 4 (- 4 {- 4 [- 2 (- 2,6 - Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l -y 1 }butoxy )pheny !]piperidin-1 -y 1} -1 //-i ndo lc-3 -carbonitrile ;{- 4 [- 4 (- 4 {- 4 [- 4 (- 2,4 - Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l -; y 1 }butoxy )pheny !]piperidin-1 -y 1} -1 //-i ndo lc-3 -carbonitrile WO 2024/189488 PCT/IB2024/052251 7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/f-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- yl]phenyl}piperidin-l-yl)-l/7-indole-3-carbonitrile;4-Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-177-isoindol-5- y !]piperazin-1 -yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177-pynolo[3,4- c]pyridin-6-y !]piperazin-1 -yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -y 1)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]pyridazin-3 -yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin- -y 1 }methy !)piperidin-1 -y l]py ridazin-3 -y 1 }piperidin-1 -y1)-1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-[(37?*)-3-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(3S'*)-3-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]pyrazin-2-yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin--yl}methy !)piperidin-1 -yl]pyrazin-2-yl}piperidin-1 -y 1)-1 //-i ndolc-3-carbonitri 1c:7-[4-(4-{4-[(4-{[l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazol-4- y 1] methyl }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -yl] -4-methy 1-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[4-(4-{4-[(4-{[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177- benzimidazol-4-y 1] methyl }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 - carbonitrile;7-[4-(4-{4-[(4-{[l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazol-4- y 1] methyl }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -yl] -4-fluoro -1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-(4-{4-[4-({4-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazol- 4-yl]piperazin-l -yl}methyl)piperidin-l -yl]phenyl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-(4-{4-[(4-{ [l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177- benzimidazol-4-y 1] methyl }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 - carbonitrile;7-[(3S)-3-(4-{4-[(4-{ [l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazol-4- y 1] methyl }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -yl] -4-fluoro -1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-{4-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f] isoindol-2( l//)-yl] methy 1 }piperidin-1-y !)pheny !]piperidin-1-yl}-l/7-indole-3-carbonitrile;4-Chloro-7-{(3S)-3-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f] isoindol-2( l//)-yl] methy 1 }piperidin-1-y !)pheny !]piperidin-1-yl}-l/7-indazole-3-carbonitrile;4-Chloro-7-{(3S)-3-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4- f] isoindol-2( l//)-yl| methy 1 }piperidin-1 -y !)pheny !]piperidin-1 -yl}-1//-indolc-3 -carbonitrile; WO 2024/189488 PCT/IB2024/052251 7-{(37?*)-l-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-17/-indole-3-carbonitrile;7-{(3S'*)-l-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-17/-indole-3-carbonitrile;7-{(37?*)-l-[3-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-17/-indole-3-carbonitrile;7-{(3S'*)-l-[3-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-17/-indole-3-carbonitrile;7-[(37?*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-3 -yl] -4-methyl- 17/-indole-3-carbonitrile;7-[(3S'*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-3 -yl] -4-methyl- 17/-indole-3-carbonitrile;4-Chloro-7-(4-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-17/-indol-2-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin- -yl}methy !)piperidine-1 -carbony !]phenyl }piperidin-1 -yl)-1H-indole-3-carbonitrile;4-Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-17/-pyrrolo[3,4- c]pyridin-6-y !]piperazin-1 -yl}piperidin-l -yl)pheny !]piperidin-1 -yl}-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{4-[4-(2-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pyrrolo [3,4-c]pyridin-6-y !]piperazin-1 -yl}ethyl)piperidin-l -yl]phenyl}piperidin-1 -y 1)-1 //-indolc-3 - carbonitrile;4-Chloro-7-(4-{4-[4-(3-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pyrrolo [3,4-c]pyridin-6-y !]piperazin-1 -yl}propy !)piperidin- 1-y !]phenyl }piperidin-1 -yl)-1 //-i ndolc-3 - carbonitrile;7-(4-{4-[4-({4-[5-(2,4-Dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- yl|phcny !]pipe ridin-l-yl)-4-fh1oro-l//-indolc-3-carbonitrilc:4-Chloro-7-(4-{4-[4-({4-[5-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-[(37?*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pyrrolo [3,4-c]pyridin-6-y !]piperazin-1 -yl}methyl)piperidin-l -y !]phenyl }piperidin-3 -yl] -1 //-i ndolc-3- carbonitrile;4-Chloro-7-[(3S'*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pyrrolo [3,4-c]pyridin-6-y !]piperazin-1 -yl}methyl)piperidin-l -y !]phenyl }piperidin-3 -yl] -1 //-i ndolc-3- carbonitrile;4-Chloro-7-[(37?*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5- y !]piperazin-1 -yl}methy !)piperidin-1 -y !]phenyl }piperidin-3 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(3S'*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -y !]phenyl }piperidin-3 -yl] -1 //-i ndolc-3 -carbonitrile;7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l-y 1 }butoxy )pheny !]piperazin-1 -y 1} -4-methyl-1 //-i ndo lc-3 -carbonitrile; WO 2024/189488 PCT/IB2024/052251 4-Chloro-7-[(37?*)-l-{4-[l-({l-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5- yl]piperidin-4-yl}methyl)piperidin-4-yl]phenyl}piperidin-3-yl]-l/7-indole-3-carbonitrile;4-Chloro-7-[(3S'*)-l-{4-[l-({l-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5- yl]piperidin-4-yl}methyl)piperidin-4-yl]phenyl}piperidin-3-yl]-lH-indole-3-carbonitrile;4-Chloro-7-[(37?*)-l-{4-[l-({l-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pyrrolo [3,4-c]pyridin-6-yl]piperidin-4-yl}methyl)piperidin-4-yl]phenyl}piperidin-3-yl] -1 //-indolc-3 - carbonitrile;4-Chloro-7-[(3S'*)-l-{4-[l-({l-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pyrrolo [3,4-c]pyridin-6-yl]piperidin-4-yl}methyl)piperidin-4-yl]phenyl}piperidin-3-yl] -1 //-indolc-3 - carbonitrile;4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-177-isoindol-5- y !]piperazin-1 -yl}methy !)piperidine-1 -carbony !]phenyl }piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;7-[4-(4-{[l-({l-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperidin-4- yl}methyl)piperidin-4-yl]oxy }pheny !)piperidin-1 -yl] -4-fluoro-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{4-[4-({4-[5-(2,4-dioxo-l,3-diazinan-l-yl)-7-methyl-l/7-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-(4-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l/7-pynolo[3,2-b]pyridin-2- y !]piperidin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1H-indole-3-carbonitrile;4-{4-[(l-{4-[(3S)-l-(4-chloro-3-cyano-177-indol-7-yl)piperidin-3-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}-#-(2,6-dioxopiperidin-3-yl)-2-fluorobenzamide;4-{4-[(l-{4-[l-(3-Cyano-4-fluoro-177-indol-7-yl)piperidin-4-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}-#-(2,6-dioxopiperidin-3-yl)-2-fluorobenzamide;4-{4-[(l-{4-[l-(4-Chloro-3-cyano-177-indol-7-yl)piperidin-4-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}-#-(2,6-dioxopiperidin-3-yl)-2-fluorobenzamide;7-[4-(4-{[4-({l-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperidin-4-yl]mcthyl)pipcrazin-l-yl | methyl] phcnyl)pipcridin-l-yl|-4-nuoro-l//-indolc-3-carbonitrilc:4-Chloro-7-(4-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]pyridin-3 -yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin- -y 1 }methy !)piperidin-1 -y l]py ridin-3 -y 1 }piperidin-1 -y1)-1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin--y 1 }piperidin-1 -y !)phenyl] piperidin-1 -y 1} -1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-[4-(4-{4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl][l,d'-bipiperidin]-!'-y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile;4-chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-lH-isoindol-5- y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 -methyl- lH-indole-3 -carbonitrile;4-Chloro-7-(4-{3-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin- -yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-2-methyl-l/7-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indolc-3 -carbonitrile; WO 2024/189488 PCT/IB2024/052251 4-Chloro-7-[(3S'*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]pyridin-3 -yl}piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(37?*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]pyridin-3 -yl}piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(2S'*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]phenyl}morpholin-4-yl] -1 //-indolc-3 -carbonitrile;4-Chloro-7-[(27?*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3־diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]phenyl}morpholin-4-yl] -1 //-indolc-3 -carbonitrile;4-Chloro-7-[(2S'*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]phenyl}morpholin-4-yl] -1 //-indazolc-3 -carbonitrile;4-Chloro-7-[(27?*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3־diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]phenyl}morpholin-4-yl] -1 //-indazolc-3 -carbonitrile;4-Chloro-7-[(37?*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]pyridazin-3 -yl}piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(3S'*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]pyridazin-3 -yl}piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-2-methyl-l/7-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-(4-{2-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin- -y 1 }methy !)piperidin-1 -y l]py rimidin-5 -y 1 }piperidin-1 -y!)-1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-(4-{2-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]pyrimidin-5-yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;7-(4-{4-[(27?)-2-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}methyl)morpholin-4-yl]phenyl}piperidin-1 -yl)-4-fluoro-1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-(4-{4-[(27?)-2-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl |pipc razin-l-yl] methy l)morpholin-4-yl|phcnyl] pipe ridin-l-yl)-l//-indolc-3-carbonitrilc:7-(4-{4-[7-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}methyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl)-4-fluoro-177-indole-3-carbonitrile;4-Chloro-7-(4-{4-[7-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin--yl}methyl)-2-azaspiro [3.5]nonan-2-yl]phenyl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[7-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-y !]piperazin-1 -yl}methyl)-2-azaspiro [3.5]nonan-2-yl]phenyl}piperidin-1 -yl]-1H-indole-3-carbonitrile;4-Chloro-7-[(3S)-3-{4-[7-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methyl)- 2-azaspiro [3.5]nonan-2-y !]phenyl }piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(37?)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l/7-indol-2-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indazolc-3 -carbonitrile;7-[(3S)-3-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -4-fluoro-1 //-indazolc-3-carbo nitrile:7-[(3S)-3-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methyl)piperidin--yl]phenyl}piperidin-1 -yl] -4-fluoro-1 //-indazolc-3-carbonitri 1c: u On o to 00 00 o £ WO 2024/189488 PCT/IB2024/052251 #-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl]-4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo- 3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(l//)-yl]methyl}piperidin-l-yl)-2-fluorobenzamide;#-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl]-4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5- fluoro-1 -methyl-1 //-indol-2-y !]piperidin-1 -yl}methy !)piperidin-1 -yl] -2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-177-indol-7-yl)piperidin-4-yl]-4-[4-({4-[ l-(2,6-dioxopiperidin-3-yl)-3 - methyl-2-oxo-2,3-dihydro-l//-benzimidazol-4-yl]piperazin-l-yl}methyl)piperidin-l-yl]-2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-177-indol-7-yl)piperidin-4-yl]-4-[4-({4-[6-(2,4-dioxo-l ,3-diazinan-1-yl)-1 - methyl-1 //-i ndol-2-y 11 pipcridin-1 -yl}methy !)piperidin-1 -yl] -2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-177-indol-7-yl)piperidin-4-yl]-4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo- 2,3 -dihydro- l//-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -yl] -2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-177-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l ,3-diazinan-1-yl)-1/7- indol-1 -y !]piperidin-1 -y 1 }methy !)piperidin-1 -y 1] -2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6- fluoro-l,3-dioxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]-2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-2-cyano-4-[4-({4-[4-(2,4-dioxo-1,3-diazinan- -yl)-l//-indol-1 -y !]piperidin-1 -yl}methyl)piperidin-1 -y !]benzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l ,3-diazinan-1-yl)-1//- indol-1 -y !]piperidin-1 -yl}methy !)piperidin- 1-yl] -2-fluoro-6-methy !benzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l ,3-diazinan-1-yl)-1//- indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y 1] -3 -methylbenzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-3-cyano-4-[4-({4-[4-(2,4-dioxo-1,3-diazinan--yl)-l//-indol-1 -y !]piperidin-1 -yl}methyl)piperidin-1 -y !]benzamide;#-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl]-5-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro- l,3-dioxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l-yl}piperidin-l-yl)pyridine-2-carboxamide;#-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//- indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo- 2,3 -dihydro- 17/-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -yl]pyridine-2-carboxamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6- fluoro-l,3-dioxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide;#-[l-(4-Chloro-3-cyano-l//-indazol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)- !//-indol-1 -y !]piperidin-1 -yl}methy !)piperidin- l-yl]pyridine-2-carboxamide;#-[l-(3-Cyano-4-methyl-l//-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6- fluoro-l,3-dioxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide;#-[l-(3-Cyano-4-methyl-l//-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo- 2,3 -dihydro- l//-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -yl]pyridine-2-carboxamide;#-[ 1-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l ,3-diazinan-1-yl)-1//- indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y !]benzamide;#-[4-(4-Chloro-3-cyano-l//-indol-7-yl)cyclohexyl]-4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//-indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y 1] -2-fluorobenzamide; WO 2024/189488 PCT/IB2024/052251 #-[ 1-(4-Chloro-3-cyano-17f-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l ,3-diazinan-1-yl)-1/f- indol-1 -y !]piperidin-1 -yl}methy !)piperidin- 1-yl] -2,6-difluorobenzamide;#-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//- indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl]pyrazine-2-carboxamide;#-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//- indol-1 -y !]piperidin-1 -y 1 }methy !)piperidin-1 -y l]py rimidine-2-carboxamide;#-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//- indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y 1] -2-methy !benzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-6-[4-({4-[4-(2,4-dioxo-l ,3-diazinan-1-yl)-1//- indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y l]py ridazine-3 -carboxamide;#-[(3/?*)-l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-3-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l- oxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide; and#-[(3>S'*)-l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-3-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l- oxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide;or pharmaceutically acceptable salts thereof.
Specific compounds of this specification include:4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l//-isoindol-5-yl]piperazin- -yl}methy !)piperidin-1 -y !]phenyl }piperidin-1 -yl)- l//-indole-3 -carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro- l//-indole-3-carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro- l//-indole-3-carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro- l//-indole-3-carbonitrile;4-Chloro-7-(4-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)- l//-indole-3 -carbonitrile;7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l//-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- yl]phenyl}piperidin-l-yl)-4-fluoro-l//-indole-3-carbonitrile;4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-l//-isoindol-5- y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)- l//-indole-3 -carbonitrile;7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l//-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- yl]phenyl}piperidin-l-yl)-4-methyl-l//-indole-3-carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] - l//-indazole-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l//-isoindol-5- y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl] - l//-indazole-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] - l//-indole-3 -carbonitrile; WO 2024/189488 PCT/IB2024/052251 4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l/7-indol-2-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l/7-indol-2-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indazolc-3 -carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-177-isoindol-5- y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-4-methyl-1 //-indolc-3 -carbonitrile;4-Chloro-7-[4-(4-{4-[(4-{2-[(37?* )-2.6-dioxopipcridin-3-yl|-7-mcthoxy-l-oxo-2.3-dihydro-l//- isoindol-5 -y 1 }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-[4-(4-{4-[(4-{2-[(3S** )-2.6-dioxopipcridin-3-yl|-7-mcthoxy-l-oxo-2.3-dihydro-l//- isoindol-5 -y 1 }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-[4-(4-{4-[(4-{2-[(37? *)-2.6-dioxopipcridin-3-yl|-l-oxo-2.3-dihydro-l//-isoindol-5- y 1 }piperazin-1 -yl)methy !]piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-[4-(4-{4-[(4-{2-[(3S* *)-2.6-dioxopipcridin-3-yl|-l-oxo-2.3-dihydro-1//-isoindol-5-y 1 }piperazin-1 -yl)methy !]piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-177-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-4-fluoro-1 //-indolc-3 -carbonitrile;4-Chloro-7-[(37?)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl] -1 //-i ndolc-3 -carbonitrile;7-(4-{4-[4-({l-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperidin-4- yl}methyl)piperazin-l-yl]phenyl}piperidin-l-yl)-4-fluoro-177-indole-3-carbonitrile;7-[(3S)-3-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methyl)piperidin- -yl]phenyl}piperidin-1 -yl] -4-fluoro-1 //-indolc-3 -carbonitrile;7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -4-fluoro-1 //-indo lc-3-carbo nitrile:4-Chloro-7-[(37?)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]pipe ridin-1-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indazolc-3 -carbonitrile;4-Chloro-7-[(37?)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indolc-3 -carbonitrile;7-*4-|4-(4-*4-|2-(2.6-Dioxopipcridin-3-yl)-7-mcthoxy-l-oxo-2.3-dihydro-l//-isoindol-5-yl|pipcrazin-l-y !]butoxy )pheny l|pipcridin-l-yl]-4-mcthyl-l//-indolc-3-carbonitrilc:7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lH-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-lH-indole-3-carbonitrile;7-{4-[4-(4-{4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-l/7-indole-3-carbonitrile;or pharmaceutically acceptable salts thereof.
Further specific compounds of this specification include: WO 2024/189488 PCT/IB2024/052251 4-Chloro-7-(4-{4-[7-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//-indol-l-yl]piperidin-l-yl}methyl)-2- azaspiro [3.5]nonan-2-yl]phenyl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-17/-pynolo[3,4- c]pyridin-6-yl]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 //-indazolc-3 -carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-17/-pynolo[3,4-c]pyridin- 6-yl|pipcrazin-l-yl] methy l)pipcridin-l-yl|phcnyl]pipcridin-l-yl)-4-fluoro-l//-indazolc-3-carbonitrilc: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-17/-isoindol-5-yl]piperazin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro-1 //-indazolc-3-carbo nitrile: 4-Chloro-7-(4-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indazolc-3 -carbonitrile;7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l//-indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl|phcny !]pipe ridin-l-yl)-4-nuoro-l//-indazolc-3-carbonitrilc:7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-17/-isoindol-5-yl |pipc razin-1-yl; butoxy )phcnyl|pipcridin-l-yl;-4-mcthyl-l//-indazolc-3-carbonitrilc:7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-17/-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-4-methyl-1 //-indazolc-3 -carbonitrile;7-{(3S'*)-3-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-17/-isoindol-5-yl]piperazin-l- yl]butoxy)phcnyl|pyrrohdin-l-yl]-4-mcthyl-l//-indolc-3-carbonitrilc:7-{(37?*)-3-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-17/-isoindol-5-yl]piperazin-l- yl]butoxy)phcnyl|pyrrohdin-l-yl]-4-mcthyl-l//-indolc-3-carbonitrilc:'-| l-(4-Chloro-3-cyano-l//-indazol-7-yl)pipcridin-4-yl|-4-|4-(2.4)-4|-4؛-dioxo-1.3-diazinan-l-yl)- !//-indol-1 -y !]piperidin-1 -yl}methy !)piperidin- 1-yl] -2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-177-indol-7-yl)piperidin-4-yl]-4-[4-({4-[5-(2,4־dioxo-l ,3-diazinan-1-yl)-1/7- indol-1 -y !]piperidin-1 -y 1 }methy !)piperidin-1 -y 1] -2-fluorobenzamide;#-[l-(4-chloro-3-cyano-l~{H}-indol-7-yl)-4-piperidyl]-4-[4-[[4-[4-[(2,6-dioxo-3- piperidy !)carbamoyl] -3-fluoro-pheny !]piperazin-1 -yl] methyl] -1 -piperidyl] -2-fluoro-benzamide;#-[l-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo- 3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(l//)-yl]methyl}piperidin-l-yl)-2-fluorobenzamide;#-[l-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5- fluoro-1 -methyl- l//-indol-2-y !]piperidin-1 -yl}methy !)piperidin-1 -yl] -2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[ l-(2,6-dioxopiperidin-3-yl)-3 - methyl-2-oxo-2,3-dihydro-17/-benzimidazol-4-yl]piperazin-l-yl}methyl)piperidin-l-yl]-2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[6-(2,4-dioxo-l ,3-diazinan-1-yl)-1 - methyl- l//-indol-2-y !]piperidin-1 -yl}methy !)piperidin-1 -yl] -2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-1-oxo- 2,3 -dihydro- 17/-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -yl] -2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l ,3-diazinan-1-yl)-1//- indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y 1] -2-fluorobenzamide;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6- fluoro-l,3-dioxo-2,3-dihydro-17/-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]-2-fluorobenzamide; and WO 2024/189488 PCT/IB2024/052251 1 (- 4 - Chloro-3-cyano-17f-indol-7-yl)piperidin-4-yl]-2-cyano-4-[4-({4-[4-(2,4-dioxo-1,3-diazinan - #-]- y I)-1 //-i ndol-1 -y !]piperidin-1 -yl}methyl)piperidin-1 -y !]benzamide ; or pharmaceutically acceptable salts thereof .
Further specific compounds of this specification include :- Chloro-7-[(37?)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-l/f -- 3 - pyrrolo [3,4-c]pyridin-6-y!]piperazin-1 -yl}methyl)piperidin-l -y!]phenyl}piperidin-1 -yl] -1 //-i ndolc carbonitrile ;- 5-7 - * 4 |- 4 (- 4 *- 4 |- 2 (- 2.6 - Dioxopipcridin-3-yl)-7-mcthoxy-1.3-dioxo-2.3-dihydro-l//-isoindolyl|pipcrazin-l-y !]butoxy )pheny l|pipcridin-l-yl]-4-mcthyl-l//-indolc-3-carbonitrilc :- Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l,3-dioxo-2,3-dihydro-l/7-isoindol -- yl]piperazin-l -yl}methyl)piperidin-l -yl]phenyl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile ;- 5-7 - [ 4 |- 4 (- 4 [- 4 |- 2 (- 2.6 - Dioxopipcridin-3-yl)-6-nuoro-1.3-dioxo-2.3-dihydro-l//-isoindolyl !pipe razin-l-yl] butoxy )phcnyl|pipcridin-l-yl]-4-mcthyl-l//-indolc-3-carbonitrilc :- 5-4 - Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-l/7-isoindoly !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 //-i ndolc-3 -carbonitrile ;- 5-7 (- 4 ]- 4 |- 4 ](- 4 |- 2 (- 2.6 - Dioxopipcridin-3-yl)-6-nuoro-1.3-dioxo-2.3-dihydro-l//-isoindoly !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-4-fluoro-1 //-indolc-3 -carbonitrile ;- 7/4 - Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-lisoindol-5 -y !]piperazin-1 -y 1 }methy !)piperidin-1 -y !]phenyl }piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile ;- 7 / dioxo-2,3-dihydro-l ־ 3,4 - Chloro-7-[(37?)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l isoindol-5 -y !]piperazin-1 -y 1 }methy !)piperidin-1 -y !]phenyl }piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile ; - 5-4 |- 2 (- 2.6 - dioxopipcridin-3-yl)-1.3-dioxo-2.3-dihydro-l//-isoindol -)؛ 4 -| 4 -؛ 4 -) 7 - 4 - Chloroy !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 //-i ndolc-3 -carbonitrile ;{- 4 [- 4 (- 4 {- 4 [- 2 (- 2,6 - Dioxopiperidin-3-yl)-l,3-dioxo-2,3-dihydro-l/7-isoindol-5-yl]piperazin-l -yl]butoxy)phcnyl|pipcridin-l-yl]-4-mcthyl-l//-indolc-3-carbonitrilc :{- 4 [- 4 (- 4 {- 4 [- 2 (- 2,6 - Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/7-isoindol-5-yl]piperazin-l -y 1 }butoxy )pheny !]piperidin-1 -y 1} -1 //-i ndo lc-3 -carbonitrile ;{- 4 [- 4 (- 4 {- 4 [- 4 (- 2,4 - Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l -; y 1 }butoxy )pheny !]piperidin-1 -y 1} -1 //-i ndo lc-3 -carbonitrile|- 4 (- 2.4 - Dioxo-1.3-diazinan-l-yl)-l//-indol-l-yl|pipc ridin-1-yl] methy l)pipcridin-l -)؛- 4 -| 4 -؛ 4 -) 7yl|phcny !]pipe ridin-l-yl)-l//-indolc-3-carbonitrilc :- 5-4 - Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-l/7-isoindoly !]piperazin-1 -yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile ;- 3,4 ] 4 - Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-l/7-pynoloc]pyridin-6-y !]piperazin-1 -yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -y 1)-1 //-i ndolc-3 -carbonitrile ; - Chloro-7-(4-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l -yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile ;- Chloro-7-(4-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l -; yl}methy !)piperidin-1 -yl]pyridazin-3 -yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile WO 2024/189488 PCT/IB2024/052251 4 - Chloro-7-(4-{6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-LH-isoindol-5-yl]piperazin -- yl} methyl) piperidin-1 -y 1] py ridazin-3 -y 1 }piperidin-1 -yl)-1H-indole-3 -carbonitrile ;- Chloro-7-[(37?*)-3-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l -yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl] -I //-i ndolc-3 -carbonitrile ;- Chloro-7-[(3S'*)-3-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l -yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile ;- Chloro-7-(4-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l -yl}methy !)piperidin-1 -yl]pyrazin-2-yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile ;- Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin -- yl}methy !)piperidin-1 -yl]pyrazin-2-yl}piperidin-1 -yl)-1H-indole-3-carbonitrile ;- 4-7 [- 4 (- 4 {- 4 ([- 4 [{- l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l/7-benzimidazoly 1] methyl }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -yl] -4-methy 1-1 //-i ndolc-3 -carbonitrile ;- 177-4 - Chloro-7-[4-(4-{4-[(4-{[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro- 3 - benzimidazol-4-y 1] methyl }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc carbonitrile ;- 4-7 [- 4 (- 4 {- 4 ([- 4 [{- l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazoly 1] methyl }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -yl] -4-fluoro -1 //-i ndo lc-3 -carbonitrile ;- Chloro-7-(4-{4-[4-({4-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazol -- yl]piperazin-l -yl}methyl)piperidin-l -yl]phenyl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile ;- 177-4 - Chloro-7-[(3S)-3-(4-{4-[(4-{ [l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro- 3 - benzimidazol-4-y 1] methyl }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc carbonitrile ;- 4-7 ([- 3S)-3-(4-{4-[(4-{ [l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazoly 1] methyl }piperazin-1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -yl] -4-fluoro -1 //-i ndo lc-3 -carbonitrile ;- 3,4 ] 4 - Chloro-7-{4-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolof] isoindol-2( l//)-yl] methyl }piperidin-1-y !)pheny !]piperidin-1-yl}-l/7-indole-3-carbonitrile ;- 3,4 ] 4 - Chloro-7-{(3S)-3-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolof] isoindol-2( 1 //)-y11 methyl }piperidin-1 -y !)pheny !]piperidin-1 -y 1} -1 //-i ndazo lc-3 -carbonitrile; and- 3,4 ] 4 - Chloro-7-{(3S)-3-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolof] isoindol-2( l//)-yl] methyl }piperidin-1-y !)pheny !]piperidin-1-yl}-l/7-indole-3-carbonitrile ; or pharmaceutically acceptable salts thereof . - 2 -] 4 -)} 4 -] 4 -} 4 -) 7 - In one embodiment, this specification relates to a compound which is 4-Chloro- 1-2,6 - dioxopiperidin-3 -yl)-1-oxo-2,3 -dihydro-1 //-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin )pipe ridin-l-yl)-l//-indolc-3-carbonitrilc ؛ yl|phcnyl WO 2024/189488 PCT/IB2024/052251 or a phamaceutically acceptable salt thereof.In one embodiment, this specification relates to a compound which is 7-(4-{4-[4-({4-[2-(2,6- Dioxopiperidin-3 -yl)-1 -oxo-2,3 -dihydro-1 //-isoindol-5-y !]piperazin- l-yl}methy !)piperidin-1 -yl]phenyl}piperidin- l-yl)-4-fluoro-1 //-indolc-3 -carbonitrile or a pharmaceutically acceptable salt thereof.In one embodiment, this specficiation relates to a compound which is 7-(4-{4-[4-({4-[4-(2,4-Dioxo-1.3-diazinan-l-yl)-l//-indol-l-yl|pipcridin-l-yl]mcthyl)pipcridin-l-yl|phcnyl]pipcridin-l-yl)-4-fl11oro-l//-indole-3-carbonitrile or a pharmaceutically acceptable salt thereof.
In one embodiment, this specification relates to a compound which is 4-Chloro-7-(4-{4-[4-({4-[2- (2,6-dioxopiperidin-3 -yl)-7-methoxy-1 -oxo-2,3 -dihydro-l/7-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 - yl|phcny !]pipe ridin-1-yl)-l//-indolc-3-carbonitrilc WO 2024/189488 PCT/IB2024/052251 or a pharmaceutically acceptable salt thereof.
In one embodiment, this specification relates to a compound which is 7-(4-{4-[4-({4-[4-(2,4-Dioxo- l.3-diazinan-l-yl)-l//-indol-l-yl|pipcridin-l-yl;mcthyl)pipcridin-l-yl|phcnyl;pipcridin-l-yl)-4-mcthyl-l//- indole-3-carbonitrile or a pharmaceutically acceptable salt thereof.
In another embodiment, this specification relates to a compound which is 4-Chloro-7-[(3S)-3-{4-[4- ({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l- y 1] -1 //-i ndazo lc-3 -carbonitrile or a pharmaceutically acceptable salt thereof.
In another embodiment, this specification relates to a compound which is 4-Chloro-7-[(3S)-3-{4-[4- ({4-[2-(2,6-dioxopiperidin-3 -yl)-1 -oxo-2,3 -dihydro-1 //-iso indo 1-5-yl | pipcrazi n-1 -yl}methy !)piperidin-1 - yl|phcny !)pipe ridin-l-yl|-l//-indazolc-.3-carbonitrilc WO 2024/189488 PCT/IB2024/052251 or a pharmaceutically acceptable salt thereof.
In another embodiment, this specification relates to a compound which is 4-Chloro-7-[(3S)-3-{4-[4-([4-|4-(2.4-dioxo-l.3-diazinan-l-yl)-l//-indol-l-yl|pipcridin-l-yl;mcthyl)pipcridin-l-yl|phcnyl;pipcridin-l- y 1] -1 //-i ndo lc-3 -carbonitrile or a pharmaceutically acceptable salt thereof.
In another embodiment, this specification relates to a compound which is 4-Chloro-7-[(3S)-3-{4-[4- ({4-[2-(2,6-dioxopiperidin-3 -yl)-1 -oxo-2,3 -dihydro-1 //-iso indo 1-5-yl | pipcrazi n-1 -yl}methy !)piperidin-1 - yl|phcnyl;pipcridin-l-yl|-l//-indolc-3-carbonitrilc 15or a pharmaceutically acceptable salt thereof.
WO 2024/189488 PCT/IB2024/052251 In another embodiment, this specification relates to a compound which is 4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l/7-indol-2-yl]piperidin-l-yl}methyl)piperidin-l-yl|phcny IJpipc ridin-l-yl|-l//-indolc-3-carbonitrilc or a pharmaceutically acceptable salt thereof.
In another embodiment, this specification relates to a compound which is 4-Chloro-7-[(3S)-3-{4-[4- ({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l/7-indol-2-yl]piperidin-l-yl}methyl)piperidin-l-yl|phcnyl;pipcridin-l-yl|-l//-indazolc-3-carbonitrilc or a pharmaceutically acceptable salt thereof.
In another embodiment, this specification relates to a compound which is 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3 -y l)-7-methoxy-1 -oxo-2,3 -dihydro- l/7-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -yl|phcny !]pipe ridin-1-yl)-4-mcthyl-l//-indolc-3-carbonitrilc or a pharmaceutically acceptable salt thereof.
WO 2024/189488 PCT/IB2024/052251 In another embodiment, this specification relates to a compound which is 7-[(3S)-3-{4-[4-({4-[4-(2,4- Dioxo-1.3 -diazi nan-1 -y 1)-1 //-i ndol-1 -y !]piperidin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -4-fluoro- I //-i ndolc-3 -carbonitrile or a pharmaceutically acceptable salt thereof.
In another embodiment, this specification relates to a compound which is 7-{4-[4-(4-{4-[4-(2,4-Dioxo-1.3-diazinan-l-yl)-l//-indol-l-yl |pipcridin-l-y !]butoxy )phenyl |pipcridin-l-yl]-4-fluoro-l//-indolc-3- carbonitrile or a pharmaceutically acceptable salt thereof.
In another embodiment, this specification relates to a compound which is 4-Chloro-7-[(3S)-3-{4-[4- ({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-l/7-pyrrolo[3,4-c]pyridin-6-yl]piperazin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indolc-3 -carbonitrile or a pharmaceutically acceptable salt thereof.
WO 2024/189488 PCT/IB2024/052251 In another embodiment, this specification relates to a compound which is 4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-l/7-isoindol-5-yl]piperazin-l-yl}methy!)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indolc-3 -carbonitrile or a pharmaceutically acceptable salt thereof.
In another embodiment, this specification relates to a compound which is 4-Chloro-7-[(3S)-3-{4-[4- ({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-2-methyl-l/7-indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl|phenyl؛pipcridin-l-yl|-l//-indolc-3-carbonitrilc or a pharmaceutically acceptable salt thereof.
A further embodiment provides any of the embodiments, claims or aspects defined herein with the proviso that one or more specific Examples(for instance one Example,or two or three specific Examples) selected from the group consisting of Examples1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77,78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, WO 2024/189488 PCT/IB2024/052251 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126,127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148,149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 153, 164, 165, 166, 167, 168, 169, 170,171, 172, 173, 174, 175, 176, 177, 178, 179, 180 and 181 is individually disclaimed.The compounds of Formula (I)and PROTAC compounds containing binding units of Formula (la) may have one or more chiral centres and it will be recognised that such compounds may be prepared, isolated and/or supplied with or without the presence of one or more of the other possible enantiomeric and/or diastereomeric isomers of said compounds or that such isomers may be provided in any relative proportions. The preparation of enantioenriched/ enantiopure and/or diastereoenriched/ diastereopure compounds may be carried out by standard techniques of organic chemistry that are well known in the art, for example by synthesis from enantioenriched or enantiopure starting materials, and/or by use of an appropriately enantioenriched or enantiopure catalyst during synthesis, and/or by resolution of a racemic or partially enriched mixture of stereoisomers, for example via chiral chromatography.Accordingly, in one embodiment there is provided a composition comprising a compound of Formula (I)[or PROTAC compound containing a unit of Formula (la)]or a pharmaceutically acceptable salt thereof, optionally together with one or more of the other stereoisomeric forms of the compound of Formula (I)[or PROTAC compound containing a unit of Formula (la)]or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I)[or PROTAC compound containing a unit of Formula (la)]or pharmaceutically acceptable salt thereof is present within the composition with a diastereomeric excess (%de) of >90%.In a further embodiment the %de in the above-mentioned composition is > 95%.In a further embodiment the %de in the above-mentioned composition is > 98%.In a further embodiment the %de in the above-mentioned composition is > 99%.In a further embodiment there is provided a composition comprising a compound of Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein] or a pharmaceutically acceptable salt thereof, optionally together with one or more of the other stereoisomeric forms of the compound of Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein] or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein] or pharmaceutically acceptable salt thereof is present within the composition with an enantiomeric excess (%ee) of > 90%.In a further embodiment the %ee in the above-mentioned composition is > 95%.In a further embodiment the %ee in the above-mentioned composition is > 98%.In a further embodiment the %ee in the above-mentioned composition is > 99%.In a further embodiment there is provided a composition comprising a compound of Formula(I) [or PROTAC compound containing a unit of Formula (la)as defined herein] or a pharmaceutically acceptable salt thereof, optionally together with one or more of the other stereoisomeric forms of the compound of Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein], or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein], or pharmaceutically acceptable salt thereof is present WO 2024/189488 PCT/IB2024/052251 within the composition with an enantiomeric excess (%ee) of > 90% and a diastereomeric excess (%de) of > 90%.In further embodiments of the above-mentioned composition the %ee and %de may take any combination of values as listed below:• The %ee is <5% and the %de is > 80%.• The %ee is <5% and the %de is > 90%.• The %ee is <5% and the %de is > 95%.• The %ee is <5% and the %de is > 98%.• The %ee is > 95% and the %de is > 95%.• The %ee is > 98% and the %de is > 98%.• The %ee is > 99% and the %de is > 99%.In a further embodiment there is provided a pharmaceutical composition which comprises a compound of the Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein], or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient.In one embodiment there is provided a pharmaceutical composition which comprises a compound of the Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein], or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient, optionally further comprising one or more of the other stereoisomeric forms of the compound of Formula(I) [or PROTAC compound containing a unit of Formula (la)as defined herein], or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I)[or PROTAC compound containing a unit of Formula (la) as defined herein], or pharmaceutically acceptable salt thereof is present within the composition with an enantiomeric excess (%ee) of > 90%.In a further embodiment the %ee in the above-mentioned composition is > 95%.In a further embodiment the %ee in the above-mentioned composition is > 98%.In a further embodiment the %ee in the above-mentioned composition is > 99%.In one embodiment there is provided a pharmaceutical composition which comprises a compound of the Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein], or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient, optionally further comprising one or more of the other stereoisomeric forms of the compound of Formula(I) [or PROTAC compound containing a unit of Formula (la)as defined herein], or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I)[or PROTAC compound containing a unit of Formula (la) as defined herein], or pharmaceutically acceptable salt thereof is present within the composition with a diastereomeric excess (%de) of > 90%.In a further embodiment the %de in the above-mentioned composition is > 95%.In a further embodiment the %de in the above-mentioned composition is > 98%.In a further embodiment the %de in the above-mentioned composition is > 99%.In one embodiment there is provided a pharmaceutical composition which comprises a compound of the Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein], or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable excipient, WO 2024/189488 PCT/IB2024/052251 optionally further comprising one or more of the other stereoisomeric forms of the compound of Formula (I) [or PROTAC compound containing a unit of Formula (la)as defined herein], or pharmaceutically acceptable salt thereof, wherein the compound of Formula (I)[or PROTAC compound containing a unit of Formula (la) as defined herein], or pharmaceutically acceptable salt thereof is present within the composition with an enantiomeric excess (%ee) of > 90% and a diastereomeric excess (%de) of > 90%.In further embodiments of the above-mentioned pharmaceutical composition the %ee and %de may take any combination of values as listed below:• The %ee is > 95% and the %de is > 95%.• The %ee is > 98% and the %de is > 98%.• The %ee is > 99% and the %de is > 99%.The compounds of Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein], and pharmaceutically acceptable salts thereof may be prepared, used or supplied in amorphous form, crystalline form, or semicrystalline form and any given compound of Formula(I) [or PROTAC compound containing a unit of Formula (la)as defined herein], or pharmaceutically acceptable salt thereof may be capable of being formed into more than one crystalline / polymorphic form, including hydrated (e.g. hemi-hydrate, a mono-hydrate, a di-hydrate, a tri-hydrate or other stoichiometry of hydrate) and/or solvated forms. It is to be understood that the present specification encompasses any and all such solid forms of the compound of Formula (I)[or PROTAC compound containing a unit of Formula (la)as defined herein], and pharmaceutically acceptable salts thereof.In further embodiments there is provided a compound of Formula(I) [or PROTAC compound containing a unit of Formula (la)as defined herein] which is obtainable by the methods described in the ‘Examples’ section hereinafter.
Intermediate CompoundsAs demonstrated in the experimental section hereinafter, the compounds of Formula (I)or PROTACs of Formula (la)may be prepared, for example, by the following methods.A compound of Formula (I)[or salt thereof] or a PROTAC compound of Formula (la)[or a salt thereof[ may be prepared from a compound of Formula (II): (11) or a salt thereof, where:QA is -G-QH- or -G-(C1.5alkylene)-;G is a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)- where RG is H or Ci.galkyl; WO 2024/189488 PCT/IB2024/052251 QHis a 4 to 12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; QDis a direct bond or C!.2alkylene optionally substituted by one or more F; RL1and RL2together form "=O", RL3is H;where when QDis a direct bond and QAis -G-QH-,the value of QHis selected so that QDconnects to a C atom of QH;and R1, p, X1, RN, n, m, R2a , R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qmay take any of the values disclosed herein for each of those groups/variables respectively.In one embodiment QH is a 4-12-membered nitrogen-containing saturated heterocyclic group.Accordingly such compound of Formula (II)as described above is an aldehyde which may be reacted with a suitable molecule containing an amine group (for example a secondary amine group) to form the compound of Formula(I) or PROTAC compound of Formula (la) -either directly, or after one or more additional reaction steps. Such reaction of said aldehyde with said amine can be carried out under reductive amination conditions, using for example NaBH(OAc)3 or another reductive amination protocol known to the skilled person.Such aldehyde may in turn be prepared from the corresponding acetal, for example a compound of Formula (II),or salt thereof, as defined above, except that: RL1and RL2are each independently C!.6alkoxy (for example Ci.galkoxy) or RL1 & RL2together form -O-(CH2)k-O- where kis 2 or 3. Such acetal may be converted to the corresponding aldehyde under acidic conditions, for example using formic acid under conditions well known to the skilled person.Alternatively, as shown in the experimental section hereinafter, the above-mentioned aldehyde may be prepared by oxidation of the corresponding primary alcohol, i.e. a compound of Formula (II),or salt thereof, as defined above except that RL1is OH and RL2is H. Such oxidation may be carried out using mild oxidising conditions, for example Dess-Martin periodinane or some other mild oxidation protocol known to the skilled person.As shown in the experimental section hereinafter, a compound of Formula(I) [or salt thereof] or a PROTAC compound of Formula (la)[or a salt thereof[ may be prepared from a compound of Formula (II) or a salt thereof, as described above except that RL1is a leaving group and RL2is H. Accordingly, such compound of Formula (II)is an electrophile that may be reacted with a molecule containing an amine group (for example a secondary amine group) via an alkylation reaction to form the compound of Formula(I) or PROTAC compound of Formula (la) -either directly, or after one or more additional reaction steps. Suitable leaving groups for alkylation reactions are well known to the skilled person and include Cl, Br, I, trifluoromethanesulfonate, mesylate and tosylate. Alkylation reaction conditions are well known to the skilled person and generally involve a non-nucleophilic base (e.g. DIPEA) and a polar aprotic solvent (e.g. MeCN). As demonstrated in the experimental section hereinafter, in cases where the leaving group is not 1, a metal iodide salt may be used in the reaction mixture to form the corresponding iodide in-situ (i.e. where RL1 is 1) to facilitate the overall alkylation process. As shown in the experimental section hereinafter, a compound of Formula (II)where RL1is a bromo leaving group may be prepared from the corresponding primary alcohol (i.e. as already described above where RL1is OH, and RL2 & RL3are both H.In turn, the above-mentioned primary alcohol compound of Formula (II)may be prepared by the reduction of the corresponding ester compound, i.e. a compound of Formula (II),or salt thereof, as defined WO 2024/189488 PCT/IB2024/052251 above, except that: RL1and RL2together form "=O" and RL3is C!.6alkoxy (for example C!.3alkoxy). Such reduction may be carried out using strong reduction conditions, for example using DIBAL or other stronger reducing conditions which are well known to the skilled person.Alternatively, as demonstrated in the experimental section hereinafter, it may be convenient to form the above-mentioned primary alcohol compound of Formula (II)via deprotection of a protected form of the alcohol. For example, deprotection of a compound where there alcohol is protected by a silicon-based protecting group, using a source of fluoride in order to achieve the deprotection, for example TBAF or other deprotection methods well-known to the skilled person.Therefore, as described above, various compounds of Formula (II),and salts thereof, may be useful as intermediates in the synthesis of the compounds of Formula (I)or PROTAC compounds of Formula (la), and accordingly such intermediate compounds provide a further aspect of the specification.Therefore, in a further aspect there is provided a compound of Formula (II),as shown above, or a salt thereof, wherein:QA is -G-QH- or -G-(C1.5alkylene)-;G is a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)- where RG is H or C1-3alkyl;QH is a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;QD is a direct bond or C!.2alkylene optionally substituted by one or more F (for example 1 or 2 F); and(i) RL1 & RL2together form "=O" and RL3is H or C!.6alkoxy (for example OMe);(ii) RL1 & RL2are each independently C!.6alkoxy (for example OMe), and RL3is H;(iii) RL1 & RL2together form -O-(CH2)k-O- where kis 2 or 3, and RL3is H; or(iv) RL1is OH, OPG1(where PG1is a protecting group), or LG1(where LG1is a leaving group), and RL2 & RL3are both H;where when QD is a direct bond and QA is -G-QH-, the value of QH is selected so that QD connects to a C atom 0fQH;and R1, p, X1, X2, X3, X4, n, m, Q, R2a , R2b, Y1, Y2, Y3, Y4, R3and qmay take any of the values disclosed herein for each of those groups/variables respectively.In one embodiment QH is a 4-12-membered nitrogen-containing saturated heterocyclic group.The skilled person is aware of suitable protecting groups for alcohol groups and therefore is aware of suitable values of PG1.For example PG1is an alcohol protecting group.In one embodiment PG1is a silicon-based alcohol protecting group.In one embodiment PG1 is Si(Rs,)3 where each RSl is independently a C!.6hydrocarbyl group.In one embodiment PG1is /cr/-buty idimcthy isily 1 or /cr/-buty Idiphcny Isily 1.In one embodiment the LG1 is selected from Cl, Br, 1, trifluoromethanesulfonate and C1-7hydrocarbylsulfonate (for example mesylate or p-toluenesulfonate).In one embodiment LG1is Br or I.In one embodiment LG1is Br.In one embodiment LG1is Cl.In one embodiment LG1is 1.In one embodiment LG1is trifluoromethanesulfonate.In one embodiment LG1 is C1-7hydrocarbylsulfonate.
WO 2024/189488 PCT/IB2024/052251 In one embodiment LG1is mesylate.In one embodiment LG1is p-toluenesulfonate.In one embodiment QD is a direct bond, -CH2-, -CH2CH2- or -CF2CH2-.In one embodiment QD is a direct bond.In one embodiment QD is CH2.In one embodiment QD is C!.2alkylene optionally substituted by 1 or 2 F.In one embodiment QD is C!.2alkylene.In one embodiment QD is -CH2CH2-.In one embodiment QD is -CF2CH2-.In further embodiments of this specification Formula (II)may be Formula (Ila): rl1 L*—Q—QD / RL2 rl3 (Ha) where Lxmay be any of the groups (1) to (43) listed hereinabove in connection with Formula (la);and where QA, QD, RL1, RL2and RL3may take any of the values disclosed herein for each of said groups respectively.As demonstrated in the experimental section hereinafter, certain compounds of Formula (I)and certain PROTACS of Formula (la)and certain intermediate compounds of Formula (II)may be prepared using a compound of Formula (III): (III) or a salt thereof, where Gx is OH, where the oxygen atom of said OH is alkylated by a suitable molecule to form certain compounds of Formula (I)or PROTACs of Formula (la) -either directly, or after one or more further reaction steps (for example via Formula (II)as described hereinabove). Such alkylation reactions may be carried out under conditions well known to the skilled person, for example using a primary alkyl bromide (or using some other leaving group in place of Br) using a non-nucleophilic base such as a metal carbonate (e.g. K2CO3) in a polar aprotic solvent such as MeCN, optionally in the presence of a metal iodide salt such as KI.Alternatively, as shown in the experimental section hereinafter, a compound of Formula (HI)where Gx is -NH(Rg ) [where RG is H or C!.3alkyl (for example Me)] may be used as an intermediate to prepare WO 2024/189488 PCT/IB2024/052251 compounds of Formula (I)or PROTACs of Formula (la)via reductive amination chemistry with an appropriate aldehyde-containing compound.Alternatively, as shown in the experimental section hereinafter, a compound of Formula (III)where Gx is bromo may be coupled with a secondary amine compound to give certain compounds of Formula (I)or PROTACs of Formula (la) -either directly, or after one or more further reaction steps (for example via Formula (II)as described hereinabove). Similarly, compounds of Formula (III)where Gx is chloro or trifluoromethanesulfonate may also be used in a coupling reaction with the relevant secondary amine to give certain compounds of Formula (I)or PROTACs of Formula (la).Such coupling may be carried out under palladium-based coupling conditions (e.g. using ‘Ruphos Pd G3’ and ‘Ruphos‘) in the presence of abase and an anhydrous solvent such as 1,4-dioxane under an inert atmosphere, or by heating with Cui in the presence of a base such as K3PO4 in a polar solvent such as DMSO. Alternatively, also as shown in the experimental section herein, a compound of Formula (III)where Gx is bromo may be coupled with a suitable alcohol to form certain compounds of Formula (I)or PROTACs of Formula (la) -either directly, or after one or more further reaction steps (for example via Formula (II)as described hereinabove). Such coupling may be carried out using a palladium-based reagent such as ‘Rockphos Pd G3 ’ in the presence of a base such as C52CO3 in a solvent such as toluene.Accordingly, compounds of Formula (III),and salts thereof, may be useful as intermediates in the synthesis of certain compounds of Formula (I)or PROTAC compounds of Formula (la)or compounds of Formula (II),and accordingly such intermediate compounds provide a further aspect of the specification.Therefore, in a further aspect there is provided a compound of Formula (III),as shown above, or a salt thereof, wherein:Gx is OH, Cl, Br, triflouoromethanesulfonate or -NH(RG) where RG is H or C!.3alkyl; and R1, p, X1, RN, n, m, R2a , R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qmay take any of the values disclosed herein for each of those groups/variables respectively.Gx is OH, Cl, Br, triflouoromethanesulfonate or -NH(RG) where RG is C!.3alkyl (for example Me).In one embodiment Gx is OH, Br, trifluoromethanesulfonate or -NH(RG) where RG is C!.3alkyl (for example Me).In one embodiment Gx is OH, Br or -NH(RG) where RG is C!.3alkyl (for example Me). In one embodiment Gx is OH or Br.In one embodiment Gx is OH.In one embodiment Gx is Br.In one embodiment Gx is Cl.In one embodiment Gx is trifluoromethanesulfonate.In one embodiment Gx is -NH(RG) where RG is H or C1-3alkyl.In one embodiment Gx is -NH(RG) where RG is C1-3alkyl.In one embodiment Gx is -NH(Me).In further embodiments of this specification, Formula (III)may be Lx—Gxwherein Lxmay be any of the groups (1) to (43) listed hereinabove in connection with Formula (la);and where Gx may take any value(s) disclosed herein for Gx.
WO 2024/189488 PCT/IB2024/052251 As demonstrated in the experimental section hereinafter, certain compounds of Formula (I)andPROTACs of Formula (la)may be prepared using an intermediate compound of Formula (IV): (IV) or a salt thereof, as further defined below. For example, a compound of Formula (IV),or salt thereof, where J is H (i.e. a secondary amine compound) may be coupled to a further chemical fragment, using chemistry well known to the skilled person and exemplified in the experimental section hereinafter, to provide a compound of Formula (I)or PROTAC of Formula (la),either directly, or after one or more further reaction steps.In turn, such a compound of Formula (IV)where Jis H may conveniently be prepared via deprotection of an A-protected form of the aforementioned amine compound. Accordingly compounds of Formula (IV)where Jis H may be conveniently be prepared using a compound of Formula (IV)where Jis PG2where PG2is a nitrogen protecting group (for example a C!.6alkoxy carbonyl group such as tert- butoxycarbonyl). Therefore, compounds of Formula (IV)where Jis PG2are useful intermediates in the preparation of the compound of Formula (I)and PROTAC of Formula (la)and provide a further aspect of the specification.Therefore in a further aspect of the specification there is provided a compound of Formula (IV)as depicted above, or a salt thereof, wherein: Jis H or PG2where PG2is a nitrogen protecting group (for example a tert-butoxycarbonyl group);QA is -G-QH- or -G-(C1.5alkylene)-;G is a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)- where RG is H or C1-3alkyl;QB is a direct bond, -QB1-QB2-QB3- or C!.3alkylene optionally substituted by one or more F (e.g. 1 or 2); where:QB1 & QB3 each independently represent a direct bond or C!.2alkylene;QB2 is QH, -0-CHCH-o- -0- or -N(RJ)- where RJ is H or C1-3alkyl;and each QH(including the "QH Ring "attached to J)is independently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;where the values of QA, QBand QH Ringare selected so that Formula (IV)does not contain any N-N or N-O bonds;and where R1, p, X1, RN, n, m, R2a , R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qmay take any of the values defined herein for each of these groups/variables respectively.In one embodiment each QH(including the "QH Ring "attached to J)is independently a 4-12-membered nitrogen-containing saturated heterocyclic group.In one embodiment the QH Ringis piperidin-1,4-diyl or piperazin- 1,4-diyl.
WO 2024/189488 PCT/IB2024/052251 In one embodiment Jis H.In one embodiment Jis PG2. In one embodiment PG2is Ci-salkoxycarbonyl.In one embodiment PG2is ter/-butoxycarbonyl.In one embodiment where PG2is C!.6alkoxycarbonyl (e.g. tert-butoxycarbonyl) the ‘and salts thereof element of the claim is excluded.In further embodiments the compound of Formula (IV)may take any combination of alternative values mentioned in relation toQA,QBand QH in any other context, embodiment, aspect or claim found herein.In further embodiments of this specification Formula (IV)may be Formula (IVa): X where Lxmay be any of the groups (1) to (43) listed hereinabove in connection with Formula (la);and where QA, QB, QHand J may take any of the values disclosed herein for each of said groups respectively.As also demonstrated in the experimental section hereinafter, certain compounds of Formula (I)and PROTACs of Formula (la)may be prepared using an intermediate compound of Formula (V): (V) or a salt thereof, wherein: Xxis N substituted by Jwhere Jis H; Gis a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)- where RG is H or C!.3alkyl; QH Ringis a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; where the values of Gand QH Ringare selected so that Formula (V)does not contain any N-N or N-O bonds; and where R1, p, X1, RN, n, m, R2a , R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qmay take any of the values defined herein for each of these groups/variables respectively.Such a compound of Formula (V)may be converted to a compound of Formula (I)or PROTAC of Formula (la)via reductive amination or alkylation or other coupling chemistry known to the skilled person - to provide the compound of Formula (I)or PROTAC of Formula (la)either directly, or after one or more additional steps.In turn, as shown in the experimental section hereinafter, such a compound of Formula (V),or a salt thereof, may be conveniently prepared by deprotection of the corresponding V-protcctcd compound. Such A- WO 2024/189488 PCT/IB2024/052251 protected form may be a BOC-protected form (i.e. tert-butoxycarbonyl) or may use another N-protecting group known to the skilled person. Accordingly, such A-protected compounds are also useful intermediates in the preparation of the compounds of Formula (I)and PROTACs of Formula (la)and provide a further aspect of the specification.Accordingly one aspect of the specification provides a compound of Formula (V),or a salt thereof, as described above except that Xxis N substituted by Jwhere Jis PG3and PG3is a protecting group. In one embodiment PG3is C1-salkoxycarbonyl. In one embodiment PG3is tert-butoxycarbonyl. In one embodiment where PG3is C!.6alkoxycarbonyl (e.g. tert-butoxycarbonyl) the ‘and salts thereof‘ element of the claim is excluded.Other compounds of Formula (I)and PROTACs of Formula (la) -and salts thereof - may be prepared from an intermediate compound of Formula (V),or a salt thereof, as described above except that Xx is C=O. Such an intermediate may be converted to a compound of Formula (I)or PROTAC of Formula (la) by reductive amination chemistry using an appropriate amine-containing compound, using reductive amination conditions that well-known to the skilled person - either directly or via one or more additional synthetic steps.In turn, as demonstrated in the experimental section hereinafter, such compounds of Formula (V) where Xx is C=O may be conveniently prepared from the corresponding compound where the ketone is protected/masked as a ketal. Accordingly such ketal compounds, and salts thereof are useful intermediates in the preparation of a compound of Formula (I)or a PROTAC of Formula (la)and provide a further aspect of the specification.Accordingly such ketal compound may be represented as a compound of Formula (V),or a salt thereof, as described above except that Xxis C substituted by RU1and Ru2;where RU1and Ru2are each C1-6alkoxy; or RU1and Ru2together represent -O-(CH2)U-O- where uis 2 or 3.Therefore, in a further aspect of the specification there is provided compound of Formula (V),as depicted above, or a salt thereof, wherein: Xxis selected from:(i) N substituted by Jwhere Jis H or PG3where PG3is a protecting group; and(ii) C substituted by oxo, or by RU1and Ru2;where RU1and Ru2are each C!.6alkoxy; or RU1and Ru2 together represent -O-(CH2)U-O- where u is 2 or 3; Gis a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)- where RG is H or C1-3alkyl; QH Ringis a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; and the values of Gand QH Ringare selected so that Formula (V)does not contain any N-N or N-O bonds; and where R1, p, X1, RN, n, m, R2a , R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qmay take any of the values defined herein for each of these groups/variables respectively.In one embodiment Jis H.In one embodiment Jis PG3. In one embodiment PG3is Ci-salkoxycarbonyl.In one embodiment PG3is tert-butoxycarbonyl.In one embodiment Xxis C=O.In one embodiment Xxis C substituted by RU1and Ru2;where RU1and Ru2are each C!.6alkoxy.
WO 2024/189488 PCT/IB2024/052251 In one embodiment Xxis C substituted by RU1and Ru2;where RU1and Ru2together represent -O-(CH2)U-O- where uis 2 or 3 (for example u= 2).In one embodiment Gis a direct bond or -O-.In one embodiment QH Ringis a 4-12-membered nitrogen-containing saturated heterocyclic group.The values of QH Ringmay take any of the values mentioned herein for QH. In one embodiment QH Ringis a piperidine ring, a piperazine ring, a 9-azaspiro[5.5]undecane ring or a 3,9- diazaspiro[5.5]undecane ring.In further embodiments of this specification Formula (V)may be Formula (Va): where Lxmay be any of the groups (1) to (43) listed hereinabove in connection with Formula (la);and where G,QHRing and Xxmay take any of the values disclosed herein for each of said groups respectively.In addition to the methods described above, the compounds of Formulae (I), (II), (III), (IV) & (V) and PROTAC compounds including Formula (la)may be prepared according to the general procedures and chemical transformations demonstrated in the experimental section hereinafter and using standard procedures and knowledge known to the skilled chemist.In further embodiments of this specification there is/are provided compound(s), or a salt thereof, wherein said compound(s) is/are selected from one or more of the "Intermediates "listed hereinafter in the experimental section.It is to be understood that the compound of an Intermediatelisted hereinafter relates to the title chemical name listed in the experimental section, and is not limited in any way by the method of preparation nor whether a given intermediate compound was isolated in the form of a salt rather than as a neutral molecule.According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, in association with a pharmaceutically acceptable excipient.According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of cancer.According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of a solid tumour.According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase (Va) WO 2024/189488 PCT/IB2024/052251 cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of an AR-sensitive tumour type.According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of tumour types that harbour one or more mutated forms of the androgen receptor.According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of prostate cancer (for example CRPC, for example metastatic CRPC).According to a further aspect of the specification there is provided a pharmaceutical composition, which comprises a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of AR-mutated cancer.In any embodiment, aspect or claim herein that mentions "cancer" without further specificity, further embodiments, aspects or claims may be provided where said cancer is (or includes) AR+ breast cancer.The compositions may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous or intramuscular dosing). The compositions may be obtained by conventional procedures using conventional pharmaceutical excipients that are well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and/or preservative agents.For further information on formulations the reader is referred to Chapter 25.2 in Volume 5 of Comprehensive Medicinal Chemistry (Corwin Hansch; Chairman of Editorial Board), Pergamon Press 1990.The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the host being treated and the particular route of administration.The size of the dose for therapeutic purposes of compounds of the present specification will naturally vary according to the nature and severity of the disease state, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine.As explained hereinabove, the compounds of the present specification may be of value as anti-tumour agents, in particular as selective inhibitors of the proliferation, survival, motility, dissemination and invasiveness of mammalian cancer cells leading to inhibition of tumour growth and survival and to inhibition of metastatic tumour growth. Particularly, the compounds of the present specification may be of value as anti- proliferative and anti-invasive agents in the containment and/or treatment of solid tumour disease.Accordingly, the compounds of the present specification may be useful in the prevention or treatment of those tumours which are sensitive to degradation of the androgen receptor and that are involved in the signal transduction steps which lead to the proliferation and survival of tumour cells and the migratory ability WO 2024/189488 PCT/IB2024/052251 and invasiveness of metastasising tumour cells. Further, the compounds of the present specification may be useful in the prevention or treatment of those tumours which are treatable by degradation of androgen receptors, i.e. the compounds may be used to produce an androgen receptor degradation effect in a warm- blooded animal in need of such treatment.According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use as a medicament.According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in therapy.According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in a method of treatment of the human or animal body by therapy.According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein for use in the production of an anti-proliferative effect (for example, in a warm-blooded animal such as man).According to a further aspect of the specification, there is provided the use of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the production of an anti-proliferative effect (for example, in a warm- blooded animal such as man).According to a further aspect of the specification, there is provided a method for producing an anti- proliferative effect in a warm-blooded animal, such as man, in need of such effect, which comprises administering to said animal an effective amount of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein.According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use as an anti- invasive agent in the containment and/or treatment of solid tumour disease (for example: in a warm-blooded animal such as man).According to a further aspect of the specification, there is provided the use of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease (for example: in a warm-blooded animal such as man).
WO 2024/189488 PCT/IB2024/052251 According to a further aspect of the specification, there is provided a method for producing an anti- invasive effect by the containment and/or treatment of solid tumour disease, in a warm-blooded animal, such as man, in need of such effect, which comprises administering to said animal an effective amount of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein.According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the prevention or treatment of cancer (for example: in a warm-blooded animal such as man).According to a further aspect of the specification there is provided the use of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the prevention or treatment of cancer (for example: in a warm-blooded animal such as man).According to a further aspect of the specification there is provided a method for the prevention or treatment of cancer in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein.According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the prevention or treatment of solid tumour(s) (for example, in a warm-blooded animal such as man).According to a further aspect of the specification, there is provided the use of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the prevention or treatment of solid tumour(s) (for example, in a warm- blooded animal such as man).According to a further aspect of the specification, there is provided a method for the prevention or treatment of solid tumour(s) in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein.According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the prevention or treatment of tumour types that are sensitive to degradation of androgen receptors.According to a further aspect of the specification, there is provided the use of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked WO 2024/189488 PCT/IB2024/052251 to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the prevention or treatment of those tumour types that are sensitive to degradation of androgen receptors.According to a further aspect of the specification, there is provided a method for the prevention or treatment of those tumour types that are sensitive to degradation of androgen receptors in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein.As explained hereinabove, tumour types that are sensitive to degradation of androgen receptors include prostate cancer (for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC).According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in providing a degrading effect on androgen receptors (for example in a warm-blooded animal such as man).According to a further aspect of the specification, there is provided the use of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for providing a degrading effect on androgen receptors (for example in a warm-blooded animal such as man).According to a further aspect of the specification, there is provided a method for providing a degrading effect on androgen receptors in a warm-blooded animal, such as man, in need of such effect, which comprises administering to said animal an effective amount of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein.According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in providing a selective degrading effect on androgen receptors (for example in a warm-blooded animal such as man).According to a further aspect of the specification, there is provided the use of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for providing a selective degrading effect on androgen receptors (for example in a warm-blooded animal such as man).According to a further aspect of the specification, there is provided a method for providing a selective degrading effect on androgen receptors in a warm-blooded animal, such as man, in need of such effect, which comprises administering an effective amount of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein.
WO 2024/189488 PCT/IB2024/052251 According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of tumour types that harbour androgen receptor mutations.According to a further aspect of the specification, there is provided the use of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the prevention or treatment of those tumour types that harbour androgen receptor mutations.According to a further aspect of the specification, there is provided a method for the prevention or treatment of those tumour types that harbour androgen receptor mutations in a warm-blooded animal, such as man, in need of such prevention or treatment, which comprises administering to said animal an effective amount of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein.As mentioned above, tumour types known to harbour androgen receptor mutations include prostate tumours and therefore prostate cancer, castrate-resistant prostate cancer (CRPC), and metastatic (CRPC).According to a further aspect of the specification, there is provided a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for use in the treatment of prostate cancer (for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC).According to a further aspect of the specification, there is provided the use of a compound of the Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein, for the manufacture of a medicament for the treatment of prostate cancer (for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC).According to a further aspect of the specification, there is provided a method for treating prostate cancer (for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC) in a warm- blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I),[or a PROTAC compound containing an E3 ubiquitin ligase cereblon binder unit and (e.g. linked to) an AR binding unit of Formula (la)]or a pharmaceutically acceptable salt thereof, as defined herein.In one embodiment where cancer is mentioned herein, said cancer is prostate cancer.In one embodiment where cancer is mentioned herein, said cancer is CRPC.In one embodiment where cancer is mentioned herein, said cancer is metastatic CRPC.
General Experimental Conditions and Abbreviations The following abbreviations are used: AcOH = Acetic acid; AIBN = 2,2׳-azobis(2-methylpropionitrile); aq. = aqueous; Boc = butoxycarbonyl; Brettphos = 2-(Dicyclohexylphosphino)3,6-dimethoxy-2 ׳ 6 ׳, 4 ׳, -triisopropyl- 1,1'-biphenyl; Brettphos Pd G3 = [(2-Di-cyclohexylphosphino-3,6-dimethoxy-2 ׳ 6 ׳, 4 ׳, - triisopropy 1-1,1'- WO 2024/189488 PCT/IB2024/052251 biphenyl)-2-(2'-amino-l,l' -biphenyl)]palladium(II) methanesulfonate; tert-butylBrettPhos = Di-tert- butyl(2',4',6'-triisopropyl-3,6-dimethoxy-[l,l'-biphenyl]-2-yl)phosphine; tert-BuOH = ter/-butanol; GDI = 1,1'-Carbonyldiimidazole; CPhos = 2-Dicyclohexylphosphino-2 ׳ 6 ׳, -bis(N,N-dimethylamino)biphenyl; Dave- phos-Pd G3 = Methanesulfonato 2-dicyclohexylphosphino-2-(X,X-dimethylamino)biphenyl(2׳-amino-l,l'- biphenyl-2-yl) palladium(!!); DCM = dichloromethane; DEA = Diethylamine; DIAD = Diisopropyl azodicarboxylate; DIPEA = A,A-diisopropylethylamine; Cbz = carboxybenzyl; DMAP = 4- (dimethylamino)pyridine; Dess-Martinperiodinane = 3-Oxo-115-benzo[d][l,2]iodaoxole-l,l,l(3A)-triyl triacetate; DMF = A,A-dimethylformamide; DMSO = dimethylsulfoxide; EDC = (l-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride); Ephos = dicyclohexyl(3 -isopropoxy-2',4',6'-triisopropyl- [l,l'-biphenyl]-2-yl)phosphane; Et20 = diethyl ether; EtOAc = ethyl acetate; EtOH = ethanol; ESC = flash silica chromatography; h = hour(s); HATU = l-[Bis(dimethylamino)methylene]-lH-l,2,3-triazolo[4,5- b]pyridinium 3-oxid hexafluorophosphate; HOBt = hydroxybenzotriazole; HPLC = high-performance liquid chromatography; IP A = isopropyl alcohol; LHMDS = Lithium bis(trimethylsilyl)amide; MeCN = acetonitrile; MeOH = methanol; mins. = minutes; m z = mass to charge ratio observed for major mass spectrometry peak(s); MTBE = methyl-/er/-butyl-ether; 2-MeTHF = 2-Methyltetrahydrofuran; NBS = Abromosuccinimide; NMP = A-methyl-2-pyrrolidone; NMR = nuclear magnetic resonance; [Pd(cinnamyl)Cl]2 = Di- chlorobis[(l,2,3-)-l-phenyl-2-propenyl]dipalladium(II); PdC12(dtbpf) = [l,l'-Bis(di-ter/- butylphosphino)ferrocene]dichloropalladium(II); Pd2(dba)3 = tris(dibenzylideneacetone)dipalladium; PdC12(PPh3)2 = Bis(triphenylphosphine)palladium(II) dichloride; Pd-PEPPSI-IHeptcl = dichloro[!,3-bis(2,6- di-4-heptylphenyl)imidazol-2-yldiene(3-chloropyridyl)palladium(II); Pd-PEPPSI-IPent = dichloro[!,3-bis(2,6- Di-3-pentylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II), Pd(dppf)2C12-DCM = 1,1'- bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex; Pd(dppf)C12 = [!,!'- Bis(diphenylphosphino)ferrocene]dichloropalladium(II); Pd(t-Bu3P)2 = Bis(tri-tert- butylphosphine)palladium(O); RockPhos = 2-di(tert-butyl)phosphino-2 ׳ 6 ׳, 4 ׳, -triisopropyl-3-methoxy-6- methylbiphenyl; RockPhos Pd G3 = [(2-di-tert-butylphosphino-3-methoxy-6-methyl-2',4',6'-triisopropyl-l,r- biphenyl)-2-(2-aminobiphenyl)]-palladium(II) methanesulfonate; RT = room temperature (~17-25°C); RuPhos = 2-dicyclohexylphosphino-2 ׳ 6 ׳, -diisopropoxybiphenyl; RuPhos Pd G3 = methanesulfonato(2- dicyclohexylphosphino-2',6'-di-iso-propoxy-l,l'-biphenyl)(2'-amino-l,l'-biphenyl-2-yl)-palladium(II); TEA = trifluoroacetic acid; THE = tetrahydrofuran; sat. = saturated; SEC = supercritical fluid chromatography; S Phos = 2-dicyclohexylphosphino-2,6-di-methyloxy-1,1 -biphenyl; Xantphos = 4,5-bis(diphenylphosphino)-9,9- dimethylxanthene; XPhos = 2-dicyclo-hexylphosphino-2',4',6'-triisopropylbiphenyl. NMRwas carried out at 300 - 500 MHz in deuterated DMSO and at a temperature of 20-30 °C unless otherwise stated. The following standard abbreviations are used for NMR data: s = singlet, d = doublet, m = multiplet, br = broad, dd = doublet of doublets, q = quartet, dt = doublet of triplets, etc. Preparative reverse phase HPLC(RP HPLC) using decreasingly polar mixture of eluents (e.g. water and MeCN) may typically involve a gradient over 10-20 minutes, at 40-50mL per minute, from a 95:5 mixture of solvents a 5:95 mixture. The following Column and Eluent conditions are used herein: Column A:Waters XSelect CSH C18 ODB column, 5 pm silica, 30 mm diameter, 100 mm length Eluent A:Decreasingly polar mixtures of water (containing 0.1% formic acid) and MeCN Eluent B:Decreasingly polar mixtures of water (containing 0.1% NH3) and MeCN WO 2024/189488 PCT/IB2024/052251 After HPLC (which often involves the presence of formic acid or trifluoroacetic acid in the eluent), the fractions containing desired product were in some cases treated with a suitable base as part of a further work- up step in order to ensure delivery of the title compound as a neutral molecule rather than a salt accordingly where "Basic Work-Up A" is mentioned: fractions containing the desired compound were concentrated to remove MeCN. The resulting, mainly-aqueous fractions were basified with NaHCO3 solution (e.g. 50 mL) and extracted into DCM (e.g. 3 x 100 mL). The combined organic solutions were washed with NaCI solution (e.g. 100 mL), dried (e.g. with Na2S04 or MgSO4) and concentrated to give the title compound. Concentration / Evaporation:where solutions or mixtures are described as being concentrated or evaporated, this is generally performed on a rotary evaporator under reduced pressure using a warm or hot water bath. Salts:Where certain compounds were obtained as an acid-addition salt, for example a mono-hydrochloride salt or a bis-hydrochloride salt, the stoichiometry of the salt is assumed, based on the number and nature of the basic groups in the compound, and may not have been determined experimentally e.g. by means of elemental analysis data. Chemical naming:In general Examples and Intermediate compounds were named using ACD Name, "Structure to Name" part of ChemDraw Ultra (CambridgeSoft) or Biovia Draw 2016.
Example 1: Intermediate la: 7-Bromo-4-chloro-l//-indole H l-Bromo-4-chloro-2-nitro-benzene (7x 100 g, 422.9 mmol) was added to THE (7x 700 mL) followed by dropwise addition of vinylmagnesium bromide (IM, 7x 1.69 L) at -60 °C and the mixture was stirred for l h. NH4C1 (aq, 2.0 L) was added to the solution at 0 °C and the product mixtures were combined and extracted into EtOAc (2.0 L). The organic layer was washed with NaCI solution (1.0 L) and the solvent was evaporated to dryness to afford crude product which was purified by column chromatography, elution gradient 10 to 25% Et2O:EtOAc to give the title compound (260 g, 34 %) as a yellow solid. 1H NMR (CDCI)) 5 6.64 (1H, s), 6.(1H, m), 7.18 (2H, m), 8.35 (1H, s).
Intermediate lb: 7-Bromo-4-chloro-l//-indole-3-carbonitrile 7-Bromo-4-chloro-l//-indole (4x 70.0 g, 303.7 mmol) was added to MeCN (4x 560 mL), followed bydropwise addition of chlorosulfonyl isocyanate (4x 51.6 g, 364.4 mmol, 4x 31.6 mL) at 0 °C and stirred for 2 WO 2024/189488 PCT/IB2024/052251 h. DMF (4x 266.0 g, 3.64 mol, 4x 280.0 mL) was then added dropwise and the solution was continued to stir at 0 °C for 2 h and then to RT for 16 h. Water was added dropwise at 10 °C until a solid formed which was isolated by filtration. The batches of solid were combined and triturated with Et2O:EtOAc:DCM (4:1:1) to give the title compound (105.0 g, 33.3%) as a white solid. 1H NMR 5 7.22 - 7.24 (1H, d, 1=8.4 Hz), 7.50 - 7.52 (1H, d, 1=8.4 Hz), 8.46 (1H, s); m/z; ES+ [M+H]+ = 255.1.
Intermediate 1c: Benzyl 4-(4-bromophenyl)piperidine-l-carboxylate Benzyl carbonochloridate (14.27 mL, 96.17 mmol) was added dropwise over 5 mins to a solution of 4-(4- bromophenyl)piperidine (25.0 g, 100.98 mmol) and DIPEA (42.0 mL, 240.43 mmol) in2-MeTHF (250 mL) at °C. The resulting mixture was stirred at RT for 24 h and then quenched with water (250 mL). The layers were separated and the organic layer was washed with water (250 mL), NaCI solution (50 mL), dried using MgSO4, filtered and evaporated to afford crude product as a colourless oil. The oil was diluted with IPA:water (1:1, 200 mL) and was stirred at RT for 1 h. The resulting solid was collected by filtration, washed with water (2 x 20 mL) and dried under vacuum at 50 °C for 16 h to give the title compound (32.9 g, 91 %) as a white solid. 1H NMR 5 1.50 (2H, qd), 1.75 (2H, d), 2.72 (1H, m), 2.90 (2H, s), 4.14 (2H, d), 5.10 (2H, s), 7.18 - 7.(2H, m), 7.29 - 7.44 (5H, m), 7.45 - 7.53 (2H, m).
Intermediate Id: Benzyl 4-{4-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]phenyl}piperidine-l-carboxylate To 4-( 1,3-dioxolan-2-y!)piperidine (15.02 g, 95.52 mmol), benzyl 4-(4-bromophenyl)piperidine-l-carboxylate (32.5 g, 86.83 mmol) and C52CO3 (56.6 g, 173.67 mmol) in 1,4-dioxane (325 ml) under nitrogen was added tri-tert-butylphosphonium tetrafluoroborate (2.52 g, 8.68 mmol). The mixture was degassed with nitrogen followed by addition of Pd(LBu3P)2 (2.21 g, 4.34 mmol). The resulting mixture was stirred at 100 °C for 20 h, cooled to RT and the solid was filtered under vacuum. The solid was washed with 1,4-dioxane (3x 65 ml) and the filtrate was evaporated to afford a pale yellow solid. The solid was suspended in cyclopentyl methyl etherheptane (1:10, 300 ml), stirred at 50 °C for 30 mins and then left to cool to RT for a further 2 h. The solid was filtered to give the title compound (28.9 g, 73.9 %) as a cream solid. 1H NMR 5 1.43 (4H, m), 1.57 - 1.67 (1H, m), 1.73 (4H, m), 2.54 - 2.63 (3H, m), 2.89 (2H, s), 3.65 (2H, m), 3.75 - 3.93 (4H, m), 4.13 (2H, m), 4.61 (1H, d), 5.09 (2H, s), 6.85 (2H, m), 7.06 (2H, m), 7.29 - 7.44 (5H, m); m/z; ES+ [M+H]+ = 451.5.
WO 2024/189488 PCT/IB2024/052251 Intermediate le: 4-(l,3-Dioxolan-2-yl)-l-[4-(piperidin-4-yl)phenyl]piperidine Benzyl 4-{4-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]phenyl}piperidine-l-carboxylate (762 mg, 1.69 mmol) was dissolved in EtOH (20 mL) and Pd/C (10%, 180 mg, 0.17 mmol) was added under nitrogen. The reaction was stirred under an atmosphere of hydrogen at 4 bar for 16 h. The catalyst was then filtered off through a pad of Celite®, the solvent was removed under reduced pressure and azeotroped with excess MeCN. The product was dried in a vacuum oven for 2 h to give the title compound (449 mg, 84 %) as a waxy white solid. 1H NMR 1.33 - 1.51 (4H, m), 1.54 - 1.68 (3H, m), 1.72 (2H, d), 2.4 - 2.46 (1H, m), 2.54 - 2.64 (4H, m), 3.01 (2H, d), 3.64 (2H, d), 3.74 - 3.94 (4H, m), 4.61 (1H, d), 6.85 (2H, d), 7.04 (2H, d); m/z; ES+ [M+H]+ = 317.7.
Intermediate If: 4-Chloro-7-(4-{4-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile [Pd(cinnamyl)Cl]2 (0.218 g, 0.42 mmol) and CPhos (0.735 g, 1.68 mmol) were added to a degassed mixture of 4-( 1,3-dioxolan-2-yl)-l-[4-(4-piperidyl)pheny !]piperidine (11.72 g, 37.03 mmol) and7-bromo-4-chloro-1H- indole-3-carbonitrile (intermediate lb) (8.6 g, 33.66 mmol) in 2-MeTHE (86 mL). LHMDS (IM in THF, 1mL, 117.81 mmol) was added dropwise and the reaction was stirred at 50 °C for 1.5 h. The reaction was left to cool to RT, diluted with water (200 mL) and stirred for 10 mins. A precipitate formed which sat between the two layers, this solid was collected by filtration, was washed with water (25 mL) and vacuum oven dried at °C overnight to give the title compound (13.95 g, 84 %) as a cream solid. 1H NMR 5 1.39 (2H, m), 1.56 - 1.67 (1H, m), 1.67 - 1.78 (2H, m), 1.83 (2H, m), 1.88 - 2.03 (2H, m), 2.58 (3H, td), 2.71 - 2.82 (2H, m), 3.(2H, d), 3.66 (2H, d), 3.72 - 3.82 (2H, m), 3.82 - 3.91 (2H, m), 4.60 (1H, d), 6.83 (1H, d), 6.88 (2H, d), 7.04 - 7.21 (3H, m), 8.28 (1H, s), 12.21 (1H, s); m/z; ES+ [M+H]+ = 491.5.
Intermediate 1g: 4-Chloro-7-{4-[4-(4-formylpiperidin-l-yl)phenyl]piperidin-l-yl}-n/-indole-3-carbonitrile HCI (2M, 274 mL, 547.83 mmol) was added portion wise to a suspension of 4-chloro-7-(4-{4-[4-(l,3- dioxolan-2-yl)pipcridin-l-yl|phcnyl]pipcridin-l-yl)-l//-indolc-3-carbonilrilc (13.45 g, 27.39 mmol) in THF (135 mL) at RT. The resulting solution was stirred at 60 °C for 4 h. The resulting solution was pooled in an ice WO 2024/189488 PCT/IB2024/052251 bath and neutralised with NaOH (2M, 180 mL) until ~pH7 is reached. The product was filtered off and the solid was washed with water (20 mL) and dried under vacuum to give the title compound (12.85 g) as a cream solid which was used without further purification. 1H NMR 5 1.64 (2H, s), 1.83 (2H, d), 1.88 - 2.06 (4H, m), 2.71 - 2.92 (4H, m), 3.40 (3H, d), 3.51 - 3.62 (3H, m), 6.85 (1H, d), 6.99 (2H, s), 7.15 (3H, d), 8.30 (1H, d), 9.63 (IH, s), 12.25 (1H, s); m/z; ES+ [M+H]+ = 447.4.
Intermediate ih: 3-(5-Bromo-l-oxo-l,3-dihydro-2Zf-isoindol-2-yl)piperidine-2,6-dione o DIPEA (25 mL, 143.52 mmol) was added to methyl 4-bromo-2-(bromomethy!)benzoate (14.65 g, 47.mmol) and 3-aminopiperidine-2,6-dione hydrochloride (11.74 g, 71.35 mmol) inMeCN (200 mL) under nitrogen. The resulting suspension was stirred at 80 °C for 48 h. The reaction mixture was cooled to RT and filtered. The solid was washed with MeCN (60 mL), MeCN:Et2O (2:3, 50 mL) and Et20 (2 x 50 mL) to give the title compound (13.1 g, 85%) as a dark blue solid; 1H NMR 5 1.95 - 2.08 (IH, m), 2.34 - 2.46 (IH, m), 2.57-2.65 (IH, m), 2.91 (IH, m), 4.35 (IH, d), 4.48 (IH, d), 5.11 (IH, dd), 7.67 (IH, d), 7.72 (IH, dd), 7.- 7.96 (IH, m), 10.98 (IH, sm/z: ES+ [M+H]+ = 323.0.
Intermediate li: tert-Butyl 4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazine-l-carboxylate CS2C03(57.4 g, 176 mmol) and Pd-PEPPSI-IPent (2.33 g, 2.94 mmol) were added in one portion to a degassed solution of tert-butyl piperazine-1-carboxylate (14.22 g, 76.36 mmol) and 3-(5-bromo-l-oxo-l,3- dihydro-2rt-isoindol-2-yl)piperidine-2,6-dione (19.0 g, 58.74 mmol) in 1,4-dioxane (590 mL) under nitrogen. The resulting mixture was stirred at 90 °C for 24 h. The reaction mixture was cooled to RT, diluted with DCM (IL) and washed sequentially with 5% AcOH in water (500 mL) and NaCI solution (500 mL). The organic layer was dried over MgSO4, fdtered and evaporated to afford crude product. The crude product was triturated with EtOAc (250 mL), the solid collected by filtration, washed with Et20 (100 mL) and dried under vacuum to give the title compound (22.1 g, 88%) as a grey solid; 1H NMR 5 1.43 (9H, s), 1.96 (IH, d), 2.31 - 2.41 (IH, m), 2.59 (IH, d), 2.87 (IH, s), 3.29 (4H, d), 3.47 (4H, d), 4.22 (IH, d), 4.34 (IH, d), 5.05 (IH, dd), 7.07 (2H, d), 7.54 (IH, d), 10.92 (IH, s); m/z: ES+ [M+H]+ = 429.2.
Intermediate ij: 3-[l-Oxo-5-(piperazin-l-yl)-l,3-dihydro-2Z/-isoindol-2-yl]piperidine-2,6-dione hydrochloride WO 2024/189488 PCT/IB2024/052251 A solution of 4M HC1 in 1,4-dioxane (8.75 mL, 35.0 mmol) was added to ter/-Butyl 4-[2-(2,6-dioxopiperidin- 3-yl)-l-oxo-2,3-dihydro-l/7-isoindol-5-yl]piperazine-l-carboxylate (1.50 g, 3.50 mmol) in 1,4-dioxane (2 mL) at RT. The reaction was stirred at RT for 1 h. EtOAc (5 mL) was added and the reaction mixture stirred for mins. The resulting precipitate was collected by filtration and the solid washed with EtOAc (2x5 mL) and then dried under vacuum to give the title compound (1.08 g, 85%) as a dark grey solid (HC1 salt); 1H NMR 1.97 (1H, dd), 2.36 - 2.44 (1H, m), 2.60 (1H, d), 2.84 - 2.99 (1H, m), 3.23 (4H, s), 3.5 - 3.57 (4H, m), 4.(1H, s), 4.34 (1H, s), 5.06 (1H, dd), 7.11-7.18 (2H, m), 7.59 (1H, d), 9.17 (2H, s), 10.93 (1H, s); m/r. ES+ [M+H]+ = 329.0.
Example 1: 4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-n/-indole-3-carbonitrile 4-Chloro-7-{4-[4-(4-formylpiperidin-l-yl)phenyl]piperidin-l-yl}-l/7-indole-3-carbonitrile (intermediate 1g) (9.3 g, 20.81 mmol) and 3-[l-oxo-5-(piperazin-l-yl)-l,3-dihydro-2/7-isoindol-2-yl]piperidine-2,6-dione hydrochloride (intermediate ij) (7.97 g, 21.85 mmol) were stirred in NMP (65.0 mL) atRT followed by DIPEA (3.81 mL, 21.85 mmol). After stirring for 5 h, sodium triacetoxyborohydride (5.29 g, 24.97 mmol) was added in one portion and was stirred at RT 30 mins. The reaction was quenched with water (260 mL), stirred for 30 mins and then filtered under vacuum. The solid was washed with water (10 mL) and was dissolved in IPA:DCM (1:3, 720 mL), was washed withNaHCO3 solution (180 mL), NaCl solution (180 mL), dried over MgSO4 and filtered to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 50 to 100% EtOAc in heptane followed by 0-7% MeOH in DCM to afford a cream solid. The solid was suspended in MeCN (65 mL) and stirred at 80 °C for 1 h. The suspension was left to cool to RT for h and was filtered under vacuum to give the title compound (6.06 g, 38.4 %) as a white solid. 1H NMR 1.17-1.29 (2H, m), 1.64 - 1.74 (1H, m), 1.83 (4H,brt), 1.91 -2.02 (3H, m), 2.23 (2H, brd), 2.31 -2.43 (2H, m), 2.51 - 2.54 (4H, m), 2.54 - 2.66 (4H, m), 2.78 (2H, brt), 2.85 - 2.95 (1H, m), 3.29 - 3.31 (4H, m), 3.(2H, brd), 3.64 (2H, brd), 4.21 (1H, d), 4.33 (1H, d), 5.05 (1H, dd), 6.86 (1H, d), 6.91 (2H, d), 7.05 - 7.(1H, m), 7.07 (1H, s), 7.13 (2H, br d), 7.16 (1H, d), 7.53 (1H, d), 8.32 (1H, s), 10.94 (1H, s), 12.26 (1H, br s); m/z; ES+ [M+H]+ = 759.8.
WO 2024/189488 PCT/IB2024/052251 Example 2 Intermediate 2a: 7-Bromo-4-fluoro-l//-indole H l-Bromo-4-fluoro-2-nitro-benzene (6x 100.0 g, 454 mmol) was dissolved in THF (6x 700.0 mL) at -45 °C followed by dropwise addition of vinylmagnesium bromide (IM, 6x 1.82 L) under nitrogen and stirred for mins. NH4C1 (aq, 2.0 L) was added to the solution and the 6 batches were combined. THF was evaporated and the product was extracted with EtOAc (9.0 L), washed with NaCI solution (1.0 L), dried with Na2SO4, filtered and the solvent evaporated. The crude product was purified by column chromatography, elution gradient 0 to 20% Et2O:EtOAc to give the title compound (148.5 g, 24.3%) as a brown oil. 1H NMR 5 6.64 (1H, s), 6.(1H, m), 7.27 (1H, m), 7.45 (1H, s), 11.65 (1H, s).
Intermediate 2b: 7-Bromo-4-fluoro-l//-indole-3-carbonitrile 7-Bromo-4-fluoro-l//-indole (140.0 g, 654 mmol) was added to MeCN (848 mL) followed by chlorosulfonyl isocyanate (111.1g, 785 mmol, 68.2 mL) dropwise at 0 °C and stirred for 2 h. DMF (574.0 g, 7.85 mol, 6mL) was added dropwise into the solution at 0 °C and stirred for a further 2 h. Water (1.6 L) was added and the resulting solid was washed with water (100.0 mL) to obtain a yellow solid. The yellow solid was extracted into EtOAc (500.0 mL), dried with Na2S04 and concentrated under reduced pressure. The crude product was triturated with Et20:EtOAc (4:1, 800.0 mL) to give the title compound (100.78 g, 62.9%) as a yellow solid. 1H NMR 5 7.03 (1H, m), 7.50 (1H, m), 8.40 (1H, m), 12.77 (1H, s); m/z; ES־ [M-H]237.0 = ־.
Intermediate 2c: 7-(4-{4-[4-(l,3-Dioxolan-2-yl)piperidin-l-yl]phenyl}piperidin-l-yl)-4-fluoro-l//-indole-3-carbonitrile [Pd(cinnamyl)Cl]2 (0.068 g, 0.13 mmol), CPhos (0.228 g, 0.52 mmol), 4-(l,3-dioxolan-2-yl)-l-[4-(piperidin- 4-yl)phenyl]piperidine intermediate le (3.64 g, 11.50 mmol) and 7-bromo-4-fluoro-lH-indole-3-carbonitrile intermediate 2b (2.5 g, 10.46 mmol) were degassed in 2-MeTHF (25 mL) for 10 mins. LHMDS (IM in THF, 36.6 mL, 36.60 mmol) was added in one portion and the reaction was stirred at 50 °C for 1.5 h. The reaction WO 2024/189488 PCT/IB2024/052251 mixture was then cooled to RT, diluted with water (65 mL) and stirred for 10 mins. A precipitate formed which sat between the two layers, this was collected by filtration and was washed with water (25 mL) and vacuum oven dried at 50 °C for 16 h to give the title compound (3.41 g, 68.7 %) as a cream solid. 1H NMR 1.39 (2H, qd), 1.56 - 1.67 (1H, m), 1.67 - 1.77 (2H, m), 1.77 - 1.86 (2H, m), 1.94 (2H, qd), 2.52 - 2.64 (3H, m), 2.68 - 2.8 (2H, m), 3.36 (2H, d), 3.66 (2H, d), 3.72 - 3.91 (4H, m), 4.60 (1H, d), 6.80 (1H, dd), 6.85 - 6.94 (3H, m), 7.12 (2H, d), 8.24 (1H, s), 12.19 (1H, s); m/z; ES+ [M+H]+ = 475.5.
Intermediate 2d: 4-Fluoro-7-{4-[4-(4-formylpiperidin-l-yl)phenyl]piperidin-l-yl}-lZ/-indole-3-carbonitrile To a stirred suspension of 7-(4-[4-|4-( 1.3-dioxolan-2-y !)pipcridin-1 -y 1 |phcny 1) pipcridin-1 -y l)-4-fluoro-1 //- indole-3-carbonitrile (3.41 g, 7.19 mmol) in THF (34.0 mL) at RT was added HC1 (2M, 71.9 mL, 143.mmol). The mixture was stirred at 60 °C for 2.5 h, cooled in an ice bath and neutralised with NaOH (2M) until pH7 was reached. The mixture was extracted with 2-MeTHF (2x 100 mL) then the organic extracts were washed with NaO solution:water (1:1, 50 mL), dried by passing through a phase separating cartridge, filtered and evaporated to afford the crude product. The crude product was slurried in MeCN (50 mL) at 80 °C for l h and then cooled to RT over 16 h. The solid was collected by filtration, washed with excess MeCN and dried under vacuum at 45 °C to give the title compound (2.45 g, 79 %) as a cream solid. 1H NMR 5 1.53 - 1.66 (2H, m), 1.78 - 1.88 (2H, m), 1.88 - 2.03 (4H, m), 2.43 - 2.48 (1H, m), 2.53 - 2.63 (1H, m), 2.7 - 2.85 (4H, m), 3.37 (2H, d), 3.55 (2H, dt), 6.82 (1H, dd), 6.87 - 6.96 (3H, m), 7.14 (2H, d), 8.26 (1H, d), 9.64 (1H, d), 12.(1H, s); m/z; ES- [M-H]429.3 = ־.
Example 2: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-4-fh1oro-l//-indole-3-carbonitrile 4-Fluoro-7-{4-[4-(4-formylpiperidin-l-yl)phenyl]piperidin-l-yl}-lH-indole-3-carbonitrile (3.46 g, 8.mmol) and 3-[l-oxo-5-(piperazin-l-yl)-l,3-dihydro-2/7-isoindol-2-yl]piperidine-2,6-dione HC1 intermediate ij (3.08 g, 8.44 mmol) were suspended in DCM (25.0 mL) and IP A (8.3 mL) at RT. DIPEA (1.47 mL, 8.mmol) was added and the suspension was stirred at RT for 2 h. Sodium triacetoxyborohydride (2.04 g, 9.mmol) was then added and the suspension was stirred at RT for 5 mins. The reaction mixture was diluted with WO 2024/189488 PCT/IB2024/052251 IPA:DCM (1:3, 135 mL), washed with water (70 mL), NaHCO3 solution (70 mL), NaCl solution (75 mL) and dried by passing through a phase separating cartridge. The solvent was evaporated to afford the crude product and was purified by flash silica chromatography, elution gradient 50 to 100% EtOAc in heptane followed by to 10% MeOH in DCM. The fractions were evaporated and the product was stirred in MeCN (35 mL) at 80 °C for l h and then cooled to RT for 16 h. The solid was collected by filtration, washed with MeCN (10 mL) and dried under vacuum at 45 °C to give the title compound (3.5 g, 58.6 %) as a cream solid. 1H NMR 5 1.16 - 1.(2H, m), 1.63 - 1.75 (1H, m), 1.76 - 1.88 (4H, m), 1.9 - 2.03 (3H, m), 2.23 (2H, d), 2.31 - 2.42 (1H, m), 2.(4H, d), 2.54 - 2.68 (4H, m), 2.71 - 2.81 (2H, m), 2.85 - 2.96 (1H, m), 3.31 (4H, s), 3.37 (2H, d), 3.64 (2H, d), 4.21 (1H, d), 4.33 (1H, d), 5.05 (1H, dd), 6.82 (1H, dd), 6.86 - 6.97 (3H, m), 7.06 (2H, d), 7.13 (2H, d), 7.52 (1H, d), 8.26 (1H, s), 10.93 (1H, s), 12.23 (1H, s); m/z; ES+ [M+H]+ = 743.5.
Examples 3 & 4 The enantiomers of 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/7-isoindol-5-y!]piperazin-1 -yl}methy!)piperidin-1 -yl]phenyl}piperidin-l -yl)-4-fluoro-1 //-indolc-3 -carbonitrile (example 2) (30 mg, 0.04 mmol) were separated on a Sepiatec 100 SEC using SFC conditions Regis (R,R) Whelk-01, 21.x 250 mm, 5 micron, 50% MeOH/MeCN 3:7 / 50% scCO2 at a flow rate of 60 mL/min, 40 °C to give, in order of elution, example 3(isomer 1, 9.0 mg, 30.0 %) and example 4(isomer 2, 7.2 mg, 24.0 %) as white solids.
Example 3: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-4-fluoro-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR 5 1.17-1.31 (2H, m), 1.64 - 1.76 (1H, m), 1.78- 1.88 (4H, m), 1.89-2.03 (3H, m), 2.23 (2H, d), 2.34 - 2.4 (1H, m), 2.51 - 2.53 (4H, m), 2.53 - 2.55 (1H, m), 2.55 - 2.59 (1H, m), 2.61 (2H, d), 2.71 - 2.(2H, m), 2.84-2.96 (1H, m), 3.25 - 3.31 (4H, m), 3.37 (2H, d), 3.64 (2H, d), 4.16-4.37 (2H, m), 5.04 (1H, dd), 6.82 (1H, dd), 6.87 - 6.96 (3H, m), 7.02 - 7.09 (2H, m), 7.13 (2H, d), 7.52 (1H, d), 8.26 (1H, d), 10.(1H, s), 12.23 (1H, s); m/r. ES+ [M+H]+ = 743.5; >99% ee.
Example 4: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-4-fluoro-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 1H NMR 5 1.24 (3H, s), 1.63 - 1.76 (1H, m), 1.77 - 1.88 (4H, m), 1.89 - 2.03 (3H, m), 2.23 (2H, d), 2.34 - 2.4 (1H, m), 2.51 - 2.56 (4H, m), 2.55 - 2.59 (1H, m), 2.59 - 2.65 (2H, m), 2.71 - 2.81 (2H, m), 2.84 - 2.(1H, m), 3.30 (4H, s), 3.34 - 3.41 (2H, m), 3.6 - 3.68 (2H, m), 4.16 - 4.38 (2H, m), 5.04 (1H, dd), 6.82 (1H, dd), 6.88 - 6.96 (3H, m), 7.03 - 7.09 (2H, m), 7.13 (2H, d), 7.52 (1H, d), 8.26 (1H, d), 10.93 (1H, s), 12.(1H, s); m/z; ES+ [M+H]+ = 743.5; >99% ee.
Example 5 Intermediate 5a: tert-Butyl 4-(4-nitro-l//-indol-l-yl)piperidine-l-carboxylate 4-Nitro-l//-indole (5x 95.0 g, 585 mmol), tert-butyl 4-[(methanesulfonyl)oxy]piperidine-l-carboxylate (5x 409.0 g, 1.46 mol) and C52CO3 (5x 573.0 g, 1.76 mol) were added to DMF (1.5 L). The solution was degassed with nitrogen and stirred at 80 °C for 12 h. Water (10.0 L) was added to each mixture and the batches were combined by extracting with EtOAc (6.0 L). The organic layer was washed with NaO solution (10.0 L x3) and dried with Na2S04. The solvent was evaporated and the crude product was purified by re-crystallisation from MTBE:Et20 (1:4, 500.0 mL) at RT for 20 mins. The solid was filtered and dried under vacuum to give the title compound (910.0 g) as a brown solid. 1H NMR 5 1.39 (s, 9H), 1.82-1.93 (m, 4H), 2.85 (s, 2H), 4.08- 4.11 (m, 2H), 4.69-4.75 (m, 1H), 7.02 (d, J = 3.2 Hz, 1H), 7.32 (t, J = 8.4 Hz, 1H), 7.92 (d, J = 3.6 Hz, 1H), 8.05 (d, J = 7.6 Hz, 1H), 8.13 (d, J = 8.4 Hz, 1H).
Intermediate 5b: tert-Butyl 4-(4-am ino-l//-indol-l-yl)piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 tert-Butyl 4-(4-nilro-1//-indol-1-y !)piperidine-1-carboxy laic (7x 140.0 g, 405 mmol) was added to 7 separate solutions of Pd/C (20.0 g, 10% purity) in MeOH:THF (1:1, 1.0 L). The solutions were degassed with nitrogen and stirred for 12 h under an atmosphere of hydrogen (30 PSI). The 7 batches were combined by filtering off Pd/C and evaporating the solvent. The resulting solid was used without further purification to give the title compound (770.0 g, 86%) as a brown solid. 1H NMR 5 1.43 (s, 9H), 1.86-1.98 (m, 4H), 3.46-3.82 (m, 2H), 4.12 (d, J = 10.4 Hz, 2H), 4.59 (t, J = 3.6 Hz, 1H), 5.36 (s, 2H), 6.34 (d, J = 3.2 Hz, 1H), 6.89 (d, J = 7.2 Hz, 1H), 7.16 (t, J = 7.6 Hz, 1H), 7.56 (t, J = 3.6 Hz, 1H).
Intermediate 50: tert-Butyl 4-{4-[(3-methoxy-3-oxopropyl)amino]-lZ/-indol-l-yl}piperidine-l-carboxylate tert-Butyl 4-(4-amino-1 //-indol-1 -y !)piperidine-1 -carboxylate (5x 175.0 g, 555 mmol) was added to 5 separate portions of MeOH (1.2 L). AcOH (5x 499.0 g, 8.32 mol, 476 mL) was added to each mixture followed by methyl acrylate (471.0 g, 5.47 mol, 4923 mL) and was stirred at 80 °C for 18 h. The batches were combined and the solvent was evaporated to afford crude product which was extracted with EtOAc (10.0 L) and washed with NaHCO3 (15.0 L). The aqueous layer was back extracted with EtOAc (5.0 L x3). The combined organics were washed with NaCI solution and dried with Na2S04. The solvent was evaporated to give the title compound (1.08 kg, crude) as a black oil and was used without further purification. 1H NMR 5 1.79 (s, 9H), 1.89-1.91 (m, 2H), 1.98 (s, 1H), 2.65 (t, 6.8 Hz, 1H), 2.67 (s,2H), 3.32-3.42 (m, 1H), 3.51 (s, 1H), 3.61 (s, 2H), 4.02-4.09 (m2 ״H), 4.11-4.41 (m, 1H), 6.10 (d, 7.2 Hz, 1H), 6.39-6.54 (m, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.77-6.89 (m, 1H), 7.23 (s, 1H), 11.89 (s, 1H).
Intermediate 5d: tert-Butyl 4-{4-[carbamoyl(3-methoxy-3-oxopropyl)amino]-lfl-indol-l-yl}piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 100 tert-Butyl 4-{4-[(3-methoxy-3-oxopropyl)amino]-lrt-indol-l-yl}piperidine-l-carboxylate (6x 200 g, 4mmol) were added to DCM (6x 1.0 L). AcOH (6x 2.1 kg, 34.97 mol, 2.0 L) in DCM (6x 1.0 L) was added to the mixture followed by potassium cyanate (6x 40.4 g, 498 mmol) and stirred at RT for 2 h. The 6 batches were combined and water (5.0 L) was added to the mixture. DCM (8 L x2) was added to the extraction which was washed with NaO solution. The organic layer was dried with Na2S04 and evaporated. The residue was purified by column chromatography, elution gradient 30:1 to 1:1 Et2O:EtOAc to give the title compound (260.0 g, 19.6%) as a brown solid. 1H NMR 5 1.82 (s, 9H), 1.93-1.98 (m,4 H), 2.44-2.50 (m, 2H), 2.98 (s, 2H), 3.46 (s, 3H), 3.84 (s, 2H), 4.66 (d, J = 8.4 Hz, 2H), 4.66-4.78 (m, 1H), 5.36 (s, 2H), 6.34 (d, J = 3.2 Hz, 1H), 6.90 (d, J = 7.6 Hz, 1H), 7.16 (t, J = 8.4 Hz, 1 H), 7.56 (t, J = 4 Hz, 2H).
Intermediate 5e: tert-Butyl 4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-n/-indol-l-yl]piperidine-l-carboxylate tert-Butyl 4-{4-[carbamoyl(3-methoxy-3-oxopropyl)amino]-lrt-indol-l-yl}piperidine-l-carboxylate (3x 105.g, 236 mmol) inMeOH (3x 779.0 g, 24.3 mol, 3x 984 mL) were added to 3 separate vessels of MeOH (1.0 L) followed by MeONa/MeOH (42.5 g, 236 mmol, 30% purity). The reaction was stirred at RT for 2 h and the combined solids were collected by filtration. The filtrate was evaporated and purified by column chromatography, elution gradient 10:1 DCM:MeOH to give the title compound (180 g, 70.7%) as a white solid. 1H NMR 5 1.43 (s, 9H), 1.92-1.81 (m, 4H), 2.75 (t, J = 6.8 Hz, 2H), 2.7 5(s, 2H), 3.37-3.77 (m, 2H), 4.12 (d, J = 5.6 Hz, 2H), 4.59-4.60 (m, 1H), 6.41 (d, J = 3.2 Hz, 1 H), 6.96 (d, J = 7.6 Hz, 1H), 7.15 (t, J = 7.Hz, 1H), 7.52-7.54 (m, 2 H), 10.3 (s, 1H).
Intermediate 5f: l-[l-(Piperidin-4-yl)-lZ/-indol-4-yl]-l,3-diazinane-2,4-dione tosylate WO 2024/189488 PCT/IB2024/052251 101 tert-Butyl 4-|4-(2.4-dioxo-l.3-diazinan-l-yl)-l//-indol-l-yl|pipcridinc-l-carboxylatc (140.0 g, 339.41 mmol) in a solution of MeCN (300 mL) was added to p-toluenesulfonic acid hydrate (82.6 g, 434 mmol) in MeCN (560 mL) dropwise at RT. The reaction was stirred at 60 °C for 1 h. p-toluenesulfonic acid hydrate (6.46 g, 33.9 mmol) was added to the mixture and stirred at 60 °C for a further 1 h. The reaction was then filtered and dried under vacuum to give the title compound (120.0 g, 70.8%) as a grey solid. 1H NMR 5 2.06-2.16 (m, 4H), 2.29 (s,3H), 2.76 (t, J = 6.8 Hz, 2H), 3.19-3.45 (m, 2H), 3.45-3.48 (m, 3H), 3.77 (t, J = 6.4 Hz, 2H), 4.42-4.(m, 1H), 6.46 (d, J = 3.2 Hz, 1H), 6.99 (d, J = 7.6 Hz, 1H), 7.10 (d, J = 44.0 Hz, 2H), 7.14 (t, J = 14.0 Hz, 1H), 7.40 (d, J = 3.6 Hz, 1H), 7.52 (d, J = 8.0 Hz, 1 H), 7.56 (d, J = 8.4 Hz, 2H), 8.41(d, J = 10.0 Hz, 1H), 8.68 (d, J = 10.0 Hz, 1 H), 10.3 (s, 1H); m/z; ES+ [M+H]+ = 313.1.
Example 5: 4-Chloro-7-(4-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZr ־indol-l-yl]piperidin-l-yl}methyl)piperidin- l-yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile A suspension of intermediate 1g (2.79 g, 6.24 mmol) and l-| l-(pipcridin-4-yl)-l//-indol-4-yl|-l.3-diazinanc- 2,4-dione TsOH (intermediate 5f) (3.18 g, 6.55 mmol) in NMP (27.0 mL) was stirred at RT for 2.5 h. Sodium triacetoxyborohydride (1.58 g, 7.49 mmol) was added and the solution was continued to stir at RT for l h. The reaction mixture was quenched with water (100 mL) and the suspension was stirred at RT for 30 mins. The solid was collected by filtration, washed with water (100 mL) and extracted into DCMTPA (3:1, 500 mL). The organics were washed with NaHCO3 solution (150 mL) and NaCI solution (100 mL), dried over a phase separating cartridge and the solvent was evaporated to dryness. The crude product was purified by flash silica chromatography, elution gradient 50 to 100% EtOAc in heptane followed by 100% EtOAc for 15 mins, 0 to 10% MeOH in DCM over 25 mins and 10% MeOH in DCM for 20 mins to afford product as a solid. The product was slurried in MeCN (100 mL) at 80 °C for l h and then left to stir to RT for 18 h. The solid was collected by filtration, washing with MeCN and dried under vacuum at 50 °C to give the title compound (2.g, 54.3 %) as an off white solid. 1H NMR S 1.15 - 1.32 (3H, m), 1.61 - 1.74 (1H, m), 1.79 - 1.9 (4H, m), 1.- 2.04 (6H, m), 2.13 - 2.22 (2H, m), 2.26 (2H, d), 2.51 - 2.53 (1H, m), 2.53 - 2.65 (2H, m), 2.73 - 2.82 (3H, m), 3.01 (2H, d), 3.42 (2H, d), 3.65 (2H, d), 3.78 (2H, t), 4.32 - 4.43 (1H, m), 6.42 (1H, d), 6.86 (1H, d), 6.88 WO 2024/189488 PCT/IB2024/052251 102 -6.95 (2H, m), 6.96 (1H, d), 7.09 -7.2 (4H, m), 7.51 (1H, d), 7.54 (1H, d), 8.31 (1H, s), 10.31 (1H, s), 12.(1H, s); m/z; ES+ [M+H]+ = 743.4.
Example 6: 7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- H O A suspension of intermediate 2d (2.34 g, 5.44 mmol) and intermediate 5f (2.77 g, 5.71 mmol) in NMP (23.mL) was stirred at RT for 2.5 h. Sodium triacetoxyborohydride (1.38 g, 6.52 mmol) was added and the solution was continued to stir at RT for l h. The reaction mixture was quenched with water (100 mL) and the suspension was stirred at RT for 30 mins. The solid was collected by filtration and was washed with water. The solid was slurried in MeCN (50 mL) at 80 °C for 1 h and then left to cool to RT for 18 h. The suspension was filtered under vacuum and washed with MeCN to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 50 to 100% EtOAc in heptane over 15 mins followed by 100% EtOAc for 15 mins, 0 to 10% MeOH in DCM over 25 mins and 10% MeOH in DCM for 20 mins to afford product as a solid. The product was slurried in MeCN (100 mL) at 80 °C for l h and then left to stir to RT for h. The solid was collected by filtration, washing with MeCN and dried under vacuum at 50 °C to give the title compound (2.22 g, 56.2 %) as an off white solid. 1H NMR 5 1.18- 1.3 (2H, m), 1.6 - 1.73 (1H, m), 1.(4H, d), 1.9 - 2.06 (6H, m), 2.13 - 2.23 (2H, m), 2.26 (2H, d), 2.55 - 2.58 (1H, m), 2.58 - 2.68 (2H, m), 2.- 2.82 (4H, m), 3.01 (2H, d), 3.38 (2H, d), 3.65 (2H, d), 3.78 (2H, t), 4.3 - 4.46 (1H, m), 6.42 (1H, d), 6.(1H, dd), 6.86 - 7.04 (4H, m), 7.14 (3H, t), 7.44 - 7.6 (2H, m), 8.26 (1H, s), 10.31 (1H, s), 12.24 (1H, s); m/z; ES+[M+H]+ = 727.5.
Example 7 Intermediate 7a: Methyl 4-bromo-2-methoxy-6-methylbenzoate A 25% methanolic solution of sodium methanolate (512 pL, 2.24 mmol) was added dropwise to a stirred solution of methyl 4-bromo-2-fluoro-6-methylbenzoate (527 mg, 2.13 mmol) in DMF (10 mL) at RT under nitrogen. The resulting mixture was stirred at RT for 18 h. The reaction mixture was cooled to 0 °C and quenched with EtOAc (20 mL) and HCI (IM, 10 mL). The phases were separated and the aqueous phase was yl]phenyl}piperidin-l-yl)-4-fluoro-lZf-indole-3-carbonitrile O o WO 2024/189488 PCT/IB2024/052251 103 extracted with EtOAc (2 x 30 mL). The organic phases were combined, dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 25% EtOAc in heptane to give the title compound (0.410 g, 74 %) as a colourless oil which solidified on standing; 1H NMR (CDC13) 5 2.25 (3H, s), 3.81 (3H, s), 3.90 (3H, s), 6.91 (1H, d), 6.98 (1H, dd); m/z; ES+[M+H]+ = 227.3.
Intermediate 7b: 3-(5-Bromo-7-methoxy-l-oxo-l,3-dihydro-2Z/-isoindol-2-yl)piperidine-2,6-dione NBS (1.57 g, 8.84 mmol) was added to a stirred solution of methyl 4-bromo-2-methoxy-6-methylbenzoate (1.43 g, 5.53 mmol) and AIBN (0.182 g, 1.11 mmol) in /-butyl acetate (20 mL). The reaction was stirred at 100 °C for 3 h. The reaction was cooled to RT, diluted with EtOAc (50 mL) and washed with water (50 mL). The organic layer was passed through a phase sep cartridge and concentrated. The crude product was purified by flash silica chromatography, elution gradient 0 to 15% EtOAc in heptane to afford 4-bromo-2- (bromomethyl)-6-methoxybenzoate (1.49 g, 80 %) as a yellow gum, that was 70% pure. The solid was added to MeCN (20 mL) followed by DIPEA (1.65 ml, 9.29 mmol) and 3 -aminopiperidine-2,6-dione hydrochloride (0.510 g, 3.10 mmol) at RT. The resulting solution was stirred at 80 °C for 16 h. The reaction mixture was cooled to 0 °C and the solid was collected by filtration. The solid was washed with MeCN (50 mL) and Et(50 mL) and dried under vacuum to give the title compound (0.761 g, 39% over 2 steps) as a mauve solid. 1H NMR 5 1.97 (1H, dtd), 2.34 (1H, qd), 2.54 - 2.63 (1H, m), 2.90 (1H, m), 3.90 (3H, s), 4.25 (1H, d), 4.38 (1H, d), 5.02 (1H, dd), 7.26 (1H, d), 7.39 (1H, d), 10.94 (1H, s); m/r. ES+ [M+H]+ = 353.0.
Intermediate 70: tert-Butyl 4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazine-l- carboxylate Pd-PEPPSI-IHeptcl (0.380 g, 0.39 mmol) was added to tert-butyl piperazine-1-carboxylate (2.18 g, 11.mmol), C52CO3 (3.82 g, 11.72 mmol) and 3-(5-bromo-7-methoxy-l-oxo-l,3-dihydro-2rt-isoindol-2- yl)piperidine-2,6-dione (1.38 g, 3.91 mmol) in degassed 1,4-dioxane (39 mL) atRT under nitrogen. The resulting suspension was stirred at 100 °C for 6 h. The reaction mixture was diluted with DCM (100 mL) and washed sequentially with 5% AcOH in water (100 mL), water (100 mL), NaHCO3 solution (100 mL) and WO 2024/189488 PCT/IB2024/052251 104 NaCI solution (100 mL). The organic layer was dried with MgSO4, filtered and evaporated to afford crude product. The crude product was triturated with EtOAc (40 mL) and washed with Et20 (50 mL) to give a solid which was collected by filtration and dried under vacuum to give the title compound (1.15g, 64%) as a dark grey solid. 1H NMR 5 1.43 (9H, s), 1.79 - 1.97 (1H, m), 2.28 (1H, dd), 2.53 - 2.62 (1H, m), 2.76 - 2.94 (1H, m), 3.32 (4H, s), 3.41 - 3.54 (4H, m), 3.85 (3H, s), 4.12 (1H, d), 4.24 (1H, d), 4.95 (1H, dd), 6.51 (1H, d), 6.(1H, s), 10.87 (1H, s); m/z; ES+ [M+H]+ = 459.2.
Example 7: Intermediate if (780 mg, 1.59 mmol) and tert-butyl 4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3- dihydro-l//-isoindol-5-yl|pipcrazinc-l-carboxy late (874 mg, 1.91 mmol) were heated in formic acid (5 mL, 132.54 mmol) at 60 °C for 2 h. The reaction mixture was concentrated and the crude residue was suspended in NMP (5 mL) at RT, stirred for 5 minutes and sodium triacetoxyborohydride (673 mg, 3.18 mmol) was added. The resulting suspension was stirred at RT for 10 mins. The reaction mixture was poured into NaHCOsolution (20 mL) and the resulting solid was collected by filtration, washed with MeCN (20 mL) and EtOAc (20 mL). The solid was purified by preparative HPLC (Column A, Eluent A). The fractions containing product were evaporated and dissolved in DCM (250 mL), washed with NaHCO3 solution (100 mL) and NaCI solution (100 mL). The organic layer was dried over MgSO4 and evaporated to dryness to give the title compound (3mg, 27.9 %) as a white solid. 1H NMR S 1.19 - 1.3 (2H, m), 1.70 (1H, s), 1.79 - 1.88 (4H, m), 1.9-2.03 (3H, m), 2.24 (2H, d), 2.31 (1H, d), 2.53 (4H, d), 2.60 (4H, dd), 2.79 (2H, t), 2.85 - 2.97 (1H, m), 3.43 (2H, d), 3.(2H, d), 3.84 (3H, s), 4.11 (1H, d), 4.24 (1H, d), 4.97 (1H, dd), 6.50 (1H, s), 6.62 (1H, s), 6.89 (3H, dd), 7.(3H, dd), 8.32 (1H, s), 10.90 (1H, s), 12.26 (1H, s); m/r. ES+ [M+H]+ = 790.0.
Example 8 Intermediate 8a: 7-Bromo-4-methyl-lZ/-indole-3-carbonitrile Chlorosulfonyl isocyanate (1.9 mL, 22.61mmol) was added dropwise to a cooled solution of 7-bromo-4- methyl-1 //-indole (5.0 g, 23.8 mmol) in MeCN (94 mL) and DMF (23 mL) at 0 °C. The reaction was stirred to RT for 1.5 h. The reaction was then quenched with NaHCO3 solution (50 mL) and diluted with DCM (1mL). The organic layer was dried over a phase separating cartridge and the solvent evaporated to afford crude 4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3 ־dihydro-lZ/-isoindol-5- yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 105 product which was purified by column chromatography, elution gradient 0 to 30% EtOAc in heptane to give the title compound (3.93 g, 70.2%) as a cream solid. 1H NMR (CDC13) 5 2.75 (3H, d), 6.92 (1H, m), 7.35 (1H, m), 7.78 (1H, m), 8.73 (1H, s); m/z; ES+ [M+H]+ = 235.0.
Intermediate 8b: 7-(4-{4-[4-(l,3-Dioxolan-2-yl)piperidin-l-yl]phenyl}piperidin-l-yl)-4-methyl-lZ/-indole-3-carbonitrile To a mixture of 7-bromo-4-mcthyl-l//-indolc-3-carbonitrilc (459 mg, 1.95 mmol), intermediate le (1.23 g, 3.90 mmol), RuPhos (27.3 mg, 0.06 mmol) and RuPhos Pd G3 (49.0 mg, 0.06 mmol) in 1,4-dioxane (3 mL) under nitrogen was added LHMDS (IM in THE, 10.63 mL, 10.63 mmol) and the reaction was stirred at 90 °C for l h. The reaction mixture was cooled to RT, diluted with EtOAc (50 mL), washed with water (2x 50 mL) and NaCI solution (25 mL). The organic layer was dried with a phase separating cartridge and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane give the title compound (0.388 g, 42.2 %) as a yellow solid. 1H NMR 5 1.37 - 1.(3H, m), 1.57 - 1.7 (3H, m), 1.7 - 1.79 (3H, m), 2.57 - 2.63 (4H, m), 2.69 - 2.79 (2H, m), 3.38 (2H, d), 3.(2H, d), 3.74 - 3.95 (6H, m), 4.58 - 4.66 (1H, m), 6.78 (1H, d), 6.91 (3H, d), 7.14 (2H, d), 8.12 - 8.21 (1H, m), 11.90 (1H, s); m/z; ES+ [M+H]+= 471.4.
Example 8: 7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- yl]phenyl}piperidin-l-yl)-4-methyl-lZ/-indole-3-carbonitrile 7-(4-{4-[4-( 1,3 -Dioxolan-2-y!)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-methyl- lH-indole-3 -carbonitrile (4mg, 0.76 mmol) was heated in formic acid (5 mL, 129.46 mmol) at 40 °C for 2.5 h. The reaction mixture was concentrated and the crude residue was suspended in NMP (2 mL) at RT. Intermediate 5f (528 mg, 1.mmol) was added and the reaction mixture was stirred at RT for 5 mins. Sodium triacetoxyborohydride (5mg, 2.67 mmol) was added and the resulting suspension was continued to stir at RT for 10 mins. The reaction mixture was quenched with water (10 mL) and the product was extracted with DCM:IPA (9:1, 25 mL). The organic layer was washed with NaHCO3 solution, NaCI solution (10 mL) and dried over a phase separating cartridge. The solvent was evaporated and the crude product was purified by flash silica chromatography, elution gradient 0 to 25% IP A in DCM to give the title compound (291 mg, 0.403 mmol, 52.9 %) as a white WO 2024/189488 PCT/IB2024/052251 106 solid. 1HNMRS 1.16- 1.31 (3H, m), 1.61 - 1.75 (1H, m), 1.84 (4H, d), 1.89-2.09 (6H, m), 2.13 - 2.31 (4H, m), 2.55 - 2.61 (4H, m), 2.61 - 2.7 (1H, m), 2.7 - 2.82 (4H, m), 3.02 (2H, d), 3.38 (2H, d), 3.65 (2H, d), 3.- 3.83 (2H, m), 4.39 (1H, s), 6.42 (1H, d), 6.77 (1H, d), 6.84 -6.94 (3H, m), 6.96 (1H, dd), 7.11-7.18 (3H, m), 7.51 (1H, d), 7.54 (1H, d), 8.16 (1H, d), 10.31 (1H, s), 11.89 (1H, s); m/r. ES+ [M+H]+ = 723.5.
Example 9 Intermediate 9a: 7-Bromo-4-chloro-l//-indazole 3-Bromo-6-chloro-2-fluorobenzaldehyde (23.0 g, 96.86 mmol) was added to 1,2-dimethoxyethane (230 mL) and hydrazine hydrate (14.55 g, 290.58 mmol) was added. The mixture was stirred at reflux for 36 h, cooled to RT and then poured into rapidly stirred water (460 mL) for 30 mins. The resulting solid was filtered and washed with water (2 x 200 mL) and dried in a vacuum oven at 50 °C for 24 h to give the title compound (21.80 g, 97 %) as a white solid. 1H NMR 5 7.16 (1H, d), 7.60 (1H, d), 8.30 (1H, s), 13.02 (1H, s); m/2׳ . ES+ [M+H]+= 231.1.
Intermediate 9b: 7-Bromo-4-chloro-3-iodo-l//-indazole 7-Bromo-4-chloro-17/-indazole (21.0 g, 90.72 mmol) was added to DMF (100 mL) and potassium hydroxide (20.36 g, 362.89 mmol) and cooled to 0 °C. Iodine (29.9 g, 117.94 mmol) was added and after 5 mins the reaction was stirred to RT for 30 mins. The reaction was quenched with sodium thiosulfate (20% aq, 250 mL) and extracted with EtOAc (250 mL). The organic layer was washed with lithium chloride (10% aq, 250 mL), water (2x 250 mL), NaO solution (100 mL), dried over a phase separating cartridge and the solvent evaporated to give the title compound (31.2 g, 96 %) as a cream solid. 1H NMR 5 7.15 (1H, d), 7.63 (1H, d), 14.23 (1H, s); m/2•. ES- [M-H]355.0 = ־.
Intermediate 90: 7-Bromo-4-chloro-l//-indazole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 107 7-Bromo-4-chloro-3-iodo-1 //-indazole (10.0 g, 27.98 mmol) and potassium hexacyanoferrate(II) trihydrate (4.73 g, 11.19 mmol) were added to dimethylacetamide (80 mL) under nitrogen and stirred at 60 °C for mins. Water (60 mL) was added followed by Xantphos (0.810 g, 1.40 mmol) and allylpalladium(II) chloride dimer (0.256 g, 0.70 mmol) and the mixture was stirred at 95 °C for 4.5 h. The reaction was cooled to RT, filtered through Celite® and washed with 2-MeTHF (200 mL). The mother liquor was diluted with water (2mL) and washed with water (2x 200 mL), NaCI solution (100 mL), dried over a phase separating cartridge and the solvent was evaporated. The crude product was suspended in MeCN (50 mL) and stirred at reflux. Water (50 mL) was added followed by MeCN (20 mL). The solution was decanted hot through cotton wool and left to cool to RT. The resulting solid was filtered, dried under vacuum and slurried in DCM (20 mL) for 5 mins. The resulting solid was dried under vacuum to give the title compound (4.55 g, 63.4 %) as an off-white solid. 1H NMR 5 7.40 (1H, d), 7.79 (1H, d), 15.17 (1H, s); m/z; ES־ [M-H]254.0 = ־.
Intermediate 9d: Benzyl (3S)-3-(4-bromophenyl)piperidine-l-carboxylate K2CO3 (2M, 159.0 mL, 318.01 mmol) was added portion wise to a solution of (S)-3-(4- bromophenyl)piperidine oxalate (35.0 g, 106.00 mmol) in THE (250 mL) and water (100 mL) at RT. 1 - {[(Benzyloxy )carbonyl]oxy }pyrrolidine-2,5-dione (26.4 g, 106.00 mmol) was then added portion wise and was stirred at RT for 18 h. The mixture was diluted with EtOAc (500 mL) and water (250 mL), stirred for mins and the layers separated. The organic layer was washed with citric acid (IM, 250 mL), NaCI solution (200 mL), dried over a phase separating cartridge and evaporated to dryness to afford crude product. The crude product was dissolved in EtOH (100 mL) and water (300 mL), stirred at 60 °C and then cooled to RT. The resulting solid was filtered under vacuum and dried in a vacuum oven at 45 °C to give the title compound (37.6 g, 94 %) as a cream solid. 1H NMR 5 1.48 (1H, m), 1.63 (1H, m), 1.72 (1H, m), 1.83 - 1.93 (1H, m), 2.65 (1H, tt), 2.87 (2H, s), 3.96 - 4.08 (2H, m), 5.10 (2H, s), 7.24 (2H, d), 7.28 - 7.42 (5H, m), 7.50 (2H, d); m/z; ES+[M+H]+= 374.1.
Intermediate 9e: Benzyl (3S)-3-{4-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]phenyl}piperidine-l-carboxylate O^O WO 2024/189488 PCT/IB2024/052251 108 4-( 1,3-Dioxolan-2-y !)piperidine (25.9 g, 164.74 mmol), benzyl (3S)-3-(4-bromopheny!)piperidine-1- carboxylate (56.1 g, 149.77 mmol) and C52CO3 (98.0 g, 299.54 mmol) were degassed with nitrogen in 1,4- dioxane (500 mL) for 10 mins. Pd(t-Bu3P)2 (3.83 g, 7.49 mmol) and tri-tert-butylphosphonium tetrafluoroborate (4.35 g, 14.98 mmol) were then added and the mixture stirred at 100 °C for 20 h. The reaction mixture was cooled to RT and the solid was filtered through Celite®. The solid was washed with 1,4- dioxane (200 mL) and the filtrate was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 10 to 50% EtOAc in heptane to give the title compound (28.5 g, 42.2 %) as a cream solid. 1H NMR 5 1.33 - 1.52 (3H, m), 1.55 - 1.68 (2H, m), 1.68 - 1.78 (3H, m), 1.85 (1H, d), 2.54 (1H, s), 2.59 (2H, td), 2.84 (2H, s), 3.67 (2H, d), 3.74 - 3.83 (2H, m), 3.83 - 3.92 (2H, m), 3.94 - 4.(2H, m), 4.61 (1H, d), 5.09 (2H, s), 6.87 (2H, d), 7.08 (2H, d), 7.27 - 7.45 (5H, m); m/z; ES+ [M+H]+ = 451.3.
Intermediate 9f: 4-(l,3-Dioxolan-2-yl)-l-{4-[(3S)-piperidin-3-yl]phenyl}piperidine Benzyl (3S)-3-{4-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]phenyl}piperidine-l-carboxylate (27.5 g, 61.03 mmol) was suspended in EtOH (100 mL) and DCM (20 mL). Pd/C (10%, 2.6 g, 2.44 mmol) was added and the reaction was hydrogenated at RT with 2 bar pressure for 16 h. DCM (50 mL) was added to the reaction mixture and was filtered through Celite®. The filtrate was evaporated to dryness and stirred in MTBE (50 mL) for 16 h, filtered and dried under vacuum to give the title compound (14.95 g, 77 %) as a cream solid. 1H NMR 5 1.33 - 1.44 (2H, m), 1.48 (2H, d), 1.62 (2H, m), 1.72 (2H, d), 1.82 (1H, d), 2.47 (4H, d), 2.58 (2H, m), 2.94 (2H, d), 3.65 (2H, d), 3.75 - 3.83 (2H, m), 3.83 - 3.9 (2H, m), 4.61 (1H, d), 6.84 (2H, d), 7.04 (2H, d); m/z; ES+[M+H]+= 317.2.
Intermediate 9g: 4-Chloro-7-[(3S)-3-{4-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indazole-3- carbonitrile CI CN Intermediate 9c (2.3 g, 8.98 mmol) and4-(l,3-dioxolan-2-yl)-l-{4-[(3S)-piperidin-3-yl]phenyl}piperidine(2.90 g, 9.16 mmol) were suspended in 2-MeTHF (25 mL). The mixture was degassed with nitrogen for 10 WO 2024/189488 PCT/IB2024/052251 109 mins followed by addition of CPhos (0.39 g, 0.90 mmol) and [Pd(cinnamyl)Cl]2 (0.23 g, 0.45 mmol). LHMDS (IM in THF, 31.4 mL, 31.45 mmol) was added and the reaction was stirred at 50 °C for l h. The reaction was then cooled to RT and partitioned between water (25 mL) and 2-MeTHF (25 mL). The organic layer was washed with NaCI solution (25.0 mL), dried through a phase separating cartridge and the solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane to give the title compound (2.46 g, 55.6 %) as a pale orange solid. 1H NMR 5 1.39 (2H, m), 1.62 (2H, m), 1.72 (2H, d), 1.84 - 1.98 (3H, m), 2.59 (2H, m), 2.66 - 2.8 (2H, m), 3.(1H, t), 3.47 (2H, t), 3.67 (2H, d), 3.75 - 3.83 (2H, m), 3.83 - 3.9 (2H, m), 4.61 (1H, d), 6.87 (2H, d), 6.(1H, d), 7.18 (2H, d), 7.28 (1H, d), 14.69 (1H, s); m/r. ES+ [M+H]+ = 492.3.
Intermediate 9h: 4-Chloro-7-{(3S)-3-[4-(4-formylpiperidin-l-yl)phenyl]piperidin-l-yl}-lZ/-indazole-3-carbonitrile 61 CN To a stirred solution of 4-chloro-7-|(jS)-3-[4-|4-( 1.3-dioxolan-2-yl)pipcridin-l -yl Iphcnyl; pipcridin-l -yl |-I //- indazole-3-carbonitrile (3.15 g, 6.40 mmol) in THF (32.0 mL) was added HC1 (2M, 64.0 mL, 128.04 mmol). The reaction mixture was stirred at 60 °C for 4 h and then cooled to 0 °C in an ice bath. The mixture was neutralised to pH7 with NaOH (2M), extracted with 2-MeTHF (100 mL), washed with water (100 mL), NaCI solution (50 mL), dried over a phase separating cartridge and the solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane to give the title compound (2.5 g, 87 %) as a yellow solid. 1H NMR 5 1.58 (3H, m), 1.83 - 1.98 (5H, m), 2.46 (1H, m), 2.66 - 2.82 (4H, m), 2.94 - 3.06 (1H, m), 3.4 - 3.6 (4H, m), 6.89 (2H, d), 6.93 (1H, d), 7.(2H, d), 7.27 (1H, d), 9.63 (1H, d), 14.69 (1H, s); m/2׳ . ES+ [M+H]+ = 448.3.
Example 9: 4-Chloro-7-[(3S)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-Lff-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indazole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 110 N A suspension of 4-chloro-7-{(3S)-3-[4-(4-formylpiperidin-l-yl)phenyl]piperidin-l-yl}-l/f-indazole-3- carbonitrile (9.22 g, 20.58 mmol) and intermediate 5f (10.47 g, 21.61 mmol) inNMP (92 mL) was stirred at RT for 18 h. Sodium triacetoxyborohydride (5.23 g, 24.70 mmol) was added and the solution was continued to stir at RT for 2 h. The reaction mixture was quenched with water (250 mL) and the suspension was stirred at RT for 30 mins. The solid was collected by filtration, was washed with excess water and extracted with DCM:IPA (3:1, 250 mL). The organic layer was washed withNaHCO3 solution (100 mL), NaCl solution (1mL) and dried over a phase separating cartridge. The solvent was evaporated and the crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane followed by 0 to 10% MeOH in EtOAc. The product was then slurried in MeCN (225 mL) at 80 °C for 3 h and then left to cool to RT for 16 h. The solid was collected by filtration, washing with excess MeCN and dried under vacuum at °C to give the title compound (11.57 g, 76 %) as a pale orange solid. 1H NMR 5 1.17 - 1.29 (2H, m), 1.53 - 1.72 (2H, m), 1.79 - 1.85 (2H, m), 1.85 - 1.99 (5H, m), 1.98 - 2.06 (2H, m), 2.15 - 2.24 (2H, m), 2.27 (2H, d), 2.57 - 2.65 (2H, m), 2.66 - 2.79 (4H, m), 2.95 - 3.05 (3H, m), 3.43 - 3.55 (2H, m), 3.63 (2H, d), 3.78 (2H, t), 4.33 - 4.43 (1H, m), 6.41 (1H, d), 6.88 (2H, d), 6.92 (1H, d), 6.96 (1H, d), 7.12 - 7.2 (3H, m), 7.26 (1H, d), 7.51 (1H, d), 7.53 (1H, d), 10.31 (1H, s), 14.55 (1H, s); m/r. ES+ [M+H]+ = 744.4.
Example 10: 4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin- l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indazole-3-carbonitrile Intermediate 9g (2.0 g, 3.46 mmol) and intermediate li (1.48 g, 3.46 mmol) were heated in formic acid (mL) at 40 °C for 2 h. The reaction mixture was cooled, evaporated to dryness and the residue was stirred in NMP (20 mL) at RT for 16 h. The reaction mixture was poured into NaHCO3 solution (300 mL) and the precipitate was collected by filtration, washed with water (100 mL) and dried under vacuum to afford crude product which was purified by flash silica chromatography, elution gradient 0 to 6% DCM in EtOH. Pure WO 2024/189488 PCT/IB2024/052251 ill fractions were evaporated to dryness to afford product which was slurried in MeCN (50 mL) and filtered under vacuum to give the title compound (1.17 g, 44.5 %) as a yellow solid. 1H NMR 5 1.12-1.27 (2H, m), 1.49- 1.59 (1H, m), 1.59-1.71 (1H, m), 1.73-2.01 (6H, m), 2.19 (2H, d), 2.28-2.43 (1H, m), 2.49 (4H, dd), 2.54- 2.78 (5H, m), 2.83-3.04 (2H, m), 3.27 (4H, t), 3.46 (2H, t), 3.60 (2H, d), 4.16-4.37 (2H, m), 5.05 (1H, dd), 6.88 (3H, dd), 7.04 (2H, d), 7.15 (2H, d), 7.25 (1H, d), 7.52 (1H, d), 10.95 (1H, s), 14.62 (1H, s); m/r. ES+ [M+H]+ = 760.0.
Example 11 Intermediate lla: Benzyl (3S)-3-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidine-l-carboxylate Pd(t-Bu3P)2 (0.55 g, 1.07 mmol) was added to intermediate 9d (4.0 g, 10.69 mmol), 4- (dibutoxymethyl)piperidine (2.6 g, 10.69 mmol), C52CO3 (6.96 g, 21.37 mmol) andtri-tert-butylphosphonium tetrafluoroborate (0.310 g, 1.07 mmol) in 1,4-dioxane (50 mL) under nitrogen. The resulting mixture was stirred at 100 °C for 2 h. The mixture was then cooled to RT and the solvent evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 40% EtOAc in Et2O to give the title compound (2.3 g, 40.1 %) as a yellow oil. 1H NMR 5 0.89 (6H, t), 1.24-1.55 (12H, m), 1.57-1.91 (6H, m), 2.59 (1H, s), 2.82 (2H, s), 3.32-3.46 (3H, m), 3.49-3.71 (4H, m), 4.01 (2H, t), 4.19 (1H, d), 5.09 (2H, s), 6.86 (2H, d), 7.07 (2H, d), 7.35 (5H, q); m/2׳ . (ES+), [M+H]+ = 537.5.
Intermediate 11b: 4-(Dibutoxymethyl)-l-{4-[(3S)-piperidin-3-yl]phenyl}piperidine WO 2024/189488 PCT/IB2024/052251 112 Pd/C (10%, 0.912 g, 0.86 mmol) was added to benzyl (3S)-3-{4-[4-(dibutoxymethyl)piperidin-l- yl]phenyl}piperidine-l-carboxylate (2.3 g, 4.28 mmol) inEtOAc:MeOH (5:1, 30 mL) atRT under an atmosphere of hydrogen for 3 h. The mixture was filtered through Celite® and evaporated to dryness to give the title compound (1.6 g, 93 %) as a white oil which was used without further purification. 1H NMR 5 0.(6H, t), 1.24-1.42 (4H, m), 1.43-1.57 (5H, m), 1.59-1.87 (4H, m), 2.43 (4H, d), 2.57 (1H, s), 2.91 (2H, d), 3.22-3.47 (7H, m), 3.49-3.69 (4H, m), 4.19 (1H, d), 6.84 (2H, d), 7.04 (2H, d); m/z; (ES+), [M+H]+ = 403.1.
Intermediate lie: 4-Chloro-7-[(3S)-3-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indole-3- carbonitrile LHMDS (IM in THE, 10.43 mL, 10.43 mmol) was added to 4-(dibutoxymethyl)-l-{4-[(3S)-piperidin-3- yl]phenyl}piperidine (1.2 g, 2.98 mmol), intermediate lb (0.838 g, 3.28 mmol) and Pd-PEPPSI-IHeptcl (0.1g, 0.15 mmol) in THF (5.0 mL). The resulting mixture was stirred at 60 °C for 2 h. The reaction mixture was cooled to RT, quenched with NH4C1 solution (10 mL), extracted with EtOAc (2 x 20 mL), dried over Na2SO4, filtered and evaporated to afford to crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et20 to give the title compound (1.4 g, 81 %) as a brown solid. 1H NMR 5 0.89 (6H, t), 1.27-1.4 (6H, m), 1.43-1.54 (5H, m), 1.72 (4H, d), 1.79-1.98 (3H, m), 2.53-2.(4H, m), 2.98 (1H, d), 3.36-3.43 (3H, m), 3.49-3.7 (4H, m), 4.18 (1H, d), 6.8-6.9 (3H, m), 7.09-7.2 (3H, m), 8.31 (1H, d), 12.28 (1H, d); m/z; (ES+), [M+H]+ = 577.3.
Example 11: 4-Chloro-7-[(3S)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-n/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 113 4-Chloro-7-[(3S)-3-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl]-l/f-indole-3-carbonitrile (1.g, 2.08 mmol) was heated in formic acid (16.0 ml, 417.16 mmol) at 40 °C for 1 h. The mixture was cooled and evaporated and diluted inNMP (16.0 mL). Intermediate 5f (1.01 g, 2.08 mmol) and sodium acetate (0.205 g, 2.49 mmol) was added and the resulting mixture was stirred at 40 °C for 2 h. The reaction mixture was then poured into Na2CO3 solution (150 mL) and the precipitate was collected by filtration, washed with water (mL) and dried under vacuum to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% DCM in EtOH to afford product which was slurried in MeCN (mL) and filtered under vacuum to give the title compound (1.16 g, 75 %) as a white solid. 1H NMR 5 1.(2H, m), 1.46-1.72 (2H, m), 1.82 (3H, dd), 1.87-2.05 (6H, m), 2.17 (4H, dd), 2.63 (4H, dq), 2.76 (2H, t), 2.(3H, d), 3.30 (1H, d), 3.36 (1H, s), 3.61 (2H, d), 3.77 (2H, t), 4.36 (1H, tt), 6.41 (1H, d), 6.84 (3H, dd), 6.(1H, d), 7.14 (4H, dd), 7.44-7.61 (2H, m), 8.31 (1H, s), 10.34 (1H, s), 12.28 (1H, s); m/z; ES+ [M+H]+ = 743.3.
Example 12: 4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin- l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indole-3-carbonitrile Intermediate 11c (2.3 g, 3.98 mmol) and intermediate li (1.7 g, 3.98 mmol) were heated in formic acid (mL) at 40 °C for 1 h. The reaction was then cooled and evaporated to afford a residue which was diluted with NMP (20 mL). The resulting mixture was stirred at 40 °C for 16 h and then poured into Na2CO3 solution (3mL). The precipitate was collected by filtration, washed with water (50 mL) and dried under vacuum to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 6% DCM in EtOH to afford product which was slurried in MeCN and filtered under vacuum to give the title compound (0.93 g, 30.7 %) as a white solid. 1H NMR 5 1.14-1.28 (2H, m), 1.46-1.61 (1H, m), 1.68 (1H, d), 1.74-1.(3H, m), 1.88-2 (3H, m), 2.20 (2H, d), 2.28-2.44 (1H, m), 2.45-2.5 (3H, m), 2.51 (1H, s), 2.54-2.73 (5H, m), WO 2024/189488 PCT/IB2024/052251 114 2.83-3.03 (2H, m), 3.24-3.31 (4H, m), 3.35 (2H, d), 3.61 (2H, d), 4.21 (1H, d), 4.33 (1H, d), 5.05 (1H, dd), 6.84 (3H, dd), 7.05 (2H, d), 7.14 (3H, dd), 7.52 (1H, d), 8.31 (1H, s), 10.94 (1H, s), 12.27 (1H, s); m/r. ES+ [M+H]+= 759.5.
Example 13 Intermediate 13a: tert-Butyl 4-[(2-amino-4-bromophenyl)ethynyl]piperidine-l-carboxylate PdC12(PPh3)2 (3.36 g, 4.78 mmol) was added in one portion to tert-butyl 4-ethynylpiperidine-1-carboxylate (10.01 g, 47.83 mmol), 5-bromo-2-iodoaniline (14.25 g, 47.83 mmol), copper(I) iodide (1.36 g, 7.17 mmol) and triethylamine (19.97 ml, 143.49 mmol) in DMF (145 mL) at RT under nitrogen. The resulting dark brown solution was stirred at RT for 18 h. The reaction mixture was diluted with water (150 mL) and the product extracted into MTBE (150 mL). The organic layer was washed with water (150 mL), NaCI solution (50 mL), dried with MgSO4 and evaporated to afford crude product. The crude product was purified by column chromatography, elution gradient 5 to 20% heptane:EtOAc to give the title compound (24.14g, 55%) as an orange oil. 1H NMR 5 1.46 (9H, s), 1.68 (2H, m), 1.88 (2H, m), 2.83 (1H, m), 3.18 - 3.26 (2H, m), 3.76 (2H, m), 4.18 (2H, s), 6.78 (1H, m), 6.84 (1H, m), 7.08 (1H, m); m/z; ES+ [M+H]+ = 379.1.
Intermediate 13b: tert-Butyl 4-(6-bromo-l-methyl-lZf-indol-2-yl)piperidine-l-carboxylate Potassium tert-butoxide (13.30 g, 118.48 mmol) was added portion wise to tert-butyl 4-[(2-amino-4- bromophenyl)ethynyl]piperidine-l-carboxylate (21.4 g, 39.49 mmol) in NMP (200 mL) and stirred at RT for h. Iodomethane (7.38 ml, 118.48 mmol) was added portion wise and stirred at RT for a further l h. The reaction mixture was then quenched with NH4C1 solution (100 mL) and water (100 mL). The product was extracted with 2-MeTHF (2 x 200 mL) and the combined organic layers were washed with water (2 x 1mL), NaCI solution (100 mL), dried over MgSO4 and evaporated to afford crude product as a brown oil. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in heptane. Pure fractions were evaporated to afford a solid which was triturated with heptane (50 mL). The solid was collected by filtration and dried in a vacuum oven at 45 °C to give the title compound (13.74 g, 88 %) as a white solid. 1H NMR 5 1.51 (9H, s), 1.68 (2H, qd), 1.99 (2H, d), 2.79 - 2.96 (3H, m), 3.70 (3H, s), 4.28 (2H, m), 6.24 (1H, s), 7.19 (1H, m), 7.39 - 7.44 (1H, m), 7.45 (1H, m); m/z; ES+ [M+H]+ = 393.3.
WO 2024/189488 PCT/IB2024/052251 115 Intermediate 13c: tert-Butyl 4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l//-indol-2-yl |piperidine-l-carboxylate H tert-Butyl 4-(6-bromo-l-methyl-lrt-indol-2-y!)piperidine-1 -carboxylate (10.82 g, 27.51 mmol) was dissolved in 1,4-dioxane (180 mL) followed by addition of hexahydropyrimidine-2,4-dione (9.42 g, 82.53 mmol), KCO3 (11.41 g, 82.53 mmol) and tert-butylBrettPhos (1.33 g, 2.75 mmol). The mixture was degassed with nitrogen then tert-butylBrettPhos Pd G3 (2.350 g, 2.75 mmol) was added and the mixture stirred at 100 °C for h. The reaction mixture was cooled, water (180 mL) and 2-MeTHF (180 mL) were added and the layers separated. The organic layer was washed with water (180 mL), NaCI solution (50 mL), dried with MgS04, filtered and evaporated to afford crude product as a dark brown solid. The solid was slurried in EtOAc (mL) and the resulting brown suspension was filtered and washed with a EtOAc (10 mL) to give the title compound (6.59 g, 56.2 %) as a pale brown solid. 1H NMR 5 1.43 (11H, m), 1.94 (2H, dm, 2.73 (2H, t), 2.82 - 3.07 (3H, m), 3.70 (3H, s), 3.79 (2H, m), 4.06 (2H, dd), 6.24 (1H, s), 6.94 (1H, dd), 7.37 (1H, d), 7.43 (1H, d), 10.26 (1H, s); m/z; ES+ [M-tert-Bu+H]+ = 371.1.
Example 13: 4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-lZ/-indol-2-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indole-3-carbonitrile tert-Butyl 4-|6-(2.4-dioxo-1.3-diazinan-l-yl)-l-mcthyl-l//-indol-2-yl|pipcridinc-l-carboxylatc (1.55 g, 3.mmol) and intermediate 11c (2.1 g, 3.64 mmol) were heated in formic acid (20 mL, 3.64 mmol) at 40 °C for h. The reaction was then cooled and evaporated to afford a residue which was diluted with NMP (20 mL). The resulting mixture was stirred at 40 °C for 16 h. The reaction mixture was then poured into Na2CO3 solution (150 mL) and the precipitate was collected by filtration, washed with water (50 mL) and dried under vacuum to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% DCM in EtOH to afford product which was slurried in MeCN and filtered under vacuum to give the title compound(!.10 g, 39.9 %) as a pale yellow solid. 1H NMR S 1.12-1.28 (2H, m), 1.47-1.58 (1H, m), 1.58- 1.73 (3H, m), 1.73-1.88 (3H, m), 1.88-1.99 (4H, m), 2.04 (2H, t), 2.18 (2H, d), 2.53-2.69 (4H, m), 2.73 (3H, t), 2.85-3.05 (3H, m), 3.30 (1H, d), 3.36 (1H, d),3.61 (2H, d), 3.68 (3H, s), 3.78 (2H, t), 6.22 (1H, s), 6.79-6.9 WO 2024/189488 PCT/IB2024/052251 116 (3H, m), 6.93 (1H, dd), 7.14 (3H, dd), 7.36 (1H, d), 7.42 (1H, d), 8.31 (1H, s), 10.30 (1H, s), 12.28 (1H, s);m/z; ES+ [M+H]+ = 757.4.
Example 14 Example 14a: l-[l-Methyl-2-(piperidin-4-yl)-lZ/-indol-6-yl]-l,3-diazinane-2,4-dione tosylate A mixture of intermediate 13c (1.6 g, 3.75 mmol) and 4-methylbenzenesulfonic acid hydrate (0.856 g, 4.mmol) in MeCN (16.0 mL) was stirred at 70 °C for 2.5 h. The reaction mixture was cooled to RT, diluted with MTBE (16 mL) and stirred for 15 mins. The solid was filtered, washing the solid with excess MTBE. The solid was dried under vacuum at 40 °C to give the title compound (1.65 g, 88 %) as a cream solid. 1H NMR 1.71 - 1.85 (2H, m), 2.12 (2H, m), 2.29 (3H, m), 2.74 (2H, t), 3.03 - 3.24 (3H, m), 3.41 (1H, m), 3.71 (3H, s), 3.79 (2H, t), 6.26 (1H, s), 7.45 - 7.52 (3H, m); m/z; ES+ [M+H]+ = 327.3.
Example 14: 4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-lZ/-indol-2-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indazole-3-carbonitrile A suspension of intermediate 9h (1.38 g, 3.08 mmol) and l-| l-mclhyl-2-(pipcridin-4-yl)-l//-indol-6-yl|-l.3- diazinane-2,4-dione TsOH (1.61 g, 3.23 mmol) inNMP (14.0 mL) was stirred atRT for 18 h. Sodium triacetoxyborohydride (0.78 g, 3.70 mmol) was added and the solution was stirred at RT for 2 h. The reaction mixture was quenched with water (40 mL) and the suspension was stirred at RT for 30 mins. The solid was collected by filtration and was washed with water. The solid was dissolved in DCM:IPA (3:1, 150 mL) and washed with NaHCO3 solution (150 mL), NaCI solution (100 mL), dried over a phase separating cartridge and evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane followed by 0 to 10% MeOH in DCM to afford the desired WO 2024/189488 PCT/IB2024/052251 117 product which was slurried in MeCN (30 mL) at 80 °C for 3 h and then left to cool to RT for 18 h. The solid was filtered under vacuum to give the title compound (1.27 g, 54.4 %) as a pale pink solid. 1H NMR 5 1.16 - 1.28 (2H, m), 1.53 - 1.73 (4H, m), 1.76 - 1.98 (7H, m), 2.07 - 2.17 (2H, m), 2.25 (2H, d), 2.56 - 2.65 (2H, m), 2.66 - 2.84 (5H, m), 2.93 - 3.04 (3H, m), 3.47 - 3.57 (2H, m), 3.63 (2H, d), 3.68 (3H, s), 3.78 (2H, t), 6.23 (1H, s), 6.85-6.91 (3H, m), 6.93 (1H, dd), 7.18 (2H, d), 7.24 (1H, d), 7.36 (1H, s), 7.42 (1H, d), 10.(1H, s), 14.43 (1H, s); m/z; ES+ [M+H]+ = 758.4.
Example 15: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-4-methyl-lZ/-indole-3-carbonitrile Intermediate 8b was reacted with Intermediate 7c using the general synthetic method illustrated by Example after purification by HPLC (Column A, Eluent A) to give the title compound (formate salt) (31 mg, 18 %) as a white solid. 1H NMR 5 1.20 - 1.27 (3H, m), 1.68 (2H, s), 1.82 (4H, d), 1.95 (3H, s), 2.23 (2H, s), 2.31 (1H, d), 2.51 (4H, s), 2.56 - 2.68 (7H, m), 2.74 (2H, t), 2.88 (1H, q), 3.30 (2H, s), 3.38 (2H, d), 3.64 (2H, d), 3.84 (3H, s), 4.05 - 4.27 (2H, m), 4.96 (1H, dd), 6.49 (1H, s), 6.61 (1H, s), 6.77 (1H, d), 6.89 (3H, dd), 7.13 (2H, d), 8.16 (1H, d), 10.91 (1H, s), 11.90 (1H, s); m/z; ES+ [M+H]+ = 769.4.
Examples 16 and 17 The enantiomers of Example7 were separated by SEC purification on a Sepiatec 100 SFC using SFC conditions Regis (R,R) Whelk-01, 21.1 x 250 mm, 5 micron, 50% MeOH/MeCN 3:7 / 50% scCO2 at a flow rate of 60 mL/min, 40 °C to give, in order of elution, example 16(isomer 1, 12 mg, 28.6 %) and example 17 (isomer 2, 13 mg, 31.0 %) as white solids.
Example 16: 4-Chloro-7-[4-(4-{4-[(4-{2-[(37?* )-2,6-dioxopiperidin-3-yl]-7-methoxy-l-oxo-2,3-dihydro-lZ/-isoindol-5- yl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] cl Isomer 1 WO 2024/189488 PCT/IB2024/052251 118 1H NMR 5 1.26 (2H, s), 1.70 (1H, s), 1.84 (4H, s), 1.97 (3H, d), 2.24 (3H, d), 2.54 - 2.65 (4H, m), 2.72 - 2.(2H, m), 2.88 (1H, d), 3.43 (2H, d), 3.65 (2H, d), 3.84 (3H, s), 4.11 (1H, d), 4.24 (1H, d), 4.97 (1H, dd), 6.(1H, s), 6.62 (1H, s), 6.87 (1H, d), 6.91 (2H, d), 7.15 (3H, dd), 8.32 (1H, s), 10.90 (1H, s), 12.26 (1H, s); m/r. ES+ [M+H]+ = 789.6; >99% ee.
Example 17: 4-Chloro-7-[4-(4-{4-[(4-{2-[(3،2,6-( *؟-dioxopiperidin-3-yl]-7-methoxy-l-oxo-2,3-dihydro-lZZ-isoindol-5- yl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] cI.
Isomer 21H NMR 5 1.26 (2H, s), 1.70 (1H, s), 1.84 (4H, s), 1.98 (3H, d), 2.24 (2H, d), 2.31 (1H, s), 2.62 (4H, d), 2.73- 2.83 (2H, m), 2.83 - 2.95 (1H, m), 3.43 (2H, d), 3.65 (2H, d), 3.84 (3H, s), 4.11 (1H, d), 4.24 (1H, d), 4.(1H, dd), 6.50 (1H, s), 6.62 (1H, s), 6.89 (3H, dd), 7.15 (3H, dd), 8.32 (1H, s), 10.90 (1H, s), 12.26 (1H, s); m/z; ES+ [M+H]+ = 789.6; >99% ee.
Examples 18 and 19: The enantiomers of Example Iwere separated by SEC purification on a Sepiatec 100 SFC using SFC conditions Regis (R,R) Whelk-01, 21.1 x 250 mm, 5 micron, 50% MeOH/MeCN 3:7 / 50% scCO2 at a flow rate of 60 mL/min, 40 °C to give, in order of elution, example 18(isomer 1, 410 mg, 20.8 %) and example 19 (isomer 2, 400 mg, 20.3 %) as white solids.
Example 18: 4-Chloro-7-[4-(4-{4-[(4-{2-[(37? *)-2,6-dioxopiperidin-3-yl]-l-oxo-2,3-dihydro-lZ/-isoindol-5- yl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR 5 1.25 (3H, s), 1.70 (1H, s), 1.84 (4H, s), 1.97 (4H, d), 2.24 (2H, d), 2.35 - 2.43 (2H, m), 2.55 - 2.(3H, m), 2.78 (2H, t), 2.84 - 2.97 (1H, m), 3.43 (2H, d), 3.65 (2H, d), 4.22 (1H, d), 4.34 (1H, d), 5.05 (1H, dd), 6.86 (1H, d), 6.91 (2H, d), 7.07 (2H, d), 7.11-7.19 (3H, m), 7.53 (1H, d), 8.31 (1H, s), 10.94 (1H, s), 12.26 (1H, s); m/z; ES+ [M+H]+ = 759.7; >99% ee.
WO 2024/189488 PCT/IB2024/052251 119 Example 19: 4-Chloro-7-[4-(4-{4-[(4-{2-[(3،2,6-(* ؟-dioxopiperidin-3-yl]-l-oxo-2,3-dihydro-lZ/-isoindol-5- yl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR 5 1.16 - 1.32 (2H, m), 1.70 (1H, s), 1.78 - 1.9 (4H, m), 1.97 (3H, d), 2.24 (2H, d), 2.37 (2H, dd), 2.55 - 2.59 (1H, m), 2.62 (2H, d), 2.78 (2H, t), 2.84 - 2.96 (1H, m), 3.43 (2H, d), 3.65 (2H, d), 4.22 (1H, d), 4.34 (1H, d), 5.05 (1H, dd), 6.87 (1H, d), 6.91 (2H, d), 7.07 (2H, d), 7.15 (3H, dd), 7.53 (1H, d), 8.32 (1H, s), 10.94 (1H, s), 12.26 (1H, s); m/z; ES+ [M+H]+ = 759.7; >99% ee.
Example 20: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l- yl] mcthyl)piperidin-l-yl| phenyl] pipcrid in-1-yl)-4-tluoro-l//-indole-3-carbonitrile Intermediate 2c was reacted with Intermediate 7c using the general synthetic method illustrated by Example after purification by HPLC (Column A, Eluent A) to give the title compound in the form of a formate salt (mg, 14 %) as a white solid. 1H NMR 5 1.24 (2H, d), 1.69 (1H, s), 1.85 (4H, s), 1.88 - 2.05 (3H, m), 2.23 (2H, d), 2.25 - 2.37 (1H, m), 2.56 - 2.74 (4H, m), 2.78 (2H, d), 2.88 (1H, d), 3.30 (8H, d), 3.39 (1H, s), 3.65 (3H, d), 3.84 (3H, s), 4.03 - 4.29 (2H, m), 4.91 - 5.03 (1H, m), 6.50 (1H, s), 6.62 (1H, s), 6.77 - 6.87 (1H, m), 6.- 7.00 (3H, m), 7.14 (2H, d), 8.28 (1H, s), 10.92 (1H, s), 12.26 (1H, s); m/z; ES+ [M+H]+ = 773.0.
Example 21 Intermediate 21a: Benzyl (37?)-3-(4-bromophenyl)piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 120 (R)-3-(4-Bromopheny !)piperidine oxalate was reacted with benzyl carbonochloridate using the general synthetic method illustrated by example 1c to give the title compound (1.0 g, 64.2%) as a colourless oil. 1H NMR 5 1.4-1.54 (1H, m), 1.58-1.67 (1H, m), 1.67-1.77 (1H, m), 1.87 (1H, dd), 2.59-2.71 (1H, m), 2.87 (2H, s), 3.9M.12 (2H, m), 5.09 (2H, d), 7.24 (2H, d), 7.34 (5H, q), 7.47-7.53 (2H, m); m/z; ES+ [M+H]+ = 374.0.
Intermediate 21b: Benzyl (37?)-3-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidine-l-carboxylate Benzyl (3R)-3-(4-bromophenyl)piperidine-l-carboxylate was reacted with 4-(dibutoxymethy!)piperidine using the general synthetic method illustrated by example I la to give the title compound (462 mg, 32.1 %) as a yellow oil. 1H NMR 5 0.88 (6H, t), 1.24-1.37 (7H, m), 1.41-1.54 (6H, m), 1.54-1.76 (6H, m), 1.84 (1H, d), 2.52-2.59 (2H, m), 3.35-3.45 (2H, m), 3.51-3.6 (2H, m), 3.63 (2H, d), 4.01 (2H, t), 4.18 (1H, d), 5.08 (2H, s), 6.85 (2H, d), 7.07 (2H, d), 7.27-7.47 (5H, m); m/z; ES+ [M+H]+ = 537.2.
Intermediate 210: 4-(Dibutoxymethyl)-l-{4-[(37?)-piperidin-3-yl]phenyl}piperidine Benzyl (3R)-3-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidine-l-carboxylate was reacted with Pd/C (10%) and hydrogen gas using the general synthetic method illustrated by example 1 lb to give the title compound (300 mg, 87.0 %) as a colourless oil. 1H NMR 5 0.88 (6H, t), 1.23-1.4 (7H, m), 1.41-1.55 (6H, m), WO 2024/189488 PCT/IB2024/052251 1.58- 1.89 (5H, m), 2.42 (3H, q), 2.54 (2H, d), 2.90 (2H, d), 3.34-3.43 (2H, m), 3.52-3.57 (2H, m), 3.58-3.(2H, m), 4.18 (1H, d), 6.76-6.9 (2H, m), 6.99-7.1 (2H, m); m/z; ES+ [M+H]+ = 403.2.
Intermediate 21d: 4-Chloro-7-[(37?)-3-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indole-3- carbonitrile 4-(Dibutoxymethyl)-l-{4-[(3R)-piperidin-3-yl]phenyl}piperidine was reacted with intermediate lb using the general synthetic method illustrated by example He to give the title compound (60 mg, 27.9 %) as a brown solid. 1H NMR 5 0.89 (6H, t), 1.3-1.42 (5H, m), 1.48 (5H, q), 1.72 (3H, d), 1.8-2.06 (4H, m), 2.66 (3H, d), 3.00 (1H, s), 3.41 (5H, s), 3.5-3.72 (4H, m), 4.19 (1H, d), 6.86 (3H, t), 7.15 (3H, t), 8.31 (1H, d), 12.28 (1H, s); m/z; ES+ [M+H]+ = 577.2.
Example 21: 4-Chloro-7-[(37?)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lfl-isoindol-5-yl]piperazin- 1-yl} methyl)piperidin-l-yl| phenyl} piperidin-1-yl|-l/f-indole-3-carbonitrile Intermediate 2Id was reacted with Intermediate li using the general synthetic method illustrated by Example after purification by HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (mg, 28 %) as a white solid. 1H NMR 5 1.21 (2, q), 1.48-1.62 (1H, m), 1.68 (1H, s), 1.72-2.03 (7H, m), 2.(2H, d), 2.28-2.48 (2H, m), 2.5-2.75 (6H, m), 2.84-3.07 (2H, m), 3.28 (5H, s), 3.35 (2H, s), 3.62 (2H, d), 4.(1H, d), 4.33 (1H, d), 5.05 (1H, dd), 6.85 (3H, dd), 7.07 (2H, d), 7.15 (3H, dd), 7.52 (1H, d), 8.31 (1H, d), 10.95 (1H, s), 12.28 (1H, d); m/z; ES+ [M+H]+ = 759.4.
VO N O WO 2024/189488 PCT/IB2024/052251 122 Example 22 Intermediate 22a: tert-Butyl 4-(4-{l-[(benzyloxy)carbonyl]piperidin-4-yl}phenyl)piperazine-l-carboxylate Pd(t-Bu3P)2 (0.137 g, 0.27 mmol) was added to tri-tert-butylphosphonium tetrafluoroborate (0.078 g, 0.mmol), C52CO3 (1.741 g, 5.34 mmol), tert-butyl piperazine-1-carboxylate (0.498 g, 2.67 mmol) and intermediate ic (1.00 g, 2.67 mmol) in 1,4-dioxane (10 mL) under nitrogen. The resulting mixture was stirred at 100 °C for 19 h. The reaction was then cooled to RT and the solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 40 % EtOAc in E12O to give the title compound (1.0 g, 78 %) as a yellow solid. m2׳. ES+ [M+H]+ = 480.4.
Intermediate 22b: tert-Butyl 4-[4-(piperidin-4-yl)phenyl]piperazine-l-carboxylate Pd/C (10%, 0.67 g, 0.63 mmol) and tert-butyl 4-(4-{l-[(benzyloxy)carbonyl]piperidin-4- yl}phenyl)piperazine-l-carboxylate (1.00 g, 2.08 mmol) inMeOH:EtOAc (1:5, 1.2 mL) was stirred under an atmosphere of hydrogen at RT for 2 h. The mixture was filtered through Celite® and evaporated to dryness to give the title compound which was used without further purification. m/r. ES+ [M+H]+ = 346.3.
Intermediate 220: tert-Butyl 4-4؛-[l-(3-cyano-4-tluoro-l//-indol-7-yl)piperidin-4-yl | phenyl{ piperazine-1-carboxylate WO 2024/189488 PCT/IB2024/052251 123 (DiMeIHeptCl)Pd(cinnamyl)cl (152 mg, 0.14 mmol) was added to tert-butyl 4-(4-(piperidin-4- yl)phenyl)piperazine-l-carboxylate (500 mg, 1.45 mmol), intermediate 2b (346 mg, 1.45 mmol) and C52CO(1.6 g, 5.07 mmol) in 1,4-dioxane (1 mL) under nitrogen and stirred at 100 °C for 3 h. The reaction was cooled to RT and the solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound as a yellow solid. m/r. ES+[M+H]+= 504.3.
Intermediate 22d: 3-{5-[4-(Dibutoxymethyl)piperidin-l-yl]-l-oxo-l,3-dihydro-2H-isoindol-2-yl}piperidine-2,6-dione Pd-PEPPSI-IHeptcl (0.23 g, 0.24 mmol) was added to a degassed mixture of intermediate ih (1.5 g, 4.mmol), 4-(dibutoxymethyl)piperidine (1.5 g, 6.16 mmol) and C52CO3 (4.54 g, 13.93 mmol) in 1,4-dioxane (mL) at RT under nitrogen. The resulting mixture was stirred at 100 °C for 3 h under nitrogen. The reaction mixture was cooled to RT, diluted with DCM (75 mL) and AcOH (10%, 50 mL). The organic layer was washed with NaHCO3 solution (50 mL), dried with MgSO4, filtered and evaporated to afford crude product. The crude product was triturated with EtOAc (15 mL) to give a solid which was collected by filtration, washed with EtOAc (2x 5 mL), EtOAc:Et2O (1:1; 5 mL), Et20 (5 mL) and dried under vacuum to give the title compound (1.66 g, 73.6 %) as a white solid. 1H NMR 5 0.89 (6H, t), 1.23 - 1.42 (6H, m), 1.43 - 1.56 (4H, m), 1.67 - 1.85 (3H, m), 1.96 (IH, m), 2.28 - 2.44 (IH, m), 2.55 - 2.64 (IH, m), 2.72 - 2.84 (2H, m), 2.90 (IH, m), 3.40 (2H, dt), 3.56 (2H, dt), 3.89 (2H, d), 4.09 - 4.25 (2H, m), 4.32 (IH, d), 5.04 (IH, dd), 7.04 (2H, d), 7.50 (IH, d), 10.91 (IH, s); m/z; ES+ [M+H]+ = 486.0.
Example 22: 7-(4-{4-[4-({l-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZf-isoindol-5-yl]piperidin-4- yl}methyl)piperazin-l-yl]phenyl}piperidin-l-yl)-4-fluoro-lZf-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 124 Intermediate 22c was reacted with intermediate 22d using the general synthetic method illustrated by Example after purification by HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (25.0 mg, 14.12 %) as a yellow solid. 1H NMR 5 1.19 (2H, q), 1.82 (5H, t), 1.89-2.03 (3H, m), 2.20 (2H, d), 2.29-2.44 (1H, m), 2.54-2.62 (2H, m), 2.65-2.8 (3H, m), 2.83 (2H, t), 2.85-2.97 (1H, m), 3.06-3.13 (4H, m), 3.26-3.38 (5H, m), 3.88 (2H, d), 4.19 (1H, d), 4.32 (1H, d), 5.05 (1H, dd), 6.82 (1H, dd), 6.87-6.97 (3H, m), 7.04 (2H, d), 7.14 (2H, d), 7.50 (1H, d), 8.27 (1H, s), 10.95 (1H, s), 12.26 (1H, s); m/r. ES+ [M+H]+ = 743.5.
Example 23 Intermediate 23a: 7-[(3S)-3-{4-[4-(Dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl]-4-fluoro-lZ/-indole-3-carbonitrile LHMDS (IM in THE, 2.61 mL, 2.61 mmol) was added to intermediate 11b (300 mg, 0.75 mmol), intermediate 2b (178 mg, 0.75 mmol), and Pd-PEPPSI-IHeptcl (21.74 mg, 0.02 mmol) in THF (2 mL) under nitrogen. The resulting mixture was stirred at 60 °C for 2 h. The reaction mixture was quenched with saturated NH4C1 (25 mL) and extracted with EtOAc (3 x 50 mL). The organic layer was dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 60% EtOAc in Et20 to give the title compound (280 mg, 67.0 %) as a yellow solid. 1H NMR 0.87 (6H, t), 1.27-1.4 (6H, m), 1.42-1.52 (5H, m), 1.59-1.76 (3H, m), 1.79-1.98 (3H, m), 2.54 (2H, dd), 2.59-2.7 (2H, m), 2.94-3.04 (1H, m), 3.27 (2H, d), 3.35-3.41 (2H, m), 3.54 (2H, dt), 3.62 (2H, d), 4.16 (1H, d), 6.74-6.93 (4H, m), 7.11-7.18 (2H, m), 8.26 (1H, d), 12.26 (1H, s); m/z; ES+ [M+H]+ = 561.0.
Example 23: WO 2024/189488 PCT/IB2024/052251 125 7-[(3S)-3-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- yl]phenyl}piperidin-l-yl]-4-fluoro-l/f-indole-3-carbonitrile Formic acid (2 ml, 52.15 mmol) was added to 7-[(3S)-3-{4-[4-(dibutoxymethyl)piperidin-l- yl]phenyl}piperidin-l-yl]-4-fluoro-177-indole-3-carbonitrile (150 mg, 0.27 mmol) at RT and the mixture was stirred for l h. The solvent was then evaporated and the residue combined with intermediate 5f (84 mg, 0.mmol), in NMP (2 mL). The mixture was stirred at RT for l h. Purification of the reaction mixture by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (27.0 mg, 13.89 %) as a white solid. 1HNMRS 1.21 (2H, q), 1.47-1.6 (1H, m), 1.65 (1H, s), 1.76-1.88 (3H, m), 1.88- 2.06 (6H, m), 2.16 (2H, t), 2.23 (2H, d), 2.54-2.72 (4H, m), 2.76 (2H, t), 2.89-3.07 (3H, m), 3.40 (3H, s), 3.(2H, d), 3.77 (2H, t), 4.3-4.46 (1H, m), 6.41 (1H, d), 6.70 (1H, dd), 6.84 (3H, dd), 6.96 (1H, d), 7.14 (3H, t), 7.47-7.6 (2H, m), 8.17 (1H, s), 10.34 (1H, s); m/z; ES+ [M+H]+ = 727.0.
Example 24: 7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl} methyl)piperidin-l-yl| phenyl} piperidin-1-yl|-4-fluoro-1/f-indole-3-carbonitrile Intermediate 23a (140 mg, 0.25 mmol) was stirred in formic acid (1 mL) at RT for 1 h and then evaporated to dryness. Intermediate li (107 mg, 0.25 mmol) was also stirred in formic acid (1 mL) at RT for l h and then evaporated to dryness. The two residues were then combined in NMP (2 mL) and the resulting mixture was stirred at RT for l h. The reaction mixture was purified by C18-flash chromatography, elution gradient 5 to 100% MeCN in water (1% NHHCO,) to give the title compound (53.0 mg, 28.6 %) as a white solid. 1H NMR 1.11-1.32 (2H, m), 1.44-1.6 (1H, m), 1.66 (1H, s), 1.74-2 (6H, m), 2.20 (2H, d), 2.3-2.43 (1H, m), 2.(3H, d), 2.52-2.72 (6H, m), 2.84-3.04 (2H, m), 3.23-3.33 (6H, m), 3.61 (2H, d), 4.16-4.38 (2H, m), 5.05 (1H, dd), 6.79 (1H, dd), 6.83-6.93 (3H, m), 7.05 (2H, d), 7.15 (2H, d), 7.52 (1H, d), 8.26 (1H, s), 10.96 (1H, s), 12.27 (1H, s); m/z; ES+ [M+HL = 743.0.
Example 25: N O WO 2024/189488 PCT/IB2024/052251 126 4-Chloro-7-[(37?)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indazole-3-carbonitrile The title compound was prepared according to the procedure described in Example 9 but using (S)-3-(4- bromophenyl)piperidine oxalate in step 9d. Purification by HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (43.0 mg, 33.4 %) as a yellow solid; 1H NMR 5 0.85 (1H, q), 1.16-1.(2H, m), 1.52-1.72 (2H, m), 1.78-1.91 (2H, m), 1.9-2.1 (6H, m), 2.24 (4H, dd), 2.63 (2H, dd), 2.67-2.8 (4H, m), 3.02 (3H, d), 3.51 (3H, q), 3.64 (2H, d), 3.78 (2H, t), 4.39 (1H, tt), 6.42 (1H, d), 6.85-7 (4H, m), 7.11-7.(4H, m), 7.53 (2H, dd), 10.33 (1H, s); m/z; ES+ [M+H]+ = 744.5.
Example 26: 4-Chloro-7-[(37?)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-n/-indole-3-carbonitrile N Intermediate 2Id was reacted with intermediate 5f using the general synthetic method illustrated by example after purification by HPLC (Column A, Eluent A) to give the title compound in the form of a formate salt (42.0 mg, 54.4 %) as a white solid; 1H NMR 5 0.84 (1H, d), 1.22 (3H, d), 1.57 (1H, t), 1.66 (1H, s), 1.81 (3H, d), 1.94 (5H, d), 2.00 (1H, d), 2.07 (1H, s), 2.17 (2H, t), 2.24 (2H, d), 2.55-2.7 (3H, m), 2.76 (2H, t), 2.99 (3H, d), 3.63 (2H, d), 3.78 (2H, t), 4.37 (1H, s), 6.41 (1H, d), 6.85 (3H, dd), 6.96 (1H, d), 7.1-7.19 (4H, m), 7.47- 7.56 (2H, m), 8.31 (1H, s), 10.32 (1H, s), 12.28 (1H, s); m/z; ES+ [M+H]+ = 743.0.
Example 27 Intermediate 27a: tert-Butyl 4-[4-(benzyloxy)phenyl]piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 127 Benzyl bromide (2.89 g, 16.87 mmol) was added to tert-butyl 4-(4-hydroxypheny!)piperidine-1-carboxylate (3.6 g, 12.98 mmol) and K2CO3 (5.38 g, 38.94 mmol) inDMF (52 mL). The resulting mixture was stirred at RT for 5 h. The reaction mixture was diluted with EtOAc (200 mL), washed water (100 mL) and NaCI solution (50 mL). The organic layer was dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 20% EtOAc in Et20 to give the title compound (4.50 g, 94 %) as a white solid. 1H NMR 5 1.29 (11H, d), 1.59 (2H, d), 2.40 - 2.(1H, m), 2.65 (2H, s), 3.93 (2H, d), 4.94 (2H, d), 6.76 - 6.86 (2H, m), 6.97 - 7.08 (2H, m), 7.14 - 7.37 (5H, m); m/z; ES+ [M+H]+ = 353.2.
Intermediate 27b: tert-Butyl 4-[4-(benzyloxy)phenyl]piperidine-l-carboxylate (4.5 g, 12.25 mmol) was stirred in formic acid (mL) at RT for 2 h. The reaction mixture was then evaporated to dryness to afford crude product. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7M NH3/MeOH to give the title compound (3.20 g, 98 %) as a white solid. 1H NMR 1.33 - 1.52 (2H, m), 1.56 - 1.68 (2H, m), 2.39 - 2.60 (2H, m), 2.63 (2H, s), 2.92 - 3.03 (2H, m), 5.04 (2H, s), 6.85 - 6.96 (2H, m), 7.05 - 7.16 (2H, m), 7.24 - 7.47 (5H, m); m/z; ES+ [M+H]+ = 268.2.
Intermediate 270: 7-{4-[4-(Benzyloxy)phenyl]piperidin-l-yl}-4-methyl-n/-indole-3-carbonitrile Pd-PEPPSI-IPent (0.304 g, 0.31 mmol) was added to 4-[4-(benzyloxy)phenyl]piperidine (3.20 g, 11.99 mmol), intermediate 8a (2.45g, 10.42 mmol) and LHMDS (IM in THE, 36.5 ml, 36.48 mmol) in 1,4-dioxane (25 mL) under nitrogen. The resulting mixture was stirred at 60 °C for 2 h. The reaction mixture was cooled to RT and was quenched with water (5 mL). The solvent was removed under reduced pressure to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% DCM in Etfollowed by 0 to 10% EtOAc in DCM to give the title compound (2.60 g, 59.2 %) as a yellow solid. 1H NMR 1.85 (2H, d), 1.89 - 2.08 (2H, m), 2.60 (4H, s), 2.67 - 2.82 (2H, m), 3.38 (2H, d), 5.09 (2H, s), 6.77 (1H, d), 6.88 (lH,d), 6.93 -7.04 (2H, m), 7.17 - 7.28 (2H, m), 7.30 - 7.51 (5H, m), 8.17 (1H, d), 11.88- 11.95 (1H, m); m/z; ES+ [M+H]+ = 422.3.
Intermediate 27d: 7-{4-[4-(Benzyloxy)phenyl]piperidin-l-yl}-4-methyl-l-{[2-(trimethylsilyl)ethoxy]methyl}-lZ/-indole-3- carbonitrile 4- [4-(Benzyloxy)phenyl] piperidine WO 2024/189488 PCT/IB2024/052251 128 Sodium hydride (0.144 g, 3.61 mmol) was added to 7-[4-|4-(bcnzyloxy)phcnyl|pipcridin-l-yl;-4-mcthyl-l//- indole-3-carbonitrile (1.17 g, 2.78 mmol) in THF (18 mL) at 0 °C and stirred for 1 h. 2-(Trimethylsily!)ethoxymethyl chloride (0.591 ml, 3.33 mmol) was added and the resulting solution was stirred at RT for 2 h. The reaction mixture was quenched with water and the reaction was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 90% DCM in Et20 to give the title compound (1.3 g, 85 %) as a white solid. 1H NMR 5 -0.09 (9H, s), 0.76 - 0.87 (2H, m), 1.85 (4H, s), 2.57 (4H, d), 2.84 (2H, s), 3.16 (2H, d), 3.48 - 3.59 (2H, m), 5.09 (2H, s), 5.97 (2H, s), 6.92 - 7.04 (3H, m), 7.12 (1H, d), 7.18 - 7.26 (2H, m), 7.28 - 7.51 (5H, m), 8.36 (1H, s); m/z; ES+ [M+H]+ = 552.4.
Intermediate 27e: 7-[4-(4-Hydroxyphenyl)piperidin-l-yl]-4-methyl-l-{[2-(trimethylsilyl)ethoxy]methyl}-lZ/-indole-3- carbonitrile Pd/C (10%, 1.24 g, 11.65 mmol) was added to 7-{4-[4-(benzyloxy)phenyl]piperidin-l-yl}-4-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l/7-indole-3-carbonitrile (1.24 g, 2.25 mmol) inEtOAc (60 mL) under hydrogen and stirred at RT for 2 h. The reaction mixture was filtered through Celite® and the solvent was evaporated to give the title compound (0.94 g, 91 %) as a white solid. 1H NMR (CDCI)) 5 -0.03 (9H, s), 0.83 - 1.01 (2H, m), 1.83 - 2.01 (4H, m), 2.56 - 2.69 (1H, m), 2.77 (3H, s), 2.93 (2H, td), 3.29 (2H, d), 3.50 - 3.(2H, m), 6.06 (2H, s), 6.79 - 6.90 (2H, m), 6.96 - 7.04 (1H, m), 7.12 (1H, d), 7.15 - 7.23 (2H, m), 7.73 (1H, s) OH not observed; m/r. ES+ [M+H]+ = 462.3.
Intermediate 27f: 7-(4-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}piperidin-l-yl)-4-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 129 K2CO3 (0.808 g, 5.85 mmol) was added to 7-[4-(4-hydroxyphenyl)piperidin-l-yl]-4-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l/7-indole-3-carbonitrile (0.90 g, 1.95 mmol) and 2-(3-bromopropyl)-l,3- dioxolane (0.760 g, 3.90 mmol) in DMF (10 mL). The resulting mixture was stirred at 80 °C for 8 h. The reaction mixture was cooled to RT and purified by flash C18-flash chromatography, elution gradient 0 to 100% MeOH in water (0.1% NH,HCO,) to give the title compound (0.75 g, 66.8 %) as a yellow solid. 1H NMR (MeOD) 5 0.70 (9H, s), 1.60 (2H, t), 2.02 (1H, s), 2.46 - 2.60 (3H, m), 2.63 (5H, s), 3.41 (3H, s), 3.90 - 4.00 (2H, m), 4.11 (2H, s), 4.32 (2H, t), 4.48 - 4.81 (6H, m), 5.64 (1H, t), 6.76 (2H, s), 7.66 (2H, d), 7.78 (1H, d), 7.91 (1H, d), 7.99 (2H, d), 9.15 (1H, s); m/r. ES+ [M+H]+ = 576.5.
Intermediate 27g: 7-(4-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}piperidin-l-yl)-4-methyl-lH-indole-3-carbonitrile Tetrabutylammonium fluoride (IM in THF, 9.3 mL, 9.38 mmol) was added to 7-(4-{4-[3-(l,3-dioxolan-2- yl)propoxy]phenyl}piperidin-l -yl)-4-methyl-1 -{[2-(trimethylsilyl)ethoxy]methyl) -1 //-indolc-3 -carbonitrile (360 mg, 0.63 mmol) and the resulting mixture was stirred at 40 °C for 16 h. The reaction was cooled to RT and the mixture was evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% DCM in Et20 followed by 0 to 12% EtOAc in DCM to give the title compound (0.19 g, 68.2 %) as a white solid. 1H NMR 5 1.73 (3H, m), 1.81 - 1.89 (3H, m), 1.98 (2H, qd), 2.61 (4H, d), 2.70 - 2.80 (2H, m), 3.38 (2H, d), 3.73 - 3.82 (2H, m), 3.87 - 3.92 (2H, m), 3.97 (2H, t), 4.86 (1H, t), 6.77 (1H, d), 6.89 (3H, dd), 7.20 (2H, d), 8.17 (1H, d), 11.91 (1H, d); m/z; ES+ [M+H]+ = 446.35.
Example 27: 7-2,6)-2]-4 -؛ 4 -) 4 -] 4 ؛ -Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-l/f-isoindol-5-yl| piperazin-1- yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 130 7-(4-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}piperidin-l-yl)-4-methyl-l/f-indole-3-carbonitrile (0.159 g, 0.31 mmol) and intermediate 7c (0.162 g, 0.35 mmol) were heated in formic acid (4 mL) to 40 °C for 1 h. The reaction was cooled to RT and evaporated to dryness. NMP (4 mL) was added to the residue and the resulting solution was stirred at RT for 16 h. The reaction mixture was quenched with NaHCO3 solution (10 mL), extracted with DCM (30 mL) and the organic layer was dried over MgSCL, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% MeOH in DCM to give the title compound (0.11 g, 48.2 %) as a white solid. 1H NMR 5 1.50 - 1.65 (2H, m), 1.67 - 1.84 (2H, m), 1.87 - 2.00 (5H, m), 2.18 - 2.46 (6H, m), 2.57 (5H, s), 2.59 - 2.78 (3H, m), 2.80 - 2.(1H, m), 3.26 (4H, d), 3.33 - 3.35 (2H, m), 3.81 (3H, s), 3.97 (2H, t), 4.02 - 4.27 (2H, m), 4.94 (1H, dd), 6.(1H, d), 6.58 (1H, s), 6.75 (1H, d), 6.82 - 6.93 (3H, m), 7.18 (2H, d), 8.15 (1H, d), 10.88 (1H, s), 11.89 (1H, s); m/z; ES+ [M+H]+ = 744.4.
Example 28: 7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lH-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-lH-indole-3-carbonitrile Intermediate 27g was reacted with intermediate li using the general synthetic method illustrated by example to give the title compound (31.6 mg, 12.75 %) as a white solid. 1H NMR 5 1.51 (2H, q), 1.58 - 1.76 (4H, m), 1.77 - 1.90 (3H, m), 2.25 (6H, q), 2.47 (5H, s), 2.62 (3H, t), 2.75 (1H, d), 3.15 (4H, t), 3.26 (2H, d), 3.(2H, t), 4.03 - 4.26 (2H, m), 4.92 (1H, dd), 6.65 (1H, d), 6.71 - 6.83 (3H, m), 6.93 (2H, d), 7.08 (2H, d), 7.(1H, d), 8.04 (1H, d), 10.81 (1H, s), 11.77 (1H, s); m/r. ES+ [M+H]+ = 714.3.
Example 29: 7-{4-[4-(4-{4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}butoxy)phenyl]piperidin-l- yl}-4-methyl-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 131 The title compound was prepared using methodology described in example 23 using intermediate 27g and intermediate 5f to give the title compound in the form of a formate salt (14.4 mg, 53.0 %) as a beige solid. 1H NMR 5 1.77 - 1.91 (6H, m), 1.93 - 2.05 (3H, m), 2.16 - 2.29 (4H, m), 2.55 - 2.66 (4H, m), 2.72 - 2.83 (4H, m), 3.09 - 3.29 (3H, m), 3.40 (2H, d), 3.64 - 3.75 (1H, m), 3.79 (2H, t), 3.99 -4.11 (2H, m), 4.62 - 4.87 (1H, m), 6.41 - 6.55 (1H, m), 6.79 (1H, d), 6.87 - 6.91 (1H, m), 6.94 (2H, d), 7.01 (1H, d), 7.1 - 7.3 (3H, m), 7.- 7.49 (1H, m), 7.56 (1H, d), 8.17 (1H, d), 9.09 - 9.33 (1H, m), 10.34 (1H, s), 11.84 - 11.98 (1H, m); m/z; ES+ [M+H]+ = 698.4.
Example 30 Intermediate 30a: 6-Chloro-2-methoxy-4-methylpyridine-3-carboxylic acid To a stirred solution sodium methoxide (20.67 ml, 112 mmol) in THF (50.0 mL) was added 2,6-dichloro-4- methylpyridine-3-carboxylic acid (10.0 g, 48.5 mmol) in THF (50.0 ml) at 0 °C. The reaction mixture was stirred at 70 °C for 16 h. The reaction was then cooled to RT and acidified with a HCI (2M, aq) to pH 3 -4, then extracted with EtOAc (160 mL). The organic layer was washed with water (100 mL), NaCI solution (100 mL), dried over Na2SO4, filtered and evaporated to dryness to give the title compound (8.0 g, 78 % yield) which was used without further purification. 1H NMR 5 2.27 (3H, s), 3.87 (3H, s), 7.10 (1H, s), 13.42 (1H, s). no mass ion.
Intermediate 30b: Methyl 6-chloro-2-methoxy-4-methylpyridine-3-carboxylate To a stirred solution of 6-chloro-2-methoxy-4-methylpyridine-3-carboxylic acid (8.0 g, 39.7 mmol) inDMF (80 mL) was added K2CO3 (6.58 g, 47.6 mmol) and methyl iodide (8.45 g, 59.5 mmol) which was stirred at RT for 16 h. The reaction mixture was diluted with water (80 mL) and extracted with MTBE (240 mL). The organic layer was washed with NaCI solution (160 mL, dried over Na2SO4, filtered and evaporated to dryness WO 2024/189488 PCT/IB2024/052251 132 to give the title compound (8.5 g, 37.1 mmol, 93 % yield) as pale yellow solid. 1H NMR 5 2.26 (3H, s), 3.(3H, s), 3.87 (3H, s),7.13(lH, s).
Intermediate 300: Methyl 4-(bromomethyl)-6-chloro-2-methoxypyridine-3-carboxylate O/ O Methyl 6-chloro-2-methoxy-4-methylpyridine-3-carboxylate (8.0 g, 37.1 mmol) was added to tert-butyl acetate (150 mL) under nitrogen. MBS (9.24 g, 51.9 mmol) and benzoyl peroxide (1.79 g, 7.42 mmol) were added at RT and was then stirred at 110 °C for 14 h. Additional MBS (2.64 g, 14.84 mmol) was added and was continued to stir at 110 °C for 12 h. The reaction mixture was cooled to RT and diluted with NaHCO3 solution (10%, 50 mL) and extracted with EtOAc (120 mL). The organic layer was washed with NaCI solution (mL), dried over Na2S04, filtered and evaporated to dryness to give the crude title compound (11.0 g, 10.mmol, 27.0 % yield) as brown liquid which was used without further purification. m z ES+ [M+H]+ = 294.0. no nmr data Intermediate 30d: 3-(6-Chloro-4-methoxy-3-oxo-l,3-dihydro-2Zf-pyrrolo[3,4-c]pyridin-2-yl)piperidine-2,6-dione 9X O 1 iT^ N־^^=° Ci^^V O H Methyl 4-(bromomethyl)-6-chloro-2-methoxypyridine-3-carboxylate (11.0 g, 10.01 mmol) was dissolved in MeCN (80 mL). 3-Aminopiperidine-2,6-dione hydrochloride (1.65 g, 10.01 mmol) and DIPEA (5.17 g, 40.mmol) were added and the reaction mixture was stirred at 85 °C for 16 h. The reaction mixture was then cooled to RT and was diluted with DCM (200 mL), washed AcOH (5%, aq 200 mL), water (200 mL), NaHCO3 solution (200 mL), NaCI solution (200 mL), dried with Na2S04, filtered and evaporated to afford crude product. The crude product was triturated with EtOAc (10 mL) and washed with MTBE (30 mL) to afford solid which was collected by filtration and dried under vacuum to give the title compound (1.6 g, 4.mmol, 43.5 % yield) as brown solid. 1H NMR 5 1.89 - 2.02 (1H, m), 2.30 - 2.35 (1H, m), 2.50 - 2.59 (1H, m), 2.84 - 2.98 (1H, m), 3.99 (3H, s), 4.26 - 4.39 (1H, m), 4.40 - 4.53 (1H, m), 5.05 (1H, dd), 7.40 (1H, s), 10.(1H, br s); m/z; ES+ [M+H]+ = 310.2.
Intermediate 30e: tert-Butyl 4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4-c]pyridin-6- yl]piperazine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 133 Pd-PEPPSI-IPent (47.1 mg, 0.048 mmol) was added to tert-butyl piperazine-1-carboxylate (541 mg, 2.mmol), C52CO3 (947 mg, 2.91 mmol) and 3-(6-chloro-4-methoxy-3-oxo-l,3-dihydro-2/7-pynolo[3,4- c]pyridin-2-yl)piperidine-2,6-dione (300 mg, 0.969 mmol) in 1,4-dioxane (10 mL) atRT under nitrogen. The resulting suspension was stirred at 120 °C for 2 h. The reaction mixture was cooled to RT and diluted with DCM (20 mL), washed with AcOH (5%, aq 20 mL), water (20 mL), NaHCO3 solution (20 mL), NaCl solution (20 mL), dried with Na2S04, filtered and evaporated to afford crude product. The crude product was triturated with EtOAc (4 mL) and washed with MTBE (16 mL) to afford solid which was collected by filtration and dried under vacuum to give the title compound (260 mg, 0.485 mmol, 50.1 % yield) as brown solid. 1H NMR 1.43 (9H, s), 1.88 - 2.00 (1H, m), 2.29 - 2.39 (1H, m), 2.58 - 2.68 (1H, m), 2.86 - 2.96 (1H, m), 3.34 -3.(4H, m), 3.53 - 3.63 (4H, m), 3.90 (3H, s), 4.09 - 4.18 (1H, m), 4.24 - 4.34 (1H, m), 4.97 (1H, brdd), 6.(1H, s), 10.92 (1H, br s); m/z; ES+ [M+H]+ = 460.2.
Example 30: Intermediate 8b (59 mg, 0.13 mmol) and tert-butyl 4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3- dihydro-l//-pyrrolo|3.4-c|pyridin-6-yl|pipcrazinc-l-carboxylatc (63.4 mg, 0.14 mmol) were heated in formic acid (3 mL, 79.52 mmol) at 60 °C for 2 h. The reaction mixture was concentrated and the crude residue was suspended in NMP (2 mL) at RT. The reaction mixture was stirred for 5 mins and sodium triacetoxyborohydride (66.4 mg, 0.31 mmol) was added. The resulting suspension was stirred at RT for 16 h. NaHCO3 solution was added and the solids formed were collected by filtration, washed with water (5 mL) and dried over vacuum to afford crude product. Purification by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (3.0 mg, 3 %) as a yellow solid. 1H NMR 8 1.17 - 1.39 (9H, m), 1.75 - 2.05 (11H, m), 2.23 (3H, d), 2.60 (3H, s), 2.75 (1H, t), 3.35 - 3.41 (2H, m), 3.58 - 3.7 (6H, m), 3.(3H, s), 4.08 - 4.2 (1H, m), 4.22 - 4.34 (1H, m), 4.9 - 5.02 (1H, m), 6.49 (1H, s), 6.78 (1H, d), 6.86 - 6.(3H,m),7.14(2H,d), 8.11-8.23 (1H, m), 10.91 (1H, s), 11.90 (1H, s); m/z; ES+ [M+H]+= 770.5.
Example 31: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4-c]pyridin-6- yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-4-methyl-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 134 7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4-c]pyridin-6- yl]piperazin-l-yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-lZ/-indole-3-carbonitrile Intermediate 27g (28 mg, 0.07 mmol) and intermediate 30e (32 mg, 0.07 mmol) were stirred in formic acid (mL) at 60 °C for 1 h. The mixture was evaporated and diluted with NMP (1 mL). Sodium triacetoxyborohydride (37 mg, 0.17 mmol) was added and the mixture was stirred at RT for 30 mins. The reaction was neutralised with NaHCO3 solution until pH 12. The solid was filtered under vacuum and washed with water (5 mL). The solid was added to a mixture of EtOAc :Heptane (1:1, 70 mL) with addition of DCM (mL) and stirred at 50 °C for 16 h. The suspension was filtered hot and the solids were washed with cold EtOAc:Heptane (1:1) and dried under vacuum to give the title compound (20.0 mg, 36.3 %) as a pale green solid. 1H NMR (CDC13) 5 1.77 - 1.89 (4H, m), 1.91 - 2.04 (4H, m), 2.1 - 2.2 (1H, m), 2.26 (1H, qd), 2.63 - 2.71 (3H, m), 2.74 (3H, s), 2.75 - 2.96 (8H, m), 3.42 (2H, d), 3.69 - 3.85 (4H, m), 3.95 - 4.04 (5H, m), 4.(1H, d), 4.35 (1H, d), 5.13 (1H, dd), 6.17 (1H, s), 6.77-6.9 (2H, m), 6.91 (1H, d), 6.94-6.98 (1H, m), 7.(2H, d), 7.73 (1H, d), 7.96 (1H, s), 8.19 (1H, s), 9.20 (1H, s); m/r. ES+ [M+H]+ = 745.4.
Example 32 Intermediate 32a: O^N Benzyl carbonochloridate (7.3 ml, 51.47 mmol) was added to triethylamine (19.5 ml, 140.38 mmol) and 4- (piperidin-4-yl)phenol HC1 (10 g, 46.79 mmol) in THE (441.0 mL). The resulting mixture was stirred at RT for 16 h. The reaction mixture was diluted with EtOAc (100 mL) and washed with NaHCO3 solution (2x 1mL). The organic layer was dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 40% EtOAc in Et20 to give the title compound (1.5 g, 10.29 %) as a white solid. 1H NMR 5 1.32 - 1.55 (2H, m), 1.70 (2H, d), 2.49 - 2.63 (1H, m), 2.85 (2H, s), 4.10 (2H, d), 5.07 (2H, s), 6.60 - 6.71 (2H, m), 6.94 - 7.05 (2H, m), 7.36 (5H, d), 9.14 (1H, s); m/z; ES+ [M+H]+ = 312.2.
Intermediate 32b: Benzyl 4-(4-hydroxyphenyl)piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 135 Benzyl 4-{4-[3-(l,3-dioxolan-2-yl)propoxy]phenyl}piperidine-l-carboxylate K2CO3 (1.59 g, 11.56 mmol) was added to benzyl 4-(4-hydroxyphenyl)piperidine-l-carboxylate (1.8 g, 5.mmol) and 2-(3-bromopropyl)-l,3-dioxolane (2.25 g, 11.56 mmol) inMeCN (15 mL). The resulting mixture was stirred at 80 °C for 16 h. The reaction was cooled to RT, filtered under vacuum and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc inEt2O to give the title compound (1.7 g, 69.1 %) as a white solid. 1H NMR (CDCL,) 5 1.58 - 1.(3H, m), 1.82 (2H, s), 1.81 - 1.99 (3H, m), 2.57 - 2.69 (1H, m), 2.89 (2H, s), 3.78 - 3.99 (2H, m), 3.96 - 4.(3H, m), 4.33 (3H, s), 4.95 (1H, t), 5.18 (2H, s), 6.77 - 6.90 (2H, m), 7.03 - 7.16 (2H, m), 7.29 - 7.38 (1H, m), 7.34 - 7.44 (4H, m); m/z; ES+ [M+H]+ = 426.2.
Intermediate 320: 4-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}piperidine Pd/C (10%, 0.85 g, 0.80 mmol) was added to benzyl 4-{4-[3-(l,3-dioxolan-2-yl)propoxy]phenyl}piperidine-l- carboxylate (1.7 g, 4.00 mmol) in EtOAc (15.0 mL) under an atmosphere of hydrogen. The resulting mixture was stirred at RT for 4 h. The mixture was filtered through Celite® and evaporated to dryness to give the title compound (1.1 g, 94 %) as a white solid, which was used without further purification. 1H NMR (CDCL) 1.65 (3H, m), 1.88 (5H, s), 2.33 (2H, s), 2.52 - 2.66 (1H, m), 2.77 (2H, td), 3.23 (2H, d), 3.79 - 3.97 (2H, m), 3.95 - 4.02 (3H, m), 4.96 (1H, t), 6.82 - 6.91 (2H, m), 7.10 - 7.24 (2H, m); m/z; ES+ [M+H]+ = 292.1.
Intermediate 32d: 4-Chloro-7-(4-{4-[3-(l,3-dioxolan-2-yl)propoxy]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile 4-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}piperidine was reacted with intermediate lb using the general synthetic method illustrated by intermediate 11c to give the title compound (266 mg, 55 %) as a white solid. 1H NMR (CDC13) 5 1.79-1.97 (3H, m), 1.98 (6H, s), 2.65 (1H, d), 2.90 (2H, s), 3.40 (2H, d), 3.79-3.96 (2H, m), 3.98-4.01 (3H, m), 4.95 (1H, t), 6.81-6.95 (3H, m), 7.13-7.23 (3H, m), 7.76 (1H, s), 9.02 (1H, s); m/z; ES+ [M+H]+ = 466.0.
Example 32: WO 2024/189488 PCT/IB2024/052251 136 4-Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4- c]pyridin-6-yl]piperazin-l-yl}butoxy)phenyl]piperidin-l-yl}-lZ/-indole-3-carbonitrile 4-Chloro-7-(4-1.3)-3|-4؛-dioxolan-2-yl)propoxy |phcnyl؛pipcridin-l-yl)-l//-indolc-3-carbonitrilc was reacted with intermediate 30e using the general synthetic method illustrated by example 23 to give the title compound in the form of a formate salt (20.0 mg, 36.3 %) as a white solid. 1H NMR 5 1.56 - 1.76 (2H, m), 1.76 - 1.(2H, m), 1.87 -2.11 (5H, m), 2.31 - 2.49 (4H, m), 2.84 (2H, t), 2.9 - 3.05 (1H, m), 3.48 (3H, d), 3.6 - 3.(4H, m), 3.95 (3H, s), 4.05 (2H, t), 4.19 (1H, d), 4.33 (1H, d), 5.02 (1H, dd), 6.54 (1H, s), 6.83 - 7.07 (3H, m), 7.15-7.38 (3H, m), 8.25 (2H, s), 8.38 (1H, s), 10.96 (1H, s) 3H under DMSO ; m/z; ES+ [M+H]+ = 766.6.
Example 33 Intermediate 33a: 7-(4-3]-4؛-(l,3-Dioxolan-2-yl)propoxy|phenyl ؛piperidin-l-yl)-4-t1uoro-l//-indole-3-carbonitrile Intermediate 32c was reacted with intermediate 2b using the general synthetic method illustrated by intermediate 11c to give the title compound (240 mg, 52 %) as a yellow solid. 1H NMR 5 1.77 (4H, s), 1.65 - 2.04 (4H, m), 2.60 (1H, s), 2.67 - 2.81 (2H, m), 3.36 (2H, d), 3.75 (1H, s), 3.73 - 3.84 (1H, m), 3.84 - 4.(4H, m), 4.83 (1H, t), 6.80 (1H, dd), 6.86 (1H, d), 6.85 - 6.97 (2H, m), 7.14 - 7.23 (2H, m), 8.25 (1H, d), 12.24 (1H, s); m/z; ES+ [M+H]+ = 450.2.
Example 33: 7-{4-[4-(4-{4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}butoxy)phenyl]piperidin-l- yl4- ؛-fluoro-l/f-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 137 7-(4-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}piperidin-l-yl)-4-fluoro-lH-indole-3-carbonitrile was reacted with intermediate 5f using the general synthetic method illustrated by example 23 and purification by HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (24 mg, 36 %) as a white solid. 1H NMR 5 1.64 - 1.76 (2H, m), 1.78 - 1.96 (4H, m), 1.96 - 2.1 (6H, m), 2.21 - 2.34 (2H, m), 2.49 - 2.53 (2H, m), 2.64 - 2.7 (1H, m), 2.78 - 2.88 (4H, m), 3.12 (2H, d), 3.42 - 3.5 (2H, m), 3.83 (2H, t), 4.06 (2H, t), 4.38 - 4.54 (1H, m), 6.43 - 6.54 (1H, m), 6.84 - 6.92 (1H, m), 6.95 - 7.01 (3H, m), 7.01 - 7.04 (1H, m), 7.16 - 7.(1H, m), 7.25 - 7.31 (2H, m), 7.52 - 7.63 (2H, m), 8.20 (1H, s), 8.32 (1H, s), 10.37 (1H, s); m/z; ES+ [M+H]+ = 702.9.
Example 34: 4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZZ-pyrrolo[3,4- c]pyridin-6-yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-n/-indole-3-carbonitrile Intermediate if was reacted with intermediate 30e using the general synthetic method illustrated by example to give the title compound (59.0 mg, 43 %) as a yellow solid. 1H NMR 5 1.19 - 1.31 (3H, m), 1.70 (1H, s), 1.84 (4H, s), 1.9 - 2 (3H, m), 2.23 (2H, d), 2.26 - 2.32 (1H, m), 2.47 (4H, d), 2.54 - 2.67 (3H, m), 2.79 (2H, t), 2.84 - 2.95 (1H, m), 3.38 - 3.47 (2H, m), 3.65 (6H, d), 3.90 (3H, s), 4.14 (1H, d), 4.28 (1H, d), 4.96 (1H, dd), 6.49 (1H, s), 6.89 (3H, dd), 7.16 (3H, dd), 8.32 (1H, s), 10.91 (1H, s), 12.26 (1H, s); m/r. ES+ [M+H]+ = 790.8.
Examples 35 and 36 The enantiomers of Example 34were separated by SEC purification on a Sepiatec 100 SFC using SFC conditions Regis (R,R) Whelk-01, 21.1 x 250 mm, 5 micron, 50% MeOH/DCM / 50% scCO2 at a flow rate of mL/min, 40 °C to give, in order of elution, example 35(isomerl, 61 mg, 29 %) and example 36(isomer 2, mg, 32 %) as white solids.
Example 35: 4-Chloro-7-[4-(4-{4-[(4-{2-[(37?*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-lZf-pyrrolo[3,4- c]pyridin-6-yl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 138 1H NMR 5 1.19-1.29 (2H, m), 1.67 (1H, s), 1.77-1.91 (4H, m), 1.88-2.03 (3H, m), 2.20 (2H, d), 2.31 (1H, dd), 2.44 (4H, s), 2.59 (4H, q), 2.76 (2H, t), 2.84-2.95 (1H, m), 3.41 (2H, d), 3.63 (6H, d), 3.89 (3H, s), 4.(1H, d), 4.27 (1H, d), 4.97 (1H, dd), 6.48 (1H, s), 6.79-6.96 (3H, m), 7.09-7.2 (3H, m), 8.34 (1H, s), 10.(1H, s), 12.28 (1H, s); m/z; ES+ [M+H]+ = 790.5; >99% ee.
Example 36: 4-Chloro-7-[4-(4-{4-[(4-{2-[(3،2,6-(* ؟-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4- c]pyridin-6-yl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-n/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR 5 1.19-1.29 (2H, m), 1.67 (1H, s), 1.77-1.91 (4H, m), 1.88-2.03 (3H, m), 2.20 (2H, d), 2.31 (1H, dd), 2.44 (4H, s), 2.59 (4H, q), 2.76 (2H, t), 2.84-2.95 (1H, m), 3.41 (2H, d), 3.63 (6H, d), 3.89 (3H, s), 4.(1H, d), 4.27 (1H, d), 4.97 (1H, dd), 6.48 (1H, s), 6.79-6.96 (3H, m), 7.09-7.2 (3H, m), 8.34 (1H, s), 10.(1H, s), 12.28 (1H, s); m/z; ES+ [M+H]+ = 790.4; >99% ee.
Example 37: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4-c]pyridin-6- yl | piperazin-1-yl ؛methyl)piperid in-1-yl | phenyl] piperidin-l-yl)-4-tluoro-l//-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 Intermediate 2c was reacted with intermediate 30e using the general synthetic method illustrated by example to give the title compound (37.0 mg, 19 %) as a white solid. 1H NMR 5 1.16-1.3 (2H, m), 1.69 (1H, s), 1.83 (4H, d), 1.86-2.02 (3H, m), 2.21 (2H, d), 2.24-2.37 (1H, m), 2.45 (4H, t), 2.53-2.6 (4H, m), 2.75 (2H, t), 2.82-2.96 (1H, m), 3.37 (2H, d), 3.58-3.68 (6H, m), 3.89 (3H, s), 4.13 (1H, d), 4.27 (1H, d), 4.96 (1H, dd), 6.48 (1H, s), 6.82 (1H, dd), 6.87-6.97 (3H, m), 7.13 (2H, d), 8.27 (1H, s), 10.92 (1H, s), 12.26 (1H, s); m/z; ES+ [M+H]+ = 774.4.
Example 38: 4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4- c]pyridin-6-yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-n/-indole-3-carbonitrile Intermediate He was reacted with intermediate 30e using the general synthetic method illustrated by example to give the title compound (70.0 mg, 64 %) as a white solid. 1H NMR 5 1.21 (2H, q), 1.55 (1H, q), 1.(1H, s), 1.82 (2H, d), 1.89-1.94 (4H, m), 2.21 (2H, s), 2.23-2.35 (1H, m), 2.45 (3H, s), 2.54 (1H, s), 2.56-2.(5H, m), 2.82-2.95 (1H, m), 2.99 (1H, t), 3.30 (1H, s), 3.33 (1H, s), 3.54-3.68 (6H, m), 3.88 (3H, s), 4.13 (1H, d), 4.27 (1H, d), 4.96 (1H, dd), 6.48 (1H, s), 6.85 (3H, dd), 7.14 (3H, dd), 8.31 (1H, d), 10.92 (1H, s), 12.(1H, s); m/z; ES+ [M+H]+ = 790.4.
Examples 39 & 40: The enantiomers of Example 38were separated by SEC purification on a Sepiatec 100 SFC using SFC conditions Regis (R,R) Whelk-01, 21.1 x 250 mm, 5 micron, 50% MeOH/MeCN / 50% scCO2 at a flow rate of 60 mL/min, 40 °C to give, in order of elution, example 39(isomer 1, 6.6 mg, 22 %) and example 40 (isomer 2, 5.7 mg, 19 %) as white solids.
Example 39: 4-Chloro-7-[(3S)-3-(4-{4-[(4-{2-[(37?*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-lZ/- pyrrolo[3,4-c]pyridin-6-yl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-lZ/-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] X-O N O WO 2024/189488 PCT/IB2024/052251 140 1H NMR 5 1.13 - 1.3 (2H, m), 1.49 - 1.63 (1H, m), 1.62 - 1.74 (1H, m), 1.73 - 1.85 (2H, m), 1.85 - 1.(4H, m), 2.21 (2H, d), 2.24 - 2.31 (1H, m), 2.45 (4H, d), 2.53 - 2.76 (5H, m), 2.82 - 2.95 (1H, m), 2.95 - 3.(1H, m), 3.33 - 3.43 (2H, m), 3.54 - 3.69 (6H, m), 3.88 (3H, s), 4.08 - 4.33 (2H, m), 4.95 (1H, dd), 6.48 (1H, s), 6.77 - 6.96 (3H, m), 7.04 - 7.22 (3H, m), 8.29 (1H, s), 10.90 (1H, s), 12.27 (1H, s); m/z; ES+ [M+H]+ = 790.5; >99% ee.
Example 40: 4-Chloro-7-[(3S)-3-(4-{4-[(4-{2-[(3S'*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-lZ/- pyrrolo[3,4-c]pyridin-6-yl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-lZ/-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR S 1.15 - 1.3 (2H, m), 1.5 - 1.62 (1H, m), 1.62 - 1.74 (1H, m), 1.75 - 1.85 (2H, m), 1.84- 1.97 (4H, m), 2.21 (2H, d), 2.23 - 2.3 (1H, m), 2.4 - 2.47 (4H, m), 2.52 - 2.66 (4H, m), 2.68 - 2.74 (1H, m), 2.83 - 2.(1H, m), 2.94 - 3.05 (1H, m), 3.31 - 3.4 (2H, m), 3.56 - 3.67 (6H, m), 3.88 (3H, s), 4.1 -4.31 (2H, m), 4.(1H, dd), 6.48 (1H, s), 6.77 - 6.93 (3H, m), 7.09 - 7.21 (3H, m), 8.30 (1H, d), 10.90 (1H, s), 12.26 (1H, d); m/z; ES+ [M+H]+ = 790.5; >99% ee.
Example 41 Intermediate 41a: Benzyl 4-(4-bromo-2-fluorophenyl)-3,6-dihydropyridine-l(2Zf)-carboxylate 4-Bromo-2-fluoro-l-iodobenzene (1.00 g, 3.32 mmol) and benzyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-l(2//)-carboxylate (1.36 g, 3.99 mmol) were added to toluene:EtOH (2:1, 15 mL).
WO 2024/189488 PCT/IB2024/052251 141 Na2CO3 (2M, 5 mL, 9.97 mmol) was added and the mixture was degassed with nitrogen. Pd(dppf)C12 (0.271 g, 0.33 mmol) was added and the mixture was stirred at 100 °C for l h. The reaction mixture cooled to RT, diluted with water (25 mL), extracted with EtOAc (60 mL) and the organic layer was washed with NaCI solution (30 mL). The organics were dried with MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% EtOAc in heptane to give the title compound (0.988 g, 76 %) as a pale brown gum. 1H NMR (CDCI)) 5 2.49 (2H, s), 3.69 (2H, t), 4.14 (2H, q), 5.18 (2H, s), 5.92 (1H, s), 7.01-7.16 (1H, m), 7.19-7.26 (2H, m), 7.29-7.43 (5H, m).
Intermediate 41b: Benzyl 4-{4-[4-(dibutoxymethyl)piperidin-l-yl]-2-fluorophenyl}-3,6-dihydropyridine-l(2L/)-carboxylate Benzyl 4-(4-bromo-2-fluorophenyl)-3,6-dihydropyridine-l(27/)-carboxylate (1.06 g, 2.73 mmol), 4- (dibutoxymethyl)piperidine (0.785 g, 2.87 mmol) and sodium tert-butoxide (0.788 g, 8.20 mmol) were added to 1,4-dioxane (15.0 mL) and was degassed with nitrogen for 5 minutes, RuPhos (0.128 g, 0.27 mmol) and RuPhos Pd G3 (0.229 g, 0.27 mmol) were then added and the reaction was stirred at 80 °C for 2 h. The reaction was then cooled to RT and the solvent was evaporated. The residue was suspended in DCM (10 mL), filtered and the filtrate was purified by flash silica chromatography, elution gradient 0 to 25% EtOAc in heptane to give the title compound (0.349 g, 23.09 %) as a yellow gum. 1H NMR (CDCI)) 5 0.93 (6H, t), 1.(5H, m), 1.5 - 1.65 (4H, m), 1.7 - 1.97 (3H, m), 2.50 (2H, s), 2.69 (2H, td), 3.44 (2H, dt), 3.55 - 3.84 (5H, m), 4.03 - 4.26 (3H, m), 5.18 (2H, d), 5.85 (1H, s), 6.46 - 6.73 (2H, m), 7.03 - 7.16 (1H, m), 7.27 - 7.5 (5H, m); m/z; ES+[M+H]+= 553.0.
Intermediate 410: 4-(Dibutoxymethyl)-l-[3-fluoro-4-(piperidin-4-yl)phenyl]piperidine Benzyl 4-{4-[4-(dibutoxymethyl)piperidin-l-yl]-2-fluorophenyl}-3,6-dihydropyridine-l(27/)-carboxylate (2.39 g, 4.31 mmol) was dissolved in EtOH (25 mL) and Pd/C (10%, 0.458 g, 4.31 mmol) was added. The reaction was stirred under an atmosphere of hydrogen at 2 bar pressure for 4 h at RT. The catalyst was filtered off through a pad of Celite® and evaporated to dryness to give the title compound (1.70 g, 94 %) as a pale yellow solid which was used without further purification. 1H NMR (CDCI) 5 0.93 (6H, t), 1.33 - 1.49 (6H, WO 2024/189488 PCT/IB2024/052251 142 m), 1.5 - 1.61 (4H, m), 1.62 - 1.9 (7H, m), 2.64 (2H, td), 2.7 - 2.81 (2H, m), 2.86 (1H, m), 3.19 (2H, dd), 3.(2H, dt), 3.62 (4H, dt), 4.18 (1H, d), 6.57 (1H, dd), 6.65 (1H, dd), 7.04 - 7.1 (1H, m).
Intermediate 41d: 7-(4-{4-[4-(Dibutoxymethyl)piperidin-l-yl]-2-fluorophenyl}piperidin-l-yl)-4-methyl-lZ/-indole-3- carbonitrile The intermediate was prepared using methodology described in intermediate 11c using intermediate 8a and 4- (dibutoxymethyl)-l-[3-fluoro-4-(piperidin-4-yl)phenyl]piperidine to give the title compound (22 mg, 4.5 %) as a white solid. 1H NMR (CDCh) 5 0.93 (6H, t), 1.33 - 1.5 (6H, m), 1.52 - 1.62 (4H, m), 1.69 - 1.82 (1H, m), 1.87 (2H, d), 1.93 - 2.05 (4H, m), 2.67 (2H, td), 2.72 - 2.75 (3H, m), 2.86 - 3 (3H, m), 3.36 (2H, d), 3.44 (2H, dt), 3.57 - 3.71 (4H, m), 4.19 (1H, d), 6.61 (1H, dd), 6.68 (1H, dd), 6.90 (1H, d), 6.95 (1H, dd), 7.12 (1H, t), 7.70 (1H, s), 8.74 - 8.82 (1H, m); m/z; ES+ [M+H]+ = 575.6.
Example 41: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]-2-fluorophenyl}piperidin-l-yl)-4-methyl-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 23 using 7-(4-{4-[4- (dibutoxymethyl) piperidin-1-yl] -2-fluorophenyl }piperidin-1 -yl)-4-methyl-1 //-indolc-3 -carbonitrile and intermediate 7c to give the title compound in the form of a formate salt (15 mg, 53.3 %) as a white solid. 1H NMR 5 1.12 - 1.35 (3H, m), 1.67 - 1.87 (5H, m), 1.89 - 1.96 (1H, m), 1.98 - 2.12 (3H, m), 2.17 - 2.38 (5H, m), 2.45 - 2.57 (5H, m), 2.58 - 2.63 (3H, m), 2.64 - 2.98 (6H, m), 3.39 (2H, d), 3.70 (2H, d), 3.84 (3H, s), 4.11 (1H, d), 4.24 (1H, d), 4.97 (1H, dd), 6.50 (1H, s), 6.62 (1H, s), 6.67-6.81 (3H, m), 6.88 (1H, d), 7.(1H, t), 8.17 (1H, s), 10.90 (1H, s), 11.91 (1H, s); m/z; ES+ [M+H]+ = 787.5.
Example 42: 7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl]-2- fluorophenyl}piperidin-l-yl)-4-methyl-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 143 The title compound was prepared using methodology described in example 24 using intermediate 4Id and intermediate 5f to give the title compound (17 mg, 44 %) as a white solid. 1H NMR 5 1.13- 1.32 (2H, m), 1.62 - 1.76 (1H, m), 1.82 (4H, t), 1.91-2.12 (6H, m), 2.14 - 2.29 (4H, m), 2.57 - 2.62 (3H, m), 2.64 - 2.(7H, m), 3.01 (2H, d), 3.42 (2H, d), 3.71 (2H, d), 3.79 (2H, t), 4.33 -4.48 (1H, m), 6.42 (1H, d), 6.67 - 6.(3H, m), 6.87 (1H, d), 6.97 (1H, dd), 7.16 (2H, td), 7.52 (1H, d), 7.55 (1H, d), 8.15 (1H, s), 10.32 (1H, s), 11.71 - 12.17 (1H, m); m/z; ES+ [M+H]+ = 741.5.
Example 43 Intermediate 43a: 5-Bromo-2,3-dimethylphenol Br OH To a stirred solution of 5-bromo-2,3-dimethylaniline (3.0 g, 14.99 mmol) and H2SO4 (4.0 ml, 75.0 mmol) in water (24 mL) was added sodium nitrite (1.2 g, 17.39 mmol) at 0 °C. The reaction mixture was stirred at 0 °C for l h then stirred to 50 °C for 5 h. The reaction mixture was diluted with water (50 mL) and extracted with EtOAc (200 mL). The organic layer was dried over Na2SO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 5 to 7 % EtOAc in heptane to give the title compound (1.5 g, 41.7 %) as a pale brown solid. 1H NMR (CDCI,) 5 2.12 (3H, s), 2.26 (3H, s), 4.84 (1H, br s), 6.82 (1H, s), 6.93 (1H, s); m/z; ES- [M-H]199.0 = ־.
Intermediate 43b: 5-Bromo-l-methoxy-2,3-dimethylbenzene To a stirred solution of 5-bromo-2,3-dimethylphenol (1.5 g, 7.46 mmol) in acetone (12 mL) was added K2CO(2.06 g, 14.92 mmol) and methyl iodide (0.46 mL, 7.46 mmol) at RT. The reaction mixture was stirred at °C for 6 h. The reaction mixture was evaporated under vacuum, diluted with water (50 mL) and extracted with EtOAc (150 mL). The organic layer was washed with NaCI solution (30 mL), dried over Na2SO4, filtered WO 2024/189488 PCT/IB2024/052251 144 and evaporated to dryness to afford crude product. The crude product was flash silica chromatography, elution gradient 1 to 3 % EtOAc in heptane to give the title compound (1.21 g, 74.3 %) as a pale brown liquid. 1H NMR (CDC13) 5 2.10 (3H, s), 2.26 (3H, s), 3.82 (3H, s), 6.86 (1H, s), 6.95 (1H, s).
Intermediate 430: 5-Bromo-3-methoxybenzene-l,2-dicarboxylic acid O O To a stirred solution of 5-bromo-1-methoxy-2,3-dimethylbenzene (1.2 g, 5.58 mmol) in tert-BnOH (5 mL) and water (20 mL) was added KMnO4 (5.73 g, 36.3 mmol) at RT. The reaction mixture was stirred at 110 °C for h. The reaction mixture was filtered over Celite® and washed with water (80 mL). The filtrate was acidified to pH l with HC1 and the product was extracted with EtOAc (200 mL). The organic layer was dried over Na2SO4, filtered and evaporated to dryness to give the title compound (1.4 g, 83 %) as a white solid. 1H NMR 5 3.85 (3H, s), 7.55 (1H, s), 7.58 (1H, d), 13.36 (2H, s); m/z; ES+ [M+H]+ = 273.0.
Intermediate 43d: Dimethyl 5-bromo-3-methoxybenzene-l,2-dicarboxylate To a stirred solution of 5-bromo-3-methoxybenzene-l,2-dicarboxylie acid (1.3 g, 4.73 mmol) inMeOH (mL) was added H2SO4 (5.0 ml, 94 mmol) at 0 °C. The reaction mixture stirred at 70 °C for 24h. The reaction mixture was evaporated and diluted with water (50 mL), basified to pH8 with Na2CO3 (2M), extracted with EtOAc (200 mL). The organic layer was dried over Na2SO4, filtered and evaporated to dryness to give the title compound (1.4 g, 92 %). 1H NMR (CDC13) 5 3.88 (3H, s), 3.91 (3H, s), 3.96 (3H, s), 7.27 (1H, d), 7.77 (1H, d). no mass ion Intermediate 43e: Dimethyl 5-[4-(tert-butoxycarbonyl)piperazin-l-yl]-3-methoxybenzene-l,2-dicarboxylate To a stirred solution of Dimethyl 5-bromo-3-methoxybenzene-l,2-dicarboxylate (1.2 g, 3.96 mmol) in toluene (10 mL) was added Cs2CO3 (3.87 g, 11.88 mmol), tert-butyl piperazine-1 -carboxylate (1.10 g, 5.94 mmol) and RuPhos (0.37 g, 0.436 mmol). The reaction mixture was degassed with nitrogen for 15 mins and RuPhos Pd OH OH 0 WO 2024/189488 PCT/IB2024/052251 145 G3 (0.310 mg, 1.321 mmol) was added to the reaction mixture followed by stirring at 100 °C for 12 h. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (300 mL). The organic layer was washed with NaO solution (30 mL), dried over Na2S04, filtered and evaporated to dryness afford crude product. The crude product was triturated with hexane (100 mL) to give the title compound (1.05 g, 48.7 %) as a pale brown liquid. 1H NMR (CDC13) 5 1.51 (9H, s), 3.25 (3H, s), 3.60 (3H, s), 3.86 - 3.94 (9H, m), 6.60 (1H, s), 7.07 (1H, s); m/z; ES+ [M+H]+ = 409.2.
Intermediate 43f: 5-[4-(tert-Butoxycarbonyl)piperazin-l-yl]-3-methoxybenzene-l,2-dicarboxylic acid To a stirred solution of dimethyl 5-[4-(tert-butoxycarbonyl)piperazin-l-yl]-3-methoxybenzene-l,2- dicarboxylate (1.0 g, 2.448 mmol) in MeOH (5 mL), THE (5 mL) and water (5 mL) was added NaOH (0.2g, 7.34 mmol) at RT and stirred for 72 h. The mixture was evaporated under vacuum, diluted with water (mL) and acidified with citric acid (IM) to pH3. The product was extracted with EtOAc (300 mL), dried over Na2S04, filtered and evaporated under vacuum to give the title compound (900 mg, 70.7 %) as a pale yellow solid. 1H NMR 5 1.41 - 1.44 (9H, m), 3.18 - 3.25 (4H, m), 3.44 - 3.49 (4H, m), 3.80 (3H, s), 6.78 (1H, d), 6.(1H, d); m/z; ES- [M-H]379.2 = ־.
Intermediate 43g: tert-Butyl 4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l,3-dioxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazine- 1-carboxylate A stirred solution of 5-[4-(tert-butoxycarbonyl)piperazin-l-yl]-3-methoxybenzene-l,2-dicarboxylic acid (9mg, 2.366 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (506 mg, 3.08 mmol) in pyridine (10 mL) was heated to 120 °C for 4 h. The reaction mixture was cooled to RT and diluted with water (70 mL) and extracted with EtOAc (150 mL). The organic layer was dried over Na2S04, filtered and evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 1 to % MeOH in DCM to give the title compound (580 mg, 48.1 %) as a pale yellow solid. 1H NMR 5 1.21- 1.28 (2H, m), 1.43 (9H, s), 1.93 - 2.03 (1H, m), 2.54 - 2.62 (2H, m), 2.81 - 2.94 (1H, m), 3.49 (8H, d), 3.(3H, s), 5.01 (1H, dd), 6.68 (1H, s), 6.97 (1H, s), 11.05 (1H, s). no mass ion.
Example 43: WO 2024/189488 PCT/IB2024/052251 146 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l,3-dioxo-2,3-dihydro-lZf-isoindol-5-yl]piperazin- l-yl}methyl)piperidin-l-yl]-2-fh1orophenyl}piperidin-l-yl)-4-methyl-n/-indole-3-carbonitrile The title compound was prepared using methodology described in example 23 using intermediate 4Id and tert- butyl 4-[2-(2,6-dioxopiperidin-3 -yl)-7-methoxy-1,3-dioxo-2,3 -dihydro- 17/-isoindol-5-y !]piperazine-1 - carboxylate to give the title compound in the form of a formate salt (17 mg, 44 %) as a white solid. 1H NMR 1.15-1.31 (2H, m), 1.67- 1.87 (5H, m), 1.93-2.1 (4H, m), 2.24 (2H, d), 2.45 - 2.54 (4H, m), 2.58 - 2.(3H, m), 2.64 - 2.96 (6H, m), 3.36 - 3.43 (3H, m), 3.45 - 3.53 (4H, m), 3.71 (2H, d), 3.93 (3H, s), 5.01 (1H, dd), 6.66 - 6.82 (4H, m), 6.88 (1H, d), 6.97 (1H, s), 7.17 (1H, t), 8.17 (1H, d), 11.04 (1H, s), 11.91 (1H, s); m/r. ES+[M+H]+= 801.5.
Example 44: 7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZf-isoindol-5-yl]piperazin-l- yl ؛butoxy)phenyl|piperidin-l-yl4- ؛-fluoro-l/f-indole-3-carbonitrile Intermediate 33a was reacted with intermediate li using the general synthetic method illustrated by example to give the title compound (20.0 mg, 36.3 %) as a white solid. 1H NMR 5 1.60 (2H, t), 1.72 (2H, d), 1.73 - 1.87 (2H, m), 1.93 (3H, t), 2.20 - 2.41 (3H, m), 2.55 (6H, d), 2.70 - 2.93 (3H, m), 3.25 (4H, d), 3.36 (2H, d), 3.97 (2H, t), 4.08 - 4.46 (2H, m), 5.03 (1H, dd), 6.54 - 7.01 (4H, m), 7.04 (2H, d), 7.18 (2H, d), 7.51 (1H, d), 8.25 (1H, d), 10.92 (1H, s), 12.23 (1H, s); m/z; ES+ [M+H]+ = 718.4.
Example 45: 4-Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-l-yl}-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 147 Intermediate 32d was reacted with intermediate li using the general synthetic method illustrated by example to give the title compound (47.0 mg, 30 %) as a white solid. 1H NMR 5 1.45 - 2.05 (8H, m), 2.36 (3H, dt), 2.53 (1H, s), 2.63 (2H, d), 2.71 - 2.99 (3H, m), 3.28 (4H, s), 3.41 (2H, d), 3.99 (2H, t), 4.20 (1H, d), 4.33 (1H, d), 5.04 (1H, dd), 6.81 - 6.95 (3H, m), 7.05 (2H, d), 7.12 - 7.24 (3H, m), 7.52 (1H, d), 8.32 (1H, s), 10.93 (1H, s), 12.26 (1H, s) 4H under DMSO; m/z; ES+ [M+H]+ = 734.3.
Example 46: 4-Chloro-7-{4-[4-(4-{4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l- yl}butoxy)phenyl]piperidin-l-yl}-lZ/-indole-3-carbonitrile Intermediate 32d was reacted with intermediate 5f using the general synthetic method illustrated by example to give the title compound in the form of a formate salt (27.0 mg, 41 %) as a white solid. 1H NMR 5 1.56 - 1.7(2H,m), 1.72- 1.82 (2H, m), 1.81 - 1.91 (2H, m), 1.91-2.05 (7H, m), 2.19 (3H, t), 2.42-2.47 (2H, m), 2.72 - 2.81 (3H, m), 3.05 (2H, d), 3.43 (2H, d), 3.78 (2H, t), 4.00 (2H, t), 4.28 - 4.55 (1H, m), 6.42 (1H, d), 6.83 -7.02 (4H, m), 7.1-7.25 (4H, m), 7.45-7.6 (2H, m), 8.15 (1H, s), 8.32 (1H, s), 10.31 (1H, s); m/z; ES+ [M+H]+= 718.6.
Example 47: 4-Chloro-7-[(37?)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4- c]pyridin-6-yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-n/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 148 Intermediate 2Id was reacted with intermediate 30e using the general synthetic method illustrated by example to give the title compound (31.0 mg, 28 %) as a white solid. 1H NMR 5 1.21 (2H, d), 1.55 (1H, q), 1.(1H, s), 1.75-1.93 (6H, m), 2.20 (2H, d), 2.31 (1H, tt), 2.44 (4H, s), 2.49 (1H, s), 2.51-2.74 (5H, m), 2.82- 2.98 (1H, m), 3.01 (1H, d), 3.37 (1H, d), 3.60 (6H, s), 3.88 (3H, s), 4.13 (1H, d), 4.27 (1H, d), 4.96 (1H, dd), 6.48 (1H, s), 6.85 (3H, dd), 7.14 (3H, dd), 8.31 (1H, d), 10.92 (1H, s), 12.28 (1H, d); m/r. ES+ [M+H]+ = 790.4.
Example 48 Intermediate 48a: 4-Methyl-7-{4-[4-(4-oxobutoxy)phenyl]piperidin-l-yl}-lZf-indole-3-carbonitrile Intermediate 27g (377 mg, 0.85 mmol) was stirred at 60 °C in formic acid (5 mL) for 1 h. The mixture was evaporated, diluted with DCM (50 mL), washed with NaHCO3 solution (20 mL) and the organic layer was dried over a phase separating cartridge. The solvent was evaporated to give the title compound (0.377 g, 111 %) which was used without further purification. 1H NMR (CDCI)) 5 1.84 - 2.03 (4H, m), 2.07 - 2.18 (2H, m), 2.6 - 2.7 (3H, m), 2.71 - 2.75 (3H, m), 2.89 (2H, td), 3.31-3.41 (2H, m), 4.01 (2H, t), 6.84 - 6.88 (2H, m), 6.90 (1H, d), 6.96 (1H, dd), 7.17 - 7.22 (2H, m), 7.71 (1H, d), 8.75 (1H, s), 9.85 (1H, t); m/2׳ . ES+ [M+H]+ = 402.3.
Example 48: 7-2,6)-2]-4 -؛ 4 -) 4 -] 4 ؛ -Dioxopiperidin-3-yl)-7-methoxy-l,3-dioxo-2,3-d ihydro-l//-isoindol-5-yl | piperazin- l-yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 Intermediate 43g (133 mg, 0.28 mmol) was stirred in formic acid (2 mL) at 60 °C for 1 h. The mixture was evaporated to dryness and the residue was dissolved in NMP (1 mL) at RT followed by the addition of 4- methyl-7-{4-[4-(4-oxobutoxy)phenyl]piperidin-l-yl}-l/f-indole-3-carbonitrile (94 mg, 0.23 mmol). Sodium triacetoxyborohydride (124 mg, 0.59 mmol) was added after 5 minutes and the resulting suspension was stirred at RT for 20 mins. Purification of the reaction mixture by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (0.061 g, 34.4 %) as a yellow solid. 1H NMR 5 1.56 - 1.69 (2H, m), 1.7 - 1.81 (2H, m), 1.8 - 1.88 (2H, m), 1.98 (3H, q), 2.37 - 2.46 (3H, m), 2.49 - 2.56 (4H, m), 2.58 - 2.64 (4H, m), 2.72 - 2.8 (2H, m), 2.8 - 2.96 (1H, m), 3.35 - 3.43 (3H, m), 3.43 - 3.52 (4H, m), 3.(3H, s), 4.00 (2H, t), 5.00 (1H, dd), 6.68 (1H, d), 6.78 (1H, d), 6.85 - 6.93 (3H, m), 6.96 (1H, d), 7.21 (2H, d), 8.15 (1H, s), 8.17 (1H, d), 11.04 (1H, s); m/z; ES+ [M+H]+= 758.5.
Example 49: 4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l,3-dioxo-2,3-dihydro-lZ/-isoindol-5- yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-lLf-indole-3-carbonitrile H Ck The title compound was prepared using methodology described in example 23 using intermediate if and intermediate 43g to give the title compound in the form of a formate salt (28 mg, 31 %) as a yellow solid. 1H NMR 5 1.22- 1.4 (3H, m), 1.71 - 1.82 (1H, m), 1.85- 1.96 (4H, m), 1.96-2.1 (4H, m), 2.30 (2H, d), 2.65 - 2.71 (3H, m), 2.79 - 3.02 (7H, m), 3.45 - 3.59 (6H, m), 3.71 (2H, d), 3.99 (3H, s), 5.06 (1H, dd), 6.66 - 6.(1H, m), 6.88-7.1 (4H, m), 7.15-7.28 (3H, m), 8.22 (1H, s), 8.38 (1H, s), 11.10 (1H, s); m/z; ES+ [M+H]+ = 803.6.
Example 50 H WO 2024/189488 PCT/IB2024/052251 150 Intermediate 50a: 2-(2,6-Dioxopiperidin-3-yl)-5,6-difluoroisoindoline-l,3-dione Potassium acetate (5.04 g, 51.37 mmol) was added in one portion to 3 -aminopiperidine-2,6-dione hydrochloride salt (3 g, 18.23 mmol) and 4,5-difluorophthalic acid (3.35 g, 16.57 mmol) in AcOH (30 mL) at RT. The resulting solution was stirred at 90 °C for 18h. The mixture was then cooled to RT and a solid formed. Water (30 mL) was added. The solid was collected by filtration, washed with water (2x5 mL) and dried at 45°C under vacuum overnight to give the title compound (3.43 g, 70%) as a dark grey solid; 1H NMR 5 2.01- 2.12 (1H, m), 2.53-2.7 (2H, m), 2.83-2.95 (1H, m), 5.17 (1H, dd), 8.15 (2H, t), 11.13 (1H, s); m/z; ES- [M-H]־ 293.
Intermediate 50b: tert-Butyl 4-[2-(2,6-dioxo-3-piperidyl)-6-fluoro-l,3-dioxo-isoindolin-5-yl]piperazine-l-carboxylate DMSO (0.5 mL) and then DIPEA (118 pL, 0.68 mmol) were added to a mixture of 2-(2,6-dioxopiperidin-3- yl)-5,6-difluoroisoindoline-l,3-dione (100 mg, 0.34 mmol) and tert-butyl piperazine-1-carboxylate (69.6 mg, 0.37 mmol). This mixture was then heated at 100 °C for 2h. Sat. NH4C1 solution (0.5mL) and water (1.5 mL) were then added. A brown precipitate was collected by filtration, washed with water and dried in a vacuum oven to give the title compounds (86 mg, 55%) as dark brown solid; 1H NMR 5 1.44 (9H, s), 2.04 (1H, dq), 2.55-2.62 (1H, m), 2.89 (1H, m), 3.09 (1H, d), 3.16-3.26 (4H, m), 3.45-3.55 (4H, m), 5.11 (1H, dd), 7.49 (1H, d), 7.75 (1H, d), 11.09 (1H, s); m/r. ES- [M-H]459 ־.
Example 50: 7-2,6)-2]-4 -؛ 4 -) 4 -] 4 ؛ -Dioxopiperidin-3-yl)-6-tluoro-l,3-dioxo-2,3-d ihydro-l//-isoindol-5-yl| piperazin-l- yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 151 The title compound was prepared using methodology described in example 48 using ter/-butyl 4-[2-(2,6- dioxo-3-piperidyl)-6-fluoro-l,3-dioxo-isoindolin-5-yl]piperazine-l-carboxylate and intermediate 48a to give the title compound in the form of a formate salt (95 mg, 54.4 %) as a white solid. 1H NMR (CDC13) 8 1.71 - 1.88 (4H, m), 1.89 - 2.03 (4H, m), 2.08 - 2.16 (1H, m), 2.5 - 2.95 (15H, m), 3.26 - 3.37 (4H, m), 3.42 (2H, d), 3.99 (2H, t), 4.92 (1H, dd), 6.84 - 6.92 (3H, m), 6.93 - 6.97 (1H, m), 7.19 (2H, d), 7.38 (1H, d), 7.46 (1H, d), 7.70 (1H, s), 8.77 (1H, s), 9.25 (1H, s); m/r. ES+ [M+H]+ = 746.5.
Example 51: 4-Chloro-7-(4-2,6)-2]-4 -)؛ 4 -] 4 ؛ -dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-l/f-isoindol-5- yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 7 using intermediate if and intermediate 50b to give the title compound (35 mg, 35.5 %) as a yellow solid. 1H NMR (90 °C) 8 1.27 - 1.(3H, m), 1.68 - 1.79 (1H, m), 1.82- 1.93 (4H, m), 1.95-2.04 (2H, m), 2.09 - 2.15 (lH,m),2.31 (2H, d), 2.6- 2.65 (4H, m), 2.71 - 2.79 (2H, m), 2.83 - 2.91 (4H, m), 3.3 - 3.37 (4H, m), 3.46 (2H, d), 3.65 (2H, d), 5 - 5.2 (1H, m), 6.67 (1H, d), 6.85 - 6.97 (3H, m), 7.02 (1H, d), 7.1 - 7.23 (3H, m), 7.46 (1H, d), 7.64 (1H, d), 8.04 - 8.24 (2H, m); m/z; ES+ [M+H]+ = 791.7.
Example 52: 7-(4-2,6)-2]-4 -)؛ 4 -] 4 ؛ -Dioxopipcridin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-l/f-isoindol-5-yl|pipcrazin-l- yl ؛ mcthyl)piperidin-l-yl| phenyl{ piperid in-1-yl)-4-nuoro-l//-indole-3-carbonitrile H WO 2024/189488 PCT/IB2024/052251 152 The title compound was prepared using methodology described in example 7 using intermediate 2c and intermediate 50b to give the title compound (58 mg, 29.2 %) as a yellow solid. 1H NMR 5 1.24 (2H, q), 1.(1H, s), 1.77-1.88 (4H, m), 1.88-2.1 (3H, m), 2.24 (2H, d), 2.51-2.56 (6H, m), 2.62 (3H, t), 2.75 (2H, t), 2.82-2.96 (1H, m), 3.25 (4H, t), 3.38 (2H, d), 3.64 (2H, d), 5.11 (1H, dd), 6.82 (1H, dd), 6.87-6.97 (3H, m), 7.13 (2H, d), 7.45 (1H, d), 7.73 (1H, d), 8.27 (1H, s), 11.12 (1H, s), 12.25 (1H, s); m/r. ES+ [M+H]+= 775.3.
Example 53 4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-lZ/-isoindol-5- yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 7 using intermediate He and intermediate 50b to give the title compound (53 mg, 48.3 %) as a yellow solid. 1H NMR 5 1.21 (2H, q), 1.(1H, q), 1.67 (1H, s), 1.74-1.87 (3H, m), 1.93 (2H, d), 2.04 (1H, dd), 2.22 (2H, s), 2.49 (1H, s), 2.51-2.(9H, m), 2.81-3.05 (2H, m), 3.13-3.31 (5H, m), 3.33 (1H, s), 3.62 (2H, d), 5.11 (1H, dd), 6.85 (3H, dd), 7.(3H, dd), 7.45 (1H, d), 7.73 (1H, d), 8.31 (1H, d), 11.12 (1H, s), 12.29 (1H, s); m/2׳ . ES+ [M+H]+= 791.3.
Example 54 4-Chloro-7-[(37?)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fh1oro-l,3-dioxo-2,3-dihydro-lZ/-isoindol-5- yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indole-3-carbonitrile O^N 0 WO 2024/189488 PCT/IB2024/052251 153 The title compound was prepared using methodology described in example 7 using intermediate 21d and intermediate 50b to give the title compound (30 mg, 27.4 %) as a yellow solid. 1H NMR 5 1.22 (2H, q), 1.(1H, d), 1.67 (1H, s), 1.73-1.99 (5H, m), 2-2.09 (1H, m), 2.23 (2H, d), 2.50 (1H, s), 2.53-2.58 (4H, m), 2.(5H, dd), 2.84-3.05 (2H, m), 3.2-3.33 (5H, m), 3.37 (1H, s), 3.62 (2H, d), 5.11 (1H, dd), 6.86 (3H, dd), 7.(3H, dd), 7.45 (1H, d), 7.73 (1H, d), 8.32 (1H, s), 11.12 (1H, s), 12.29 (1H, s); m/r. ES+ [M+H]+ = 791.35.
Example 55 Intermediate 55a: 2-(2,6-Dioxopiperidin-3-yl)-5-fh1oro-lZ/-isoindole-l,3(2Z/)-dione Sodium acetate (14.82 g, 180.61 mmol) was added to 3 -aminopiperidine-2,6-dione hydrochloride (14.86 g, 90.30 mmol) and 5-fluoro-2-benzofuran-l,3-dione (15 g, 90.30 mmol) in AcOH (200 mL). The resulting mixture was stirred at 120 °C for 16 h. The solvent was evaporated and the residue was poured into water (3mL) which was stirred for 10 mins. The solid was filtered under vacuum and was washed with water (100 mL) to give the title compound (22.0 g, 88 %) as a grey solid. 1H NMR 5 2.06 (1H, ddt, 1=3.2, 5.8, 11.0 Hz), 2.50 - 2.65 (2H, m), 2.88 (1H, m, 1=5.5, 14.0, 17.5 Hz), 5.15 (1H, dd, 1=5.4, 12.9 Hz), 7.71 (1H, m, 1=2.3, 8.2, 9.Hz), 7.83 (1H, dd, 1=2.3, 7.5 Hz), 7.99 (1H, dd, 1=4.5, 8.3 Hz), 11.11 (1H, s); m/z; ES+ [M+H]+= 277.0.
Intermediate 55b: tert-Butyl 4-[2-(2,6-dioxopiperidin-3-yl)-l,3-dioxo-2,3-dihydro-l//-isoindol-5-yl|piperazine-l- carboxylate tert-Butyl piperazine-1-carboxylate (0.742 g, 3.98 mmol), DIPEA (1.95 mL, 10.86 mmol) and 2-(2,6-Dioxopiperidin-3-yl)-5-fluoro-lH-isoindole-l,3(2H)-dione (1.0 g, 3.62 mmol) were dissolved inNMP (mL) and was stirred at 140 °C under microwave heating for 2 h. The mixture was cooled to RT, diluted with CL WO 2024/189488 PCT/IB2024/052251 154 water (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organics were washed with NaCI solution (2 x 50 mL) and dried over Na2S04, fdtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane to give the title compound (2.400 g, 32.6 %) as a yellow solid. 1H NMR 5 1.43 (9H, s), 2.03 (1H, dd), 2.54 - 2.65 (2H, m), 2.89 (1H, m), 3.48 (8H, s), 5.08 (1H, dd), 7.25 (1H, dd), 7.35 (1H, d), 7.70 (1H, d), 11.06 (1H, s); m/r. ES+ [M-BOC] = 343.0.
Example 55: 4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l,3-dioxo-2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-n/-indole-3-carbonitrile The title compound was prepared using methodology described in example 7 using intermediate if and tert- butyl 4-[2-(2,6-dioxopiperidin-3 -yl)-1,3 -dioxo-2,3 -dihydro-1 //-isoi ndol-5-y!]piperazine-1-carboxylate to give the title compound (27 mg, 28.0 %) as a yellow solid. 1H NMR 5 1.23 - 1.4 (3H, m), 1.68 - 1.81 (1H, m), 1.- 1.95 (4H, m), 1.96 - 2.16 (3H, m), 2.29 (2H, d), 2.62 - 2.72 (4H, m), 2.84 (2H, t), 2.9 - 3.03 (1H, m), 3.46 - 3.53 (6H, m), 3.71 (2H, d), 5.04 - 5.23 (1H, m), 6.83 - 7.01 (3H, m), 7.14 - 7.25 (3H, m), 7.29 - 7.36 (1H, m), 7.41 (1H, d), 7.75 (1H, d), 8.23 (1H, s), 8.38 (1H, s); m/z; ES+ [M+H]+ = 773.7.
Example 56: 7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l,3-dioxo-2,3-dihydro-lZf-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 48 using intermediate 48a and intermediate 55b to give the title compound in the form of a formate salt (70 mg, 38.6 %) as a yellow solid. 1H NMR 5 1.57 - 1.69 (2H, m), 1.7 - 1.8 (2H, m), 1.85 (2H, d), 1.92 - 2.06 (3H, m), 2.36 - 2.47 (3H, m), 2.49 - H ,0 WO 2024/189488 PCT/IB2024/052251 155 2.54 (4H, m), 2.57 - 2.63 (4H, m), 2.75 (2H, t), 2.83 - 2.95 (1H, m), 3.34 - 3.48 (7H, m), 4.00 (2H, t), 5.(1H, dd), 6.78 (1H, d), 6.83 - 6.96 (3H, m), 7.17 - 7.24 (2H, m), 7.24 - 7.29 (1H, m), 7.34 (1H, d), 7.68 (1H, d), 8.15 (1H, s), 8.16 (1H, d), 11.07 (1H, s), 11.85 - 11.95 (1H, m); m/z; ES+ [M+H]+ = 728.5.
Example 57 Intermediate 57a: 7-Bromo-l//-indole-3-carbonitrile Sulfurisocyanatidic chloride (1.33 ml, 15.30 mmol) was added dropwise to 7-bromo-1//-indole (1.0 g, 5.mmol) in MeCN (8.0 mL) and DMF (2.0 mL) at 0 °C. The resulting mixture was stirred at RT for 2 h. The reaction mixture was diluted with EtOAc (20 mL), washed with NaHCO3 solution (20 mL), water (20 mL) and NaO solution. The organic layer was dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (0.900 g, 80 %) as a white solid. 1H NMR (CDCh) 5 7.19 (1H, t), 7.49 (1H, dd), 7.72 (1H, dt), 7.80 (1H, d), 8.94 (1H, s); m/r. ES+ [M+H]+ = 221.15.
Intermediate 57b: 7-(4-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile Pd-PEPPSI-IHeptcl (30.0 mg, 0.03 mmol) was added to intermediate 32c (300 mg, 1.03 mmol), 7-bromo-1//- indole-3-carbonitrile (273 mg, 1.24 mmol) and LHMDS (IM in THE, 3.6 mL, 3.60 mmol) in THF (4 mL) under nitrogen. The resulting mixture was stirred at 60 °C for 2 h. The reaction was evaporated to dryness and purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (0.266 g, 59.9 %) as a yellow solid. 1H NMR (CDCh) 5 1.19 - 1.32 (1H, m), 1.79 - 1.98 (3H, m), 2.00 (4H, s), 2.66 (1H, d), 2.94 (2H, s), 3.47 (2H, d), 3.80 - 3.91 (2H, m), 3.91 - 4.06 (4H, m), 4.95 (1H, t), 6.82 - 6.(2H, m), 7.00 (1H, d), 7.16 - 7.30 (3H, m), 7.49 (1H, d), 7.71 (1H, d), 8.81 (1H, s); m/z; ES+ [M+H]+ = 432.3.
Example 57: 7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZf-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-l-yl}-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 156 The title compound was prepared using methodology described in example 7 using 7-(4-{4-[3-(l,3-dioxolan- 2-y !)propoxy Iphcnyl; pipcridin-1 -yl)-l //-indolc-3-carbonitrilc and intermediate li and purified by C18-flash chromatography, elution gradient 5 to 100% MeCN in water (1% NH4HCO3) to give the title compound (mg, 29.0 %) as a white solid. 1H NMR 5 1.23 (1H, s), 1.53 - 2.06 (10H, m), 2.17 - 2.46 (3H, m), 2.53 (2H, s), 2.56 - 2.70 (2H, m), 2.70 - 2.99 (3H, m), 3.28 (4H, t), 3.46 (2H, d), 3.99 (2H, t), 4.06 - 4.42 (2H, m), 4.98 - 5.10 (1H, m), 6.89 (3H, t), 7.05 (2H, d), 7.10-7.31 (4H, m), 7.52 (1H, d), 8.18 (1H, d), 10.93 (1H, s), 11.(1H, s); m/z; ES+ [M+H]+ = 700.4.
Example 58: 7-{4-[4-(4-{4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}butoxy)phenyl]piperidin-l- yl}-lZ/-indole-3-carbonitrile O The title compound was prepared using methodology described in example 23 using intermediate 57b and intermediate 5f and purified by C18-flash chromatography, elution gradient 5 to 100% MeCN in water (1% NH4HCO3) to give the title compound (25 mg, 56.8 %) as a white solid. 1H NMR 5 1.24 - 1.36 (1H, m), 1.- 1.87 (4H,m), 1.89- 1.95 (2H, m), 1.98-2.06 (2H, m), 2.09 - 2.17 (4H, m), 2.63 - 2.72 (1H, m), 2.76 - 2.93 (5H, m), 3.53 (2H, d), 3.84 (2H, t), 4.08 (2H, t), 4.46 - 4.73 (1H, m), 6.50 (1H, d), 6.9 - 7.07 (4H, m), 7.17 - 7.42 (5H, m), 7.49 - 7.67 (2H, m), 8.20 (1H, s), 8.25 (1H, d), 10.38 (1H, s) (4H underwater); m/z; ES+ [M+H]+ = 684.5.
Example 59 Intermediate 59a: 7-(4-{4-[4-(l,3-Dioxolan-2-yl)piperidin-l-yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 157 The title compound was prepared using methodology described in intermediate He using intermediate 57a and intermediate le to give the title compound (110 mg, 25.6 %) as a white solid. m z ES+ [M+H]+ = 457.3.
Example 59: 7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 23 using 7-(4-{4-[4-(l,3-dioxolan- 2-yl)pipcridin-l-yl|phcnyl ;pipcridin-l-yl)-l//-indolc-3-carbonitrilc and intermediate 5f and purified by C18- flash chromatography, elution gradient 5 to 100% MeCN in water (1% NH4HCO3) to give the title compound (55 mg, 35.4 %) as a white solid. 1H NMR 5 1.24 (2H, q), 1.67 (1H, s), 1.84 (4H, d), 1.91-2.07 (6H, m), 2.(2H, t), 2.25 (2H, d), 2.53-2.68 (3H, m), 2.72-2.83 (4H, m), 3.00 (2H, d), 3.46 (2H, d), 3.65 (2H, d), 3.78 (2H, t), 4.28-4.45 (1H, m), 6.42 (1H, d), 6.85-6.99 (4H, m), 7.1-7.2 (4H, m), 7.27 (1H, d), 7.48-7.57 (2H, m), 8.(1H, s), 10.33 (1H, s), 11.93 (1H, s); m/z; ES+ [M+H]+= 709.4.
Example 60 Intermediate 60a: Benzyl 4-(5-bromopyridin-2-yl)piperidine-l-carboxylate Benzyl carbonchloridate (1.1 g, 6.47 mmol) was added to 5-bromo-2-(piperidin-4-yl)pyridine (1.3 g, 5.mmol) and TEA (1.88 mL, 13.48 mmol) in THE (30 mL) at RT for 16 h. The mixture was then poured into water (50 mL), extracted with EtOAc (50 mL), dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et20 to give the title compound (1.5 g, 74.1 %) as a colourless gum. 1H NMR 5 1.46-1.66 (2H, m), 1.77-1.(2H, m), 2.82-3.02 (3H, m), 3.95-4.16 (2H, m), 5.08 (2H, s), 7.25-7.43 (6H, m), 7.91-8 (1H, m), 8.60 (1H, d); m/z; ES+ [M+H]+ = 375.1.
Intermediate 60b: Benzyl 4-{5-[4-(dibutoxymethyl)piperidin-l-yl]pyridin-2-yl}piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 158 Benzyl 4-(5-bromopyridin-2-yl)piperidine-l-carboxylate (1.45 g, 3.86 mmol) was added to 4- (dibutoxymethyl)piperidine (1.13 g, 4.64 mmol), C52CO3 (2.52 g, 7.73 mmol), Bis(tri-t- butylphosphine)palladium(O) (0.197 g, 0.39 mmol) and tri-/er/-butylphosphonium tetrafluoroborate (0.112 g, 0.39 mmol) in 1,4-dioxane (1 mL) under nitrogen. The resulting mixture was stirred at 100 °C for 16 h. The reaction was then cooled to RT and evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 40% EtOAc in Et20 to give the title compound (0.85 g, 40.9 %) as a yellow gum. No nmr data m/r. ES+ [M+H]+ = 538.5.
Intermediate 600: 5-[4-Dibutoxymethyl)piperidin-l-yl]-2-(piperidin-4-yl)pyridine Pd/C (10%, 0.317 g, 0.30 mmol) was added to benzyl 4-{5-[4-(dibutoxymethyl)piperidin-l-yl]pyridin-2- yl}piperidine-1-carboxylate (0.80 g, 1.49 mmol) inMeOH (15 mL) atRT under an atmosphere of hydrogen for 2 h. The mixture was filtered through Celite® and evaporated to dryness to give the title compound (0.g, 92 %) as a yellow gum. 1H NMR 5 0.89 (6H, t), 1.3-1.38 (5H, m), 1.46-1.53 (5H, m), 1.65-1.77 (6H, m), 2.59 (4H, t), 2.99 (2H, d), 3.17 (2H, d), 3.39 (2H, dt), 3.56 (2H, dt), 3.68 (2H, d), 4.09 (1H, d), 4.20 (1H, d), 7.04 (1H, d), 7.24 (1H, dd), 8.17 (1H, d); m/z; ES+ [M+H]+ = 404.4.
Intermediate 60d: 4-Chloro-7-(4-[5-|4-(dihutoxymethyl)piperidin-l-yl|pyridin-2-yl}piperidin-l-yl)-l//- indole-3-carbonitrile Pd-PEPPSI-IHeptcl (60.3 mg, 0.06 mmol) was added to 5-[4-dibutoxymethyl)piperidin-l-yl]-2-(piperidin-4- yl)pyridine (500 mg, 1.24 mmol), intermediate lb (380 mg, 1.49 mmol) and LHMDS (IM in THE, 4.34 mL, 4.34 mmol) in THF (8 mL) under nitrogen. The resulting mixture was stirred at 60 °C for 3 h. The reaction WO 2024/189488 PCT/IB2024/052251 was cooled to RT and quenched with MeOH. The solvent was removed under reduced pressure to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et2O to give the title compound (450 mg, 62.8 %) as a yellow solid. 1H NMR 5 0.87 (6H, t), 1.24-1.41 (6H, m), 1.41-1.55 (4H, m), 1.63-1.78 (3H, m), 1.82-1.92 (2H, m), 1.94-2.15 (2H, m), 2.53-2.67 (2H, m), 2.68- 2.83 (3H, m), 3.33-3.44 (4H, m), 3.48-3.61 (2H, m), 3.69 (2H, d), 4.18 (1H, d), 6.83 (1H, d), 7.12 (2H, dd), 7.26 (1H, dd), 8.21 (1H, d), 8.29 (1H, d), 12.28 (1H, s); m/r. ES+ [M+H]+ = 578.3.
The title compound was prepared using methodology described in example 24 using 4-chloro-7-(4-{5-[4- (dibutoxymcthyl)pipcridin-l-yl|pyridin-2-yl;pipcridin-l-yl)-l//-indolc-3-carbonitrilc and intermediate 7c to give the title compound (41 mg, 30.0 %) as a white solid. 1H NMR 5 1.23 (2H, q), 1.71 (1H, s), 1.83 (2H, d), 1.85-1.95 (3H, m), 2-2.15 (2H, m), 2.23 (2H, d), 2.25-2.39 (1H, m), 2.49 (2H, s), 2.51 (1H, s), 2.54 (1H, d), 2.58 (1H, d), 2.63-2.73 (3H, m), 2.77 (2H, t), 2.83-2.96 (1H, m), 3.30 (4H, s), 3.41 (2H, d), 3.70 (2H, d), 3.(3H, s), 4.10 (1H, d), 4.23 (1H, d), 4.97 (1H, dd), 6.49 (1H, d), 6.61 (1H, s), 6.85 (1H, d), 7.14 (2H, dd), 7.(1H, dd), 8.24 (1H, d), 8.31 (1H, s), 10.92 (1H, s), 12.30 (1H, s); m/2׳ . ES+ [M+H]+= 790.3.
Example 61: 4-Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZZ-pyrrolo[3,4- c]pyridin-6-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridin-2-yl}piperidin-l-yl)-lZ/-indole-3- carbonitrile The title compound was prepared using methodology described in example 24 using intermediate 60d and intermediate 30e to give the title compound (40 mg, 29.2 %) as a white solid. 1H NMR 5 1.23 (2H, q), 1.71 Example 60: 4-Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-lZf- isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridin-2-yl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 160 (1H, s), 1.81 (2H, d), 1.85-1.94 (3H, m), 2.07 (2H, q), 2.14-2.24 (2H, m), 2.24-2.37 (1H, m), 2.46 (3H, s), 2.52-2.6 (1H, m), 2.62-2.73 (3H, m), 2.72-2.82 (3H, m), 2.82-2.96 (1H, m), 3.41 (2H, d), 3.51-3.77 (6H, m), 3.89 (3H, s), 4.13 (1H, d), 4.27 (1H, d), 4.97 (1H, dd), 6.48 (1H, s), 6.85 (1H, d), 7.14 (2H, dd), 7.29 (1H, dd), 8.22-8.34 (2H, m), 10.93 (1H, s), 12.30 (1H, s); m/z; ES+ [M+H]+ = 791.3.
Intermediate 60d (100 mg, 0.17 mmol) was stirred in formic acid (1 mL) at 60 °C for 1 h, cooled to RT and evaporated to dryness. The residue was added to a mixture of sodium acetate (42.6 mg, 0.52 mmol) and intermediate 5f (96 mg, 0.21 mmol) in NMP (2 mL). The resulting mixture was stirred at RT for 16 h. The reaction mixture was quenched with NaHCO3 solution (10 mL) and purified by flash C18-flash chromatography, elution gradient 0 to 70% MeCN in water (0.1% NH4HCO3) to give the title compound (36.mg, 28.0 %) as a yellow solid. 1H NMR 5 1.26 (2H, d), 1.73 (1H, s), 1.81-2.16 (10H, m), 2.28 (3H, s), 2.65- 2.84 (7H, m), 3.04 (2H, s), 3.42 (2H, d), 3.72 (2H, d), 3.79 (2H, t), 4.42 (1H, s), 6.43 (1H, d), 6.87 (1H, d), 6.97 (1H, d), 7.16 (4H, t), 7.31 (1H, dd), 7.5-7.57 (2H, m), 8.22-8.35 (2H, m), 10.35 (1H, s), 12.30 (1H, s); m/z; ES+[M+H]+ = 744.3.
Example 63 Intermediate 63a: 3-Bromo-6-[4-(dibutoxymethyl)piperidin-l-yl]pyridazine DIPEA (2.71 mL, 15.51 mmol) was added to 4-(dibutoxymethyl)piperidine (1.258 g, 5.17 mmol) and 3- bromo-6-chloropyridazine (1.0 g, 5.17 mmol) in DMSO (20 mL) at RT and was stirred at 100 °C for 3 h. The reaction mixture was cooled to RT, diluted with EtOAc (100 mL), washed with saturated NH4C1 solution (mL), water (25 mL), NaO solution (25 mL), dried over Na2SO4 and filtered under gravity. The solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution Example 62: 4-Chloro-7-(4-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]pyridin-2-yl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 161 gradient 0 to 30% EtOAc in Et20 to give the title compound (1.8 g, 87 %) as a colourless gum. 1H NMR (CDC13) 5 0.94 (6H, t), 1.33-1.46 (6H, m), 1.53-1.62 (4H, m), 1.84-1.98 (3H, m), 2.94 (2H, tt), 3.45 (2H, dt), 3.64 (2H, dt), 4.17 (1H, dd), 4.39 (2H, d), 6.89 (1H, dd), 7.12-7.29 (1H, m); m/z; ES+ [M+H]+ = 400.0.
Intermediate 63b: Benzyl 4-{6-[4-(dibutoxymethyl)piperidin-l-yl]pyridazin-3-yl}-3,6-dihydropyridine-l(2Zf)-carboxylate PdC12(dtbpf) (0.277 g, 0.42 mmol) was added to 3-bromo-6-[4-(dibutoxymethyl)piperidin-l-yl]pyridazine (1.g, 4.25 mmol), benzyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-l(27/)-carboxylate (1.60 g, 4.67 mmol) and KCO3 (1.76 g, 12.74 mmol) in l,4-dioxane:water (4:1, 20 mL) at RT under nitrogen. The resulting mixture was stirred at 80 °C for 1 h. The reaction was cooled to RT, filtered through Celite® and evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 60% EtOAc in Et20 to give the title compound (1.7 g, 74.6 %) as a colourless gum. 1H NMR (CDC13) 5 0.94 (6H, t), 1.35-1.45 (6H, m), 1.52-1.62 (4H, m), 1.92 (4H, t), 2.83 (2H, s), 2.95 (2H, t), 3.44 (2H, dt), 3.64 (2H, dt), 3.74 (2H, dd), 4.17 (1H, d), 4.22 (2H, q), 4.46 (2H, d), 5.19 (2H, s), 6.31 (1H, s), 6.94 (1H, d), 7.35-7.45 (5H, m); m/z; ES+ [M+H]+ = 537.1.
Intermediate 630: 3-[4-(Dibutoxymethyl)piperidin-l-yl]-6-(piperidin-4-yl)pyridazine Pd/C (10%, 1.58 g, 1.49 mmol) was added to benzyl 4-{6-[4-(dibutoxymethyl)piperidin-l-yl]pyridazin-3-yl}- 3,6-dihydropyridine-l(2H)-carboxylate (1.6 g, 2.98 mmol) in MeOH (20 mL) at RT under an atmosphere of hydrogen for 3 h. The mixture was filtered through Celite® and evaporated to dryness to give the title compound (1.0 g, 83 %) as a yellow gum. 1H NMR (CDC13) 5 0.92 (6H, t), 1.31-1.43 (6H, m), 1.49-1.61 (4H, m), 1.71-2 (7H, m), 2.73-3 (5H, m), 3.27 (2H, d), 3.37-3.45 (2H, m), 3.62 (2H, dt), 4.16 (1H, d), 4.36 (2H, d), 6.91 (1H, d), 7.12 (1H, d) NH not observed; m/r. ES+ [M+H]+ = 405.2.
WO 2024/189488 PCT/IB2024/052251 162 Intermediate 63d: 4-Chloro-7-(4-{6-[4-(dibutoxymethyl)piperidin-l-yl]pyridazin-3-yl}piperidin-l-yl)-lZ/-indole-3- carbonitrile LHMDS (IM in THF, 6.29 mL, 6.29 mmol) was added to 3-[4-(dibutoxymethyl)piperidin-l-yl]-6-(piperidin- 4-yl)pyridazine (800 mg, 1.98 mmol), intermediate lb (459 mg, 1.80 mmol), CPhos (78 mg, 0.18 mmol) and [Pd(cinnamyl)Cl]2 (93 mg, 0.18 mmol) in THF (7 mL) under nitrogen. The resulting mixture was stirred at °C for 2 h. The reaction mixture was cooled to RT, diluted with EtOAc (100 mL), washed with saturated NH4C1 solution (50 mL), water (50 mL), NaQ solution (50 mL) and dried over Na2S04. The solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 80% EtOAc in Et20 to give the title compound (500 mg, 48.0 %) as a yellow solid. 1H NMR (CDC13) 5 0.94 (6H, t), 1.38-1.43 (4H, m), 1.54-1.62 (4H, m), 1.89 (3H, d), 1.99 (2H, d), 2.21-2.43 (3H, m), 2.63 (1H, d), 2.87 (5H, dt), 3.37-3.56 (4H, m), 3.64 (2H, dt), 4.19 (1H, d), 4.35 (2H, t), 6.82 (1H, d), 6.96 (1H, d), 7.14 (2H, dd), 7.71 (1H, d), 11.09 (1H, s); m/r. ES+ [M+H]+ = 579.0.
Example 63: 4-Chloro-7-(4-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-n/-indol-l-yl]piperidin-l-yl}methyl)piperidin- 4-Chloro-7-(4-[6-|4-(dibutoxymcthyl)pipcridin-l-yl|pyridazin-3-y !)pipe ridin-l-yl)-l//-indolc-3-carbonitrilc (120 mg, 0.21 mmol) was added to formic acid (2 mL). The resulting mixture was stirred at 40 °C for 1 h and then evaporated to dryness. Intermediate 5f (100 mg, 0.21 mmol) and sodium acetate (51.0 mg, 0.62 mmol) were added to the residue in NMP (2 mL) which was stirred at 40 °C for 16 h. The reaction mixture was purified by flash C18-flash chromatography, elution gradient 0 to 30% MeCN in water (0.1% formic acid). The MeCN was removed under reduced pressure and the aqueous solution was basified with NaHCOsolution. The mixture was filtered through Celite® and the solvent was evaporated to give the title compound (65.0 mg, 42.1 %) as a white solid. 1HNMRS 1.15 (2H, d), 1.84 (3H, d), 1.9-2(4H,m), 2-2.31 (8H, m), 2.69-2.93 (7H, m), 3.02 (2H, s), 3.44 (2H, d), 3.78 (2H, t), 4.34 (3H, d), 6.42 (1H, d), 6.87 (1H, d), 6.96 (1H, d), 7.07-7.2 (2H, m), 7.26 (1H, d), 7.33 (1H, d), 7.45-7.66 (2H, m), 8.32 (1H, d), 10.33 (1H, s), 12.30 (1H, s); m/z; ES+[M+H]+ = 745.4. l-yl]pyridazin-3-yl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 163 Example 64: 4-Chloro-7-(4-{6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l- The title compound was prepared using methodology described in example 63 using intermediate 63d and intermediate ij to give the title compound (55 mg, 21 %) as a white solid. 1H NMR 5 1.06-1.27 (2H, m), 1.75-1.9 (3H, m), 1.9-2.01 (3H, m), 2.01-2.14 (2H, m), 2.21 (2H, d), 2.29-2.46 (2H, m), 2.54-2.66 (2H, m), 2.72-2.99 (6H, m), 3.26-3.37 (6H, m), 3.59 (2H, d), 4.11-4.43 (4H, m), 5.05 (1H, dd), 6.76 (1H, d), 7.08 (3H, d), 7.18-7.39 (2H, m), 7.52 (1H, d), 8.21 (1H, s), 10.95 (1H, s), 12.25 (1H, s); m/z; ES+ [M+H]+ = 761.3.
Example 65 Intermediate 65a: tert-Butyl 5-chloro-5',6'-dihydro[2,3'-bipyridine]-l'(4 '//)-carboxylate The title compound was prepared using methodology described in intermediate 63b using 2-bromo-5- chloropyridine and tert-butyl 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydropyridine-l(2//)- carboxylate to give the title compound (1.9 g, 99 %) as a brown solid. 1H NMR 5 1.43 (9H, s), 2.30 (2H, tq), 3.47 (2H, t), 4.31 (2H, q), 6.83 (1H, dp), 7.64-7.76 (1H, m), 7.90 (1H, dd), 8.58 (1H, dd); m/r. ES+ [M+H]+ = 295.0.
Intermediate 65b: 5-Chloro-l',4',5',6'-tetrahydro-2,3'-bipyridine tert-Butyl 5-chloro-5',6'-dihydro[2,3'-bipyridine]-T(4'//)-carboxylate (1.9 g, 6.45 mmol) was added to HC1(4M in 1,4-dioxane, 32 mL, 128.91 mmol) at RT under nitrogen and stirred for 16 h. The reaction was filtered yl}methyl)piperidin-l-yl]pyridazin-3-yl}piperidin-l-yl)-l//-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 164 through Celite® and evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 60% EtOAc in Et20 to give the title compound (1.2 g, 96 %) as a brown solid. 1H NMR 5 1.09-1.29 (1H, m), 2.34 (2H, qd), 3.42-3.61 (2H, m), 4.39 (2H, s), 6.84 (1H, td), 7.(1H, d), 7.89 (1H, dd), 8.57 (1H, s); m/r. ES+ [M+H]+ = 195.0.
Intermediate 650: Benzyl 5-chloro-5',6'-dihydro[2,3'-bipyridine]-l'(4'//)-carboxylate The title compound was prepared using methodology described in intermediate 60a using 5-chloro-T,4',5',6'- tetrahydro-2,3'-bipyridine to give the title compound (1.9 g, 99 %) as a brown solid. 1H NMR 5 1.20 (1H, s), 1.49 (1H, d), 2.50 (1H, p), 3.17 (3H, dt), 3.97 (3H, dq), 6.92 (1H, td), 7.78 (1H, d), 7.94 (1H, dd), 8.57 (1H, d), 9.86 (3H, s), 11.50 (1H, s); m/z; ES+ [M+H]+ = 329.0.
Intermediate 65d: Benzyl 5-[4-(dibutoxymethyl)piperidin-l-yl]-5',6'-dihydro[2,3'-bipyridine]-l'(4'//)-carboxylate The title compound was prepared using methodology described in intermediate lla using benzyl 5 -chloro- 5',6'-dihydro[2,3'-bipyridine]-T(4'//)-carboxylate to give the title compound (1.0 g, 47 %) as a brown solid. 1H NMR 5 0.88 (6H, td), 1.19-1.41 (7H, m), 1.41-1.57 (5H, m), 1.73 (3H, d), 2.29 (2H, s), 2.6-2.72 (2H, m), 3.39 (3H, dt), 3.56 (4H, dt), 3.75-3.83 (1H, m), 4.19 (1H, d), 4.38 (1H, s), 5.13 (2H, s), 6.55 (1H, d), 7.22- 7.44 (6H, m), 8.21 (1H, s); m/z; ES+ [M+H]+ = 536.4.
Intermediate 65e: 5-[4-(Dibutoxymethyl)piperidin-l-yl]-2-(piperidin-3-yl)pyridine The title compound was prepared using methodology described in intermediate 1 lb using benzyl 5-[4- (dibutoxymethyl)piperidin-l-yl]-5',6'-dihydro[2,3'-bipyridine]-T(4'//)-carboxylate to give the title compound WO 2024/189488 PCT/IB2024/052251 165 (610 mg, 67 %) as a yellow solid. 1H NMR 5 0.88 (6H, t), 1.28-1.41 (6H, m), 1.48 (6H, dq), 1.54-1.67 (3H, m), 1.66-1.75 (3H, m), 1.87 (1H, d), 2.54-2.66 (3H, m), 2.94 (1H, s), 3.02 (1H, d), 3.37-3.42 (3H, m), 3.(2H, dt), 3.68 (2H, d), 4.19 (1H, d), 7.05 (1H, d), 7.18-7.32 (1H, m), 8.17 (1H, d); m/r. ES+ [M+H]+ = 404.4 Intermediates 651 and 66a: The title compounds were prepared using methodology described in intermediate 11c using 5-[4- (dibutoxymethyl)piperidin-l-yl]-2-(piperidin-3-yl)pyridine and intermediate lb to give a racemic mixture. The enantiomers were separated by preparative chiral-HPLC on a Column: CHIRALPAK IF-3, 4.6*50mm, 3um; Flow rate: 1 mL/min; Gradient: 0% B; Mobile Phase A: Hex (0.5% 2M NH3-MeOH), Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 25% B to give, in order of elution, intermediate 65f(isomer 1, 66 mg, 8 %) and intermediate 66a(isomer 2, 88 mg, 10 %) as yellow gums.
Intermediate 65f: 4-Chloro-7-[(37?*)-3-{5-[4-(dibutoxymethyl)piperidin-l-yl]pyridin-2-yl}piperidin-l-yl]-lZ/-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] Isomer 1 1H NMR 5 0.88 (6H, t), 1.19-1.42 (6H, m), 1.48 (4H, dq), 1.64-1.79 (4H, m), 1.85 (2H, s), 1.98 (1H, d), 2.(2H, t), 2.81 (1H, d), 3.22 (4H, d), 3.39 (2H, dt), 3.56 (2H, dt), 3.74 (2H, d), 4.19 (1H, d), 6.80 (1H, d), 7.(1H, d), 7.22-7.29 (1H, m), 7.32 (1H, dd), 8.28 (1H, d), 8.41 (1H, d), 12.94 (1H, s); m/r. ES+ [M+H]+ = 578.2.
Intermediate 66a: 4-Chloro-7-[(3،4]-5}-3-(* ؟-(dibutoxymethyl)piperidin-l-yl]pyridin-2-yl}piperidin-l-yl]-lZ/-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] III a N WO 2024/189488 PCT/IB2024/052251 166 1H NMR 5 0.88 (6H, t), 1.19-1.4 (6H, m), 1.48 (4H, dq), 1.73 (4H, d), 1.85 (2H, s), 1.98 (1H, d), 2.62 (2H, t), 2.81 (1H, d), 3.11-3.28 (4H, m), 3.39 (2H, dt), 3.55 (2H, dt), 3.73 (2H, d), 4.19 (1H, d), 6.80 (1H, d), 7.(1H, d), 7.25 (1H, d), 7.32 (1H, dd), 8.28 (1H, d), 8.41 (1H, d), 12.93 (1H, s); m/r. ES+ [M+H]+ = 578.3.
Example 65: 4-Chloro-7-[(37?*)-3-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]pyridin-2-yl}piperidin-l-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 23 using intermediate 65f and intermediate 5f to give the title compound in the form of a formate salt (36 mg, 42 %) as a white solid. 1H NMR 5 1.18-1.28 (2H, m), 1.72 (2H, s), 1.8-1.89 (4H, m), 1.91-2.02 (5H, m), 2.17 (2H, t), 2.25 (2H, d), 2.63-2.83 (5H, m), 3.00 (2H, d), 3.09-3.3 (4H, m), 3.76 (4H, dt), 4.38 (1H, dt), 6.42 (1H, d), 6.79 (1H, d), 6.96 (1H, d), 7.09-7.17 (2H, m), 7.26 (1H, d), 7.34 (1H, dd), 7.47-7.56 (2H, m), 8.29 (1H, d), 8.39 (1H, s), 10.32 (1H, s), 12.93 (1H, s); m/z; ES+ [M+H]+ = 744.4.
Example 66: 4-Chloro-7-[(3S'*)-3-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]pyridin-2-yl}piperidin-l-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 167 The title compound was prepared using methodology described in example 23 using intermediate 66a and intermediate 5f to give the title compound in the form of a formate salt (29 mg, 25 %) as a white solid. 1H NMR 5 1.23 (2H, q), 1.72 (2H, s), 1.84 (4H, d), 1.91-2.07 (5H, m), 2.20 (4H, dd), 2.65-2.82 (5H, m), 3.(2H, d), 3.11-3.3 (4H, m), 3.76 (4H, dt), 4.29-4.43 (1H, m), 6.41 (1H, d), 6.80 (1H, d), 6.96 (1H, d), 7.14 (2H, t), 7.26 (1H, d), 7.34 (1H, dd), 7.52 (2H, dd), 8.29 (1H, d), 8.41 (1H, s), 10.32 (1H, s), 12.93 (1H, s); m/r. ES+ [M+H]+ = 744.4.
Example 67 Intermediate 67a: Benzyl 4-(5-fluoropyrazin-2-yl)-3,6-dihydropyridine-l(2Z/)-carboxylate The title compound was prepared using methodology described in intermediate 63b using 2-bromo-5- fluoropyrazine and benzyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-l(2H)- carboxylate to give the title compound (2.6 g, 95 %) as a colourless gum. 1H NMR 5 2.59 (2H, tt), 3.64 (2H, s), 4.16 (2H, s), 5.12 (2H, s), 6.77 (1H, s), 7.27-7.42 (5H, m), 8.51 (1H, t), 8.63 (1H, dd); m/2׳ . ES+ [M+H]+ = 314.1.
Intermediate 67b: Benzyl 4-{5-[4-(dibutoxymethyl)piperidin-l-yl]pyrazin-2-yl}-3,6-dihydropyridine-l(2Z/)-carboxylate The title compound was prepared using methodology described in intermediate 63a using benzyl 4-(5- fl no ropy razin-2-y l)-3.6-dihy dropy ridinc-1 (2//)-carboxy late and 4-(dibutoxymethyl)piperidine to give the title compound (4.0 g, 93 %) as a colourless gum. 1H NMR 5 0.87 (6H, t), 1.08-1.29 (4H, m), 1.33 (4H, dq), 1.44- WO 2024/189488 PCT/IB2024/052251 168 1.53 (4H, m), 1.64-1.86 (2H, m), 1.99 (1H, s), 2.51 (2H, dp), 2.82 (2H, td), 3.21-3.7 (4H, m), 3.76-4.21 (2H, m), 4.35 (3H, d), 5.11 (2H, s), 6.45 (1H, s), 7.16-7.59 (5H, m), 7.96-8.66 (2H, m); m/z; ES+ [M+H]+ = 537.4.
Intermediate 67c: 2-[4-(Dibutoxymethyl)piperidin-l-yl]-5-(piperidin-4-yl)pyrazine The title compound was prepared using methodology described in intermediate 63c using benzyl 4-{5-[4- (dibutoxymcthyl)pipcridin-l-yl|pyrazin-2-yl;-3.6-dihydropyridinc-l(2//)-carboxylatc to give the title compound (3.0 g, 99 %) as a colourless gum. 1H NMR 5 0.87 (6H, td), 1.11-1.3 (2H, m), 1.31 (2H, d), 1.31- 1.4 (2H, m), 1.4-1.53 (5H, m), 1.59 (2H, td), 1.67-1.82 (4H, m), 2.41-2.62 (5H, m), 2.55-3.08 (4H, m), 3.31- 3.56 (4H, m), 4.17 (1H, d), 4.26 (1H, s), 7.14-8 (1H, m), 8.21 (1H, d); m/z; ES+ [M+H]+ = 405.4.
Intermediate 67d: 4-Chloro-7-(4-{5-[4-(dibutoxymethyl)piperidin-l-yl]pyrazin-2-yl}piperidin-l-yl)-lH-indole-3- carbonitrile The title compound was prepared using methodology described in intermediate He using 2-[4- (dibutoxymethyl)piperidin-l-yl]-5-(piperidin-4-yl)pyrazine and intermediate lb to give the title compound (0.219 g, 25 %) as a white solid. 1H NMR S 0.88 (6H, t), 1.14-1.35 (4H, m), 1.32-1.4 (2H, m), 1.48 (4H, dq), 1.73 (2H, d), 1.76-1.92 (2H, m), 1.97-2.25 (2H, m), 2.68-2.87 (5H, m), 3.28-3.46 (5H, m), 3.55 (2H, dt), 4.18 (1H, d), 4.32 (2H, d), 6.86 (1H, d), 7.16 (1H, d), 8.03 (1H, d), 8.29 (2H, dd), 12.32 (1H, s); m/r. ES+ [M+H]+= 579.3.
Example 67: 4-Chloro-7-(4-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-n/-indol-l-yl]piperidin-l-yl}methyl)piperidin- l-yl|pyrazin-2-yl}piperidin-l-yl)-l//-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 169 The title compound was prepared using methodology described in example 23 using 4-chloro-7-(4-{5-[4- (dibutoxymethyl)piperidin-l-yl]pyrazin-2-yl}piperidin-l-yl)-l/7-indole-3-carbonitrile and intermediate 5f to give the title compound in the form of a formate salt (71 mg, 36.8 %) as a white solid. 1HNMRS 1.13 (2H, d), 1.71-1.92 (8H, m), 1.99 (2H, d), 2.05-2.28 (5H, m), 2.6-2.9 (7H, m), 3.01 (2H, d), 3.42 (2H, d), 3.78 (2H, t), 4.35 (3H, dd), 6.42 (1H, d), 6.86 (1H, d), 6.96 (1H, d), 7.1-7.2 (2H, m), 7.46-7.58 (2H, m), 8.04 (1H, d), 8.26-8.36 (2H, m), 10.35 (1H, s), 12.33 (1H, s); m/z; ES+ [M+H]+ = 745.4.
Example 68: 4-Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZf-isoindol-5-yl]piperazin-l- The title compound was prepared using methodology described in example 24 using intermediate 67d and intermediate li to give the title compound (112 mg, 56.8 %) as a white solid. 1H NMR 5 1.12 (2H, d), 1.(6H, m), 2.09 (2H, td), 2.29 (2H, dd), 2.49 (1H, s), 2.55-2.63 (1H, m), 2.83 (6H, m), 3.29 (4H, t), 3.40 (6H, s), 4.02-4.38 (4H, m), 5.06 (1H, dd), 6.86 (1H, d), 7.06 (2H, d), 7.17 (1H, d), 7.53 (1H, d), 8.04 (1H, d), 8.(2H, d), 10.97 (1H, s), 12.32 (1H, s); m/r. ES־ [M-H]759.3 = ־.
Example 69 Intermediate 69a: 7-Ethenyl-l-methyl-l,3-dihydro-2Z/-benzimidazol-2-one yl}methyl)piperidin-l-yl]pyrazin-2-yl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 170 Pd(dppf)2C12-DCM (0.575 g, 0.70 mmol) was added to 7-bromo-l-methyl-l,3-dihydro-2/Abenzimidazol-2- one (2.0 g, 8.81 mmol), 4,4,5,5-tetramethyl-2-vinyl-l,3,2-dioxaborolane (2.03 g, 13.21 mmol) andK2CO(3.04 g, 22.02 mmol) in l,4-dioxane:water (4:1, 48 mL) under nitrogen. The resulting mixture was stirred at °C for 18 h. The reaction was cooled to RT and evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (1.1 g, 71.7 %) as a white solid. 1H NMR 5 3.36 (3H, s), 5.24 (1H, dd), 5.57 (1H, dd), 6.74 - 6.(2H, m), 7.00 (1H, m), 7.26 (1H, dd), 10.80 (1H, s); m/z; ES+ [M+H]+ = 175.2.
Intermediate 69b: 3-Methyl-2-oxo-2,3-dihydro-lZf-benzimidazole-4-carbaldehyde Potassium osmate dihydrate (0.212 g, 0.57 mmol) was added to 7-ethenyl-l-methyl-l,3-dihydro-277- benzimidazol-2-one (1.0 g, 5.74 mmol), sodium meta periodate (3.68 g, 17.22 mmol) and 2,6-lutidine (1.ml, 11.48 mmol) in 1,4-dioxane :water (3:1, 40 mL) at RT and stirred for 2 h. The reaction mixture was quenched with water (100 mL), extracted with EtOAc (3 x 100 mL), dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 4% MeOH in DCM to give the title compound (0.95 g, 94 %) as a grey solid. 1H NMR 5 3.(3H, s), 7.11 (1H, t), 7.19-7.28 (1H, m), 7.51 (1H, dd), 10.34 (1H, s), 11.30 (1H, s); m/r. ES+ [M+H]+ = 177.2.
Intermediate 690: l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lZ/-benzimidazole-4-carbaldehyde LHMDS (153 ml, 153.26 mmol) was added to 3-methyl-2-oxo-2,3-dihydro-17/-benzimidazole-4-carbaldehyde (9.0 g, 51.09 mmol) in THE (80 mL) at 0 °C under nitrogen. The resulting mixture was stirred at RT for Ih.This mixture was added dropwise to a solution of 1-bromo-1,3-diazinane-2,4-dione (19.62 g, 102.17 mmol) in THF (80 mL) at RT. The resulting mixture was stirred at 60 °C for 3 h. The mixture was cooled to 10 °C, quenched with saturated NH4C1 solution (20 mL), water (200 mL) and the resulting solid was collected by filtration. The solid was washed with water (50 mL) and EtOAc (50 ml). The aqueous was extracted with EtOAc (300 mL) and the solvent was evaporated to afford a brown solid. The brown solid was triturated with water to give a solid which was collected by filtration and dried under vacuum to give crude product. The two solid batches were combined, triturated with Et20, collected by filtration and dried under vacuum to give the WO 2024/189488 PCT/IB2024/052251 171 title compound (10.0 g, 68.1 %) as a grey solid. 1H NMR 5 2.64 (2H, d), 2.89 (2H, d), 3.54 (3H, s), 5.39 - 5.(1H, m), 7.07 (1H, d), 7.13 (1H, t), 7.27 (1H, d), 9.27 (1H, s), 10.41 (1H, s); m/z; ES+ [M+H]+ = 288.2.
Intermediate 69d: tert-Butyl 4-؛[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l/f-benzimidazol-4- yl]methyl}piperazine-l-carboxylate Sodium triacetoxyborohydride (3.69 g, 17.40 mmol) was added to l-(2,6-dioxopiperidin-3-yl)-3-methyl-2- oxo-2,3-dihydro-lrt-benzimidazole-4-carbaldehyde (2.0 g, 3.48 mmol) and tert-butyl piperazine-1- carboxylate (1.94 g, 10.44 mmol) in DCMMeOH (1:2, 24 mL) and stirred at RT for 16 h. The solvent was reduced in volume, poured into NaO Solution (25 mL), extracted with EtOAc (300 mL) and the layers were separated. The organic layer was dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 50 to 100% EtOAc in Et20 to give the title compound (0.800 g, 50.2 %) as a yellow solid. 1H NMR 5 1.40 (9H, s), 1.95 - 2.08 (1H, m), 2.29 - 2.41 (4H, m), 2.56 - 2.95 (3H, m), 3.24 - 3.32 (4H, m), 3.59 - 3.65 (2H, m), 3.68 (3H, s), 5.30 - 5.44 (1H, m), 6.86-6.93 (lH,m), 6.94-7.01 (1H, m), 7.06 - 7.12 (1H, m), 11.11 (1H, s); m/z; ES+ [M+H]+= 458.3.
Intermediate 69e: 3-{3-Methyl-2-oxo-4-[(piperazin-l-yl)methyl]-2,3-dihydro-lZ/-benzimidazol-l-yl}piperidine-2,6-dione HN N■ TEA (2.5 mL) was added to tert-butyl 4-{[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lrt- benzimidazol-4-yl]methyl}piperazine-l-carboxylate (750 mg, 1.64 mmol) in DCM (10 mL) and stirred at RT for 1 h. The solvent was evaporated to give the title compound (1.1 g, 96 %) as yellow oil which was used without further purification. 1H NMR 5 1.92 - 2.06 (2H, m), 2.62 - 2.94 (9H, m), 3.65 (3H, s), 3.83 - 4.(3H, m), 5.36 - 5.45 (1H, m), 6.96 - 7.02 (2H, m), 7.15 (1H, d), 11.11 (1H, s) NH not observed; m/z; ES+ [M+H]+= 358.2.
Example 69: 7-[4-(4- -؛ 4 -]) 4 ؛ [l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l//-benzimidazol-4- yl]methyl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-4-methyl-lZ/-indole-3- carbonitrile N^O N^O WO 2024/189488 PCT/IB2024/052251 172 Intermediate 8b (59.3 mg, 0.13 mmol) was stirred in formic acid (2 mL) at 60 °C for 2 h and then cooled to RT. The mixture was evaporated, diluted with NMP (2 mL) and 3-{3-methyl-2-oxo-4-[(piperazin-l- yl)methyl]-2,3-dihydro-17/-benzimidazol-l-yl}piperidine-2,6-dione (45 mg, 0.13 mmol) was added followed by sodium triacetoxyborohydride (66.7 mg, 0.31 mmol) after 5 minutes. The resulting suspension was stirred at RT for 30 mins. Purification of the reaction mixture by preparative HPLC (Column A, Eluent B) gave the title compound (0.027 g, 27.9 %) as beige solid. 1H NMR (CDC13) 5 1.11- 1.3 (2H, m), 1.53 - 1.68 (1H, m), 1.7 - 1.88 (5H, m), 1.89 - 2.06 (4H, m), 2.14 (2H, d), 2.44 (6H, d), 2.53 - 2.68 (8H, m), 2.7 - 2.8 (3H, m), 2.83 - 2.96 (1H, m), 3.37 (2H, d), 3.55 - 3.65 (4H, m), 3.67 (3H, s), 5.37 (1H, dd), 6.77 (1H, d), 6.84 - 6.(4H, m), 6.96 (1H, t), 7.07 (1H, d), 7.12 (2H, d), 8.15 (1H, s), 11.09 (1H, s); m/z; ES+ [M+H]+ = 768.4.
Example 70: 4-Chloro-7-[4-(4-{4-[(4-{[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lZ/-benzimidazol-4- yl]methyl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-lZ/-indole-3-carbonitrile Intermediate If (35.6 mg, 0.06 mmol) and intermediate 69d (31 mg, 0.07 mmol) were heated in formic acid (mL, 26.51 mmol) at 60 °C for 2 h. The reaction mixture was evaporated and the residue was diluted with NMP (1 mL). The reaction mixture was stirred for 5 mins followed by the addition of sodium triacetoxy hydroborate (32.6 mg, 0.15 mmol). The resulting suspension was stirred at RT for 2 h. Purification of the reaction mixture by preparative HPLC (Column A, Eluent B) gave fractions containing the desired compound which were extracted with DCM (100 mL), dried over MgSO4, fdtered and evaporated to dryness to give the title compound (9.0 mg, 18.53 %) as a white solid. 1H NMR 5 1.19 (2H, t), 1.25 (2H, s), 1.61 (1H, s), 1.78 (2H, d), 1.84 (2H, d), 1.91 - 2.05 (3H, m), 2.11 - 2.2 (2H, m), 2.38 - 2.47 (4H, m), 2.54 - 2.63 (4H, m), 2.66 (1H, s), 2.66 - 2.84 (4H, m), 2.85 - 2.97 (1H, m), 3.42 (2H, d), 3.59 - 3.66 (4H, m), 3.68 (3H, s), 5.38 (1H, dd), 6.84 - 6.93 (4H, m), 6.97 (1H, t), 7.08 (1H, d), 7.15 (3H, dd), 8.32 (1H, d), 11.09 (1H, s), 12.26 (1H, s); m/r. ES+ [M+H]+ = 788.6.
WO 2024/189488 PCT/IB2024/052251 173 Example 71: 7-[4-(4-{4-[(4-{[l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lZf-benzimidazol-4- yl]methyl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-4-fluoro-l//-indole-3-carbonitrile The title compound was prepared using methodology described in example 70 using intermediate 67d and intermediate 2c to give the title compound (20 mg, 23 %) as a white solid. 1H NMR (90 °C) 5 1.17 - 1.37 (2H, m), 1.56- 1.73 (1H, m), 1.77- 1.93 (4H, m), 1.93 -2.02 (2H, m), 2.02-2.11 (1H, m), 2.15 - 2.25 (2H, m), 2.38 - 2.43 (4H, m), 2.44 - 2.48 (4H, m), 2.63 - 2.74 (4H, m), 2.78 - 2.99 (4H, m), 3.40 (2H, d), 3.61 (2H, d), 3.67 - 3.71 (5H, m), 5.26 - 5.37 (1H, m), 6.82 - 7.09 (7H, m), 7.14 (2H, d), 8.10 (1H, s), 8.21 (1H, s), 10.(1H, s); m/z; ES+ [M+H]+ = 772.9.
Example 72 Intermediate 72a: 3-(4-Bromo-3-methyl-2-oxo-2,3-dihydro-lZf-benzimidazol-l-yl)piperidine-2,6-dione The title compound was prepared using methodology described in intermediate 69c using 7-bromo-l-methyl- l,3-dihydro-2H-benzimidazol-2-one and 1-bromo-1,3-diazinane-2,4-dione to give the title compound (7mg, 50 %) as a grey solid. 1H NMR (CDCh) 5 2.23 (1H, m), 2.67 - 3 (3H, m), 3.79 (3H, s), 5.19 (1H, dd), 6.73 (1H, dd), 6.92 (1H, t), 7.24 (1H, dd), 8.08 (1H, s); m/z; ES+ [M+H]+ = 338.0.
Intermediate 72b: tert-Butyl 4-[ l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l//-benzimidazol-4-yl | piperazine- 1-carboxylate WO 2024/189488 PCT/IB2024/052251 174 3-(4-Bromo-3-methyl-2-oxo-2,3-dihydro-lH-benzimidazol-l-yl)piperidine-2,6-dione (2.21 g, 6.55 mmol), Pd- PEPPSI-IPent (0.550 g, 0.65 mmol), tert-butyl piperazine-1-carboxylate (3.05 g, 16.37 mmol) and sodium tert-butoxide (1.88 g, 19.64 mmol) were suspended in 1,4-dioxane (60 mL) under nitrogen. The reaction was stirred at 50 °C for l h. The reaction was cooled to RT, diluted with DCM (100 mL), washed with NH4Csolution (50 mL), water (50 mL), NaHCO3 solution (50 mL) and NaCI solution (50 mL). The organic layer was dried with Na2SO4, filtered and evaporated to afford crude product. The crude product was triturated with Hexane :EtO Ac (1:1, 100 mL) and filtered under vacuum. The solid was then slurried in EtOH (50 mL) for mins. The solid was filtered under vacuum and then slurried in MeCN (50 mL). The solid was filtered under vacuum to give the title compound (1.48 g, 51.2 %) as a beige solid. 1H NMR 5 1.42 (9H, s), 1.98 (1H, br t), 2.56 - 2.76 (4H, m), 2.79 - 2.96 (2H, m), 2.96 - 3.20 (4H, m), 3.62 (3H, s), 3.94 (1H, br s), 5.30 - 5.40 (1H, m), 6.88 - 6.94 (2H, m), 6.94 - 7.00 (1H, m), 11.09 (1H, br s); m/z; ES+ [M+Na] = 466.1.
Example 72: 4-Chloro-7-(4-{4-[4-({4-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l//-benzimidazol-4- yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-l//-indole-3-carbonitrile The title compound was prepared using methodology described in example 7 using tert-butyl 4-[l-(2,6- dioxopiperidin-3-yl)-3-methy 1-2-oxo-2,3-dihydro-lH-benzimidazol-4-y!]piperazine- 1-carboxylate and intermediate If to give the title compound (60 mg, 47 %) as a white solid. 1HNMRS 1.18- 1.31 (3H, m), 1.63 - 1.76 (1H, m), 1.76 - 1.88 (4H, m), 1.89 - 2.06 (4H, m), 2.22 - 2.35 (3H, m), 2.55 - 2.65 (4H, m), 2.- 2.83 (3H, m), 2.83 - 3.06 (6H, m), 3.42 (2H, d), 3.59 - 3.7 (5H, m), 5.35 (1H, dd), 6.8 - 7.05 (6H, m), 7.(3H, dd), 8.31 (1H, d), 11.08 (1H, s), 12.25 (1H, s); m/r. ES+ [M+H]+= 774.4.
Example 73: 4-Chloro-7-[(3S)-3-(4-{4-[(4-{[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-l//- benzim idazol-4-yl|methyl ؛ piperazin-1-yl)methyl| piperidin-1-yl ؛phenyl)piperidin-l-yl|-l//-indolc-3- carbonitrile N N^O WO 2024/189488 PCT/IB2024/052251 175 The title compound was prepared using methodology described in example 69 using intermediate He and intermediate 69d to give the title compound (6.0 mg, 5 %) as a white solid. 1H NMR 5 1.07-1.22 (2H, m), 1.24 (1H, s), 1.56 (2H, d), 1.76 (2H, d), 1.96 (4H, dt), 2.14 (2H, d), 2.27-2.47 (7H, m), 2.51-2.77 (7H, m), 2.79-3.09 (2H, m), 3.32 (1H, s), 3.47-3.7 (7H, m), 5.38 (1H, dd), 6.8-7.01 (5H, m), 7.03-7.2 (4H, m), 8.(1H, d), 11.10 (1H, s), 12.29 (1H, s); m/r. ES+ [M+H]+ = 788.4.
Example 74: 7-[(3S)-3-(4-{4-[(4-{[l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-lZ/-benzimidazol-4- yl]methyl}piperazin-l-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-4-fluoro-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 69 using intermediate 23a and intermediate 69d to give the title compound (26 mg, 19 %) as a white solid. 1H NMR 5 1.07-1.27 (2H, m), 1.46-1.61 (2H, m), 1.75 (2H, d), 1.8-2.05 (5H, m), 2.12 (2H, d), 2.37 (6H, d), 2.52-2.64 (5H, m), 2.64-2.(2H, m), 2.82-2.91 (1H, m), 2.99 (1H, t), 3.28 (2H, d), 3.53-3.72 (7H, m), 5.37 (1H, dd), 6.75-6.98 (5H, m), 7.07 (1H, d), 7.15 (2H, d), 8.25 (1H, s), 11.10 (1H, s), 12.25 (1H, s); m/2׳ . ES+ [M+H]+= 772.4.
Example 75 Intermediate 75a: tert-Butyl diprop-2-yn-l-ylcarbamate WO 2024/189488 PCT/IB2024/052251 176 To tert-butyl prop-2-yn-l-y!carbamate (5.0 g, 32.22 mmol) in DMF (150 mL) under nitrogen at 0 °C was added sodium hydride (60 % in mineral oil, 2.58 g, 64.43 mmol) and stirred for 20 mins. 3-Bromoprop-l-yne (80% in toluene, 7.18 ml, 64.43 mmol) was added dropwise and the reaction mixture was stirred to RT for h. The reaction was quenched with ice and extracted with Et20 (300 mL). The organic layer was washed with water (2x 200 mL), NaCI solution (100 mL) and dried over a phase separating cartridge. The solvent was evaporated to give the title compound (2.71 g, 43.5 %) as a yellow oil. 1H NMR 5 1.42 (9H, s), 3.22 (2H, t), 4.05 (4H, d). no mass ion data Intermediate 75b: 2-tert-Butyl 5,6-dimethyl l,3-dihydro-2//-isoindole-2,5,6-tricarhoxylate tert-Butyl diprop-2-yn-l-y!carbamate (2.71 g, 14.02 mmol) and dimethyl but-2-ynedioate (6.90 ml, 56.mmol) in EtOH (30 mL) was degassed using nitrogen for 10 minutes.Chlorotris(triphenylphosphine)rhodium(I) (0.260 g, 0.28 mmol) was then added and the reaction was heated to °C for 48 h. The reaction was cooled to RT and the solvent was evaporated. Et20 (200 mL) was added and the resulting solid was filtered under vacuum to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane to give the title compound (1.10 g, 23.39 %) as a yellow oil. 1H NMR 5 1.47 (9H, s), 3.82 (6H, s), 4.66 (4H, d), 7.71 (2H, d); m/r. ES- [M-H]־ = 334.0.
Intermediate 750: 2-(tert-Butoxycarbonyl)-2,3-dihydro-l/f-isoindole-5,6-dicarboxylic acid To 2-tert-butyl 5,6-dimethyl l,3-dihydro-27/-isoindole-2,5,6-tricarboxylate (1.1 g, 3.28 mmol) inMeOH (mL) and water (2.5 mL) was added sodium hydroxide (2M, 4.92 ml, 9.84 mmol) and stirred at 80 °C for 2 h. The solvent was removed under reduced pressure and the residue was acidified to pH 4 using HC1 (2M). The product was extracted with EtOAc (100 mL), washed with NaCI solution (50 mL), dried over a phase separating cartridge and evaporated to give the title compound (0.452 g, 44.8 %) as a yellow solid which was used without further purification. 1H NMR 5 1.47 (9H, s), 4.64 (4H, d), 7.67 (2H, d), 13.22 (2H, s). m/2׳ . ES־ [M-H]306.0 = ־.
Intermediate 75d: tert-Butyl l,3-dioxo-5,7-dihydro-l//-furo[3,4-f|isoindole-6(3//)-carboxylate O' .0.
OH OH WO 2024/189488 PCT/IB2024/052251 177 2-(tert-Butoxycarbonyl)-2,3-dihydro-lrt-isoindole-5,6-dicarboxylic acid (452 mg, 1.47 mmol) was stirred at 100 °C in acetic anhydride (3 mL, 31.74 mmol) for 2 h. The reaction mixture was cooled to RT, diluted with EtOAc (50 mL), washed with water (2x 50 mL) and NaCI solution (50 mL). The organic layer was dried with a phase separating cartridge, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane to give the title compound (0.318 g, 74.7 %) as a yellow solid. 1H NMR 5 1.48 (9H, s), 4.75 (4H, d), 8.05 (2H, d); m/r. ES+ [M+H]+ = 290.1.
Intermediate 75e: tert-Butyl 6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f|isoindole-2(n/)- carboxylate ° Oh ' 0 To tert-butyl l.3-dioxo-5.7-dihydro-l//-furo|3.4-f|isoindolc-6(3//)-carboxylatc (318 mg, 1.10 mmol) in toluene (5 mL) was added 3 -aminopiperidine-2,6-dione hydrochloride (199 mg, 1.21 mmol) and triethylamine (460 pl, 3.30 mmol). The reaction was heated to 80 °C for 3 h and was then cooled to RT, diluted with EtOAc (50 mL), washed with water (2x 50 mL), NaCI solution (20 mL) and dried over a phase separating cartridge. The solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane to give the title compound (0.290 g, 66.1 %) as a white solid. 1H NMR 5 1.54 (9H, s), 2.1 - 2.18 (1H, m), 2.65 - 2.74 (2H, m), 2.88 - 3.04 (1H, m), 4.79 (4H, d), 5.13 - 5.31 (1H, m), 7.96 (2H, s), 11.17 (1H, s); m/z; ES" [M-H]398.3 = ־.
Intermediate 75f: 2-(2,6-Dioxopiperidin-3-yl)-6,7-dihydropyrrolo[3,4-f| isoindole-l,3(2Zf,5Zf)-dione O O H 0 HCI (4M in dioxane, 1 mL, 4.27 mmol) was added to tert-butyl 6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7- tctrahydropyrrolo|3.4-f|isoindolc-2( 1 //)-carboxylate (284 mg, 0.71 mmol) and the mixture was stirred at RT for 2 h. The solvent was evaporated to give the title compound (0.149 g, 62.4 %) as a white solid and was used without further purification. 1H NMR 5 2.03 - 2.17 (2H, m), 2.83 - 2.98 (1H, m), 3.58 (1H, s), 4.66 (4H, s), 5.1 - 5.22 (1H, m), 7.98 (2H, s), 9.67 (1H, s), 11.14 (1H, s); m/z; ES+ [M+H]+= 300.3.
Example 75: WO 2024/189488 PCT/IB2024/052251 178 4-Chloro-7-{4-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f|isoindol- 2(lZf)-yl]methyl}piperidin-l-yl)phenyl]piperidin-l-yl}-n/-indole-3-carbonitrile The title compound was prepared using methodology described in example 23 using intermediate if and 2- (2,6-dioxopiperidin-3-yl)-6,7-dihydropyrrolo[3,4-f]isoindole-l,3(27/,57/)-dione to give the title compound in the form of a formate salt (44 mg, 36 %) as a pale yellow solid. 1H NMR (90 °C) 8 1.24 - 1.45 (3H, m), 1.67 - 1.78 (1H, m), 1.85 - 1.93 (4H, m), 1.95 - 2.04 (2H, m), 2.07 - 2.16 (1H, m), 2.62 - 2.69 (4H, m), 2.7 - 2.(2H, m), 2.81 - 2.93 (4H, m), 3.45 (2H, d), 3.65 (2H, d), 4.05 (4H, s), 4.99 - 5.19 (1H, m), 6.79 - 6.96 (3H, m), 7.1 - 7.2 (3H, m), 7.76 (2H, s), 8.16 (1H, s); m/z; ES+ [M+H]+ = 730.8.
Example 76: 4-Chloro-7-{(3S)-3-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f|isoindol- 2(lZ/)-yl]methyl}piperidin-l-yl)phenyl]piperidin-l-yl}-lZ/-indazole-3-carbonitrile The title compound was prepared using methodology described in example 7 using intermediate 9g and intermediate 75f to give the title compound (38 mg, 16 %) as a white solid. 1H NMR 8 1.17-1.36 (2H, m), 1.47-1.7 (2H, m), 1.75-1.99 (5H, m), 2.01-2.14 (1H, m), 2.51-2.8 (8H, m), 2.82-3.06 (2H, m), 3.47 (2H, t), 3.64 (2H, d), 3.99 (4H, s), 5.14 (1H, dd), 6.91 (3H, dd), 7.18 (2H, d), 7.27 (1H, d), 7.79 (2H, s), 11.12 (1H, s), 14.69 (1H, s); m/z; ES+ [M+H]+= 731.0.
Example 77: 4-Chloro-7-{(3S)-3-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f|isoindol- 2(lZf)-yl]methyl}piperidin-l-yl)phenyl]piperidin-l-yl}-n/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 179 The title compound was prepared using methodology described in example 7 using intermediate 11c and intermediate 75f to give the title compound (36 mg, 28 %) as a white solid. 1H NMR 5 1.03-1.37 (2H, m), 1.49-1.72 (2H, m), 1.78-1.98 (5H, m), 2.01-2.14 (1H, m), 2.53-2.77 (8H, m), 2.82-3.11 (2H, m), 3.27-3.(1H, m), 3.37 (1H, s), 3.64 (2H, d), 3.97 (4H, s), 5-5.24 (1H, m), 6.71-6.97 (3H, m), 7.04-7.29 (3H, m), 7.(2H, s), 8.32 (1H, s), 11.14 (1H, s), 12.29 (1H, s); m/r. ES+ [M+H]+ = 730.0.
Example 78 Intermediate 78a: tert-Butyl 5-(3-cyano-4-methyl-l//-indol-7-yl)-3,6-dihydropyridine-l(2//)-carboxylate 0 I N^O' The title compound was prepared using methodology described in intermediate 63b using intermediate 8a and tert-butyl 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydropyridine-l(27/)-carboxylate to give the title compound (1.9 g, 99 %) as a brown solid. 1H NMR 5 1.42 (9H, s), 2.25 - 2.35 (2H, m), 2.65 (3H, s), 3.(2H, t), 4.12 (2H, q), 6.02 -6.11 (1H, m), 6.92 - 7.07 (2H, m), 8.23 (1H, d), 11.96 (1H, s); m/z; ES+ [M+H]+ = 338.3.
Intermediate 78b: tert-Butyl 3-(3-cyano-4-methyl-lZ/-indol-7-yl)piperidine-l-carboxylate The title compound was prepared using methodology described in intermediate 63c using tert-butyl 5-(3- cyano-4-mcthyl-l //-1ndol-7-yl)-3.6-d1hydropyr1d1nc-l (2//)-carboxylatc to give the title compound (2.8 g, N^O' WO 2024/189488 PCT/IB2024/052251 180 69 %) as a white foam. 1HNMR5 1.39 (9H, s), 1.49- 1.65 (2H, m), 1.67- 1.76 (1H, m), 1.88 - 1.97 (1H, m), 2.62 (3H, s), 2.74 - 2.88 (1H, m), 2.94 - 3.16 (2H, m), 3.95 - 4.06 (2H, m), 6.93 (1H, d), 7.03 (1H, d), 8.(1H, d), 12.19 (1H, s); m/z; ES+ [M+H]+ = 340.3.
Intermediate 780: 4-Methyl-7-(piperidin-3-yl)-lZ/-indole-3-carbonitrile Formic acid (30 mL) was added to tert-butyl 3-(3-cyano-4-mcthyl-l //-indol-7-yl)pipcridinc-l -carboxylate (2.g, 8.25 mmol) at RT and was stirred for 3 h. The solvent was evaporated and the crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7M NH3:MeOH to give the title compound (1.9 g, 96 %) as a white foam. 1H NMR (CDCL) 5 1.50 - 1.69 (2H, m), 1.83 - 2.07 (3H, m), 2.76 (3H, s), 2.87 - 2.99 (1H, m), 3.11 - 3.27 (3H, m), 3.27 - 3.35 (1H, m), 6.93 (2H, d), 7.72 (1H, s) one proton exchanged; m/r. ES+ [M+H]+ = 240.1.
Intermediate 78d: 2-[3-(4-Bromophenoxy)propyl]-l,3-dioxolane 2-(3-Bromopropyl)-1,3-dioxolane (1.69 g, 8.67 mmol) was added to 4-bromophenol (1.0 g, 5.78 mmol) and KCO3 (2.39 g, 17.34 mmol) in MeCN (20 mL) and the mixture was stirred at 80 °C for 2 h. The reaction was cooled to RT and the solvent was evaporated to afford crude product which was purified by flash silica chromatography, elution gradient 0 to 100% DCM in Et20 to give the title compound (1.5 g, 90 %) as a colourless oil. 1H NMR 5 1.65 - 1.77 (4H, m), 3.73 - 3.87 (4H, m), 3.94 - 4.10 (2H, m), 4.78 - 4.89 (1H, m), 6.89 (2H, d), 7.43 (2H, d); m/z; ES+ [M+H]+ = 287.1.
Intermediate 78e and 79a: The title compounds were prepared using methodology described in intermediate He using 4-methyl-7- (piperidin-3-yl)-l/7-indole-3-carbonitrile and 2-[3-(4-bromophenoxy)propyl]-!,3-dioxolane to give a racemic mixture. The enantiomers were separated by preparative chiral-HPLC on a Column: CHIRAL ART Cellulose- SB, 2*25 cm, 5 pm; Mobile Phase A: Hex (0.5% 2M NH3-MeOH), Mobile Phase B: EtOH; Flow rate: mL/min; Gradient: 25% B in 10.5 mins to give, in order of elution, intermediate 78e(isomer 1, 86 mg, 13 %) and intermediate 79a(isomer 2, 77 mg, 11 %) as yellow foams.
WO 2024/189488 PCT/IB2024/052251 181 Intermediate 78e: 7-[(37?*)-l-{4-[3-(l,3-dioxolan-2-yl)propoxy]phenyl}piperidin-3-yl]-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] Isomer 1 1H NMR 5 1.42-1.89 (8H, m), 2.51 (3H, d), 2.55-2.69 (1H, m), 3.24-3.3 (2H, m), 3.36-3.47 (2H, m), 3.58- 3.68 (2H, m), 3.68-3.81 (4H, m), 4.71 (1H, d), 6.61-6.71 (2H, m), 6.73-6.86 (3H, m), 6.93-7.02 (1H, m), 8.08 (1H, t), 12.14 (1H, s); m/z; ES+ [M+H]+ = 446.2; >99% ee.
Intermediate 79a: 7-[(3،؟*)-l-{4-[3-(l,3-dioxolan-2-yl)propoxy]phenyl}piperidin-3-yl]-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] Isomer 2 1H NMR 5 1.47-1.79 (8H, m), 2.51 (3H, s), 2.55-2.69 (1H, m), 3.24-3.34 (2H, m), 3.4-3.46 (2H, m), 3.58- 3.68 (2H, m), 3.68-3.82 (4H, m), 4.71 (1H, t), 6.62-6.71 (2H, m), 6.74-6.86 (3H, m), 6.98 (1H, d), 8.09 (1H, d), 12.14 (1H, s); m/z; ES+ [M+H]+ = 446.3; >99% ee.
Example 78: 7-{(37?*)-l-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] IsomerThe title compound was prepared using methodology described in example 24 using intermediate 78e and intermediate li followed by purification by flash C18-flash chromatography, elution gradient 0 to 100% MeCN in water modified with 0.1% NH4HCO3 followed by purification by preparative TLC DCM:MeOH (14: 1) to give the title compound (32 mg, 25 %) as a white solid. 1H NMR 5 1.52-1.74 (5H, m), 1.81-1.87 WO 2024/189488 PCT/IB2024/052251 182 (2H, m), 1.89-1.98 (2H, m), 2.38 (3H, q), 2.49 (4H, s), 2.55 (1H, s), 2.63 (5H, s), 2.67-2.8 (1H, m), 2.81-2.(1H, m), 3.21-3.29 (4H, m), 3.52-3.58 (2H, m), 3.90 (2H, t), 4.12-4.38 (2H, m), 5.05 (1H, dd), 6.75-6.(2H, m), 6.86-6.98 (3H, m), 7.01-7.14 (3H, m), 7.52 (1H, d), 8.22 (1H, d), 10.96 (1H, s), 12.27 (1H, d); m/z; ES+[M+H]+ = 714.4.
Example 79: 7-{(3،؟*)-l-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l- 7=° N ,0 Isomer 2 The title compound was prepared using methodology described in example 24 using intermediate 79a and intermediate li followed by purification by flash C18-flash chromatography, elution gradient 0 to 100% MeCN in water modified with 0.1% NH4HCO3 followed by purification by preparative TLC DCM:MeOH (14: 1) to give the title compound (21 mg, 18 %) as a white solid. 1H NMR 5 1.52-1.76 (5H, m), 1.79-1.(4H, m), 2.36 (3H, t), 2.46-2.49 (4H, m), 2.56 (1H, s), 2.59-2.66 (5H, m), 2.67-2.8 (1H, m), 2.81-2.93 (1H, m), 3.24-3.3 (4H, m), 3.5-3.6 (2H, m), 3.90 (2H, t), 4.13-4.37 (2H, m), 5.05 (1H, dd), 6.75-6.85 (2H, m), 6.86-6.98 (3H, m), 7.01-7.14 (3H, m), 7.52 (1H, d), 8.22 (1H, d), 10.96 (1H, s), 12.27 (1H, s); m/z; ES+ [M+H]+= 714.4.
Example 80 Intermediate 80a: 2-[3-(3-Bromophenoxy)propyl]-l,3-dioxolane The title compound was prepared using methodology described in intermediate 78d using 3 -bromophenol to give the title compound (1.2 g, 72 %) as a colourless gum. 1H NMR 5 1.65-1.83 (5H, m), 1.81-1.96 (1H, m), 3.56 (1H, td), 3.79 (1H, d), 3.89 (1H, s), 4.01 (1H, td), 4.79-4.89 (1H, m), 6.94 (1H, dt), 7.07-7.15 (2H, m), 7.23 (1H, m); m/z; ES+ [M+H]+ = 287.0.
Intermediate 80b: 7-[(37?*)-l-{3-[3-(l,3-dioxolan-2-yl)propoxy]phenyl}piperidin-3-yl]-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 183 and Intermediate 81a: 7-[(3S'*)-l-{3-[3-(l,3-dioxolan-2-yl)propoxy]phenyl}piperidin-3-yl]-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] The title compounds were prepared using methodology described in intermediate 78e and intermediate 79a using 4-mclhyl-7-(pipcridin-3-yl)-l//-indolc-3-carbonilrilc and 2-[3-(3-bromophenoxy )propyl]-l,3-dioxolane to give a racemic mixture. The enantiomers were separated by preparative chiral-HPLC on a Column: CHIRAL ART Cellulose-SB, 2*25 cm, 5 pm; Mobile Phase A: Hex (0.5% 2M NH3-MeOH), Mobile Phase B: EtOH; Flow rate: 20 mL/min; Gradient: 30% B in 10.5 mins to give, in order of elution, intermediate 80b (isomer 1, 138 mg, 45 %, >99% ee) and intermediate 81a(isomer 2, 120 mg, 42 %, >99% ee) as yellow solids. No nmr or Icms data collected at this stage.
Example 80: 7-{(37?*)-l-[3-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-LH-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 24 using intermediate 80b and intermediate li and purified by flash C18-flash chromatography, elution gradient 0 to 90% MeCN in water (0.1% NHHCO,) to give the title compound (27 mg, 12 %) as a white solid. 1H NMR 5 1.59 (3H, s), 1.(3H, s), 1.81 (2H, s), 1.96 (2H, s), 2.31-2.39 (4H, m), 2.63 (5H, s), 2.78 (2H, s), 2.88-2.93 (3H, m), 3.26 (4H, s), 3.74 (2H, t), 3.9-3.97 (2H, m), 4.16-4.25 (1H, m), 4.32 (1H, d), 5.02-5.1 (1H, m), 6.34 (1H, d), 6.46 (1H, d), 6.54 (1H, d), 6.95 (1H, t), 7.01-7.13 (4H, m), 7.52 (1H, t), 8.23 (1H, d), 10.96 (1H, s), 12.27 (1H, s); m/r. ES+[M+H]+ = 714.4.
WO 2024/189488 PCT/IB2024/052251 184 Example 81: 7-{(3،؟*)-l-[3-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 24 using intermediate 81a and intermediate li and purified by flash C18-flash chromatography, elution gradient 0 to 90% MeCN in water (0.1% NHHCO,) to give the title compound (11 mg, 6 %) as a white solid. 1H NMR 5 1.54-1.64 (2H, m), 1.64-1.74 (2H, m), 1.80 (2H, s), 1.91-1.99 (2H, m), 2.31-2.41 (3H, m), 2.44-2.5 (4H, m), 2.53-2.65 (5H, m), 2.75-2.79 (1H, m), 2.84-2.97 (2H, m), 3.25 (4H, t), 3.74 (2H, t), 3.94 (2H, t), 4.20 (1H, d), 4.32 (1H, d), 5.(1H, dd), 6.3-6.37 (1H, m), 6.45 (1H, t), 6.5-6.57 (1H, m), 6.94 (1H, d), 7-7.13 (4H, m), 7.52 (1H, d), 8.(1H, d), 10.96 (1H, s), 12.26 (1H, s); m/z; ES+ [M+H]+ = 714.4.
Example 82 Intermediate 82a: l-(4-Bromophenyl)-4-(l,3 ־dioxolan-2-yl)piperidine Pd2(dba)3 (175 mg, 0.19 mmol) was added to Xantphos (110 mg, 0.19 mmol), C52CO3 (3.1 g, 9.54 mmol), 1- bromo-4-iodobenzene (1.1 g, 4.20 mmol) and 4-(l,3-dioxolan-2-yl)piperidine (600 mg, 3.82 mmol) in 1,4- dioxane (20 mL) under nitrogen. The mixture was stirred at 80 °C for 3 h and then cooled to RT. The solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 55% EtOAc in Et20 to give the title compound (0.30 g, 25.2 %) as a yellow solid. 1H NMR 5 1.30 - 1.44 (2H, m), 1.59 - 1.76 (3H, m), 2.58 - 2.69 (2H, m), 3.66 - 3.74 (2H, m), 3.74 - 3.84 (2H, m), 3.81 - 3.93 (2H, m), 4.56 - 4.63 (1H, m), 6.84 - 6.91 (2H, m), 7.27 - 7.36 (2H, m); m/z; ES+ [M+H]+ = 312.1.
Intermediate 82b: 7-[(37?*)-l-{4-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]phenyl}piperidin-3-yl]-4-methyl-lZ/-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 185 and Intermediate 83a: 7-[(3S'*)-l-{4-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]phenyl}piperidin-3-yl]-4-methyl-lZ/-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] The title compounds were prepared using methodology described in intermediate 11c using l-(4- bromophenyl)-4-(l,3-dioxolan-2-y!)piperidine and intermediate 78c to give a racemic mixture. The enantiomers were separated by preparative chiral-HPLC on a Column: CHIRAL ART Cellulose-SB, 2*25 cm, pm; Mobile Phase A: Hex (0.5% 2M NH3-MeOH), Mobile Phase B: EtOH; Flow rate: 20 mL/min;Gradient: 25% B in 10.5 mins to give, in order of elution, intermediate 82b(isomer 1, 70 mg, 15 %, >99% ee) and intermediate 83a(isomer 2, 75 mg, 17 %, >99% ee) as yellow solids.
Example 82: 7-[(37?*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-3-yl]-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 24 using intermediate 82b and intermediate li and purified by flash C18-flash chromatography, elution gradient 0 to 90% MeCN in water (0.1% NH4HCO3) to give the title compound (35 mg, 32 %) as a white solid. 1H NMR 5 1.22 (3H, q), 1.6-1.64 WO 2024/189488 PCT/IB2024/052251 186 (2H, m), 1.75-1.86 (4H, m), 1.9-1.98 (2H, m), 2.21 (2H, d), 2.36 (2H, dd), 2.50 (1H, s), 2.51-2.76 (8H, m), 2.83-2.96 (1H, m), 3.24-3.31 (4H, m), 3.36-3.43 (1H, m), 3.48 (2H, d), 3.55 (2H, t), 4.20 (1H, d), 4.33 (1H, d), 5.05 (1H, dd), 6.84 (4H, q), 6.93 (1H, d), 7.02-7.13 (3H, m), 7.52 (1H, d), 8.22 (1H, d), 10.96 (1H, s), 12.28 (1H, d); m/z; ES+ [M+H]+ = 739.4.
Example 83: 7-[(3،؟*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-3-yl]-4-methyl-lZ/-indole-3-carbonitrile N ,0 Isomer 2 The title compound was prepared using methodology described in example 24 using intermediate 83a and intermediate li and purified by flash C18-flash chromatography, elution gradient 0 to 90% MeCN in water (0.1% NH4HCO3) to give the title compound (11 mg, 9 %) as a white solid. 1H NMR 5 1.22 (3H, t), 1.62 (2H, s), 1.79 (4H, d), 1.94 (2H, s), 2.20 (2H, d), 2.32-2.4 (2H, m), 2.49-2.51 (2H, m), 2.54-2.65 (5H, m), 2.73- 2.78 (2H, m), 2.90 (2H, t), 3.28 (4H, s), 3.34 (1H, s), 3.47 (2H, d), 3.52-3.59 (2H, m), 4.19 (1H, d), 4.32 (1H, d), 5.01-5.09 (1H, m), 6.77-6.89 (4H, m), 6.9-6.97 (1H, m), 7.02-7.13 (3H, m), 7.52 (1H, dd), 8.21 (1H, t), 10.95 (1H, d), 12.27 (1H, s); m/z; ES+ [M+H]+ = 739.4.
Example 84 Intermediate 84 a: l-[l-Methyl-2-(piperidin-4-yl)-lZf-indol-6-yl]-l,3-diazinane-2,4-dione tert-Butyldimethylsilyl trifluoromethanesulfonate (81 pl, 0.35 mmol) was added dropwise to a slurry of tert- butyl 4-[6-(2,4-dioxo-1,3-diazinan-1 -yl)-1-methyl-1 //-indol-2-y 11 piperidine-1 -carboxylate (intermediate 13c) (100 mg, 0.23 mmol) in DCM (2 mL) at 0 °C. The reaction was stirred to RT for ih and evaporated to dryness to give the title compound as a grey solid in quantitative yield which was used without further purification. m/z; ES+ [M+H]+ = 327.4.
Example 84: [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 187 4-Chloro-7-(4-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-lZ/-indol-2-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-n/-indole-3-carbonitrile The title compound was prepared using methodology described in example 70 using l-[l-methyl-2-(piperidin- 4-yl)-17/-indol-6-yl]-l,3-diazinane-2,4-dione and intermediate if to give the title compound (6 mg, 5 %) as a white solid. 1H NMR S 1.19 - 1.31 (3H, m), 1.62- 1.74 (3H, m), 1.79- 1.88 (4H, m), 1.89 - 2 (4H, m), 2.03 - 2.13 (2H, m), 2.23 (2H, d), 2.56 - 2.64 (2H, m), 2.7 - 2.85 (5H, m), 2.98 (2H, d), 3.45 (2H, d), 3.61 - 3.(5H, m), 3.79 (2H, t), 6.25 (1H, s), 6.85 (1H, d), 6.88 - 6.98 (3H, m), 7.1 - 7.21 (3H, m), 7.36 (1H, s), 7.(1H, d), 8.30 (1H, s), 10.27 (1H, s), 12.24 (1H, s); m/r. ES+ [M+H]+ = 757.8.
Example 85 Intermediate 85a: tert-Butyl 4-{4-[4-(l,3 ־dioxolan-2-yl)piperidine-l-carbonyl]phenyl}piperidine-l-carboxylate 4-( 1,3-Dioxolan-2-y !)piperidine (1.23 g, 7.86 mmol), HOBt (1.605 g, 10.48 mmol), 1-ethy 1-3-carbodiimide hydrochloride (1.88 g, 9.82 mmol) and DIPEA (3.43 ml, 19.65 mmol) was added to 4-[l-(tert- butoxycarbonyl)piperidin-4-yl]benzoic acid (0.51 g, 6.55 mmol) in DMF (30 mL). The resulting mixture was stirred at RT for 16 h. The solvent was removed under reduced pressure to afford crude product which was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et20 to give the title compound (0.51 g, 17.5 %) as a white solid. 1H NMR 5 1.23 (2H, d), 1.42 (9H, s), 1.44-1.58 (1H, m), 1.70 (2H, s), 1.(3H, d), 2.70 (2H, d), 2.77 (1H, s), 2.82 (2H, s), 3.17 (4H, d), 3.72-3.92 (3H, m), 4.10 (2H, q), 4.61 (1H, d), 7.30 (4H, s); m/z; ES+ [M+H]+ = 277.2.
Intermediate 85b: [4-(l,3-Dioxolan-2-yl)piperidin-l-yl][4-(piperidin-4-yl)phenyl]methanone WO 2024/189488 PCT/IB2024/052251 188 The title compound was prepared using methodology described in intermediate 27b using [4-(l,3-dioxolan-2- yl)piperidin-l-yl] [4-(piperidin-4-yl)phenyl]methanone to give the title compound which was used without further purification, no analytical data Intermediate 850: 4-Chloro-7-(4-{4-[4-(l,3-dioxolan-2-yl)piperidine-l-carbonyl]phenyl}piperidin-l-yl)-lZ/-indole-3- carbonitrile The title compound was prepared using methodology described in intermediate He using [4-(l,3-dioxolan-2- yl)piperidin-l-yl][4-(piperidin-4-yl)phenyl]methanone and intermediate lb to give the title compound (2mg, 45 %) as a white solid. 1HNMR S -0.12 (8H, s), 1.03 (1H, s), 2.71 (5H, d), 3.15 (4H, s), 3.59-4.05 (4H, m), 4.50 (1H, s), 5.64 (1H, s), 6.40 (1H, s), 6.75 (1H, s), 7.05 (1H, d), 7.24 (2H, s), 8.22 (1H, d), 12.17 (1H, s); m/z; ES+[M+H]+ = 681.5.
Example 85: 4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- N—( >=O The title compound was prepared using methodology described in example 24 using 4-chloro-7-(4-{4-[4-(l,3- dioxolan-2-y!)piperidine-1 -carbonyl]phenyl}piperidin-1 -yl)- lH-indole-3 -carbonitrile and intermediate li followed by purification by flash C18-flash chromatography, elution gradient 0 to 100% MeCN in water (0.1% NH4HCO3) followed by purification by preparative TEC DCM:MeOH (14: 1) to give the title compound (93 mg, 61 %) as a white solid. 1H NMR 5 1.01-1.11 (2H, m), 1.6-2.1 (8H, m), 2.18 (2H, d), 2. yl}methyl)piperidine-l-carbonyl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 189 (1H, dd), 2.42-2.48 (4H, m), 2.5-2.62 (1H, m), 2.65-3.11 (6H, m), 3.21-3.29 (4H, m), 3.38-3.65 (3H, m),4.12 4.36 (2H, m), 4.44 (1H, s), 5.03 (1H, dd), 6.84 (1H, d), 6.98-7.07 (2H, m), 7.15 (1H, d), 7.31-7.37 (4H, m), 7.50 (1H, d), 8.32 (1H, s), 10.95 (1H, s), 12.24 (1H, s); m/z; ES+ [M+H]+ = 787.4.
Example 86 Intermediate 86a: Benzyl 4-[4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)phenyl]piperidine-l-carboxylate The title compound was prepared using methodology described in intermediate 9g using l,4-dioxa-8- azaspiro[4.5]decane and intermediate 1c to give the title compound (5.5 g, 94 %) as a white solid. 1H NMR 1.59 (8H, dt), 2.52-2.66 (1H, m), 3.15-3.26 (4H, m), 4.01-4.09 (8H, m), 5.10 (2H, s), 6.87 (2H, d), 7.06 (2H, d), 7.22-7.46 (5H, m); m/z; ES+ [M+H]+ = 437.3.
Intermediate 86b: 8-[4-(Piperidin-4-yl)phenyl]-l,4-dioxa-8-azaspiro[4.5]decane The title compound was prepared using methodology described in intermediate 1 lb using benzyl 4-[4-(l,4- dioxa-8-azaspiro[4.5]decan-8-yl)phenyl]piperidine-l-carboxylate to give the title compound (300 mg, 71 %) as a white solid. 1H NMR 5 1.34 (2H, dd), 1.44-1.63 (6H, m), 2.37 (4H, s), 2.45 (1H, d), 2.88 (2H, d), 3.(2H, t), 3.78 (4H, s), 6.7-6.79 (2H, m), 6.92 (2H, d); m/z; ES+ [M+H]+ = 303.2.
Intermediate 860: 4-Chloro-7-{4-[4-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)phenyl]piperidin-l-yl}-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in intermediate 23a using 8-[4-(piperidin-4- yl)phenyl]-l,4-dioxa-8-azaspiro[4.5]decane and intermediate lb to give the title compound (211 mg, 45 %) as a white solid. 1H NMR S 1.69 (2H, s), 1.80 (2H, s), 1.84 (2H, s), 1.91 (2H, d), 1.99 (2H, d), 3.19 (2H, s), 3.(2H, s), 3.23 (1H, s), 3.89 (4H, s), 6.85 (1H, s), 6.91 (2H, d), 7.10 (2H, s), 7.13 (2H, s), 7.16 (1H, s), 8.31 (1H, d); m/z; ES+ [M+H]+ = 477.2.
Example 86: WO 2024/189488 PCT/IB2024/052251 190 4-Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4- c]pyridin-6-yl]piperazin-l-yl}piperidin-l-yl)phenyl]piperidin-l-yl}-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 24 using 4-chloro-7-{4-[4-(l,4- dioxa-8-azaspiro[4.5]decan-8-yl)phenyl]piperidin-l-yl}-lH-indole-3-carbonitrile and intermediate 30e to give the title compound (35 mg, 17 %) as a white solid. 1H NMR 5 1.51-1.58 (2H, m), 1.76-2.04 (7H, m), 2.26-2.(2H, m), 2.59-2.64 (8H, m), 2.78 (2H, t), 2.84-2.96 (1H, m), 3.38-3.45 (2H, m), 3.59-3.63 (4H, m), 3.67- 3.74 (2H, m), 3.89 (3H, s), 4.13 (1H, d), 4.28 (1H, d), 4.93-5.01 (1H, m), 6.49 (1H, s), 6.84-6.96 (3H, m), 7.11-7.2 (3H, m), 8.34 (1H, s), 10.94 (1H, s), 12.29 (1H, s); m/z; ES+ [M+H]+ = 776.6.
Example 87 Intermediate 87a: Benzyl 4-(4-{4-[(l,3-dioxolan-2-yl)methyl]piperidin-l-yl}phenyl)piperidine-l-carboxylate 0 The title compound was prepared using methodology described in intermediate 9g using 4-[(l,3-dioxolan-2- yl)methyl]piperidine and intermediate ic to give the title compound (1.6 g, 81 %) as a yellow solid. 1H NMR 1.21-1.34 (2H, m), 1.38-1.6 (5H, m), 1.66-1.82 (4H, m), 2.52-2.65 (3H, m), 2.83-2.96 (2H, m), 3.53-3.(2H, m), 3.69-3.82 (2H, m), 3.82-3.94 (2H, m), 4.08-4.16 (2H, m), 4.87 (1H, t), 5.09 (2H, s), 6.84 (2H, d), 7.05 (2H, d), 7.28-7.43 (5H, m); m/z; ES+ [M+H]+ = 465.3.
Intermediate 87b: 4- [(1,3-Dioxolan-2-yl)methyl] -1- [4-(piperidin-4-yl)phenyl] piperidine The title compound was prepared using methodology described in intermediate 1 lb using benzyl 4-(4-{4- [(l,3-dioxolan-2-yl)methyl]piperidin-l-yl}phenyl)piperidine-l-carboxylate to give the title compound (4mg, 72 %) as a white solid. 1H NMR S 1.22-1.33 (2H, m), 1.38-1.46 (1H, m), 1.42-1.55 (1H, m), 1.51-1.66 WO 2024/189488 PCT/IB2024/052251 191 (5H, m), 1.78 (2H, d), 2.37-2.48 (1H, m), 2.52-2.6 (4H, m), 2.94-3.03 (2H, m), 3.52-3.61 (2H, m), 3.69-3.82(2H, m), 3.82-3.94 (2H, m), 4.87 (1H, t), 6.8-6.9 (2H, m), 7-7.07 (2H, m); m/z; ES+ [M+H]+ = 331.2.
Intermediate 87c: 4-Chloro-7-[4-(4-{4-[(l,3-dioxolan-2-yl)methyl]piperidin-l-yl}phenyl)piperidin-l-yl]-lZ/-indole-3- carbonitrile The title compound was prepared using methodology described in intermediate 23a using 4-[(l,3-dioxolan-2- yl)methyl]-l-[4-(piperidin-4-yl)phenyl]piperidine and intermediate lb to give the title compound (120 mg, %) as a white solid. 1H NMR 5 1.24-1.36 (2H, m), 1.51-1.57 (3H, m), 1.75-1.87 (4H, m), 1.96 (2H, q), 2.56-2.63 (2H, m), 2.77 (2H, t), 3.17 (1H, d), 3.41 (2H, d), 3.60 (2H, d), 3.72-3.86 (2H, m), 3.86-3.91 (2H, m), 4.88 (1H, t), 6.82-6.93 (3H, m), 7.08-7.2 (3H, m), 8.33 (1H, s), 12.28 (1H, s); m/z; ES+ [M+H]+ = 505.3.
Example 87: 4-Chloro-7-(4-{4-[4-(2-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZf-pyrrolo[3,4- c|pyridin-6-yl|piperazin-l-yl}ethyl)piperidin-l-yl|phenyl}piperidin-l-yl)-l//-indole-3-carhonitrile The title compound was prepared using methodology described in example 24 using 4-chloro-7-[4-(4-{4- [(1,3 -dioxolan-2-y!)methyl]piperidin-1 -yl}pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile and intermediate 30e to give the title compound (51 mg, 29 %) as a white solid. 1H NMR 5 1.21-1.31 (2H, m), 1.42-1.48 (3H, m), 1.7-2.05 (7H, m), 2.25-2.47 (7H, m), 2.53-2.67 (4H, m), 2.71-3.02 (3H, m), 3.37-3.47 (2H, m), 3.58- 3.64 (6H, m), 3.89 (3H, s), 4.07-4.33 (2H, m), 4.97 (1H, dd), 6.49 (1H, s), 6.82-6.95 (3H, m), 7.09-7.21 (3H, m), 8.33 (1H, s), 10.93 (1H, s), 12.28 (1H, s); m/z; ES+ [M+H]+ = 804.4.
Example 88 Intermediate 88a: Benzyl 4-(3-oxopropyl)piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 192 Pyridinium chlorochromate (4.66 g, 21.63 mmol) was added to benzyl 4-(3-hydroxypropy!)piperidine-1- carboxylate (4.0 g, 14.42 mmol) in DCM (75 mL) at RT for 2 h. The solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et2O to give the title compound (2.8 g, 70.5 %) as a colourless oil. 1H NMR 5 0.87-1.06 (2H, m), 1.28-1.(3H, m), 1.57-1.67 (2H, m), 2.39-2.5 (2H, m), 2.73 (2H, s), 3.92-4.04 (2H, m), 5.04 (2H, s), 7.24-7.42 (5H, m), 9.66 (1H, t); m/z; ES+ [M+H]+ = 276.2.
Intermediate 88b: Benzyl 4- [2-(l ,3-dioxolan-2-yl)ethyl] piperidine- 1-carboxylate p-Toluenesulfonic acid (0.093 g, 0.49 mmol) was added to benzyl 4-(3-oxopropy!)piperidine-!-carboxylate (2.7 g, 9.81 mmol) in glycol (50 mL) at RT under nitrogen and stirred at 100 °C for 16 h. The reaction mixture was diluted with EtOAc (500 mL), washed with water (100 mL), NaHCO3 solution, NaCI solution and dried over Na2S04. The organic layer was filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et20 to give the title compound (1.2 g, 38.3 %) as a colourless liquid; m/z׳ . ES+ [M+H]+ = 276.2.
Intermediate 88c: 4- [2-(l ,3-Dioxolan-2-yl)ethyl] piperidine The title compound was prepared using methodology described in intermediate 1 lb using benzyl 4-[2-(l,3- dioxolan-2-yl)ethyl]piperidine-l-carboxylate to give the title compound (811 mg, 88 %) as a white solid. 1H NMR 5 1.41 (4H, s), 1.44 (5H, s), 2.26 (1H, s), 2.74 (2H, s), 2.78 (2H, s), 3.62 (2H, s), 3.74 (2H, s), 4.62 (1H, s); m/z; ES+ [M+H]+ = 186.3.
Intermediate 88d: Benzyl 4-(4-{4-[2-(l,3-dioxolan-2-yl)ethyl]piperidin-l-yl}phenyl)piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 193 The title compound was prepared using methodology described in intermediate lla using 4-[2-(l,3-dioxolan- 2-yl)ethyl]piperidine and intermediate 1c to give the title compound (547 mg, 39 %) as a white solid; m 2 ES+ [M+H]+ = 237.0.
Intermediate 88e: 4- [2-(l ,3-Dioxolan-2-yl)ethyl] -1- [4-(piperidin-4-yl)phenyl] piperidine The title compound was prepared using methodology described in intermediate 1 lb using benzyl 4-(4-{4-[2- (l,3-dioxolan-2-yl)ethyl]piperidin-l-yl}phenyl)piperidine-l-carboxylate to give the title compound (350 mg, %) as a white solid. 1H NMR 5 1.25 (4H, dd), 1.34 (5H, s), 1.58-1.74 (4H, m), 2.17 (1H, s), 2.55 (8H, d), 2.98 (1H, d), 3.67-3.77 (2H, m), 3.81-3.91 (2H, m), 4.73 (1H, s), 6.81 (1H, s), 6.84 (1H, d), 7.00 (1H, s), 7.(1H, s); m/r. ES+ [M+H]+ = 324.3.
Intermediate 88f: 4-Chloro-7-[4-(4-{4-[2-(l,3-dioxolan-2-yl)ethyl]piperidin-l-yl}phenyl)piperidin-l-yl]-lZ/-indole-3- carbonitrile The title compound was prepared using methodology described in intermediate 23a using 4-[2-(l,3-dioxolan- 2-yl)ethyl]-l-[4-(piperidin-4-yl)pheny!]piperidine and intermediate lb to give the title compound (200 mg, %) as a white solid; m2׳. ES+ [M+H]+ = 519.4. no nmr data Example 88: 4-Chloro-7-(4-{4-[4-(3-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZf-pyrrolo[3,4- c]pyridin-6-yl]piperazin-l-yl}propyl)piperidin-l-yl]phenyl}piperidin-l-yl)-n/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 194 The title compound was prepared using methodology described in example 78 using 4-chloro-7-[4-(4-{4-[2- (1,3 -dioxolan-2-y!)ethyl]piperidin-1 -y 1 }pheny!)piperidin-1 -y 1] -1 //-i ndo lc-3 -carbonitrile and intermediate 3 Oe to give the title compound (49 mg, 26 %) as a white solid. 1H NMR 5 1.18-1.29 (4H, m), 1.35 (1H, s), 1.(2H, s), 1.75 (2H, d), 1.83 (2H, d), 1.89-2.03 (3H, m), 2.27-2.35 (3H, m), 2.45 (4H, s), 2.56 (4H, d), 2.76 (2H, t), 2.89 (1H, t), 3.41 (2H, d), 3.62 (6H, d), 3.89 (3H, s), 4.13 (1H, d), 4.27 (1H, d), 4.97 (1H, dd), 6.48 (1H, s), 6.87 (3H, dd), 7.14 (3H, dd), 8.33 (1H, s), 10.94 (1H, s), 12.29 (1H, s); m/r. ES+ [M+H]+ = 818.5.
Example 89 Intermediate 89a: tert-Butyl 4-(5-bromo-l//-indol-l-yl)piperidine-l-carboxylate tert-Butyl 4-[(methanesulfonyl)oxy]piperidine-l-carboxylate (534 g, 1912.81 mmol) and potassium tert- butoxide (258 g, 2295.37 mmol) were added portion wise to 5-bromo-!//-indole (150 g, 765.12 mmol) in heptane (2400 mL) and stirred at 80 °C for 3 h. The reaction mixture was cooled to RT and was diluted with MTBE. The solid was filtered and the filtrate was evaporated to dryness. The residue was redissolved in EtOAc, washed with water, dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et20 to give a colourless foam which was crystallised from MTBE:Et20 (1:5) to give the title compound (85 g, 29.3 %) as a white solid. 1H NMR (CDC13) 5 1.36 - 1.42 (9H, s), 1.69 - 1.89 (2H, m), 1.92 - 2.02 (2H, d), 2.73 - 2.89 (2H, m), 4.14 - 4.29 (3H, m), 6.33 - 6.40 (1H, m), 7.04 - 7.12 (1H, d), 7.09 - 7.23 (2H, m), 7.60 - 7.69 (1H, m); m/z; ES+ [M-tBu]+ = 323.0.
Intermediate 89b: tert-Butyl 4-[5-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 195 [Pd(cinnamyl)Cl]2 (0.913 g, 1.65 mmol) was added to tert-butyl 4-(5-bromo-l//-indol-l-yl)pipcridinc-l- carboxylate (25 g, 65.91 mmol), 1,3 -diazinane-2,4-dione (15.04 g, 131.82 mmol), tert-butylBrettPhos (1.59 g, 3.30 mmol) and C52CO3 (43 g, 131.82 mmol) in 1,4-dioxane (750 mL) at RT under nitrogen. The resulting mixture was stirred at 90 °C for 16 h. The reaction mixture was diluted with EtOAc (2 L) and water (2 L). The organic layer was dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by crystallisation from MTBE to give the title compound (44.0 g, 57.1 %) as a white solid. 1H NMR (CDC13) 5 1.49 - 1.54 (9H, s), 1.85 - 2.00 (2H, qd), 2.04 - 2.13 (2H, m), 2.84 - 3.00 (4H, m), 3.88 - 3.95 (2H, m), 4.32 - 4.44 (3H, m), 6.52 - 6.58 (1H, m), 7.12 - 7.19 (1H, m), 7.22 - 7.27 (1H, d), 7.38 - 7.46 (2H, m), 7.52 - 7.57 (1H, d); m/z; ES+ [M+H]+ = 413.0.
Intermediate 890: l-[l-(Piperidin-4-yl)-lZf-indol-5-yl]-l,3-diazinane-2,4-dione The title compound was prepared using methodology described in intermediate 5f using tert-butyl 4-[5-(2,4- dioxo-l .3-diazinan-l -yl)-l //-indol-l-yl |pipcridinc-l -carboxylate to give the title compound as a tosylate salt (73 g, 82 %) as a white solid. 1H NMR 5 2.05 - 2.20 (4H, m), 2.27 - 2.32 (3H, d), 2.69 - 2.77 (2H, m), 3.15- 3.20 (2H, s), 3.44 - 3.51 (2H, d), 3.73 - 3.81 (2H, m), 4.71 - 4.75 (1H, s), 6.48 - 6.54 (1H, m), 7.08 - 7.(3H, m), 7.39 - 7.47 (1H, m), 7.47 - 7.53 (3H, m), 7.53 - 7.63 (1H, m), 8.37 - 8.42 (1H, s), 8.61 - 8.65 (1H, s), 10.24 - 10.29 (1H, d); m/z; ES+ [M+H]+= 313.0.
Example 89: 7-(4-{4-[4-({4-[5-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- yl | phenyl{ piperidin-1-yl)-4-tluoro-l//-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 196 The title compound was prepared using methodology described in example 23 using l-[l-(piperidin-4-yl)-lrt- indol-5-yl]-l,3-diazinane-2,4-dione and intermediate 2c to give the title compound in the form of a formate salt (46 mg, 56 %) as a white solid. 1H NMR (90 °C) 8 1.25 - 1.37 (2H, m), 1.66 - 1.77 (1H, m), 1.83 - 1.(4H, m), 1.94 - 2.09 (7H, m), 2.2 - 2.35 (5H, m), 2.69 - 2.76 (4H, m), 2.84 (2H, t), 3.03 (2H, d), 3.40 (2H, d), 3.64 (2H, d), 3.79 (2H, t), 4.29 - 4.43 (1H, m), 6.47 (1H, d), 6.82 - 6.89 (2H, m), 6.91 (3H, d), 7.07 - 7.(1H, m), 7.16 (2H, d), 7.45 - 7.55 (3H, m), 8.11 (1H, s), 9.85 (1H, s); m/z; ES+ [M+H]+ = 727.8.
Example 90: 4-Chloro-7-(4-{4-[4-({4-[5-(2,4-dioxo-l,3-diazinan-l-yl)-lZr ־indol-l-yl]piperidin-l-yl}methyl)piperidin- l-yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 23 using intermediate 89c and intermediate if to give the title compound in the form of a formate salt (34 mg, 53 %) as a white solid. 1H NMR 8 1.17 - 1.33 (2H, m), 1.59 - 1.74 (1H, m), 1.77 - 1.89 (4H, m), 1.89 - 2.09 (6H, m), 2.18 (2H, t), 2.(2H, d), 2.6 - 2.83 (7H, m), 3.01 (2H, d), 3.39 - 3.46 (2H, m), 3.61 - 3.71 (2H, m), 3.77 (2H, t), 4.31 - 4.(1H, m), 6.47 (1H, d), 6.79 - 6.99 (3H, m), 7.04 - 7.23 (4H, m), 7.47 (1H, d), 7.5 - 7.63 (2H, m), 8.32 (1H, s), 10.25 (1H, s), 12.26 (1H, s); m/z; ES+ [M+H]+ = 743.9.
Example 91 Intermediate 91a: tert-Butyl 5-(4-chloro-3-cyano-lZ/-indol-7-yl)-3,6-dihydropyridine-l(2Zf)-carboxylate The title compound was prepared using methodology described in intermediate 63b using intermediate lb and tert-butyl 5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydropyridine-l(27/)-carboxylate to give the WO 2024/189488 PCT/IB2024/052251 197 title compound (2.5 g, 59 %) as a yellow solid. 1H NMR (CDC13) 5 1.15-1.54 (9H, m), 2.29 (2H, d), 3.57 (2H, s), 4.05 (2H, s), 6.90 (1H, d), 7.06 (1H, s), 7.16 (1H, d), 7.73 (1H, s), 11.02 (1H, s); m/r. ES־ [M-H]356.1 = ־.
Intermediate 91b: tert-Butyl 3-(4-chloro-3-cyano-lZf-indol-7-yl)piperidine-l-carboxylate N O CI N Royer(R) Rhodium Catalyst Beads (1.26 g, 0.61 mmol) was added to tert-butyl 5-(4-chloro-3-cyano-lrt-indol- 7-yl)-3,6-dihydropyridine-l(27/)-carboxylate (2.2 g, 6.15 mmol) inMeOH (10 mL) and THF (10 mL) under an atmosphere of hydrogen. The resulting mixture was stirred at 80 °C for 16 h. The catalyst was filtered off through a pad of Celite® and evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 80% EtOAc in Et20 to give the title compound (1.4 g, 63.3 %)asayellow solid. 1H NMR 5 1.41 (9H, d), 1.60 (1H, t), 1.71 (1H, s), 1.94 (1H, d), 2.85 (1H, s), 3.(2H, d), 3.34 (2H, s), 4.00 (2H, d), 4.07 - 4.17 (1H, m), 7.16 (1H, d), 7.19 - 7.31 (1H, m), 8.43 (1H, d), 12.- 12.63 (1H, m); m/z; ES+ [M+H]+ = 360.0.
Intermediate 910: 4-Chloro-7-(piperidin-3-yl)-lZ/-indole-3-carbonitrile CI N The title compound was prepared using methodology described in intermediate 78c using tert-butyl 3-(4- chloro-3-cyano-l//-indol-7-y !)piperidine-1-carboxy late (780 mg, 77 %) as a white solid. 1H NMR 5 1.65 - 1.87 (3H, m), 1.93 (1H, s), 2.70 - 2.87 (2H, m), 3.10 - 3.28 (2H, m), 7.04 - 7.17 (1H, m), 7.23 (1H, d), 8.(2H, d); m/z; ES+ [M+H]+ = 260.0.
Intermediate 91d: l-(4-Bromophenyl)-4-(dibutoxymethyl)piperidine WO 2024/189488 PCT/IB2024/052251 198 The title compound was prepared using methodology described in intermediate 82a using bromo-4- iodobenzene and 4-(dibutoxymethy !)piperidine to give the title compound (1.4 g, 49 %) as a yellow solid. 1H NMR 5 0.89 (3H, t), 1.20 - 1.36 (2H, m), 1.32 - 1.58 (5H, m), 1.65 - 1.76 (2H, m), 2.47 - 2.55 (1H, m), 2.- 2.67 (1H, m), 3.32 - 3.45 (1H, m), 3.49 - 3.62 (1H, m), 3.68 (1H, d), 4.14 - 4.23 (1H, m), 6.83 - 6.96 (1H, m), 7.25 - 7.37 (1H, m); m/r. ES+ [M+H]+ = 398.2.
Intermediate 91e: 4-Chloro-7-[(37?*)-l-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-3-yl]-lZ/-indole-3- carbonitrile[absolute stereochemistry not yet confirmed] Isomer 1 and Intermediate 92a: 4-Chloro-7-[(3، ؟*)-l-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-3-yl]-lZ/-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] The title compounds were prepared using methodology described in intermediate 78e and intermediate 79a using 4-chloro-7-(pipcridin-3-yl)-l//-indolc-3-carbonitrilc and l-(4-bromophenyl)-4- (dibutoxymethyl)piperidine to give a racemic mixture. The enantiomers were separated by preparative chiral- HPLC on a Column: CHIRAL PAK Al-3, 4.6*250cm, 3 pm; Mobile Phase A: Hex (0.1% DEA), Mobile Phase B: EtOH; Flow rate: 1 mL/min; Gradient: 20% B in 10.5 mins to give, in order of elution, intermediate 91e(isomer 1, 80 mg, 4.5 %, >99% ee, m/2; ES+, [M+H]+ = 577.0.) and intermediate 92a(isomer 2, 85 mg, %, >99% ee, m/r. ES+, [M+H]+ = 577.0.) as yellow solids.
Example 91: WO 2024/189488 PCT/IB2024/052251 199 4-Chloro-7-[(37?*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZZ-pyrrolo[3,4- c]pyridin-6-yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-3-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] N .0 Isomer 1 The title compound was prepared using methodology described in example 24 using intermediate 91e and intermediate 30e and purified by flash C18-flash chromatography, elution gradient 0 to 90% MeCN in water (0.1% NHHCO,) to give the title compound (24 mg, 44 %) as a pale yellow solid. 1H NMR 5 1.22 (3H, d), 1.64 (2H, s), 1.72 - 2.02 (6H, m), 2.21 (2H, d), 2.25 - 2.37 (1H, m), 2.44 (3H, s), 2.62 (2H, d), 2.76 - 2.(4H, m), 3.42 - 3.70 (9H, m), 3.89 (3H, s), 4.11-4.31 (2H, m), 4.91 - 5.03 (1H, m), 6.49 (1H, s), 6.78 - 6.(4H, m), 7.24 (2H, s), 8.39 (1H, s), 10.93 (1H, s), 12.67 (1H, s); m/z; ES+ [M+H]+ = 790.0.
Example 92: 4-Chloro-7-[(3، ؟*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZZ-pyrrolo[3,4- c]pyridin-6-yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-3-yl]-lZ/-indole-3-carbonitrile N. -N. O N ,0 Isomer 2 The title compound was prepared using methodology described in example 24 using intermediate 92a and intermediate 30e and purified by flash C18-flash chromatography, elution gradient 0 to 90% MeCN in water (0.1% NHHCO,) to give the title compound (26 mg, 47 %) as a pale yellow solid. 1H NMR 5 1.22 (3H, d), 1.64 (2H, s), 1.72 - 2.02 (6H, m), 2.21 (2H, d), 2.25 - 2.37 (1H, m), 2.44 (3H, s), 2.62 (2H, d), 2.76 - 2.(4H, m), 3.42 - 3.70 (9H, m), 3.89 (3H, s), 4.11-4.31 (2H, m), 4.91 - 5.03 (1H, m), 6.49 (1H, s), 6.78 - 6.(4H, m), 7.24 (2H, s), 8.39 (1H, s), 10.93 (1H, s), 12.67 (1H, s); m/z; ES+ [M+H]+ = 790.4.
Example 93: 4-Chloro-7-[(37?*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZZ-isoindol- 5-yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-3-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] N. ,N. ,0 [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 200 The title compound was prepared using methodology described in example 24 using intermediate 91e and intermediate li to give the title compound (10 mg, 19 %) as a pale yellow solid. 1H NMR 5 1.22 (2H, s), 1.(2H, s), 1.80 (4H, d), 1.91 - 2.01 (2H, m), 2.22 (2H, d), 2.31 - 2.42 (1H, m), 2.47 - 2.96 (6H, m), 3.33 (7H, s), 3.44 - 3.61 (5H, m), 4.16 - 4.36 (2H, m), 4.99 -5.11 (1H, m), 6.78 - 6.93 (4H, m), 7.06 (2H, d), 7.22 (2H, s), 7.53 (1H, d), 8.37 (1H, s), 10.95 (1H, s), 12.65 (1H, s); m/z; ES+ [M+H]+ = 759.3.
Example 94: 4-Chloro-7-[(3، ؟*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5- yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-3-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 24 using intermediate 92a and intermediate li to give the title compound (14 mg, 27 %) as a pale yellow solid. 1H NMR 5 1.22 (2H, s), 1.(2H, s), 1.80 (4H, d), 1.91 - 2.01 (2H, m), 2.22 (2H, d), 2.31 - 2.42 (1H, m), 2.47 - 2.96 (6H, m), 3.33 (7H, s), 3.44 - 3.61 (5H, m), 4.16 - 4.36 (2H, m), 4.99 -5.11 (1H, m), 6.78 - 6.93 (4H, m), 7.06 (2H, d), 7.22 (2H, s), 7.53 (1H, d), 8.37 (1H, s), 10.95 (1H, s), 12.65 (1H, s); m/z; ES+ [M+H]+ = 759.3.
Example 95 Intermediate 95a: l-[4-(4,4-Dimethoxybutoxy)phenyl]piperazine WO 2024/189488 PCT/IB2024/052251 201 Triphenylphosphine (1.4 g, 5.61 mmol) was added to DIAD (818 pL, 4.21 mmol), 4-(piperazin-1-y !)phenol (500 mg, 2.81 mmol) and 3-(l,3-dioxolan-2-yl)propan-l-ol (556 mg, 3.37 mmol) in THE (13 mL) and was stirred at RT for 2 h under nitrogen. The solvent was evaporated to afford the crude product. The crude product was purified by flash C18-flash chromatography, elution gradient 0 to 50% MeOH in water (0.1% NH4HCO3) followed by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7M NHVMcOH to give the title compound (0.380 g, 46.0 %) as a yellow oil. 1H NMR 1.63 - 1.73 (4H, m), 2.81 (4H, t), 2.89 (4H, d), 3.23 (6H, s), 3.89 (2H, d), 4.39 (1H, t), 6.80 - 6.86 (4H, m) 1H not observed; m/z: ES+ [M+H]+ = 295.2.
Intermediate 95b: 7-{4-[4-(4,4-Dimethoxybutoxy)phenyl]piperazin-l-yl}-4-methyl-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in intermediate 27c using l-[4-(4,4- Dimethoxybutoxy )phenyl]piperazine and intermediate 8a to give the title compound (370 mg, 75 %) as a white solid. 1H NMR (CDC13) 5 1.83 - 1.90 (4H, m), 2.77 (3H, s), 3.15 - 3.27 (4H, m), 3.31 (5H, d), 3.37 (5H, s), 3.99 (2H, d), 4.47 (1H, t), 6.89 (2H, d), 6.99 (4H, h), 7.75 (1H, d), 8.91 (1H, s); m/z: ES+ [M+H]+ = 449.2.
Example 95: 7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperazin-l-yl}-4-methyl-lZ/-indole-3-carbonitrile Intermediate li (172 mg, 0.40 mmol) was added to 7-{4-[4-(4,4-dimethoxybutoxy)phenyl]piperazin-l-yl}-4- methyl-l/7-indole-3-carbonitrile (150 mg, 0.33 mmol) in formic acid (2.5 mL) under nitrogen. The resulting mixture was stirred at 40 °C for 1 h. The solvent was evaporated and diluted with DCM (1.7 mL). Sodium triacetoxy hydroborate (354 mg, 1.67 mmol) was added and the mixture was stirred ar RT for 16 h. The reaction mixture was quenched with saturated NaHCO3 solution (5 mL) and the product was extracted with DCM (5 mL), dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by preparative TLC (DCM: MeOH = 12: 1) to give the title compound (0.026 g, 10.8 %) as a white solid. 1H NMR 5 1.56 - 1.67 (2H, m), 1.69 - 1.80 (2H, m), 1.95 (1H, d), 2.22 - 2.42 (3H, m), 2.55 (3H, s), 2.61 (4H, s), 2.69 - 3.04 (2H, m), 3.11 (4H, t), 3.28 (8H, q), 3.95 (2H, t), 4.14 - 4.39 (2H, m), 5.05 (1H, dd), WO 2024/189488 PCT/IB2024/052251 202 6.75-6.98 (6H, m), 7.06 (2H, d), 7.53 (1H, d), 8.19 (1H, d), 10.94 (1H, s), 11.97 (1H, s); m/z: ES+ [M+H]+ =715.4.
Example 96 Intermediate 96a: l-Benzyl-4-(4-bromophenyl)piperidine Triethylamine (3.48 mL, 24.99 mmol) was added to 4-(4-bromopheny!)piperidine (2.0 g, 8.33 mmol) and (bromomethyl)benzene (2.85 g, 16.66 mmol) in THF (15 mL) under nitrogen and was stirred at RT for 16 h. The solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 60% EtOAc in Et20 to give the title compound (2.2 g, 80 %) as a yellow gum. 1H NMR 5 1.50 - 1.74 (4H, m), 1.93 - 2.07 (2H, m), 2.82 - 2.94 (2H, m), 3.47 (2H, s), 7.14 - 7.35 (7H, m), 7.39 - 7.52 (2H, m); m/z; ES+ [M+H]+ = 330.0.
Intermediate 96b: 7-{l-[4-(l-Benzylpiperidin-4-yl)phenyl]piperidin-3-yl}-4-chloro-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in intermediate He using 1 -benzyl-4-(4- bromophenyl)piperidine and intermediate 91c to give the title compound (400 mg, 36 %) as a yellow solid. 1H NMR 5 1.6-1.68 (5H, m), 1.81 (2H, s), 1.99 (4H, s), 2.21-2.47 (2H, m), 2.68-2.81 (1H, m), 2.90 (4H, d), 3.(2H, d), 6.45-6.52 (1H, m), 6.85-6.9 (2H, m), 7.01-7.09 (2H, m), 7.25 (4H, d), 7.33 (2H, s), 8.39 (1H, s), 12.65 (1H, s); m/z; ES+ [M+H]+ = 509.3.
Intermediates 960 and 97a 1-Chloroethyl carbonochloridate (1.4 g, 9.82 mmol) was added to 7-{l-[4-(l-benzylpiperidin-4- yl)phenyl]piperidin-3-yl}-4-chloro-l/7-indole-3-carbonitrile (500 mg, 0.98 mmol) in 1,2-dichloroethane (mL) and was stirred at 80 °C for 16 h. The solvent was evaporated to afford the crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in Et20 to give the racemic mixture (200mg) as a yellow solid. The enantiomers were separated by preparative HPLC on a Column: CHIRALPAK IE-3, 4.6*50mm, 3 micron; Mobile Phase 25% Hexane:DCM (0.1% DEA): WO 2024/189488 PCT/IB2024/052251 203 EtOH:MeCN 50%; Flow rate: 1 ml/min. to give, in order of elution, intermediate 960(isomer 1, 70 mg, %, >99% ee) and intermediate 97a(isomer 2, 72 mg, 17.5 %, >99% ee) as colourless gums.
Intermediate 96c: 4-Chloro-7-{(37?*)-l-[4-(piperidin-4-yl)phenyl]piperidin-3-yl}-n/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR 5 1.43-1.54 (2H, m), 1.67 (3H, d), 1.81 (2H, s), 1.98 (2H, t), 2.58-2.68 (2H, m), 2.76 (1H, s), 2.(2H, t), 3.05 (2H, d), 3.69 (2H, d), 6.90 (2H, d), 7-7.07 (2H, m), 7.22 (2H, s), 8.37 (1H, s) 2H not observed; m/z; ES+[M+H]+ = 419.2.
Intermediate 97a: 4-Chloro-7-{(3، ؟*)-l-[4-(piperidin-4-yl)phenyl]piperidin-3-yl}-W/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR 5 1.4-1.49 (2H, m), 1.64 (3H, d), 1.81 (2H, s), 1.96 (1H, d), 2.44 (1H, d), 2.53-2.62 (2H, m), 2.(1H, t), 2.88 (1H, t), 3.01 (2H, d), 3.41 (2H, d), 3.69 (2H, d), 6.90 (2H, d), 7.04 (2H, d), 7.20 (2H, s), 8.35 (1H, s) 1H not observed; m/r. ES+ [M+H]+ = 419.2.
Example 96: 4-Chloro-7-[(37?*)-l-{4-[l-({l-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-W/-isoindol-5-yl]piperidin- 4-yl}methyl)piperidin-4-yl]phenyl}piperidin-3-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 204 Intermediate 22d (40.6 mg, 0.08 mmol) were stirred in formic acid (2 mL) at 40 °C for 1 h. The solvent was evaporated and the residue was added to NMP (2 mL) with intermediate 96c and stirred RT for 16 h. The reaction mixture was quenched with NaHCO3 solution (10 mL) and purified by flash C18-flash chromatography, elution gradient 0 to 60% MeCN in water (0.1%NH4HCO3) to give the title compound (20.00 mg, 30.6 %) as a white solid. 1H NMR 5 1.12-1.25 (2H, m), 1.53-1.73 (5H, m), 1.79 (5H, d), 1.91- 2.08 (4H, m), 2.21 (2H, d), 2.36 (2H, d), 2.58 (1H, d), 2.71-2.91 (5H, m), 2.96 (2H, d), 3.41 (1H, s), 3.68 (2H, d), 3.86 (2H, d), 4.19 (1H, d), 4.31 (1H, d), 5.04 (1H, dd), 6.89 (2H, d), 6.98-7.15 (4H, m), 7.22 (2H, s), 7.(1H, d), 8.38 (1H, s), 10.95 (1H, s), 12.67 (1H, s); m/r. ES+ [M+H]+ = 758.4.
Example 97: 4-Chloro-7-[(3S'*)-l-{4-[l-({l-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lLf-isoindol-5-yl]piperidin- 4-yl}methyl)piperidin-4-yl]phenyl}piperidin-3-yl]-lH-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] Isomer 2 The title compound was prepared using methodology described in example 96 using intermediate 97a and intermediate 22d to give the title compound (20 mg, 29 %) as a white solid. 1H NMR 5 1.11-1.25 (2H, m), 1.54-1.73 (5H, m), 1.79 (5H, d), 1.95 (4H, d), 2.18 (2H, d), 2.29-2.44 (2H, m), 2.58 (1H, d), 2.73 (2H, d), 2.81 (1H, s), 2.85 (1H, d), 2.88-2.97 (3H, m), 3.42 (1H, s), 3.68 (2H, d), 3.86 (2H, d), 4.19 (1H, d), 4.31 (1H, d), 5.04 (1H, dd), 6.89 (2H, d), 6.98-7.12 (4H, m), 7.23 (2H, s), 7.50 (1H, d), 8.38 (1H, s), 10.95 (1H, s), 12.67 (1H, s); m/z; ES+ [M+H]+ = 758.4.
Example 98 Intermediate 98a: 3-{6-[4-(Dibutoxymethyl)piperidin-l-yl]-4-methoxy-3-oxo-l,3-dihydro-2Z/-pyrrolo[3,4-c]pyridin-2- yl}piperidine-2,6-dione Isomer 1 WO 2024/189488 PCT/IB2024/052251 205 The title compound was prepared using methodology described in intermediate He using intermediate 30d and 4-(dibutoxymethyl)piperidine to give the title compound (200 mg, 30 %) as a white solid. 1H NMR 5 0.(6H, t), 1.15-1.24 (2H, m), 1.26-1.4 (4H, m), 1.48 (4H, dq), 1.72 (2H, d), 1.8-1.95 (2H, m), 2.23-2.39 (1H, m), 2.56 (1H, d), 2.87 (2H, dd), 3.34-3.44 (2H, m), 3.55 (3H, d), 3.87 (3H, s), 4.06-4.2 (2H, m), 4.25 (1H, d), 4.40 (2H, d), 4.95 (1H, dd), 6.47 (1H, s), 10.91 (1H, s); m/r. ES+ [M+H]+ = 517.5.
Example 98: 4-Chloro-7-[(37?*)-l-{4-[l-({l-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZZ-pyrrolo[3,4- c]pyridin-6-yl]piperidin-4-yl}methyl)piperidin-4-yl]phenyl}piperidin-3-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 96 using intermediate 96c and 3 - (6-[4-(dibutoxymethy !)piperidin-1 -yl] -4-methoxy-3 -oxo-1,3 -di hy dro-2//-py rrolo [3,4-c]pyridin-2- yl}piperidine-2,6-dione to give the title compound (20 mg, 30 %) as a white solid. 1H NMR 5 1.02-1.13 (2H, m), 1.51-1.72 (5H, m), 1.79 (5H, d), 1.9-2.04 (4H, m), 2.17 (2H, d), 2.26-2.41 (2H, m), 2.58 (1H, s), 2.(1H, s), 2.82-2.98 (6H, m), 3.43 (1H, d), 3.68 (2H, d), 3.88 (3H, s), 4.11 (1H, d), 4.25 (1H, d), 4.37 (2H, s), 4.95 (1H, dd), 6.46 (1H, s), 6.89 (2H, d), 7.06 (2H, d), 7.23 (2H, s), 8.38 (1H, s), 10.91 (1H, s), 12.67 (1H, s); m/z; ES+ [M+H]+ = 789.4.
Example 99: 4-Chloro-7-[(3، ؟*)-l-{4-[l-({l-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZZ- pyrrolo[3,4-c]pyridin-6-yl]piperidin-4-yl}methyl)piperidin-4-yl]phenyl}piperidin-3-yl]-lZ/-indole-3- carbonitrile[absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 206 Isomer 2 The title compound was prepared using methodology described in example 96 using intermediate 97a and intermediate 98a to give the title compound (20 mg, 29 %) as a white solid. 1H NMR 5 1.01-1.15 (2H, m), 1.52-1.72 (5H, m), 1.74-1.88 (5H, m), 1.88-2.02 (4H, m), 2.16 (2H, d), 2.32 (2H, dd), 2.58 (1H, s), 2.72 (1H, d), 2.90 (6H, q), 3.42 (1H, s), 3.68 (2H, d), 3.88 (3H, s), 4.11 (1H, d), 4.25 (1H, d), 4.37 (2H, s), 4.95 (1H, d), 6.47 (1H, s), 6.89 (2H, d), 7.06 (2H, d), 7.23 (2H, s), 8.38 (1H, s), 10.92 (1H, s), 12.68 (1H, s); m/r. ES+ [M+H]+ = 789.4.
Example 100: The title compound was prepared using methodology described in example 24 using intermediate 85c and intermediate 50b to give the title compound (20 mg, 12 %) as a yellow solid. 1H NMR 5 0.83 (1H, s), 1.(2H, q), 1.23 (1H, s), 1.84 (3H, s), 1.91 (2H, d), 1.97-2.07 (3H, m), 2.23 (2H, d), 2.51-2.64 (4H, m), 2.7-2.(5H, m), 3.03 (1H, s), 3.24 (4H, t), 3.45 (2H, d), 3.64 (1H, s), 4.46 (1H, s), 5.10 (1H, dd), 6.87 (1H, d), 7.(1H, d), 7.36 (4H, d), 7.45 (1H, d), 7.73 (1H, d), 8.33 (1H, s), 11.11 (1H, s), 12.29 (1H, s); m/2׳ . ES+ [M+H]+ = 819.4.
Example 101 Intermediate 101a: Benzyl 4- [4-(piperidin-4-yl)phenoxy] piperidine- 1-carboxylate 4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fh1oro-l,3-dioxo-2,3-dihydro-lZ/-isoindol-5- yl]piperazin-l-yl}methyl)piperidine-l-carbonyl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 207 DIAD (2.10 mL, 10.82 mmol) was added to triphenylphosphine (2.84 g, 10.82 mmol), tert-butyl 4-(4- hydroxyphenyl)piperidine-l-carboxylate (2.0 g, 7.21 mmol) and 1-benzylpiperidin-4-ol (1.65 g, 8.65 mmol) in THF (20 mL) under nitrogen which was stirred at RT for 2 h. The reaction was diluted with EtOAc (50 mL), washed with NH4C1 solution (25 mL), water (25 mL), NaO solution (25 mL), dried over Na2SO4, filtered and evaporated to afford crude solid. The crude solid was stirred in formic acid (20 mL) at RT for 2 h and then evaporated to afford crude product. The crude product was purified by flash C18-flash chromatography, elution gradient 0 to 30% MeOH in water (0.1% formic acid). Product containing fractions were purified by ion exchange chromatography, using an SCX column. The product was eluted from the column using 7M NH3/MeOH to give the title compound (300 mg, 11.8 %) as a white solid. 1H NMR 5 1.15-1.23 (2H, m), 1.4- 1.47 (2H, m), 1.54-1.69 (4H, m), 1.91 (2H, t), 2.21 (2H, t), 2.61-2.7 (2H, m), 2.99 (2H, d), 3.45 (2H, d), 4.2- 4.38 (1H, m), 4.77 (1H, d), 6.84 (2H, d), 7.09 (2H, d), 7.21-7.36 (5H, m) 1H not observed; m/z; ES+ [M+H]+ = 351.3.
Intermediate 101b: Benzyl 4-{4-[l-(3-cyano-4-fh1oro-lZ/-indol-7-yl)piperidin-4-yl]phenoxy}piperidine-l-carboxylate The title compound was prepared using methodology described in intermediate 11c using benzyl 4-[4- (piperidin-4-yl)phenoxy]piperidine-l-carboxylate and intermediate 2b to give the title compound (150 mg, %) as a yellow solid. 1H NMR 5 1.55-1.69 (2H, m), 1.79-1.88 (2H, m), 1.89-2 (4H, m), 2.23 (2H, t), 2.55- 2.71 (3H, m), 2.71-2.81 (2H, m), 3.37 (2H, d), 3.49 (2H, s), 4.29-4.4 (1H, m), 6.82 (1H, dd), 6.88-6.96 (3H, m), 7.15-7.21 (2H, m), 7.21-7.28 (1H, m), 7.32 (4H, d), 8.27 (1H, d), 12.25 (1H, s); m/z; ES+ [M+H]+ = 509.3.
Intermediate 101c: 4-Fluoro-7-(4-{4-[(piperidin-4-yl)oxy]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in intermediate 41c using benzyl 4-{4-[l-(3- cyano-4-fluoro-l/7-indol-7-yl)piperidin-4-yl]phenoxy}piperidine-l-carboxylate to give the title compound WO 2024/189488 PCT/IB2024/052251 208 (150 mg, 41 %) as a yellow solid. 1H NMR 5 0.84 (1H, d), 1.22 (4H, d), 1.85 (3H, d), 1.98 (2H, d), 2.09 (1H, s), 2.61 (1H, d), 2.76 (2H, t), 3.03 (1H, s), 3.17 (2H, d), 4.61 (1H, s), 6.82 (1H, dd), 6.88-7.04 (3H, m), 7.(2H, d), 8.26 (1H, s); m/z; ES+ [M+H]+ = 419.3.
Example 101: 7-[4-(4-{[l-({l-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZf-isoindol-5-yl]piperidin-4- yl}methyl)piperidin-4-yl]oxy}phenyl)piperidin-l-yl]-4-fluoro-lZ/-indole-3-carbonitrile Intermediate 22d (69.6 mg, 0.14 mmol) was stirred in formic acid (1.5 mL) at 40 °C for 1 h. The solvent was evaporated and the residue was added to 4-nuoro-7-(4-[4-|(pipcridin-4-yl)oxy Iphcnyl; pipcridin-1 -yl)-l //- indole-3-carbonitrile (60 mg, 0.14 mmol) in NMP (1.5 mL) and stirred at RT for 16 h. The reaction mixture was purified by flash C18-flash chromatography, elution gradient 0 to 40% MeCN in water (0.1% formic acid). The fractions were combined and MeCN was removed under reduced pressure. The aqueous was basified with NaHCO3 solution until pH 7 and extracted with DCM (6 x 50 mL), dried over Na2SO4, filtered and evaporated to afford yellow solid. The yellow solid was purified by preparative TLC (DCM:MeOH, 10:1), to give the title compound (7 mg, 6.4 %) as a white solid. 1H NMR 5 1.09-1.26 (3H, m), 1.61 (2H, d), 1.69- 1.87 (5H, m), 1.87-2.03 (5H, m), 2.16 (4H, d), 2.3-2.42 (1H, m), 2.58 (2H, d), 2.64-2.98 (7H, m), 3.40 (2H, s), 3.87 (2H, d), 4.19 (1H, d), 4.32 (2H, d), 5.05 (1H, dd), 6.78 (1H, dd), 6.86-6.97 (3H, m), 7.04 (2H, d), 7.(2H, d), 7.50 (1H, d), 8.24 (1H, s), 10.95 (1H, s); m/r. ES+ [M+H]+ = 758.3.
Intermediate 102a: tert-Butyl 4-(5-bromo-7-methyl-lZ/-indol-l-yl)piperidine-l-carboxylate tert-Butyl 4-[(methanesulfonyl)oxy]piperidine-l-carboxylate (11.9 g, 42.84 mmol), 5-bromo-7-methyl-irt- indole (3.0 g, 14.28 mmol) and C52CO3 (13.96 g, 42.84 mmol) inDMF (57 mL) were stirred at 100 °C for h. The reaction was cooled to RT and diluted with EtOAc (200 mL), washed with water (100 mL), NaCI WO 2024/189488 PCT/IB2024/052251 209 solution (200 mL), dried with MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 25% EtOAc in heptane to give the title compound (1.05 g, 18.69 %) as a pale yellow gum. 1H NMR 5 1.43 (9H, s), 1.82 (2H, qd), 1.96 (2H, d), 2.(3H, s), 2.94 (2H, s), 4.03 - 4.18 (2H, m), 4.82 (1H, m), 6.43 (1H, d), 7.01 (1H, s), 7.51 - 7.58 (2H, m); m/z; ES+ [M-tBu]+ = 337.0.
Intermediate 102b: tert-Butyl 4-[5-(2,4-dioxo-l,3-diazinan-l-yl)-7-methyl-lZ/-indol-l-yl]piperidine-l-carboxylate Ephos (0.143 g, 0.27 mmol) and Pd2(dba)3 (0.122 g, 0.13 mmol) were stirred in 1,4-dioxane (26 mL) and heated to 50 °C for 5 minutes under nitrogen. This solution was added to tert-butyl 4-(5-bromo-7-methyl-irt- indol-l-yl)piperidine-l-carboxylate (1.05 g, 2.67 mmol), 1,3 -diazinane-2,4-dione (0.457 g, 4.00 mmol) and C52CO3 (2.61 g, 8.01 mmol) under nitrogen in 1,4-dioxane (20 mL) and stirred at 100 °C for 16 h. The mixture was cooled to RT, diluted with EtOAc (100 mL), washed with NaO solution (100 mL), dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane to give the title compound (0.55 g, 48.3 %) as a pale yellow solid. 1H NMR 5 1.43 (9H, s), 1.83 (2H, qd), 1.97 (2H, s), 2.66 - 2.75 (5H, m), 2.96 (2H, s), 3.(2H, t), 4.11 (2H, d), 4.85 (1H, m), 6.45 (1H, d), 6.77-6.87 (1H, m), 7.28 (1H, d), 7.53 (1H, d), 10.23 (1H, s); m/z; ES+[M-tBu]+ = 371.0.
Example 102: 4-Chloro-7-(4-{4-[4-({4-[5-(2,4-dioxo-l,3-diazinan-l-yl)-7-methyl-lZ/-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-n/-indole-3-carbonitrile The title compound was prepared using methodology described in example 24 using tert-butyl 4-[5-(2,4- dioxo-1.3-diazinan-l -yl)-7-mcthyl-l //-indol-l -yl|pipcridinc-l -carboxylate and intermediate if to give the title compound (19 mg, 12 %) as a white solid. 1H NMR 5 1.23 (2H, m), 1.66 (1H, d), 1.82 (4H, dd), 1.89-2.(6H, m), 2.12 (2H, td), 2.24 (2H, d), 2.56-2.66 (3H, m), 2.62-2.74 (5H, m), 2.78 (2H, dd), 3.01 (2H, d), 3.38- HIST N' WO 2024/189488 PCT/IB2024/052251 210 3.45 (2H, m), 3.65 (2H, dq), 3.73 (2H, t), 4.66 (1H, td), 6.45 (1H, d), 6.79-6.95 (4H, m), 7.15 (3H, dd), 7.(1H, d), 7.55 (1H, d), 8.33 (1H, s), 10.26 (1H, s), 12.16 (1H, s); m/r. ES+ [M+H]+ = 757.4.
Example 103 Intermediate 103a: tert-Butyl 4-[(3-amino-5-bromopyridin-2-yl)ethynyl]piperidine-l-carboxylate Tetrakis(triphenylphosphine)palladium(0) (1.39 g, 1.20 mmol) was added to 5-bromo-2-iodopyridin-3 -amine (3.0 g, 10.04 mmol), tert-butyl 4-ethynylpiperidine-1 -carboxylate (2.1 g, 10.04 mmol) and copper(!) iodide (0.229 g, 1.20 mmol) in triethylamine (17 mL) at RT under nitrogen. The mixture was stirred at 80 °C for h, cooled to RT. and the solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 20% EtOAc in DCM to give the title compound (3.0 g, %) as a yellow solid. 1H NMR (CDC13) 5 1.46 (9H, s), 1.70 (2H, dtd), 1.90 (2H, ddt), 2.86 (1H, tt), 3.(2H, m), 3.72-3.85 (2H, m), 4.33 (2H, s), 7.17 (1H, d), 7.98 (1H, d); m/z; ES+ [M+H]+ = 380.0.
Intermediate 103b: tert-Butyl 4-(6-bromo-lZ/-pyrrolo[3,2-b]pyridin-2-yl)piperidine-l-carboxylate |_| Dichlorobis(acetonitrile)palladium(II) (0.409 g, 1.58 mmol) was added to tert-butyl 4-[(3-amino-5- bromopyridin-2-yl)ethynyl]piperidine-l-carboxylate (3.0 g, 7.89 mmol) inDMF (30 mL) atRT under nitrogen. The resulting mixture was stirred at 120 °C for 16 h and then cooled to RT. The reaction mixture was diluted with EtOAc (75 mL), washed with NaHCO3 solution (100 mL), dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash alumina chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (1.5 g, 50.0 %) as a yellow oil. 1H NMR 5 1.(9H, s), 1.96 (2H, d), 2.73 (2H, s), 2.89 (2H, s), 4.02-4.1 (3H, m), 6.35 (1H, s), 7.85 (1H, s), 8.30 (1H, s), 11.41 (1H, s); m/z; ES+ [M+H]+= 380.0.
Intermediate 103c: tert-Butyl 4-(6-bromo-l-methyl-lZ/-pyrrolo[3,2-b]pyridin-2-yl)piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 211 Sodium hydride (60 % in mineral oil, 0.22 g, 5.52 mmol) was added to tert-butyl 4-(6-bromo-l //-pyrrolo|3.2- b]pyridin-2-yl)piperidine-l-carboxylate (1.4 g, 3.68 mmol) in DMF (15 mL) at 0 °C under nitrogen.Iodomethane (0.229 mL, 3.68 mmol) was added after 15 mins. The resulting mixture was stirred at RT for 2 h. The reaction mixture was quenched with water (1 mL) and diluted with EtOAc (50 mL). The organic layer was washed with water (150 mL), dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 20% EtOAc in DCM to give the title compound (0.62 g, 42.7 %) as a yellow solid. 1H NMR (CDC13) 5 1.50 (9H, d), 1.64-1.78 (2H, m), 1.99 (2H, d), 2.84-2.94 (3H, m), 3.72 (3H, d), 4.30 (2H, s), 6.46 (1H, s), 7.74 (1H, s), 8.45 (1H, s); m/r. ES+ [M+H]+= 394.0.
Intermediate 103d: tert-Butyl 4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-lZ/-pyrrolo[3,2-b]pyridin-2-yl]piperidine-l- carboxylate Ephos Pd G4 (280 mg, 0.30 mmol) was added to tert-butyl 4-(6-bromo-l-methyl-!//-pyrrolo[3,2-b]pyridin-2- yl)piperidine-l-carboxylate (600 mg, 1.52 mmol), C52CO3 (992 mg, 3.04 mmol), EPhos (163 mg, 0.30 mmol) and 1,3-diazinane-2,4-dione (521 mg, 4.56 mmol) in 1,4-dioxane (8 mL) under nitrogen. The mixture was stirred at 100 °C for 2 h, cooled to RT and evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 4 % MeOH in DCM to give the title compound (400 mg, 61.5 %) as a red solid. 1H NMR 5 1.43 (9H, s), 1.96 (2H, d), 2.77 (2H, t), 3.33 (5H, s), 3.83 (2H, t), 5.76 (1H, s), 6.40 (1H, s), 8.25 (1H, d), 10.42 (1H, s); m/z; ES+ [M+H]+ = 428.3. : 103 Example - 2-4 [- 6 (- 2,4 - dioxo-l,3-diazinan-l-yl)-l-methyl-l//-pyrrolo[3,2-b|pyridin -)؛ 4 -] 4 -؛ 4 -) 7 - 4 - Chloro piperidin-l-yl)-l//-indole-3-carbonitrile ؛ methyl)piperidin-l-yl|phenyl ؛ yl|piperidin-l-yl WO 2024/189488 PCT/IB2024/052251 212 The title compound was prepared using methodology described in example 24 using tert-butyl 4-[6-(2,4- dioxo-1,3 -diazinan-1 -yl)-1 -methyl-1 //-py rrolo[3,2-b]pyridin-2-yl]piperidine-1 -carboxylate and intermediate If to give the title compound (20 mg, 11 %) as a white solid. 1H NMR 5 1.24 (2H, t), 1.68 (3H, q), 1.81 (4H, d), 1.92 (3H, t), 2.07 (5H, s), 2.22 (2H, d), 2.60 (3H, q), 2.67-2.78 (4H, m), 2.83 (1H, s), 2.97 (2H, d), 3.(2H, d), 3.73 (3H, s), 3.82 (2H, t), 6.39 (1H, s), 6.66 (1H, d), 6.89 (2H, d), 7.00 (1H, d), 7.11 (2H, d), 7.(1H, d), 8.12 (1H, s), 8.24 (1H, d), 10.42 (1H, s); m/r. ES+ [M+H]+ = 758.0.
Example 104 Intermediate 104a: tert-Butyl 4-[3-fluoro-4-(methoxycarbonyl)phenyl]piperazine-l-carboxylate Palladium (II) acetate (0.241 g, 1.07 mmol) was added to methyl 4-bromo-2-fluorobenzoate (5.0 g, 21.mmol), tert-butyl piperazine-1-carboxylate (4.4 g, 23.60 mmol), rac-2,2'-Bis(diphenylphosphino)-l,r־ binaphthyl (1.33 g, 2.15 mmol) and C52CO3 (15.3 g, 47.20 mmol) in 1,4-dioxane (20 mL) at RT under nitrogen. The mixture was stirred at 110 °C for 2 h, cooled to RT and evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et2O to give the title compound (6.0 g, 83 %) as a pale yellow solid. 1H NMR 5 1.42 (9H, d), 3.35 (4H, d), 3.42 (4H, s), 3.77 (3H, d), 6.67-6.84 (2H, m), 7.71 (1H, m); m/z; ES+ [M+H]+ = 339.0.
Intermediate 104b: 4-[4-(tert-Butoxycarbonyl)piperazin-l-yl]-2-fh1orobenzoic acid LiOH (1.20 g, 50.18 mmol) was added to tert-butyl 4-[3-fluoro-4-(methoxycarbonyl)phenyl]piperazine-l- carboxylate (6.0 g, 17.73 mmol) in THF:water (1:1, 100 mL). The mixture was stirred at 60 °C for 1 h. The solvent was evaporated and the residue was acidified with HC1 (2M, 25 ml). The solid was filtered and washed with water (100 mL) and dried under vacuum to give the title compound (5.0 g, 87 %) as a white solid. 1H NMR 5 1.4 (9H, s), 3.24-3.56 (8H, m), 6.7-6.88 (2H, m), 7.62-7.8 (1H, m) COOH not observed; m/z; ES+ [M+H]+= 325.2.
Intermediate 104c: tert-Butyl 4-{4-[(2,6-dioxopiperidin-3-yl)carbamoyl]-3-fluorophenyl}piperazine-l-carboxylate Propane phosphonic acid anhydride (50% in EtOAc, 14.7 g, 23.12 mmol) was added to 4-[4-(tert- butoxycarbonyl)piperazin-l-yl]-2-fluorobenzoic acid (5.0 g, 15.42 mmol), 3-aminopiperidine-2,6-dione 2HC1 WO 2024/189488 PCT/IB2024/052251 213 (4.65 g, 23.12 mmol) andDIPEA (10.7 mL, 61.66 mmol) inDCM (100 mL) atRT. The mixture was stirred at °C for 1 minute. The solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% MeOH in DCM to give the title compound (6.0 g, %) as a cream solid. 1H NMR 5 1.42 (9H, s), 1.92-2.22 (2H, m), 2.54 (1H, d), 2.78 (1H, m), 3.30 (4H, m), 3.44 (4H, m), 4.73 (1H, t), 6.82 (1H, s), 7.65 (1H, t), 8.10 (1H, dd), 9.86 (1H, s), 10.85 (1H, s); m/r. ES+ [M+H]+= 435.0.
Example 104: 4-{4-[(l-{4-[(3S)-l-(4-chloro-3-cyano-lZ/-indol-7-yl)piperidin-3-yl]phenyl}piperidin-4- yl)methyl]piperazin-l-yl}-/V-(2,6-dioxopiperidin-3-yl)-2-fluorobenz amide The title compound was prepared using methodology described in example 24 using tert-butyl 4-{4-[(2,6- dioxopiperidin-3-yl)carbamoyl]-3-fluorophenyl}piperazine-l-carboxylate and intermediate He to give the title compound (80 mg, 34 %) as a white solid. 1H NMR 5 1.21 (2H, d), 1.55 (1H, d), 1.67 (1H, s), 1.75-2.(6H, m), 2.06-2.16 (1H, m), 2.20 (2H, d), 2.46 (4H, s), 2.53-2.85 (6H, m), 2.97 (1H, d), 3.29 (4H, s), 3.(2H, s), 3.62 (2H, d), 4.73 (1H, s), 6.7-6.95 (5H, m), 7.14 (3H, dd), 7.63 (1H, t), 8.05 (1H, t), 8.29 (1H, s), 10.85 (1H, s), 12.30 (1H, s); m/z; ES+ [M+H]+ = 765.2.
Example 105: - 1 - piperidin-4-yl)methyl | piperazin ؛ 4 [- l-(3-Cyano-4-tluoro-l//-indol-7-yl)piperidin-4-yl|phenyl -؛ 4 ([- l ؛ - 4 yl}-/V-(2,6-dioxopiperidin-3-yl)-2-fluorobenz amide The title compound was prepared using methodology described in example 24 using intermediate 104c and intermediate 2c to give the title compound (82 mg, 44 %) as a white solid. 1H NMR 5 1.22 (2H, d), 1.68 (1H, s), 1.82 (4H, t), 1.89-2.05 (3H, m), 2.07-2.18 (1H, m), 2.21 (2H, d), 2.46 (4H, d), 2.60 (4H, q), 2.74 (3H, WO 2024/189488 PCT/IB2024/052251 214 t),3.23-3.31 (4H, m), 3.40 (2H, d), 3.63 (2H, d), 4.64-4.82 (1H, m), 6.74-6.85 (3H, m), 6.90 (3H, d), 7.(2H, d), 7.64 (1H, t), 8.04 (1H, t), 8.25 (1H, s), 10.85 (1H, s), 12.27 (1H, s); m/r. ES+ [M+H]+ = 749.2.
Example 106: 4-{4-[(l-{4-[l-(4-Chloro-3-cyano-lZf-indol-7-yl)piperidin-4-yl]phenyl}piperidin-4-yl)methyl]piperazin-l- yl}-/V-(2,6-dioxopiperidin-3-yl)-2-fluorobenz amide The title compound was prepared using methodology described in example 24 using intermediate 104c and intermediate If to give the title compound (55 mg, 34 %) as a white solid. 1H NMR 5 1.22 (2H, d), 1.68 (1H, s), 1.77-1.88 (4H, m), 1.89-2.05 (3H, m), 2.07-2.17 (1H, m), 2.21 (2H, d), 2.47 (4H, d), 2.54-2.7 (4H, m), 2.77 (3H, t), 3.27-3.31 (4H, m), 3.42 (2H, d), 3.64 (2H, d), 4.74 (1H, d), 6.73-6.94 (5H, m), 7.06-7.21 (3H, m), 7.63 (1H, t), 8.04 (1H, t), 8.32 (1H, s), 10.84 (1H, s), 12.27 (1H, s); m/z; ES+ [M+H]+ = 765.3.
Example 107 Intermediate 107a: l-Benzyl-4-[(4-bromophenyl)methyl]piperazine K2CO3 (2.84 g, 20.57 mmol) was added to l-[(4-bromophenyl)methyl]piperazine (2.0 g, 6.86 mmol) and (bromomethyl)benzene (1.17 g, 6.86 mmol) in acetone (25 mL) at RT. The solution was stirred at RT for 2 h and was then diluted with EtOAc (100 mL), washed with NH4C1 solution (50 mL), NaCI solution (50 mL), dried over Na2SO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et20 to give the title compound (1.5 g, 63.3 %) as a white solid. 1H NMR 5 2.36 (8H, s), 3.43 (4H, d), 7.17-7.36 (7H, m), 7.44-7.55 (2H, m); m/z; ES+ [M+H]+ = 344.9.
Intermediate 107b: tert-Butyl 4-{4-[(4-benzylpiperazin-7-yl)methyl]phenyl}-3,6-dihydropyridine-l(2Z/)-carboxylate WO 2024/189488 PCT/IB2024/052251 215 PdC12(dtbpf) (0.264 g, 0.41 mmol) was added to K2CO3 (1.68 g, 12.16 mmol), l-benzyl-4-[(4- bromophenyl)methyl]piperazine (1.4 g, 4.05 mmol) and tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan- 2-yl)-3,6-dihydropyridine-l(2//)-carboxylate (1.37 g, 4.46 mmol) in l,4-dioxane:water (4:1, 20 mL) atRT under nitrogen. The mixture was stirred at 80 °C for l h, cooled to RT, filtered through Celite® and the solvent was evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 60% EtOAc in Et20 to give the title compound (1.5 g, 83 %) as a brown solid; m/2; ES+ [M+H]+ = 448.1. no nmr data Intermediate 1070: l-Benzyl-4-{[4-(l,2,3,6-tetrahydropyridin-4-yl)phenyl]methyl}piperazine tert-Butyl 4-{4-[(4-benzylpiperazin-l-yl)methyl]phenyl}-3,6-dihydropyridine-l(2/7)-carboxylate (1.35 g, 3.mmol) was added to DCM (10 mL) and TEA (10 mL) at RT under nitrogen. The mixture was stirred at RT for l h and then evaporated to dryness to afford crude product. The crude product was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7M NH3/MeOH to give the title compound (0.95 g, 91 %) as a pale yellow solid. 1H NMR 5 1.24 (1H, s), 2.(1H, s), 2.36 (9H, s), 2.96 (2H, t), 3.42 (6H, d), 6.17 (1H, s), 7.1-7.48 (9H, m); m/2; ES+ [M+H]+ = 348.1.
Intermediate 107d: 7-[4-{4-[(4-Benzylpiperazin-l-yl)methyl]phenyl}-3,6-dihydropyridin-l(2Zf)-yl]-4-fh1oro-lZ/-indole-3- carbonitrile The title compound was prepared using methodology described in intermediate 63d using l-benzyl-4-{[4- (l,2,3,6-tetrahydropyridin-4-yl)phenyl]methyl}piperazine and intermediate 2b to give the title compound (8mg, 65 %) as a yellow solid. 1H NMR 5 0.73-0.91 (2H, m), 2.38 (8H, s), 2.70 (2H, s), 3.29 (2H, t), 3.74 (2H, q), 6.33 (1H, d), 6.83-7.02 (2H, m), 7.19-7.37 (9H, m), 7.45 (2H, d), 8.26 (1H, s), 12.35 (1H, s); m/2; ES+ [M+H]+ = 506.0.
Intermediate 107e: 4-Fluoro-7-(4-{4-[(piperazin-l-yl)methyl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 The title compound was prepared using methodology described in intermediate 41c using 7-[4-{4-[(4- benzylpipcrazin-l-y!)methyl Ipheny 1;-3.6-dihydropyridin-l(2//)-yl|-4-nuoro-l//-indolc-3-carbonitrilc to give the title compound (250 mg, 36 %) as a yellow solid. 1H NMR 5 0.81 (2H, q), 1.79-2.08 (4H, m), 2.29 (2H, s), 2.44 (2H, s), 2.77 (2H, t), 2.86 (4H, s), 3.3-3.53 (4H, m), 6.82 (1H, dd), 6.93 (1H, dd), 7.17 (2H, q), 7.22-7.(3H, m), 8.27 (1H, s); m/z; ES+ [M+H]+ = 418.1.
Example 107: 7-[4-(4-{[4-({l-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperidin-4- yl}methyl)piperazin-l-yl]methyl}phenyl)piperidin-l-yl]-4-fh1oro-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 24 using 4-fluoro-7-(4-{4- [(piperazin-l-yl)methyl]phenyl}piperidin-l-yl)-lH-indole-3-carbonitrile and intermediate 22d to give the title compound (20 mg, 9 %) as a white solid. 1H NMR 5 1.1-1.23 (2H, m), 1.66-1.81 (3H, m), 1.81-2 (5H, m), 2.13 (2H, d), 2.36 (8H, s), 2.53-2.74 (5H, m), 2.75-2.95 (3H, m), 3.42 (2H, s), 3.85 (4H, d), 4.19 (1H, d), 4.(1H, d), 5.04 (1H, dd), 6.46 (1H, s), 6.63 (1H, s), 7.03 (2H, d), 7.24 (4H, s), 7.49 (1H, d), 7.92 (1H, s), 10.(1H, s) 1H not observed; m/r. ES+ [M+H]+ = 757.5.
Example 108 Intermediate 108a: 5-Bromo-2-[4-(dibutoxymethyl)piperidin-l-yl]pyridine WO 2024/189488 PCT/IB2024/052251 217 The title compound was prepared using methodology described in intermediate 63a using 5-bromo-2- fluoropyridine and 4-(dibutoxymethyl)piperidine to give the title compound (1.9 g, 84 %) as a colourless gum. 1H NMR 5 0.93 (6H, t), 1.37-1.43 (4H, m), 1.53-1.6 (4H, m), 1.84 (4H, t), 2.72-2.79 (3H, m), 3.39-3.47 (2H, m), 3.63 (2H, dt), 4.17 (1H, d), 4.26 (2H, d), 6.63 (1H, d), 7.35 (1H, dd), 8.05 (1H, d); m/r. ES+ [M+H]+ = 399.1.
Intermediate 108b: Benzyl 6-[4-(dibutoxymethyl)piperidin-l-yl]-3',6'-dihydro[3,4'-bipyridine]-r(2'Zf)-carboxylate The title compound was prepared using methodology described in intermediate 63b using 5-bromo-2-[4- (dibutoxymethyl)piperidin-l-yl]pyridine and benzyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6- dihydropyridine-l(277)-carboxy late to give the title compound (1.7 g, 75 %) as a brown solid. 1H NMR 5 0.(6H, t), 1.31-1.46 (7H, m), 1.53-1.62 (4H, m), 1.82-1.94 (3H, m), 2.50 (2H, s), 2.83 (2H, t), 3.45 (2H, dt), 3.64 (2H, dt), 3.72 (2H, dd), 4.15-4.19 (2H, m), 4.34 (2H, d), 5.19 (2H, s), 5.92 (1H, d), 6.65 (1H, d), 7.3-7.(5H, m), 7.51 (1H, dd), 8.11-8.29 (1H, m); m/2; ES+ [M+H]+ = 536.1.
Intermediate 1080: 2-[4-(Dibutoxymethyl)piperidin-l-yl]-5-(piperidin-4-yl)pyridine The title compound was prepared using methodology described in intermediate 63c using benzyl 6-[4- (dibutoxymethyl)piperidin-l-yl]-3',6'-dihydro[3,4'-bipyridine]-T(2'//)-carboxylate to give the title compound (1.0 g, 83 %) as a yellow gum. 1H NMR 5 (CDCh) 5 0.93 (6H, t), 1.23-1.48 (7H, m), 1.5-1.71 (6H, m), 1.74- 1.9 (5H, m), 2.45-2.57 (1H, m), 2.69-2.81 (4H, m), 3.23 (2H, s), 3.44 (2H, dt), 3.63 (2H, dt), 4.17 (1H, d), 4.26 (2H, d), 6.63 (1H, d), 7.35 (1H, dd), 8.05 (1H, d); m/2׳ . ES+ [M+H]+ = 404.2.
Intermediate 108d: WO 2024/189488 PCT/IB2024/052251 218 4-Chloro-7-(4-{6-[4-(dibutoxymethyl)piperidin-l-yl]pyridin-3-yl}piperidin-l-yl)-lZ/-indole-3- carbonitrile The title compound was prepared using methodology described in intermediate 63d using 2-[4- (dibutoxymethyl)piperidin-l-yl]-5-(piperidin-4-yl)pyridine and intermediate lb to give the title compound (0.g, 51 %) as a yellow solid. 1H NMR 5 (CDCh) 5 0.94 (6H, t), 1.32-1.46 (6H, m), 1.53-1.63 (4H, m), 1.8-2.(7H, m), 2.55-2.69 (1H, m), 2.74-2.83 (2H, m), 2.83-2.95 (2H, m), 3.34-3.53 (4H, m), 3.55-3.7 (2H, m), 4.18 (1H, d), 4.28 (2H, d), 6.67 (1H, d), 6.90 (1H, d), 7.17 (1H, d), 7.34-7.44 (1H, m), 7.78 (1H, d), 8.11 (1H, d), 9.59 (1H, s); m/z; ES+ [M+H]+ = 578.3.
Example 108: 4-Chloro-7-(4-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}methyl)piperidin- l-yl]pyridin-3-yl}piperidin-l-yl)-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 23 using 4-chloro-7-(4-{6-[4- (dibuloxymcthyl)pipcridin-l-yl|pyridin-3-yl;pipcridin-l-yl)-l//-indolc-3-carbonilrilc and intermediate 5f to give the title compound (92 mg, 48 %) as a white solid. 1HNMRS 1.11 (2H, d), 1.68-1.88 (5H, m), 1.88-2.(6H, m), 2.1-2.33 (4H, m), 2.53-2.63 (1H, m), 2.66-2.87 (6H, m), 3.00 (2H, d), 3.43 (2H, d), 3.78 (2H, t), 4.13—1.48 (3H, m), 6.42 (1H, d), 6.82 (2H, dd), 6.96 (1H, d), 7.14 (2H, t), 7.38-7.61 (3H, m), 8.04 (1H, d), 8.31 (1H, s), 10.33 (1H, s), 12.31 (1H, s); m/z; ES+ [M+H]+ = 744.8.
Example 109: 4-Chloro-7-(4-{6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]pyridin-3-yl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 219 The title compound was prepared using methodology described in example 24 using intermediate 108d and intermediate li to give the title compound (74 mg, 28 %) as a white solid. 1H NMR 5 1.10 (2H, d), 1.80 (5H, t), 1.85-2.02 (3H, m), 2.20 (2H, d), 2.36 (2H, dd), 2.58 (4H, d), 2.64-2.82 (4H, m), 2.90 (1H, t), 3.29 (5H, s), 3.51 (2H, d), 4.06-4.4 (4H, m), 5.05 (1H, dd), 6.69-6.9 (2H, m), 7.08 (3H, q), 7.43 (1H, d), 7.52 (1H, d), 8.(1H, s), 8.25 (1H, s), 10.95 (1H, s), 12.31 (1H, s); m/r. ES+ [M+H]+ = 760.4.
Example 110: 4-Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- Intermediate 86c (130 mg, 0.30 mmol) and intermediate li (129 mg, 0.30 mmol) was stirred in formic acid (1.0 mL) at 40 °C for 1 h. The mixture was evaporated to dryness and the residue was diluted with DMF (mL). Titanium isopropoxide (85 mg, 0.30 mmol) and sodium triacetoxyborohydride (764 mg, 3.60 mmol) was added and stirred at RT for 16 h. Purification of the reaction mixture by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (8.9 mg, 4 %) as a pale yellow solid. 1H NMR 5 0.73- 0.9 (2H, m), 1.22 (3H, s), 1.53 (2H, d), 1.82 (3H, s), 1.87 (4H, s), 2.57 (1H, d), 2.65 (5H, s), 2.72 (2H, t), 2.(OH, d), 3.26 (4H, s), 3.53-3.8 (4H, m), 4.13-4.39 (2H, m), 4.98 (1H, dd), 6.58 (1H, d), 6.89 (3H, dd), 7.(2H, d), 7.10 (2H, d), 7.48 (1H, d), 7.98 (1H, s), 10.76 (1H, s); m/2׳ . ES+ [M+H]+ = 745.3.
Example ill: 4-Chloro-7-[4-(4-{4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl][l,4'-bipiperidin]-r- yl}phenyl)piperidin-l-yl]-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 110 using intermediate 86c and intermediate 5f to give the title compound in the form of a formate salt (17 mg, 5 %) as a white solid. 1H NMR 0.84 (1H, s), 1.24 (1H, s), 1.85 (3H, d), 1.91-2.04 (2H, m), 2.07 (1H, s), 2.19 (3H, s), 2.51 (5H, s), 2.67-2.(5H, m), 3.43 (3H, d), 3.67 (2H, s), 3.74-3.89 (4H, m), 4.79 (1H, s), 6.45-6.54 (1H, m), 6.87 (1H, d), 6.99 yl}piperidin-l-yl)phenyl]piperidin-l-yl}-lZf-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 (3H, dd), 7.14-7.24 (4H, m), 7.42 (1H, s), 7.58 (1H, d), 8.33 (1H, d), 10.34 (1H, s), 12.27 (1H, s); m/z; ES+ [M+H]+= 729.3.
Example 112 Intermediate 112a: 4-Chloro-7-(4-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl)-l-methyl-lZ/-indole-3- carbonitrile The title compound was prepared using methodology described in intermediate 57b using intermediate 143b and 7-Bromo-4-chloro-l-methyl-lH-indole-3-carbonitrile to give the title compound (90 mg, 41 %) as a white solid. 1H NMR (CDC13) 5 0.96 (7H, t), 1.28 (1H, d), 1.34-1.52 (4H, m), 1.5-1.85 (5H, m), 1.96 (6H, dt), 2.58- 2.75 (3H, m), 2.91 (2H, td), 3.27 (2H, d), 3.47 (2H, dt), 3.67 (4H, dq), 4.25 (4H, d), 6.99 (3H, dd), 7.18 (3H, t), 7.54 (1H, s); m/z: ES+ [M+H]+ = 591.5.
Example 112: H The title compound was prepared using methodology described in example 24 using 4-chloro-7-(4-{4-[4- (dibutoxymethyl)piperidin- 1-y!]phenyl}piperidin-1 -yl)-1 -methyl-1 //-i ndolc-3 -carbonitrile and intermediate 7c to give the title compound (55 mg, 35 %) as a white solid. 1H NMR 5 1.23 (3H, d), 1.69 (1H, s), 1.77-1.(8H, m), 2.19-2.38 (3H, m), 2.62 (4H, t), 2.79-2.93 (3H, m), 3.21 (2H, d), 3.31 (5H, s), 3.63 (2H, d), 3.(3H, s), 4.11 (1H, d), 4.21 (4H, s), 4.27 (1H, s), 4.97 (1H, dd), 6.49 (1H, s), 6.61 (1H, s), 6.89 (2H, d), 7.07- 7.19 (3H, m), 7.22 (1H, d), 8.30 (1H, s), 10.92 (1H, s); m/z: ES+ [M+H]+ = 803.3.
Example 113 4-chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-lH-isoindol-5- yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-l-methyl-lH-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 221 Intermediate 113a: Benzyl 4-(3-bromophenyl)piperidine-l-carboxylate Benzyl carbonochloridate (1.13 mL, 7.95 mmol) was added to 4-(3-bromophenyl)piperidine, HC1 (2.0 g, 7.mmol) andNa2CO3 (2.29 g, 21.69 mmol) inwater:THF (1:1, 40 mL) and was stirred atRT for 16 h. The solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 40% EtOAc in Et20 to give the title compound (1.5 g, 55.4 %) as a colourless oil. 1H NMR (CDCh) 5 1.65 (3H, tt), 1.86 (2H, d), 2.67 (1H, tt), 2.90 (2H, t), 4.36 (2H, d), 5.(2H, s), 7.1-7.24 (2H, m), 7.37 (2H, dt), 7.38-7.43 (4H, m); m/z; ES+ [M+H]+ = 373.7.
Intermediate 113b: Benzyl 4-{3-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidine-l-carboxylate The title compound was prepared using methodology described in intermediate l la using benzyl 4-(3- bromophenyl)piperidine-l-carboxylate and 4-(dibutoxymethyl)piperidine to give the title compound (1.1 g, %) as a yellow oil. 1H NMR (CDCh) 5 0.95 (6H, t), 1.23-1.33 (1H, m), 1.33-1.53 (5H, m), 1.55-1.72 (6H, m), 1.87 (5H, t), 2.54-2.76 (3H, m), 2.89 (2H, s), 3.47 (2H, dt), 3.55-3.82 (4H, m), 4.22 (1H, d), 4.35 (2H, s), 5.18 (2H, s), 6.63-6.85 (2H, m), 7.16-7.25 (1H, m), 7.31-7.43 (6H, m); m/z; ES+ [M+H]+ = 537.2.
Intermediate 1130: The title compound was prepared using methodology described in intermediate 1 lb using benzyl 4-{3-[4- (dibutoxymethyl)piperidin-l-yl]phenyl}piperidine-l-carboxylate to give the title compound (0.5 g, 66 %) as a colourless gum. 1H NMR (CDCh) 5 0.95 (6H, t), 1.35-1.54 (6H, m), 1.54-1.63 (4H, m), 1.69-1.85 (1H, m), 1.90 (2H, d), 2.07 (4H, d), 2.64-2.76 (3H, m), 3.02 (2H, s), 3.41-3.61 (4H, m), 3.61-3.75 (4H, m), 4.21 (1H, d), 6.72 (1H, d), 6.79-6.88 (2H, m), 7.22 (1H, t); m/z; ES+ [M+Na]+ = 403.1. 4-(Dibutoxymethyl)-l-[3-(piperidin-4-yl)phenyl]piperidine WO 2024/189488 PCT/IB2024/052251 222 Intermediate 113d: 4-Chloro-7-(4-{3-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile LHMDS (IM in THF, 3.48 mL, 3.48 mmol) was added to 4-(dibutoxymethyl)-l-[3-(piperidin-4- yl)phenyl]piperidine (400 mg, 0.99 mmol), intermediate lb (254 mg, 0.99 mmol) and Pd-PEPPSI-IHeptcl (mg, 0.10 mmol) in 1,4-dioxane (4 mL) under nitrogen. The mixture was stirred at 80 °C for 2 h, cooled to RT And quenched with NH4C1 solution (10 mL), extracted with EtOAc (30 mL), dried over Na2SO4, filtered and evaporated to afford crude product. The crude product was purified by flash C18-flash chromatography, elution gradient 0 to 100% MeOH in water (0.1% formic acid) to give the title compound (120 mg, 20.93 %) as a yellow gum. 1H NMR (CDC13) 5 0.96 (6H, t), 1.25-1.32 (3H, m), 1.41 (5H, dt), 1.55-1.68 (6H, m), 1.(2H, s), 1.94 (2H, s), 2.77 (3H, d), 2.96 (2H, s), 3.39-3.53 (4H, m), 3.6-3.81 (4H, m), 4.25 (1H, d), 6.95 (3H, d), 7.20 (1H, d), 7.32 (1H, s), 7.80 (1H, s) 1H not observed; m/r. ES+ [M+H]+ = 577.1.
Example 113: 4-Chloro-7-(4-{3-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- The title compound was prepared using methodology described in example 24 using 4-chloro-7-(4-{3-[4-({4- [2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/Aisoindol-5-yl]piperazin-l-yl}methyl)piperidin-l- ylIphcnyljpipcridin-l-yl)-l//-indolc-3-carbonitrilc and intermediate li to give the title compound (42 mg, %) as a white solid. 1H NMR 5 1.23 (3H, d), 1.71 (1H, s), 1.83 (4H, t), 1.97 (3H, t), 2.23 (2H, d), 2.37 (1H, d), 2.54-2.8 (8H, m), 2.85-2.97 (1H, m), 3.29 (4H, s), 3.61 (2H, s), 3.69 (3H, d), 4.21 (1H, d), 4.33 (1H, d), 5.05 (1H, dd), 6.66-6.83 (3H, m), 6.85 (1H, s), 6.97-7.13 (3H, m), 7.16 (1H, d), 7.52 (1H, d), 8.19 (1H, s), 10.95 (1H, s),12.28 (1H, s); m/z; ES+ [M+H]+ = 759.9.
Example 114 Intermediate 114a: 3-Bromo-2-(prop-l-yn-l-yl)aniline yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-n/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 223 PdC12(PPh3)2 (4.72 g, 6.73 mmol) was added to a degassed mixture of 3-bromo-2-iodoaniline (20.05 g, 67.mmol), but-2-ynoic acid (16.97 g, 201.90 mmol) and 2,3,4,6,7,8,9,10-octahydropyrimido[l,2-a]azepine (27.mL, 201.90 mmol) in DMSO (200 mL). The reaction was stirred at 80 °C for 3 h. The reaction was cooled to RT and diluted with water (500 mL). The product was extracted with DCM (1 L), washed with NaO solution (500 mL), dried over Na2S04, filtered and evaporated to give crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in heptane to give the title compound (6.g, 47.5 %) as a pale brown gum. 1H NMR (CDCh) 5 4.30 (2H, s), 6.61 (1H, dd), 6.86 - 6.94 (2H, m). no mass spec Intermediate 114b: tert-Butyl 4-[3-bromo-2-(prop-l-yn-l-yl)anilino]piperidine-l-carboxylate Sodium triacetoxyborohydride (13.56 g, 63.98 mmol) was added to a solution of 3 -bromo-2-(prop-l-yn-l- yl)aniline (6.72 g, 31.99 mmol) and tert-butyl 4-oxopiperidine-1-carboxylate (9.56 g, 47.98 mmol) in DCM (100 mL). AcOH (3.66 mL, 63.98 mmol) was added and the solution was stirred at 40 °C for 20 h. The reaction mixture was diluted with DCM (250 mL) and NaOH (2M, 250 mL) and the organic layer was evaporated to give the crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in heptane to give the title compound (7.09 g, 56.4 %) as an oil which crystallised on standing. 1H NMR (CDCh) 5 1.47 (9H, s), 1.95 - 2.07 (2H, m), 2.19 (4H, s), 2.98 (2H, t), 3.37 - 3.55 (1H, m), 3.99 (2H, s), 4.65 (1H, d), 6.51 (1H, d), 6.85 (1H, dd), 6.96 (1H, t) 1H not observed; m/r. ES+ [M-Boc]+ = 339.0.
Intermediate 1140: tert-Butyl 4-(4-bromo-2-methyl-lZf-indol-l-yl)piperidine-l-carboxylate Sodium tetrachloroaurate(III) dihydrate (0.359 g, 0.90 mmol) was added to a solution of tert-butyl 4-[3- bromo-2-(prop-l-yn-l-yl)anilino]piperidine-l-carboxylate (7.09 g, 18.03 mmol) inEtOH (100 mL) and was stirred at 60 °C for 30 min. The solvent was evaporated and the residue was partitioned between water (2mL) and DCM (250 mL). The organic layer was evaporated to afford crude product. The crude product was WO 2024/189488 PCT/IB2024/052251 224 purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in heptane to give the title compound (3.8 g, 54 %) as a white solid. 1H NMR (CDC13) 5 1.54 (9H, s), 1.83 (2H, d), 2.31 - 2.55 (5H, m), 2.86 (2H, t), 4.19 - 4.49 (3H, m), 6.31 (1H, d), 6.9 - 6.98 (1H, m), 7.22 (1H, dd), 7.35 (1H, t); m/z; ES+ [M+H]+= 395.0.
Intermediate 114d: tert-Butyl 4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-2-methyl-lZ/-indol-l-yl]piperidine-l-carboxylate A suspension of tert-butyl 4-(4-bromo-2-methyl-lrt-indol-1-y !)piperidine-1-carboxy late (1.18 g, 3.01 mmol), dihydropyrimidine-2,4(lH,3H)-dione (0.68 g, 6.03 mmol), tert-butylBrettPhos (0.073 g, 0.15 mmol) and C52CO3 (1.96 g, 6.03 mmol) was degassed with nitrogen. [Pd(cinnamyl)Cl]2 (0.039 g, 0.08 mmol) was then added and the reaction stirred at 90 °C for 6 h. The reaction mixture was cooled to RT and partitioned between EtOAc (20 mL) and water (20 mL). The aqueous phase was back extracted with EtOAc (10 mL) and the combined organics were washed with NaCI solution (15 mL), dried and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane to give the title compound (0.409 g, 31.8 %) as a brown solid. 1H NMR 5 1.46 (9H, s), 1.80 (2H, d), 2.12 - 2.31 (2H, m), 2.44 (3H, s), 2.74 (2H, t), 2.96 (2H, s), 3.73 (2H, t), 4.05 - 4.26 (2H, m), 4.49 (1H, s), 6.16 (1H, s), 6.89 (1H, d), 6.98 - 7.09 (1H, m), 7.40 (1H, d), 10.29 (1H, s); m/z; ES+ [M+H]+ = 427.3.
Intermediate 114e: l-[2-Methyl-l-(piperidin-4-yl)-lZf-indol-4-yl]-l,3-diazinane-2,4-dione tosylate To a suspension of tert-butyl 4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-2-methyl-1 //-indol-l-yl |pipcridinc-l - carboxylate (1.70 g, 3.99 mmol) inMeCN (25 mL) was added 4-methylbenzenesulfonic acid hydrate (0.910 g, 4.78 mmol) and was stirred at 70 °C for 2 h. The reaction was cooled to RT, MTBE (25.00 ml) was added and the suspension was filtered and dried to give the title compound (1.86 g, 94 %) as a grey solid (TsOH salt). 1H NMR 5 1.95 (2H, d), 2.29 (3H, s), 2.45 (3H, s), 2.57 - 2.72 (2H, m), 2.74 (2H, t), 3.15 (2H, q), 3.49 (2H, d), 3.73 (2H, t), 4.61 (1H, t), 6.18 (1H, s), 6.93 (1H, d), 7.02 - 7.19 (3H, m), 7.43 - 7.53 (2H, m), 7.64 (1H, d), 8.24 - 8.65 (2H, m), 10.30 (1H, s); m/z; ES+ [M+H]+ = 327.4.
CL N.
WO 2024/189488 PCT/IB2024/052251 225 Example 114: 4-Chloro-7-[(3S)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-2-methyl-lZ/-indol-l-yl]piperidin-l- Intermediate 11c (100 mg, 0.18 mmol) was stirred in formic acid (2 mL) at 60 °C for 2 h. The solvent was evaporated and diluted with NMP (2 mL). I -|2-Mcthyl-I -(pipcridin-4-yl)-l //-indol-4-yl |-l.3-diazinanc-2.4- dione (69.8 mg, 0.21 mmol) was added and stirred at RT for 16 h. The reaction was purified by flash C18- flash chromatography, elution gradient 0 to 60% MeCN in water (0.1% formic acid). The product was basified with NaHCO3 solution, the MeCN was evaporated with the resulting solid collected by filtration and dried under vacuum to give the title compound (47.5 mg, 35.2 %) as a white solid. 1H NMR 5 0.83 (1H, s), 1.21- 1.26 (3H, m), 1.59-1.71 (2H, m), 1.73-1.98 (7H, m), 2.14 (2H, t), 2.24 (2H, d), 2.44 (4H, s), 2.57-2.71 (4H, m), 2.74 (2H, t), 3.02 (3H, d), 3.33-3.4 (1H, m), 3.64 (2H, d), 3.74 (2H, t), 4.24 (1H, t), 6.16 (1H, s), 6.8-6.(4H, m), 7.05 (1H, t), 7.1-7.2 (3H, m), 7.47 (1H, d), 8.31 (1H, s), 10.30 (1H, s), 12.28 (1H, s); m/z; ES+ [M+H]+ = 757.4.
Example 115 Intermediate 115a: tert-Butyl 6'-fluoro-5,6-dihydro[3,3'-bipyridine]-l(4Z/)-carboxylate The title compound was prepared using methodology described in intermediate 107b using tert-butyl 4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-l(27/)-carboxylate and 5-bromo-2- fluoropyridine to give the title compound (1.1 g, 87 %) as a yellow solid. 1H NMR (CDCL) 5 1.51 (9H, s), 2.34 (2H, q), 3.57 (2H, t), 4.24 (2H, q), 6.21 (1H, tt), 6.92 (1H, dd), 7.7-7.87 (1H, m), 8.16-8.31 (1H, m); m/z; ES+[M+H]+ = 279.1.
Intermediate 115b: yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-n/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 226 6'-Fluoro-l,4,5,6-tetrahydro-3,3'-bipyridine ter/-Butyl 6'-fluoro-5,6-dihydro[3,3'-bipyridine]-l(47/)-carboxylate (1.1 g, 3.95 mmol) was added to HC1 (4M in 1,4-dioxane, 19.76 ml, 79.04 mmol) under nitrogen and was stirred at RT for 16 h. The reaction mixture was filtered through Celite® and the solvent was evaporated to give the title compound in the form of an HCI salt (1.0 g, 118 %) as a white solid and was used without further purification. 1H NMR 5 2.48 (2H, d), 3.(2H, dt), 3.97 (2H, s), 6.34-6.56 (1H, m), 7.21 (1H, dd), 8.10 (1H, td), 8.32 (1H, d), 9.89 (1H, s); m/r. ES+ [M+H]+ = 178.8.
Intermediate 1150: Benzyl 6'-fh1oro-5,6-dihydro[3,3'-bipyridine]-l(4Z/)-carboxylate The title compound was prepared using methodology described in intermediate 32a using 6'-fluoro-l,4,5,6- tetrahydro-3,3'-bipyridine and benzyl carbonochloridate to give the title compound (1.0 g, 86 %) as a yellow gum. 1H NMR (CDC13) 5 2.37 (2H, s), 3.67 (2H, t), 4.33 (2H, s), 5.21 (2H, s), 6.15-6.27 (1H, m), 6.93 (1H, dd), 7.3-7.43 (5H, m), 7.77 (1H, s), 8.23 (1H, s); m/z; ES+ [M+H]+ = 313.1.
Intermediate 115d: Benzyl 6'-[4-(dibutoxymethyl)piperidin-l-yl]-5,6-dihydro[3,3'-bipyridine]-l(4Z/)-carboxylate DIPEA (1.51 mL, 8.64 mmol) was added to benzyl 6'-fluoro-5,6-dihydro[3,3'-bipyridine]-l(47/)-carboxylate (0.9 g, 2.88 mmol) and 4-(dibutoxymethy!)piperidine (0.84 g, 3.46 mmol) in NMP (10 mL) under nitrogen. The mixture was stirred at 110 °C for 16 h. The reaction was cooled to RT and diluted with EtOAc (50 mL), washed with water (25 mL), NaQ solution (25 mL), dried over Na2SO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et20 to give the title compound (0.7 g, 45.3 %) as a colourless gum. 1H NMR (CDCI)) 5 0.94 (6H, t), 1.33-1.46 (6H, m), 1.53-1.63 (4H, m), 1.89 (3H, d), 2.33 (2H, s), 2.86 (2H, s), 3.45 (2H, dt), 3.59-3.(4H, m), 4.18 (1H, d), 4.33 (4H, d), 5.20 (2H, s), 6.09 (1H, s), 6.67 (1H, d), 7.3-7.44 (5H, m), 7.51 (1H, s), 8.20 (1H, d); m/z; ES+ [M+H]+ = 536.2.
WO 2024/189488 PCT/IB2024/052251 227 Intermediate 115e: 2-[4-(Dibutoxymethyl)piperidin-l-yl]-5-(piperidin-3-yl)pyridine The title compound was prepared using methodology described in intermediate 63c using benzyl 6'-[4- (dibutoxymethyl)piperidin-l-yl]-5,6-dihydro[3,3'-bipyridine]-l(47/)-carboxylate to give the title compound (0.4 g, 82 %) as a colourless gum. 1H NMR (CDC13) 5 0.94 (6H, t), 1.25-1.48 (7H, m), 1.53-1.62 (5H, m), 1.67-1.83 (2H, m), 1.84-1.9 (3H, m), 1.96 (2H, d), 2.54-2.71 (2H, m), 2.76 (2H, td), 2.85-3.05 (1H, m), 3.(1H, t), 3.45 (2H, dt), 3.63 (2H, dt), 4.17 (1H, d), 4.27 (2H, d), 6.62 (1H, dd), 7.3-7.39 (1H, m), 8.07 (1H, dd); m/z; ES+ [M+H]+ = 404.2.
Intermediates 115f and 116a The title compounds were prepared using methodology described in intermediate He using 2-[4- (dibutoxymethy!)piperidin-l-yl]-5-(piperidin-3-y!)pyridine and intermediate lb to give a racemic mixture. The enantiomers were separated by preparative chiral-HPLC on a Column: CHIRALPAK IE-3, 4.6*50mm 3um; Mobile Phase A: Hex:DCM, 3:l)(0.1%DEA), Mobile Phase B: EtOH; Flow rate: 1 mL/min; Gradient: 30 - % B in 10.5 mins to give, in order of elution, intermediate 115f(isomer 1, 45 mg, 9 %, >99% ee) and intermediate 116a(isomer 2, 45 mg, 9 %, >99% ee) as white solids.
Intermediate 115f: 4-Chloro-7-[(3،4]-6}-3-(* ؟-(dibutoxymethyl)piperidin-l-yl]pyridin-3-yl}piperidin-l-yl]-lZf-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] m/r. ES+ [M+H]+ = 578.3 WO 2024/189488 PCT/IB2024/052251 228 Intermediate 116a: 4-Chloro-7-[(37?*)-3-{6-[4-(dibutoxymethyl)piperidin-l-yl]pyridin-3-yl}piperidin-l-yl]-lZ/-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR (CDC13) 5 1.39 (7H, dq), 1.58 (7H, d), 2.02 (6H, d), 3.14 (4H, d), 3.34-3.55 (4H, m), 3.58-3.69 (2H, m), 3.75 (5H, d), 4.20 (1H, d), 4.35 (2H, s), 6.87 (2H, d), 7.14 (1H, d), 7.73 (1H, s), 7.91 (1H, s) 1H not observed ; m/r. ES+ [M+H]+ = 578.2 Example 115: 4-Chloro-7-[(3S'*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]pyridin-3-yl}piperidin-l-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 23 using intermediate 115f and intermediate 5f to give the title compound in the form of a formate salt (10 mg, 22 %) as a white solid. 1H NMR 5 0.99-1.16 (2H, m), 1.51-1.63 (1H, m), 1.7-1.83 (3H, m), 1.84-2.1 (7H, m), 2.1-2.27 (4H, m), 2.59- 2.82 (6H, m), 2.99 (3H, d), 3.35-3.44 (2H, m), 3.78 (2H, t), 4.23 (2H, d), 4.3-4.42 (1H, m), 6.41 (1H, d), 6.(2H, dd), 6.96 (1H, d), 7.05-7.23 (2H, m), 7.43-7.59 (3H, m), 8.08 (1H, s), 8.28 (1H, s), 10.32 (1H, s), 12.(1H, s); m/z; ES+ [M+H]+ = 744.8.
Example 116: 4-Chloro-7-[(37?*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]pyridin-3-yl}piperidin-l-yl]-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 229 [absolute stereochemistry not yet confirmed] Isomer 2 The title compound was prepared using methodology described in example 23 using intermediate 116a and intermediate 5f to give the title compound in the form of a formate salt (10 mg, 22 %) as a white solid. 1H NMR 5 1.01-1.17 (2H, m), 1.56 (1H, s), 1.67-2.1 (10H, m), 2.1-2.35 (4H, m), 2.56-2.69 (2H, m), 2.69-2.(4H, m), 2.86-3.07 (3H, m), 3.78 (4H, t), 4.24 (2H, d), 4.38 (1H, d), 6.41 (1H, d), 6.56 (1H, s), 6.76 (1H, d), 6.93 (2H, dd), 7.14 (1H, t), 7.4-7.6 (3H, m), 7.97-8.13 (2H, m), 10.32 (1H, s) 1H not observed; m/z; ES+ [M+H]+= 744.3.
Example 117 Intermediate 117a: Benzyl 2-(4-bromophenyl)morpholine-4-carboxylate The title compound was prepared using methodology described in intermediate 32a using 2-(4- bromopheny!)morpholine and benzyl carbonochloridate to give the title compound (5.0 g, 73 %) as a white solid. 1H NMR (CDC13) 5 1.86 (2H, d), 2.67 (1H, tt), 2.90 (2H, t), 4.36 (2H, d), 5.18 (2H, s), 7.1-7.25 (2H, m), 7.32-7.44 (7H, m); m/z; ES+ [M+H]+ = 376.1.
Intermediate 117b: Benzyl 2-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}morpholine-4-carboxylate The title compound was prepared using methodology described in intermediate l la using benzyl 2-(4- bromophenyl)morpholine-4-carboxylate and 4-(dibutoxymethy!)piperidine to give the title compound (1.8 g, %) as a yellow oil. 1H NMR (CDC13) 5 0.95 (6H, t), 1.36-1.52 (5H, m), 1.53-1.73 (6H, m), 1.87 (5H, t), WO 2024/189488 PCT/IB2024/052251 230 2.56-2.77 (3H, m), 2.89 (2H, s), 3.47 (2H, dt), 3.59-3.79 (3H, m), 4.16-4.49 (3H, m), 5.18 (2H, s), 6.61-6.(2H, m), 7.12-7.25 (1H, m), 7.29-7.51 (6H, m); m/2; ES+ [M+H]+ = 539.1.
Intermediate 117c: 2-{4-[4-(Dibutoxymethyl)piperidin-l-yl]phenyl}morpholine The title compound was prepared using methodology described in intermediate 63c using benzyl 2-{4-[4- (dibutoxymethyl)piperidin-l-yl]phenyl}morpholine-4-carboxylate to give the title compound (1.2 g, 89 %) as a yellow oil. 1H NMR (CDCh) 5 0.94 (6H, td), 1.36-1.48 (5H, m), 1.53-1.64 (4H, m), 1.67-1.92 (3H, m), 2.66 (2H, tt), 2.75-3.16 (4H, m), 3.37-3.53 (4H, m), 3.55-3.87 (5H, m), 3.92-4.05 (1H, m), 4.19 (1H, dd), 4.42 (1H, dt), 6.92 (2H, dd), 7.24 (2H, dd); m/2; ES+ [M+H]+ = 405.2.
Intermediate 117d and 118a The title compounds were prepared using methodology described in intermediate 11c using 2-{4-[4- (dibutoxymethyl)piperidin-l-yl]phenyl}morpholine and intermediate lb to give a racemic mixture. The enantiomers were separated by preparative chiral-HPLC on a Column: CHIRALPAK IA-3, 4.6*50mm, 3um; Flow rate: 1 mL/min; Gradient: 0%B; Mobile Phase A: Hex:DCM (3:1, 0.1%DEA), Mobile Phase B: MeCN; to give intermediate 117d(isomer 1, 120 mg, 14 %, >99 % ee) and intermediate 118a(isomer 2, 140 mg, %, >99 % ee) as white solids.
Intermediate 117d: 4-Chloro-7-[(2S'*)-2-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}morpholin-4-yl]-lZ/-indole-3- carbonitrile Isomer 1 1H NMR 5 (CDCh) 5 0.95 (6H, t), 1.16-1.31 (2H, m), 1.41 (4H, h), 1.58 (6H, q), 2.88 (3H, s), 3.15 (2H, s), 3.33 (1H, s), 3.4-3.57 (2H, m), 3.57-3.85 (5H, m), 4.08 (1H, t), 4.21 (2H, d), 4.82 (1H, s), 6.89 (2H, d), 7.(2H, d), 7.40 (2H, s), 7.78 (1H, s) 1H not observed; m/2׳ . ES+ [M+H]+ = 579.0.
Intermediate 118a: 4-Chloro-7-[(27?*)-2-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}morpholin-4-yl]-lZ/-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 231 [absolute stereochemistry not yet confirmed] Isomer 2 1H NMR (CDC13) 5 0.95 (6H, t), 1.2-1.49 (8H, m), 1.59 (7H, t), 2.89 (4H, s), 3.15 (2H, s), 3.46 (3H, q), 3.(4H, dd), 4.08 (1H, s), 4.21 (2H, d), 6.89 (2H, d), 7.18 (2H, d), 7.78 (1H, s) 1H not observed; m/r. ES+ [M+H] = 579.0.
Example 117: 4-Chloro-7-[(2S'*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}morpholin-4-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] Intermediate 117d (100 mg, 0.17 mmol) was stirred in formic acid (2 mL) at 40 °C for 1 h. The mixture was then cooled to RT and evaporated to dryness. The residue was added to intermediate 5f (84 mg, 0.17 mmol) and sodium acetate (170 mg, 0.21 mmol) in NMP (1 mL) which was stirred at 40 °C for 2 h. The reaction mixture was purified by flash C18-flash chromatography, elution gradient 0 to 60% MeCN in water (0.1% formic acid). The fractions containing product were combined and adjusted to pH 8 NaHCO3 solution. The solid was filtered and dried in a vacuum oven to give the title compound (20 mg, 15 %) as a white solid. 1H NMR 5 1.22 (3H, d), 1.68 (1H, s), 1.82 (2H, d), 1.88-2.09 (4H, m), 2.1-2.32 (4H, m), 2.57-2.7 (3H, m), 2.(2H, t), 2.88 (1H, t), 2.99 (2H, d), 3.26 (1H, s), 3.68 (2H, d), 3.78 (2H, t), 3.9-4.16 (2H, m), 4.37 (1H, s), 4.(1H, d), 6.41 (1H, d), 6.82 (1H, d), 6.93 (3H, dd), 7.14 (2H, t), 7.27 (2H, d), 7.43-7.57 (2H, m), 8.34 (1H, s), 10.32 (1H, s), 12.45 (1H, s); m/z; ES+ [M+H]+ = 745.3.
Example 118: 4-Chloro-7-[(27?*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}morpholin-4-yl]-n/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] Isomer 1 WO 2024/189488 PCT/IB2024/052251 232 The title compound was prepared using methodology described in example 117 using intermediate 118a to give the title compound (20 mg, 15 %) as a white solid. 1H NMR 5 1.22 (2H, q), 1.68 (1H, s), 1.77-1.88 (2H, m), 1.89-2.06 (4H, m), 2.16 (2H, t), 2.22-2.3 (2H, m), 2.58-2.71 (3H, m), 2.76 (2H, t), 2.84 (1H, t), 2.99 (2H, d), 3.53 (1H, s), 3.68 (3H, d), 3.78 (2H, t), 3.93 (1H, t), 4-4.09 (1H, m), 4.29-4.46 (1H, m), 4.6-4.73 (1H, m), 6.41 (1H, d), 6.63 (1H, d), 6.87-7.02 (4H, m), 7.13 (1H, q), 7.25 (2H, d), 7.45-7.6 (2H, m), 8.14 (1H, d), 10.32 (1H, s) 1H not observed; m/z; ES+ [M+H]+ = 745.3.
Intermediate 119a and 120a The title compounds were prepared using methodology described in intermediate He using intermediate 117c and intermediate 9c to give a racemic mixture. The enantiomers were separated by preparative chiral-HPLC on a Column: CHIRAL ART Cellulose-SB, 2*25 cm, 5 pm; Flow rate: 20 mL/min; Gradient: 20% B; Mobile Phase A: Hex (0.5% 2M NH3-MeOH), Mobile Phase B: EtOH; to give, in order of eluition, intermediate 119a(isomer 1, 110 mg, 12 %, >99 % ee) and intermediate 120a(isomer 2, 120 mg, 14 %, >99 % ee) as yellow solids. Intermediate 119a: 4-Chloro-7-[(2S'*)-2-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}morpholin-4-yl]-lZ/-indazole-3- carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR (CDC13) 5 0.94 (6H, t), 1.42 (6H, p), 1.58 (5H, t), 1.85 (4H, d), 2.70 (2H, d), 2.96 (1H, s), 3.14 (1H, d), 3.26 (1H, s), 3.45 (2H, td), 3.65 (2H, q), 3.73 (2H, d), 4.10 (1H, t), 4.23 (2H, d), 4.75 (1H, s), 6.93 (3H, s), 7.21 (1H, d), 7.28 (2H, s); m/z; ES+ [M+H]+ = 580.2.
Intermediate 120a: WO 2024/189488 PCT/IB2024/052251 233 4-Chloro-7-[(27?*)-2-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}morpholin-4-yl]-lZf-indazole-3- carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR (CDC13) 5 0.94 (6H, t), 1.35-1.49 (5H, m), 1.53-1.63 (5H, m), 1.83 (3H, d), 2.70 (2H, d), 2.96 (1H, s), 3.12 (1H, t), 3.27 (1H, d), 3.35 (1H, s), 3.46 (2H, dt), 3.64 (2H, dt), 3.73 (2H, d), 4.09 (1H, t), 4.22 (2H, d), 4.74 (1H, s), 6.91 (3H, d), 7.22 (1H, d), 7.28 (2H, s), 11.02 (1H, s); m/r. ES+ [M+H]+= 579.4.
Example 119: 4-Chloro-7-[(2S'*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}morpholin-4-yl]-lZ/-indazole-3-carbonitrile [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 117 using intermediate 119a and intermediate 5f to give the title compound (6 mg, 5 %) as a white solid. 1H NMR 5 1.16-1.32 (2H, m), 1.(1H, s), 1.83 (2H, d), 1.91-2.11 (4H, m), 2.11-2.4 (4H, m), 2.59-2.73 (3H, m), 2.76 (2H, t), 2.85-2.98 (1H, m), 3.03 (2H, d), 3.41 (1H, d), 3.49 (1H, d), 3.69 (2H, d), 3.78 (2H, t), 3.91-4.04 (1H, m), 4.08 (1H, d), 4.(1H, s), 4.6-4.84 (1H, m), 6.42 (1H, d), 6.8-7.06 (4H, m), 7.15 (1H, t), 7.28 (3H, dd), 7.45-7.62 (2H, m), 10.32 (1H, s) 1H not observed; m/z; ES+ [M+H]+ = 746.3.
Example 120: 4-Chloro-7-[(27?*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}morpholin-4-yl]-lZ/-indazole-3-carbonitrile [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 234 The title compound was prepared using methodology described in example 117 using intermediate 120a and intermediate 5f to give the title compound (49 mg, 38 %) as a white solid. 1H NMR 5 1.13-1.29 (2H, m), 1.(1H, s), 1.82 (2H, d), 1.88-2.11 (4H, m), 2.13-2.32 (4H, m), 2.56-2.72 (3H, m), 2.76 (2H, t), 2.87-2.97 (1H, m), 3.01 (2H, d), 3.52 (2H, d), 3.69 (2H, d), 3.78 (2H, t), 3.9-4.03 (1H, m), 4.08 (1H, d), 4.39 (1H, s), 4.(1H, d), 6.42 (1H, d), 6.79-7.02 (4H, m), 7.14 (1H, t), 7.26 (3H, dd), 7.45-7.62 (2H, m), 10.34 (1H, s) 1H not observed; m/r. ES+ [M+H]+ = 746.3.
Example 121 Intermediate 121a: tert-Butyl 5-(6-chloropyridazin-3-yl)-3,4-dihydropyridine-l(2Zf)-carboxylate The title compound was prepared using methodology described in intermediate 107b using tert-butyl 4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-l(27/)-carboxylate and 3-bromo-6- chloropyridazine to give the title compound (1.2 g, 62 %) as a white solid. 1H NMR 5 2.47-2.58 (4H, m), 3.(5H, s), 3.34 (2H, s), 4.09 (2H, s), 5.81 (2H, s), 7.96-8.58 (2H, m), 8.53 (1H, d); m/z; ES+ [M+H]+ = 296.2.
Intermediate 121b: 3-Chloro-6-(l,4,5,6-tetrahydropyridin-3-yl)pyridazine HThe title compound was prepared using methodology described in intermediate 75f using tert-butyl 5-(6- chloropyridazin-3-yl)-3.4-dihydropyridinc-l(2//)-carboxylatc to give the title compound (650 mg, 82 %) as a white solid. 1H NMR 5 1.36 (3H, s), 2.52 (2H, s), 3.58 (2H, s), 6.98 (1H, d), 7.93-8.04 (1H, m), 8.22 (1H, d); m/z; ES+[M+H]+= 196.0.
WO 2024/189488 PCT/IB2024/052251 235 Intermediate 121c: Benzyl 5-(6-chloropyridazin-3-yl)-3,4-dihydropyridine-l(2Z/)-carboxylate The title compound was prepared using methodology described in intermediate 32a using 3-chloro-6-(l,4,5,6- tetrahydropyridin-3-yl)pyridazine and benzyl carbonochloridate to give the title compound (610 mg, 66 %) as a white solid. 1H NMR 5 2.38 (2H, dp), 3.59 (2H, s), 4.51 (2H, s), 5.14 (2H, s), 6.95-7.02 (1H, m), 7.25-7.(5H, m), 7.88 (1H, d), 8.12 (1H, d); m/z; ES+ [M+H]+= 330.1.
Intermediate 121d: Benzyl 5-{6-[4-(dibutoxymethyl)piperidin-l-yl]pyridazin-3-yl}-3,4-dihydropyridine-l(2Z/)-carboxylate The title compound was prepared using methodology described in intermediate 63a using benzyl 5-{6-[4- (dibutoxymethy!)piperidin- l-yl]pyridazin-3 -yl}-3,4-dihydropyridine-1 (27/)-carboxylate and 4- (dibutoxymethyl)piperidine to give the title compound (690 mg, 71 %) as a yellow gum. 1H NMR 5 0.88 (6H, t), 1.17 (1H, t), 1.23 (2H, s), 1.33 (4H, dp), 1.48 (4H, dq), 1.72 (2H, d), 1.86 (1H, s), 1.99 (1H, s), 2.78-2.(2H, m), 3.38 (2H, dt), 3.55 (3H, dt), 4.03 (1H, q), 4.17 (1H, d), 4.39 (2H, d), 4.47 (2H, d), 5.13 (2H, s), 6.(1H, s), 7.25 (1H, d), 7.28-7.42 (5H, m), 7.69 (1H, d); m/z; ES+ [M+H]+ = 537.2.
Intermediate 121e: 3-[4-(Dibutoxymethyl)piperidin-l-yl]-6-(piperidin-3-yl)pyridazine WO 2024/189488 PCT/IB2024/052251 236 The title compound was prepared using methodology described in intermediate 63c using benzyl 5-{6-[4- (dibutoxy mcthyl)pipcridin-l-yl|pyridazin-3-yl]-3.4-dihydropyridinc-l(2//)-carboxy late to give the title compound (500 mg, 96 %) as a yellow gum. 1H NMR 5 1.17 (4H, t), 1.23 (2H, s), 1.34 (4H, m), 1.48 (4H, dq), 1.59-1.81 (3H, m), 1.99 (4H, s), 2.06-2.35 (OH, m), 2.53 (3H, s), 2.67 (3H, s), 2.64-2.93 (3H, m), 3.55 (1H, d), 4.03 (3H, q), 4.17 (1H, d), 4.32 (2H, d), 5.11 (OH, d), 7.20 (1H, d), 7.33 (2H, dd); m/r. ES+ [M+H]+ = 405.2.
Intermediates 121f and intermediate 122a The title compound was prepared using methodology described in intermediate He using 3-[4- (dibutoxymethyl)piperidin-l-yl]-6-(piperidin-3-yl)pyridazine and intermediate lb to give the title compound as a racemic mixture. The enantiomers were separated by preparative chiral-HPLC on a Column: CHIRALPAK IG-3, 4.6*50 mm, 3 pm; Flow rate: 1 mL/min; Mobile Phase A: Hex:DCM (3:1, 0.1% DEA), Mobile Phase B: EtOH; to give, in order of elution, intermediate 121f(isomer 1, 70 mg, 9 %, >99 % ee) and intermediate 122a(isomer 2, 70 mg, 9 %, >99 % ee) as yellow solids.
Intermediate 121f: 4-Chloro-7-[(37?*)-3-{6-[4-(dibutoxymethyl)piperidin-l-yl]pyridazin-3-yl}piperidin-l-yl]-lZ/-indole-3- carbonitrile [absolute stereochemistry not yet confirmed] 1H NMR 5 0.88 (6H, t), 1.24 (4H, s), 1.27-1.42 (3H, m), 1.49 (4H, p), 1.74 (3H, d), 1.86 (4H, s), 2.03 (1H, s), 2.83 (3H, t), 3.27 (2H, s), 3.30 (1H, s), 3.34-3.46 (1H, m), 3.56 (2H, dt), 4.18 (1H, d), 4.38 (2H, d), 6.83 (1H, d), 7.15 (1H, d), 7.29 (1H, d), 7.47 (1H, d), 8.35 (1H, d), 12.94 (1H, s); m/2׳ . ES+ [M+H]+ = 579.2.
WO 2024/189488 PCT/IB2024/052251 237 Intermediate 122a: 4-Chloro-7-[(3S'*)-3-{6-[4-(dibutoxymethyl)piperidin-l-yl]pyridazin-3-yl}piperidin-l-yl]-lZ/-indole-3- carbonitrile 1HNMR5 0.88 (6H, t), 1.19-1.32 (4H, m), 1.33 (1H, d), 1.35 (1H, s), 1.33-1.42 (1H, m), 1.42-1.56 (4H, m), 1.72 (2H, s), 1.86 (4H, s), 2.82 (1H, s), 3.16-3.69 (12H, m), 4.18 (1H, d), 6.82 (1H, d), 7.13 (1H, d), 7.28 (1H, d), 7.47 (1H, d), 8.34 (1H, s), 12.93 (1H, s); m/r. ES+ [M+H]+ = 579.2.
Example 121: 4-Chloro-7-[(37?*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]pyridazin-3-yl}piperidin-l-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 23 using intermediate 121 f and intermediate 5f to give the title compound in the form of a formate salt (33 mg, 36 %) as a white solid. 1H NMR 5 1.18 (3H, t), 1.73 (1H, s), 1.86 (5H, s), 2.02 (5H, d), 2.28 (4H, s), 2.3-2.36 (2H, m), 2.76 (3H, t), 2.81-2.95 (1H, m), 3.07 (3H, s), 3.27 (1H, s), 3.78 (2H, t), 4.37 (3H, d), 6.43 (1H, d), 6.83 (1H, d), 6.97 (1H, d), 7.15 (2H, t), 7.30 (1H, d), 7.39-7.57 (3H, m), 8.35 (1H, d), 10.32 (1H, s), 12.93 (1H, s); m/z; ES+ [M+H]+ = 745.4.
Example 122: 4-Chloro-7-[(3S'*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]pyridazin-3-yl}piperidin-l-yl]-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 238 The title compound was prepared using methodology described in example 23 using intermediate 122a and intermediate 5f to give the title compound in the form of a formate salt (24 mg, 26 %) as a white solid. 1H NMR 5 1.06-1.2 (2H, m), 1.82 (1H, s), 1.85 (5H, s), 1.9-2.07 (5H, m), 2.12-2.21 (4H, m), 2.23 (2H, d), 2.(3H, q), 3.00 (2H, d),3.28 (3H, s), 3.35 (1H, s), 3.78 (2H, t), 4.37 (3H, dd), 6.42 (1H, d), 6.81 (1H, d), 6.(1H, d), 7.09-7.19 (2H, m), 7.29 (1H, d), 7.42-7.61 (3H, m), 8.33 (1H, s), 10.32 (1H, s), 12.97 (1H, s); m/z; ES+[M+H]+ = 745.4.
Example 123: 4-Chloro-7-(4-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-2-methyl-lZ/-indol-l-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-n/-indole-3-carbonitrile N O Intermediate 87c (103 mg, 0.18 mmol) was added to formic acid (2 mL) and stirred at 60 °C for 2 h. The solvent was evaporated and dissolved in NMP (2 mL). Intermediate 114e was added after the reaction was stirred for 16 h. Purification of the reaction mixture by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (16 mg, 12 %) as a white solid. 1H NMR 5 1.22-1.3 (3H, m), 1.73- 2.01 (9H, m), 2.14 (2H, t), 2.26 (2H, d), 2.45 (4H, s), 2.6-2.65 (3H, m), 2.71-2.82 (4H, m), 3.03 (2H, d), 3.(2H, d), 3.67 (2H, d), 3.74 (2H, t), 4.25 (1H, t), 6.16 (1H, s), 6.79-7 (4H, m), 7.03-7.21 (4H, m), 7.48 (1H, d), 8.29 (1H, s), 10.30 (1H, s), 12.28 (1H, s); m/z; ES+ [M+H]+ = 757.3.
Example 124 Intermediate 124a: Benzyl 4-(2-fluoropyr1m1d1n-5-yl)-3,6-d1hydropyr1d1ne-l(2Z/)-carboxylate WO 2024/189488 PCT/IB2024/052251 239 The title compound was prepared using methodology described in intermediate 63b using 4-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)-3.6-di hy dropy ridi nc-1 (2//)-carboxy late and 5-bromo-2-fluoropyrimidine to give the title compound (2.5 g, 91 %) as a yellow gum. 1H NMR 5 2.55 (2H, s), 3.32 (1H, s), 4.12 (3H, s), 5.13 (2H, s), 6.40 (1H, s), 7.27-7.43 (5H, m), 8.88 (2H, d); m/z; ES+ [M+H]+ = 314.0.
Intermediate 124b: Benzyl 4-{2-[4-(dibutoxymethyl)piperidin-l-yl]pyrimidin-5-yl}-3,6-dihydropyridine-l(2Zf)-carboxylate The title compound was prepared using methodology described in intermediate 63a using benzyl 4-(2- fluoropyrimidin-5-yl)-3.6-dihydropyridinc-l (2//)-carboxylatc and 4-(dibutoxy methy !)piperidine to give the title compound (3.5 g, 85 %) as a white solid. 1H NMR 5 0.88 (6H, t), 1.08-1.23 (2H, m), 1.24-1.41 (4H, m), 1.41-1.55 (4H, m), 1.71 (2H, d), 1.83 (1H, s), 2.44 (2H, s), 2.82 (2H, t), 3.29-3.45 (3H, m), 3.58 (3H, dd), 4.06 (2H, s), 4.16 (1H, d), 4.67 (2H, d), 5.12 (2H, s), 6.07 (1H, s), 7.26-7.42 (5H, m), 8.44 (2H, s); m/r. ES+ [M+H]+ = 537.2.
Intermediate 1240: 2-[4-(Dibutoxymethyl)piperidin-l-yl]-5-(piperidin-4-yl)pyrimidine The title compound was prepared using methodology described in intermediate 63c using benzyl 4-{2-[4- (dibutoxy methy !)pipcridin-1-yl|py rimidin-5-y l)-3.6-dihydropyridinc-1 (2//)-carboxy late to give the title compound (2.5 g, 95 %) as a colourless gum. 1H NMR 5 0.88 (6H, t), 1.25-1.41 (4H, m), 1.48 (6H, p), 1.(1H, s), 1.69 (3H, d), 2.77 (2H, t), 3.01 (2H, d), 3.25-3.39 (5H, m), 3.55 (2H, dt), 4.10 (2H, s), 4.16 (1H, d), 4.35 (2H, s), 4.63 (2H, d), 8.22 (2H, s); m/z; ES+ [M+H]+ = 405.2.
Intermediate 124d: 4-Chloro-7-(4-{2-[4-(dibutoxymethyl)piperidin-l-yl]pyrimidin-5-yl}piperidin-l-yl)-lZf-indole-3- carbonitrile WO 2024/189488 PCT/IB2024/052251 240 The title compound was prepared using methodology described in intermediate 63d using 2-[4- (dibutoxymethyl)piperidin-l-yl]-5-(piperidin-4-yl)pyrimidine and intermediate lb to give the title compound (600 mg, 42 %) as a pale yellow gum. 1H NMR 5 (84 °C) 8 0.88 (6H, t), 1.07-1.25 (2H, m), 1.33 (4H, dp), 1.48 (4H, dq), 1.71 (2H, d), 1.76-2.02 (4H, m), 2.54 (1H, d), 2.71-2.84 (4H, m), 3.32 (1H, s), 3.35-3.46 (4H, m), 3.55 (2H, dt), 4.17 (1H, d), 4.65 (2H, d), 6.86 (1H, d), 7.16 (1H, d), 8.31 (3H, d), 12.28 (1H, s); m/r. ES+ [M+H]+ = 579.4.
Example 124: 4-Chloro-7-(4-{2-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- N. N Intermediate li (144 mg, 0.34 mmol) was stirred in formic acid (1 mL) at 40 °C for 1 h. 4-Chloro-7-(4-{2-[4- (dibutoxy mcthyl)pipcridin-l-yl|pyrimidin-5-yl;pipcridin-l-yl)-l//-indolc-3-carbonitrilc (150 mg, 0.26 mmol) was also stirred in formic acid (1 mL) and stirred at 60 °C for 2 h. The two mixtures were evaporated to dryness, combined with NMP (2 mL) and stirred at RT for 16 h. The reaction mixture purified by flash C18- flash chromatography, elution gradient 0 to 40% MeCN in water (0.1% formic acid). The fractions containing product were combined and basified with NaHCO3 solution. The resulting solid was filtered under vacuum and dried to give the title compound (30 mg, 15 %) as a white solid. 1H NMR 8 1.05 (2H, q), 1.84 (5H, dt), 1.91-2.03 (3H, m), 2.20 (2H, d), 2.36 (1H, tt), 2.51-2.63 (3H, m), 2.72-2.98 (5H, m), 3.29 (4H, t), 3.35 (3H, s), 3.42 (2H, d), 4.21 (1H, d), 4.33 (1H, d), 4.64 (2H, d), 5.06 (1H, dd), 6.86 (1H, d), 6.99-7.29 (3H, m), 7.(1H, d), 8.32 (3H, d), 10.97 (1H, s), 12.31 (1H, s); m/2׳ . ES+ [M+H]+ = 761.4.
Example 125: 4-Chloro-7-(4-{2-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lLf-indol-l-yl]piperidin-l-yl}methyl)piperidin- 1-yl | pyrimidin-5-yl} piperidin-1-yl)-l//-indole-3-carbonitrile yl}methyl)piperidin-l-yl]pyrimidin-5-yl}piperidin-l-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 241 The title compound was prepared using methodology described in example 63 using intermediate 124d and intermediate 5f to give the title compound (30 mg, 15 %) as a white solid. 1H NMR 5 1.05 (2H, d), 1.83 (5H, t), 1.97 (6H, q), 2.17 (2H, s), 2.22 (2H, d), 2.55 (1H, d), 2.77 (4H, q), 2.86 (2H, t), 3.00 (2H, d), 3.42 (2H, d), 3.78 (2H, t), 4.37 (1H, s), 4.65 (2H, d), 6.42 (1H, d), 6.91 (2H, dd), 7.15 (2H, dd), 7.47-7.57 (2H, m), 8.(3H, d), 10.33 (1H, s), 12.29 (1H, s); m/z; ES+ [M+H]+ = 745.5.
Example 126 Intermediate 126a: Benzyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate HCI (1.25M inMeOH, 200 mL, 800.0 mmol) was added to ter/-butyl (2S)-2-(hydroxymethyl)morpholine-4- carboxylate (15 g, 69.04 mmol) in MeOH (50 mL) at RT for 2 h. The solvent was evaporated to afford a colourless gum and was diluted inTHF:water (1:1, 300 mL). Benzyl carbonochloridate (11.8 mL, 82.mmol) was added followed by Na2CO3 (21.95 g, 207.12 mmol) and the solution was stirred at RT for 16 h. The mixture was diluted with EtOAc (200 mL), washed with water (100 mL), NaCI solution (100 mL), dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (15.4 g, 89 %) as a colourless gum. 1H NMR (CDC13) 5 2.86 (1H, t), 3.03 (1H, t), 3.46-3.73 (4H, m), 3.84-4.09 (3H, m), 5.(2H, d), 7.3-7.44 (5H, m) 1H not observed; m/z; ES+ [M+H]+ = 252.2.
Intermediate 126b: Benzyl (2S)-2-formylmorpholine-4-carboxylate Oxalyl chloride (5.30 mL, 62.08 mmol) was added to DMSO (9.0 mL) and DCM (150 mL) at -78 °C under nitrogen. Benzyl (2S)-2-(hydroxymethyl)morpholine-4-carboxylate (13.0 g, 51.73 mmol) was added to the mixture followed by triethylamine (36.1 mL, 258.67 mmol). The solution was stirred at RT for 2 h and was then diluted with DCM (150 mL), washed with water (125 mL), NaCI solution (125 mL), dried over Na2S04, OH ^^־ I ,O WO 2024/189488 PCT/IB2024/052251 242 filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 60% EtOAc in Et20 to give the title compound (10.4 g, 81 %) as a colourless gum. 1H NMR (CDCh) 5 2.72-3.24 (2H, m), 3.32-3.68 (2H, m), 3.89 (3H, dq), 5.06-5.18 (2H, m), 7.18-7.41 (5H, m), 9.59 (1H, s); m/z; ES+ [M+H]+ = 249.8.
Intermediate 1260: Benzyl (2S)-2-(dibutoxymethyl)morpholine-4-carboxylate O N 4-Methylbenzene-l-sulfonic acid (1.52 g, 8.02 mmol) was added to benzyl (2S)-2-formylmorpholine-4- carboxylate (10.0 g, 40.12 mmol) in 1-butanol (100 mL) at RT and was stirred at 90 °C for 2 h. The reaction was cooled to RT and the solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (10.5 g, 69.0 %) as a colourless oil. 1H NMR (CDCh) 5 0.93 (6H, td), 1.31-1.5 (4H, m), 1.5-1.67 (4H, m), 2.86 (1H, s), 2.95-3.11 (1H, m), 3.37-3.76 (6H, m), 3.78-4.02 (2H, m), 4.13 (1H, dd), 4.41 (1H, d), 5.17 (2H, s), 7.29- 7.43 (5H, m); m/z; ES+ [M+Na]+ = 402.3.
Intermediate 126d: (2S)-2-(Dibutoxymethyl)morpholine The title compound was prepared using methodology described in intermediate 41c using benzyl (2S)-2- (dibutoxymethyl)morpholine-4-carboxylate to give the title compound (3.0 g, 93 %) as a colourless oil and was used without further purification. 1H NMR 5 0.88 (6H, t), 1.24-1.4 (4H, m), 1.41-1.55 (4H, m), 2.34-2.(1H, m), 2.56-2.68 (2H, m), 2.73-2.81 (1H, m), 3.25-3.49 (5H, m), 3.51-3.62 (2H, m), 3.69-3.75 (1H, m), 4.27 (1H, d). no mass ion Intermediate 126e: Benzyl 4-{4-[(2S)-2-(dibutoxymethyl)morpholin-4-yl]phenyl}piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 243 The title compound was prepared using methodology described in intermediate lla using (2S)-2- (dibutoxymethy!)morpholine and intermediate ic to give the title compound (2.8 g, 44 %) as a yellow oil. 1H NMR 5 0.89 (6H, m), 1.18 (1H, t), 1.33-1.52 (8H, m), 1.75 (1H, d), 1.99 (1H, s), 2.35-2.7 (4H, m), 3.26-3.(9H, m), 3.85-4.21 (4H, m), 4.44 (1H, d), 5.10 (2H, s), 6.72-6.91 (2H, m), 6.97-7.18 (2H, m), 7.27-7.5 (5H, m); m/z; ES+ [M+H]+ = 539.1.
Intermediate 126f: (2S)-2-(Dibutoxymethyl)-4-[4-(piperidin-4-yl)phenyl]morpholine The title compound was prepared using methodology described in intermediate 1 lb using benzyl 4-{4-[(2S)-2- (dibutoxymethyl)morpholin-4-yl]phenyl}piperidine-l-carboxylate to give the title compound (1.9 g, 90 %) as a brown oil. 1H NMR S 0.8-1.01 (6H, m), 1.18 (lH,t), 1.31-1.44 (5H, m), 1.45-1.54 (4H, m), 1.58-1.71 (2H, m), 1.99 (1H, s), 2.45-2.65 (5H, m), 3.00 (2H, d), 3.16-3.7 (8H, m), 3.75-4.23 (1H, m), 4.44 (1H, d), 6.71- 6.92 (2H, m), 6.99-7.17 (2H, m); m/z; ES+ [M+H]+ = 405.1.
Intermediate 126g: 7-(4-{4-[(2S)-2-(Dibutoxymethyl)morpholin-4-yl]phenyl}piperidin-l-yl)-4-fh1oro-lZ/-indole-3- carbonitrile The title compound was prepared using methodology described in intermediate 63d using (2S)-2- (dibutoxymethyl)-4-[4-(piperidin-4-yl)phenyl]morpholine and intermediate 2b to give the title compound (2 N O Ct O.
WO 2024/189488 PCT/IB2024/052251 244 mg, 67 %) as a brown foam. 1H NMR 5 0.86-0.95 (6H, m), 1.29-1.41 (4H, m), 1.45-1.57 (4H, m), 1.78-1.(2H, m), 1.9-2.04 (2H, m), 2.51-2.71 (3H, m), 2.71-2.83 (2H, m), 3.34-3.42 (2H, m), 3.42-3.55 (4H, m), 3.55-3.69 (4H, m), 3.9 4 (1H, m), 4.45 (1H, d), 6.82 (1H, dd), 6.86-6.98 (3H, m), 7.17 (2H, d), 8.26 (1H, s), 12.24 (1H, s); m/z; ES+ [M+H]+ = 563.3.
Example 126: N N• HCI (2M aq, 2 ml, 4.00 mmol) was added to 7-(4-{4-[(2S)-2-(dibutoxymethyl)morpholin-4- yl|phcnyl{pipcridin-l-yl)-4-nuoro-l//-indolc-3-carbonitrilc (100 mg, 0.18 mmol) inTHF (2 mL). The mixture was stirred at 60 °C for 24 h and then basified using NaOH (2M, 2 mL). The suspension was extracted with EtOAc (4 mL) and the layers were separated. The organic layer was dried over MgSO4, filtered and evaporated to afford a residue. Separately, intermediate li (76 mg, 0.18 mmol) was stirred in formic acid (mL) at 40 °C for 1 h. The solvent was evaporated to afford a residue. The two residues were combined in NMP (2 mL) and stirred at 40 °C for 2 h. Purification of the reaction mixture by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (28 mg, 21 %) as a white solid. 1H NMR 1.84 (2H, d), 1.89-2.04 (3H, m), 2.29-2.46 (2H, m), 2.49 (2H, s), 2.51 (1H, s), 2.53-2.7 (7H, m), 2.71-2.(2H, m), 2.83-2.97 (1H, m), 3.29 (3H, s), 3.37 (2H, d), 3.46 (1H, d), 3.53-3.61 (1H, m), 3.61-3.72 (1H, m), 3.77 (1H, d), 3.9-3.98 (1H, m), 4.13-4.38 (2H, m), 5.05 (1H, dd), 6.82 (1H, dd), 6.89-6.98 (3H, m), 7.06 (2H, d), 7.17 (2H, d), 7.52 (1H, d), 8.26 (1H, s), 10.94 (1H, s), 12.24 (1H, s); m/r. ES+ [M+H]+ = 745.3.
Example 127 Intermediate 127a: 4-Chloro-7-(4-{4-[(2S)-2-(dibutoxymethyl)morpholin-4-yl]phenyl}piperidin-l-yl)-lZ/-indole-3- carbonitrile 7-(4-{4-[(27?)-2-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl ؛ methyl)morpholin-4-yl | phenyl{ piperidin-1-yl)-441uoro-l//-indole-3-carbonitrile Ct O.
WO 2024/189488 PCT/IB2024/052251 245 The title compound was prepared using methodology described in intermediate 63d using intermediate 126f and intermediate lb to give the title compound (230 mg, 53 %) as an orange solid. 1H NMR 5 0.86-0.91 (6H, m), 1.16 (1H, t), 1.23 (1H, s), 1.3-1.39 (4H, m), 1.50 (4H, q), 1.85 (2H, s), 2.77 (1H, s), 3.31-3.76 (14H, m), 3.92-4.02 (1H, m), 4.44 (1H, d), 6.8-6.9 (3H, m), 7.12-7.19 (3H, m), 8.31 (1H, d), 12.26 (1H, s); m/z; ES+ [M+H]+ = 579.0.
Intermediate 127b: 4-Chloro-7-(4-{4-[(2S)-2-formylmorpholin-4-yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile HCI (2M aq, 5.18 mL, 10.36 mmol) was added to 4-chloro-7-(4-{4-[(2S)-2-(dibutoxymethyl)morpholin-4- yl|phcnyl;pipcridin-l-yl)-l//-indolc-3-carbonitrilc (200 mg, 0.35 mmol) inTHF (2 mL). The mixture was stirred at 60 °C for 12 h and then cooled to RT. The solution was basified using NaOH (2M, 2ml) and the aqueous layer was extracted with EtOAc (100 mL). The organic layer was evaporated to dryness to give the title compound (120 mg, 77 %) as a brown solid and was used in the next step without further purification. 1H NMR 5 0.85 (1H, d), 1.06 (1H, t), 1.25 (5H, s), 1.58 (2H, d), 1.77 (1H, s), 1.90 (3H, s), 2.76 (3H, d), 5.33 (1H, s), 6.85-6.98 (2H, m), 7.19 (1H, d), 7.27 (1H, d), 8.15 (3H, s), 9.64 (1H, s). no mass ion Example 127: 4-Chloro-7-(4-{4-[(27?)-2-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lfl-isoindol-5-yl]piperazin- l-yl}methyl)morpholin-4-yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 23 using 4-chloro-7-(4-{4-[(2S)-2- formylmorpholin-4-yl Iphcnyl ; pipcridin-1 -yl)-l //-indolc-3-carbonitrilc and intermediate li to give the title compound in the form of a formate salt (16 mg, 8 %) as a white solid. 1H NMR 5 1.84 (2H, d), 1.9-2.04 (3H, m), 2.28-2.47 (2H, m), 2.50 (2H, s), 2.52 (1H, s), 2.54-2.71 (7H, m), 2.71-2.83 (2H, m), 2.84-2.97 (1H, m), 3.29 (1H, s), 3.32 (1H, s), 3.37-3.52 (4H, m), 3.58 (1H, d), 3.62-3.71 (1H, m), 3.77 (1H, s), 3.9-3.99 (1H, m), 4.21 (1H, d), 4.34 (1H, d), 4.98-5.1 (1H, m), 6.86 (1H, d), 6.93 (2H, d), 7.07 (2H, d), 7.14-7.2 (3H, m), 7.(1H, d), 8.33 (1H, s), 10.96 (1H, s) 1H not observed; m/r. ES+ [M+H]+ = 761.4.
Example 128 Intermediate 128a: tert-Butyl 7-methylidene-2-azaspiro[3.5]nonane-2-carboxylate WO 2024/189488 PCT/IB2024/052251 246 Potassium tert-butoxide (3.4 g, 30.29 mmol) was added to methyltriphenylphosphonium bromide (10.8 g, 30.29 mmol) in THF (30 mL) at 0 °C under nitrogen. The mixture was stirred at RT for l h followed by the addition of tert-butyl 7-oxo-2-azaspiro[3.5]nonane-2-carboxylate (2.9 g, 12.12 mmol) and was stirred at 35 °C for l h. The reaction mixture was diluted with EtOAc (125 mL), washed with NH4C1 solution (2x 75 mL), NaCI solution (75 mL), dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 4% EtOAc in DCM to give the title compound (2.7 g, 94 %) as a white solid. 1H NMR (CDCh) 5 1.46 (9H, s), 1.67 - 1.79 (4H, m), 2.06 - 2.(4H, m), 3.64 (4H, s), 4.61 - 4.69 (2H, m); m/z; ES+ [M-tBu]+ = 181.9.
Intermediate 128b: tert-Butyl 7-(hydroxymethyl)-2-azaspiro[3.5]nonane-2-carboxylate Borane-tetrahydrofuran complex (28.4 mL, 28.44 mmol) was added to tert-butyl 7-methylidene-2- azaspiro[3.5]nonane-2-carboxylate (2.7 g, 11.38 mmol) in THF (100 mL) at 0 °C under nitrogen and stirred for 48 h. H,O2 (5.81 mL, 56.88 mmol) and NaOH (2M, 17.06 mL, 34.13 mmol) was added and the mixture was stirred at RT for 3 h. The solvent was evaporated and diluted with DCM (100 mL). The organic layer was washed with NaCI solution (3x 50 mL), dried over Na2SO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 4% THF in DCM to give the title compound (2.3 g, 79 %) as a colourless oil. 1H NMR (CDCh) 5 0.89 - 1.04 (2H, m), 1.38 - 1.(12H, m), 1.70 - 1.77 (2H, m), 1.85 - 1.98 (2H, m), 3.45 (2H, t), 3.56 (2H, s), 3.60 (2H, s), 5.27 - 5.34 (1H, m); m/z; ES+ [M+H]+ = 256.1.
Intermediate 1280: 2-Azaspiro[3.5]nonan-7-yl)methanol The title compound was prepared using methodology described in intermediate 75f using tert-butyl 7- (hydroxymethyl)-2-azaspiro[3.5]nonane-2-carboxylate to give the title compound (540 mg, 76 %) as a white solid. 1H NMR 5 0.85 (2H, tdd), 1.19-1.43 (3H, m), 1.53-1.67 (2H, m), 1.91-2.07 (2H, m), 3.17 (2H, d), 3.47-3.67 (4H, m), 4.52 (1H, s), 9.39 (1H, s); m/z; ES+ [M+H]+ = 155.9.
Intermediate 128d: Benzyl 7-(hydroxymethyl)-2-azaspiro[3.5]nonane-2-carboxylate WO 2024/189488 PCT/IB2024/052251 247 The title compound was prepared using methodology described in intermediate 113a using (2- azaspiro[3.5]nonan-7-yl)methanol and benzyl carbonochloridate to give the title compound (500 mg, 66 %) as a colourless gum. 1H NMR (CDCh) 5 0.89-1.05 (2H, m), 1.46 (3H, td), 1.61 (1H, s), 1.66-1.81 (2H, m), 1.86-1.98 (2H, m), 3.45 (2H, d), 3.67 (4H, d), 5.11 (2H, s), 7.28-7.43 (5H, m); m/z; ES+ [M+H]+ = 290.2.
Intermediate 128e: Benzyl 7-formyl-2-azaspiro[3.5]nonane-2-carboxylate The title compound was prepared using methodology described in intermediate 126b using benzyl 7 - (hydroxymethyl)-2-azaspiro[3.5]nonane-2-carboxylate to give the title compound (350 mg, 88 %) as a colourless gum. 1H NMR (CDCh) 5 1.32-1.64 (4H, m), 1.8-1.96 (4H, m), 2.22 (1H, tdt), 3.66 (4H, d), 5.(2H, s), 7.27-7.43 (5H, m), 9.62 (1H, d); m/z; ES+ [M+H]+ = 288.1.
Intermediate 1281: Benzyl 7-(dibutoxymethyl)-2-azaspiro[3.5]nonane-2-carboxylate The title compound was prepared using methodology described in intermediate 126c using benzyl 7-formyl-2- azaspiro[3.5]nonane-2-carboxylate to give the title compound (5.5 g, 55 %) as a colourless gum. 1H NMR (CDCh) 5 0.84-1.09 (8H, m), 1.32-1.46 (6H, m), 1.48-1.64 (5H, m), 1.76 (2H, dd), 1.90 (2H, d), 3.39 (2H, dt), 3.51-3.71 (6H, m), 4.07 (1H, d), 5.09 (2H, s), 7.26-7.42 (5H, m); m/z; ES+ [M+H]+ = 418.4.
Intermediate 128g: 7-(Dibutoxymethyl)-2-azaspiro[3.5]nonane WO 2024/189488 PCT/IB2024/052251 248 The title compound was prepared using methodology described in intermediate 60c using benzyl 7- (dibutoxymethyl)-2-azaspiro[3.5]nonane-2-carboxylate to give the title compound (3.5 g, 99 %) as a yellow liquid. 1H NMR 5 0.88 (6H, t), 0.94-1.02 (1H, m), 1.06 (1H, t), 1.19-1.54 (10H, m), 1.54-1.65 (2H, m), 1.(2H, d), 3.15-3.41 (5H, m), 3.39-3.57 (3H, m), 4.06 (1H, d), 4.87 (2H, s); m/z; ES+ [M+H]+ = 284.3.
Intermediate 128h: Benzyl 4-{4-[7-(dibutoxymethyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidine-l-carboxylate The title compound was prepared using methodology described in intermediate 11a using 7-(dibutoxymethyl)־ 2-azaspiro[3.5]nonane and intermediate Ic to give the title compound (1.5 g, 67 %) as a yellow gum. 1H NMR 0.89 (6H, t), 1.18 (1H, t), 1.43-1.59 (15H, m), 2.51 (5H, q), 3.29-3.61 (7H, m), 4.14 (5H, dd), 5.10 (4H, d), 7.25 (2H, d), 7.38 (5H, d), 7.39 (2H, t); m/z; ES+ [M+H]+ = 577.3.
Intermediate 128i: 7-(Dibutoxymethyl)-2-[4-(piperidin-4-yl)phenyl]-2-azaspiro[3.5]nonane The title compound was prepared using methodology described in intermediate 60c using benzyl 4-{4-[7- (dibutoxymethyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidine-l-carboxylate to give the title compound (5mg, 59 %) as a yellow gum. 1H NMR 5 0.89 (6H, t), 0.95-1.14 (2H, m), 1.21-1.57 (12H, m), 1.55-1.72 (5H, m), 1.87 (2H, d), 2.32-2.5 (1H, m), 2.5-2.65 (3H, m), 2.98 (2H, d), 3.28-3.59 (7H, m), 4.11 (1H, d), 6.23- 6.44 (2H, m), 6.96-7.04 (2H, m) 1H not observed; m/z; ES+ [M+H]+ = 443.4.
Intermediate 128j: 7-(4-7]-4؛-(Dibutoxymethyl)-2-azaspiro[3.5| nonan-2-yl| phenyl{ piperidin-1-yl)-4-t1uoro-l//-indole-3- carbonitrile The title compound was prepared using methodology described in intermediate 60d using 7-(dibutoxymethyl)- 2-[4-(piperidin-4-yl)phenyl]-2-azaspiro[3.5]nonane and intermediate 2b to give the title compound (210 mg, %) as a yellow gum. 1H NMR 5 0.90 (6H, d), 1.07 (2H, t), 1.18 (1H, t), 1.24 (1H, s), 1.28-1.39 (5H, m), WO 2024/189488 PCT/IB2024/052251 249 1.37- 1.54 (7H, m), 1.78-1.93 (5H, m), 2.54 (1H, s), 2.75 (2H, t), 3.34-3.41 (3H, m), 3.43 (2H, s), 3.45-3.(4H, m), 4.04 (1H, q), 4.12 (1H, d), 6.37 (2H, dd), 6.84 (1H, d), 6.93 (1H, dd), 7.07 (2H, dd), 8.27 (1H, s), 12.25 (1H, s); m/z; ES+ [M+H]+ = 599.5.
Example 128: 7-(4-{4-[7-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l-yl}methyl)-2- X-sO N O 7-(4-{4-[7-(Dibutoxymethyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl)-4-fluoro-177-indole-3- carbonitrile (100 mg, 0.17 mmol) was stirred in formic acid (1 mL) at 60 °C for 2 h. The mixture was evaporated to dryness to afford a residue. Intermediate li (86 mg, 0.20 mmol) was stirred in formic acid (mL) at 40 °C for 1 h. The mixture was then evaporated to dryness to afford a residue. The two residues were dissolved in NMP (3 mL) and stirred at RT for 16 h. The reaction mixture was purified by flash Cl 8-flash chromatography, elution gradient 0 to 40% MeCN in water (0.1% formic acid) to give the title compound in the form of a formate salt (18 mg, 14 %) as a white solid. 1H NMR 5 0.96 (2H, q), 1.39-1.6 (3H, m), 1.73 (2H, d), 1.78-2.02 (7H, m), 2.15 (2H, d), 2.3-2.44 (1H, m), 2.48 (4H, s), 2.52-2.63 (2H, m), 2.74 (2H, q), 2.(1H, m), 3.28 (4H, s), 3.37 (2H, d), 3.48 (4H, d), 4.13-4.38 (2H, m), 5.05 (1H, dd), 6.39 (2H, d), 6.82 (1H, dd), 6.93 (1H, dd), 7.03-7.13 (4H, m), 7.53 (1H, d), 8.27 (1H, d), 10.95 (1H, s), 12.25 (1H, s); m/r. ES+ [M+H]+= 783.7.
Example 129 Intermediate 129a: 4-Chloro-7-(4-{4-[7-(dibutoxymethyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl)-lZ/-indole-3- carbonitrile The title compound was prepared using methodology described in intermediate 60d using intermediate 128i and intermediate lb to give the title compound (500 mg, 44 %) as a brown gum. 1H NMR 5 0.78-0.93 (6H, m), 0.95-1.27 (2H, m), 1.34 (3H, h), 1.48 (4H, dt), 1.66 (2H, d), 1.79-1.89 (3H, m), 1.92 (2H, d), 1.98 (1H, d), azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl)-4-fluoro-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 250 2.72-2.86 (2H, m), 3.33 (10H, s), 3.34-3.42 (2H, m), 3.53 (2H, dt), 4.12 (1H, d), 6.39 (2H, d), 6.87 (1H, t), 7.09 (2H, d), 7.14-7.27 (1H, m), 7.28-7.4 (1H, m), 8.3-8.37 (1H, m), 12.27 (1H, s); m/z; ES+ [M+H]+ = 617.0.
Example 129: 4-Chloro-7-(4-{4-[7-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl}methyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl)-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in example 128 using 4-chloro-7-(4-{4-[7- (dibutoxymethyl)-2-azaspiro [3.5]nonan-2-yl]phenyl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile and intermediate li to give the title compound in the form of a formate salt (9.5 mg, 9 %) as a white solid. 1H NMR 5 1.09 (2H, d), 1.54 (2H, t), 1.83 (5H, d), 1.89-2.11 (5H, m), 2.3-2.47 (1H, m), 2.60 (2H, d), 2.79 (2H, t), 2.85-2.99 (1H, m), 3.02 (2H, s), 3.13 (2H, d), 3.40 (4H, t), 3.56 (6H, d), 3.98 (2H, d), 4.24 (1H, d), 4.37 (1H, d), 5.07 (1H, dd), 6.51 (2H, s), 6.88 (1H, d), 7.1-7.21 (5H, m), 7.60 (1H, d), 8.34 (1H, d), 10.97 (1H, s), 12.33 (1H, s); m/r. ES+[M+H]+ = 799.3.
Example 130 Intermediate 130a: Benzyl (3S)-3-{4-[7-(dibutoxymethyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidine-l-carboxylate The title compound was prepared using methodology described in intermediate lla using intermediate 128g and intermediate 9d to give the title compound (2.5 g, 90 %) as a yellow gum. 1H NMR 5 0.88 (5H, t), 1.(1H, q), 1.17 (2H, t), 1.32 (3H, qd), 1.36-1.46 (1H, m), 1.43-1.65 (5H, m), 1.68 (3H, dd), 1.85 (3H, t), 1.(2H, s), 2.42-2.84 (6H, m), 3.28-3.41 (4H, m), 3.46 (2H, s), 3.86-4.11 (2H, m), 5.09 (2H, d), 6.34 (2H, d), 7.02 (2H, d), 7.36 (5H, d); m/z; ES+ [M+H]+ = 577.4.
Intermediate 130b: 7-(Dibutoxymethyl)-2-{4-[(3S)-piperidin-3-yl]phenyl}-2-azaspiro[3.5]nonane WO 2024/189488 PCT/IB2024/052251 251 The title compound was prepared using methodology described in intermediate 60c using benzyl (3S)-3-{4-[7- (dibutoxymethyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidine-l-carboxylate to give the title compound (8mg, 69 %) as a yellow gum. 1H NMR 5 0.89 (6H, t), 1.04 (2H, q), 1.13-1.55 (10H, m), 1.64 (3H, m), 1.73- 1.94 (4H, m), 2.51 (3H, p), 2.66-2.99 (3H, m), 3.13-3.26 (2H, m), 3.28-3.92 (8H, m), 3.95-4.28 (1H, m), 6.37 (2H, d), 7-7.1 (2H, m); m/z; ES+ [M+H]+ = 443.2.
Intermediate 1300: 4-Chloro-7-[(3S)-3-{4-[7-(dibutoxymethyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl]-lZ/-indole- 3-carbonitrile The title compound was prepared using methodology described in intermediate 60d using 7-(dibutoxymethyl)- 2-{4-[(3S)-piperidin-3-yl]phenyl}-2-azaspiro[3.5]nonane and intermediate lb to give the title compound 1mg, 43 %) as a yellow gum. 1H NMR 5 0.77 (1H, s), 0.88 (4H, t), 1.07 (1H, dd), 1.27-1.4 (2H, m), 1.4-1.(3H, m), 1.57 (2H, d), 1.65 (1H, d), 1.85-1.97 (7H, m), 2.18 (6H, t), 2.70 (8H, s), 3.36-3.6 (5H, m), 6.35 (1H, d), 6.83 (1H, dd), 6.96-7.26 (2H, m), 8.17 (3H, s), 8.40 (1H, d) 1H not observed; m/z; ES+ [M+H]+ = 617.3.
Example 130: 4-Chloro-7-[(3S)-3-{4-[7-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin- l-yl}methyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl]-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 252 The title compound was prepared using methodology described in example 128 using 4-chloro-7-[(3S)-3-{4- [7-(dibutoxymethyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl]-l/7-indole-3-carbonitrile and intermediate li to give the title compound in the form of a formate salt (18 mg, 19 %) as a white solid. 1H NMR 5 1.04 (2H, s), 1.39 (1H, dd), 1.50 (4H, dt), 1.77 (3H, s), 1.88 (6H, d), 1.93-2.02 (1H, m), 2.31-2.(2H, m), 2.53-2.61 (3H, m), 2.62-2.74 (3H, m), 2.86-2.96 (2H, m), 2.99 (2H, d), 3.13 (1H, s), 3.37 (1H, s),3.46 (4H, d), 3.58 (1H, s), 3.87-4.07 (1H, m), 4.23 (1H, d), 4.35 (1H, d), 5.07 (1H, dd), 5.76 (1H, s), 6.(2H, d), 6.83 (1H, d), 7.12 (1H, d), 7.14 (2H, d), 7.57 (1H, s), 8.32 (1H, d), 10.97 (1H, s), 12.31 (1H, s); m/r. ES+[M+H]+ = 799.3.
Example 131: 4-Chloro-7-[(3S)-3-{4-[7-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lH-indol-l-yl]piperidin-l-yl}methyl)-2- azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl]-n/-indole-3-carbonitrile The title compound was prepared using methodology described in example 63 using intermediate 130c and intermediate 5f to give the title compound (19 mg, 20 %) as a white solid. 1H NMR 5 1.09 (2H, s), 1.12-1.(1H, m), 1.54 (4H, d), 1.85 (4H, s), 1.9-1.95 (4H, m), 2.14 (2H, s), 2.51 (2H, d), 2.54-2.76 (3H, m), 2.77 (2H, t), 2.97 (3H, d), 3.30 (1H, d), 3.37 (1H, s), 3.47 (4H, d), 3.67 (1H, s), 3.78 (2H, t), 4.75 (1H, s), 6.37 (2H, d), 6.48 (1H, s), 6.91 (2H, dd), 7.08-7.21 (4H, m), 7.51 (2H, d), 8.32 (1H, d), 10.36 (1H, s), 12.32 (1H, d); m/z; ES+[M+H]+ = 783.2.
Example 132 Intermediate 132a: 4-Chloro-7-[(37?)-3-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indazole-3- carbonitrile WO 2024/189488 PCT/IB2024/052251 253 The title compound was prepared using methodology described in example 60d using intermediate 21c and intermediate 9c give the title compound (180 mg, 31 %) as a white solid. 1H NMR 5 0.89 (6H, t), 1.22-1.(7H, m), 1.43-1.58 (5H, m), 1.59-1.79 (4H, m), 1.94 (3H, d), 2.56 (1H, d), 2.62-2.84 (2H, m), 3.00 (1H, t), 3.37-3.66 (7H, m), 4.18 (1H, d), 6.83-6.91 (2H, m), 6.94 (1H, d), 7.17 (2H, d), 7.28 (1H, d), 14.70 (1H, s); m/z; ES+ [M+H]+ = 578.0.
Example 132: 4-Chloro-7-[(37?)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l//-indol-2-yl]piperidin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-l//-indazole-3-carbonitrile 4-Chloro-7-[(3R)-3-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl]-l//-indazole-3-carbonitrile (180 mg, 0.31 mmol) and intermediate 13c (133 mg, 0.31 mmol) were stirred in formic acid (2 mL) at 40 °C for 1 h. The solvent was evaporated and the residue was diluted with NMP (2 mL). The mixture was stirred at RT for 16 h. Purification of the reaction mixture by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (40 mg, 16 %) as a pale yellow solid. 1H NMR 5 1.22 (2H, d), 1.(4H, d), 1.74-2 (7H, m), 2.06 (2H, d), 2.22 (2H, d), 2.56-2.84 (7H, m), 2.96 (3H, s), 3.53-3.88 (9H, m), 6.(1H, s), 6.77 (1H, s), 6.83-6.98 (3H, m), 7.17 (3H, d), 7.32-7.48 (2H, m), 10.29 (1H, s) 1H not observed; m/z; ES+ [M+H]+ = 758.6.
Example 133 Intermediate 133a: 7-Bromo-4-fluoro-3-iodo-l//-indazole WO 2024/189488 PCT/IB2024/052251 254 Iodine solution (23.6 g, 93.01 mmol) was added to 7-bromo-4-nuoro-l//-indazole (10.0 g, 46.51 mmol) and KOH (10.4 g, 186.02 mmol) in DMF (180 mL) at RT for 2 h. The reaction mixture was quenched with saturated Na2S203 solution (200 mL), extracted with EtOAc (400 mL), dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et20 to give the title compound (8.0 g, 48.1 %) as a white solid. 1H NMR 5 2.(2H, s), 7.96 (1H, s); m/z; ES+ [M+H]+ = 340.7.
Intermediate 133b: 7-Bromo-4-fluoro-l//-indazole-3-carbonitrile Tetrakis(triphenylphosplune)palladium(0) (0.814 g, 0.70 mmol), 7-bromo-4-nuoro-3-iodo-l//-indazole (4.8 g, 14.08 mmol) and zinc(II) cyanide (1.98 g, 16.90 mmol) were added to DMF (50 mL) and sealed into a microwave tube. The reaction was heated to 100 °C for 16 h in the microwave reactor and then cooled to RT. The reaction mixture was diluted with DCM (200 mL), washed with NaHCO3 solution (100 mL), NaCI solution (50 mL), dried over Na2$04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 20% EtOAc in Et20 to give the title compound (800 mg, 23 %) as a white solid. 1H NMR 5 7.18 (1H, m), 7.46-7.63 (1H, m), 15.15 (1H, s); m/z ES־ [M-H]־ = 237.9.
Intermediate 1330: 7-[(3S)-3-{4-[4-(Dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl]-4-fh1oro-lZ/-indazole-3- carbonitrile WO 2024/189488 PCT/IB2024/052251 255 The title compound was prepared using methodology described in intermediate 60d using 7-bromo-4-fluoro- I//-indazolc-3-carbo nitrile and intermediate 11b to give the title compound (472 mg, 50 %) as a yellow solid. 1H NMR 5 0.88 (6H, t), 1.2-1.41 (7H, m), 1.42-1.56 (5H, m), 1.71 (3H, d), 1.79-2 (3H, m), 2.57-2.73 (2H, m), 3.00 (1H, t), 3.27-3.46 (5H, m), 3.51-3.7 (4H, m), 4.17 (1H, d), 6.85 (2H, d), 6.96-7.34 (4H, m), 14.(1H, s); m/z; ES+ [M+H]+ = 562.1.
Example 133: 7-[(3S)-3-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl] methvl)piperidin-l-yl| phenyl] piperid in-l-yl|-4-fluoro-1/f-indazole-3-carbonitrile The title compound was prepared using methodology described in example 123 using 7-[(3S)-3-{4-[4- (dibutoxymethyl)piperidin-1-y!]phenyl}piperidin-1 -y 1] -4-fluoro -I //-i ndazo lc-3 -carbonitrile and intermediate li to give the title compound in the form of a formate salt (98 mg, 37 %) as a white solid. 1H NMR 5 1.22 (2H, tt), 1.51-1.72 (2H, m), 1.75-2.01 (6H, m), 2.21 (2H, d), 2.36 (1H, tt), 2.51 (3H, s), 2.56-2.77 (5H, m), 2.83- 3.03 (2H, m), 3.30 (4H, s), 3.45 (3H, d), 3.62 (2H, d), 4.16-4.38 (2H, m), 5.06 (1H, dd), 6.87 (3H, d), 6.97-7.(3H, m), 7.17 (2H, d), 7.53 (1H, d), 10.95 (1H, s), 14.67 (1H, s); m/z; ES+ [M+H]+ = 744.4.
Example 134: 7-[(3S)-3-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- Intermediate 133c (235 mg, 0.42 mmol) was stirred in formic acid (1 mL) at 60 °C for 2 h. The mixture was evaporated to dryness and the residue was diluted with NMP (2 mL). Intermediate 5f (203 mg, 0.42 mmol) was added and the mixture was stirred at RT for 16 h. Purification of the reaction mixture by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (138 mg, 45.3 %) as a white solid. 1H NMR 5 1.21 (2H, q), 1.57 (2H, dd), 1.81 (2H, d), 1.97 (7H, h), 2.09-2.28 (4H, m), 2.55-2.(6H, m), 2.99 (3H, d), 3.45 (2H, t), 3.62 (2H, d), 3.78 (2H, t), 4.38 (1H, dq), 6.42 (1H, d), 6.87 (3H, d), 6.93- 7.08 (2H, m), 7.16 (3H, d), 7.52 (2H, dd), 10.35 (1H, s), 14.63 (1H, s); m/z; ES+ [M+H]+ = 728.4.
Vo N _O yl]phenyl}piperidin-l-yl]-4-fluoro-lLf-indazole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 256 Example 135: 7-(4-{4-[7-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}methyl)-2- azaspiro[3.5|nonan-2-yl|phenyl ؛piperidin-l-yl)-4-fluoro-l/f-indole-3-carbonitrile The title compound was prepared using methodology described in example 134 using intermediate 128j and intermediate 5f to give the title compound in the form of a formate salt (7 mg, 5 %) as a white solid. 1H NMR 0.97 (2H, d), 1.44-1.55 (3H, m), 1.73 (4H, s), 1.75-1.86 (6 m), 1.90 (4H, d), 1.95 (4H, s), 2.16 (2H, dd), 2.7-2.8 (3H, m), 2.98 (2H, d), 3.39 (2H, d), 3.78 (3H, t), 4.37 (1H, s), 6.37-6.44 (3H, m), 6.81 (1H, d), 6.(2H, d), 7.06-7.17 (3H, m), 7.50 (1H, s), 7.55 (1H, d), 8.26 (1H, s), 8.46 (1H, s), 10.34 (1H, s) 1H not observed; m/r. ES+ [M+H]+ = 767.7.
Example 136 Intermediate 136a: 5-Bromo-4-fluoro-2-iodoaniline l-Bromo-2-fluoro-4-iodo-5-nitrobenzene (10.0 g, 28.91 mmol) was added to ammonium chloride (7.7 g, 144.55 mmol) and iron (8.0 g, 144.55 mmol) in MeOH (100 mL) and water (25.00 mL). The mixture was stirred at 60 °C for 1 h. The reaction mixture was filtered and the solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in Et20 to give the title compound (5.2 g, 56.9 %) as a white solid. 1H NMR 5 5.30 (2H, s), 7.00 (1H, d), 7.(1H, d); m/z; ES+ [M+H]+ = 315.7.
Intermediate 136b: tert-Butyl 4-[(2-amino-4-bromo-5-fluorophenyl)ethynyl]piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 257 The title compound was prepared using methodology described in intermediate 103a using 5-bromo-4-fluoro- 2-iodoaniline and tert-butyl 4-ethynylpiperidine-l-carboxylate to give the title compound (5.0 g, 76 %) as a yellow solid. 1H NMR 5 1.41 (9H, s), 1.49-1.63 (2H, m), 1.75-1.9 (2H, m), 2.87 (1H, dd), 3.10 (2H, t), 3.6- 3.74 (2H, m), 5.36 (2H, s), 6.96 (1H, d), 7.11 (1H, d); m/z; ES+ [M+H]+ = 396.9.
Intermediate 1360: 4-(6-Bromo-5-t1uoro-l//-indol-2-yl)piperidine-l-carboxylic acid Bis(acetonitrile)palladium(II) chloride (0.653 g, 2.52 mmol) was added to tert-butyl 4-[(2-amino-4-bromo-5- fluorophenyl)ethynyl]piperidine-l-carboxylate (5.0 g, 12.59 mmol) inDMF (80 mL) under nitrogen. The mixture was stirred at 120 °C for 3 h, cooled to RT and the solvent was evaporated to afford crude product. The crude product was purified by flash C18-flash chromatography, elution gradient 0 to 50% MeOH in water (0.1% formic acid) to give the title compound (700 mg, 16.3 %) as a brown foam. 1H NMR 5 1.79 (2H, q), 2.11 (2H, d), 2.86-3.05 (3H, m), 3.28 (2H, d), 6.14-6.29 (1H, m), 7.40 (1H, d), 7.55 (1H, dd), 8.40 (1H, d), 11.39 (1H, s); m/z; ES+ [M+H]+= 341.0.
Intermediate 136d: 6-Bromo-5-fluoro-2-(piperidin-4-yl)-l/f-indole HCI (1.25M in MeOH, 3 mL, 12.00 mmol) was added to 4-(6-bromo-5-fluoro-17/-indol-2-yl)piperidine-l- carboxylic acid (200 mg, 0.59 mmol) and was stirred at RT for l h. The solvent was evaporated to afford crude product which was used without further purification. m z ES+ [M+H]+ = 297.0.
Intermediate 136e: tert-Butyl 4-(6-bromo-5-nuoro-l//-indol-2-yl)piperidine-l-carboxylate DMAP (103 mg, 0.84 mmol) was added to 6-bromo-5-fluoro-2-(piperidin-4-yl)-17/-indole (500 mg, 1.mmol), di-ter-butyl dicarbonate (0.586 mL, 2.52 mmol) and DIPEA (0.882 mL, 5.05 mmol) in MeOH (5 mL) at RT for 16 h. The solvent was evaporated to afford to crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (300 mg, 44.9 %) as a brown solid. 1H NMR 5 1.42 (9H, s), 1.47-1.64 (2H, m), 1.9-2.03 (2H, m), 2.78-2.96 (3H, m), 4.04 (2H, d), 6.20 (1H, d), 7.38 (1H, d), 7.51 (1H, dd), 11.20 (1H, s).
Intermediate 136f: WO 2024/189488 PCT/IB2024/052251 258 tert-Butyl 4-(6-bromo-5-tluoro-l-methyl-l//-indol-2-yl)piperidine-l-carboxylate The title compound was prepared using methodology described in intermediate 103c using tert-butyl 4-(6- brorno-5-nuoro-l//-indol-2-yl)pipcridinc-l-carboxylate to give the title compound (1.4 g, 67 %) as a brown solid. 1H NMR 5 1.43 (9H, s), 1.93 (2H, d), 2.74 (1H, t), 2.86-3.05 (2H, m), 3.72 (3H, d), 4.07 (2H, d), 5.(1H, s), 6.26 (1H, s), 7.31 (1H, d), 7.50 (1H, d), 10.43 (1H, s); m/r. ES+ [M+H]+= 412.0.
Intermediate 136g: tert-Butyl 4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5-fh1oro-l-methyl-n/-indol-2-yl]piperidine-l-carboxylate F The title compound was prepared using methodology described in intermediate 102b using tert-butyl 4-(6- bromo-5-nuoro-l-mcthyl-l//-indol-2-y!)piperidine-1-carboxylate and l,3-diazinane-2,4-dione to give the title compound (750 mg, 35 %) as a brown solid. 1H NMR (CDC13) 5 6.16 (9H, s), 6.59-6.81 (2H, m), 7.24 (5H, p), 7.55-7.8 (3H, m), 8.45 (4H, d), 8.79 (2H, dd), 10.99 (1H, s), 12.04 (1H, d), 12.19-12.31 (1H, m), 15.(1H, s); m/2; ES+ [M-tert-Bu+H]+ = 389.0.
Example 136: 4-Chloro-7-[(37?)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5-fluoro-l-methyl-lZ/-indol-2-yl]piperidin- l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indole-3-carbonitrile CI N The title compound was prepared using methodology described in example 123 using tert-butyl 4-[6-(2,4- dioxo-1.3-diazinan-l -yl)-5-nuoro-l-mcthyl-l //-indol-2-yl|pipcridinc-l -carboxylate and intermediate 21d to give the title compound in the form of a formate salt (35 mg, 29 %) as a white solid. 1H NMR 5 1.14-1.(2H, m), 1.56 (1H, t), 1.62-1.71 (3H, m), 1.75-1.84 (3H, m), 1.91 (4H, s), 2.06 (2H, t), 2.20 (2H, d), 2.63 (4H, dt), 2.75 (3H, q), 2.95 (3H, d), 3.41 (2H, d), 3.62 (2H, d), 3.71 (5H, d), 6.25 (1H, s), 6.79 (1H, d), 6.87 (2H, d), 7.09 (1H, d), 7.16 (2H, d), 7.30 (1H, d), 7.49 (1H, d), 8.26 (1H, s), 10.42 (1H, s),12.38 (1H, s); m/2׳ . ES+ [M+H]+ = 775.4.
WO 2024/189488 PCT/IB2024/052251 259 Example 137 Intermediate 137a: 4-Chloro-7-{(3S)-3-[4-(4-formylpiperidin-l-yl)phenyl]piperidin-l-yl}-lZ/-indole-3-carbonitrile Intermediate lie (200 mg, 0.35 mmol) was stirred in formic acid (0.5 mL) at 60 °C for 2 h. The reaction was cooled to RT and evaporated to dryness to give the title compound as a crude solid which was used without further purification. 1H NMR 5 1.08-1.31 (1H, m), 1.46-1.68 (2H, m), 1.77-2.03 (4H, m), 2.42-2.55 (4H, m), 2.6-2.85 (3H, m), 3.00 (1H, t), 3.34 (2H, t), 3.46-3.59 (2H, m), 6.72-6.96 (2H, m), 7.15 (2H, dd), 8.31 (1H, d), 9.63 (1H, d), 12.75 (2H, s); m/r. ES+ [M+H]+ = 447.0.
Example 137: 4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5-fluoro-l-methyl-lZ/-indol-2-yl]piperidin- l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indole-3-carbonitrile CI N The title compound was prepared using methodology described in example 123 using 4-chloro-7-{(3S)-3-[4- (4-formylpipcridin-l-yl)phcnyl|pipcridin-l-yl;-I//-indolc-3-carbonilrilc and intermediate 136g to give the title compound in the form of a formate salt (75 mg, 28 %) as a white solid. 1H NMR 5 1.21 (2H, t), 1.51-1.(4H, m), 1.79 (2H, d), 1.91 (5H, q), 2.05 (2H, t), 2.19 (2H, d), 2.52 (1H, s), 2.55-2.7 (4H, m), 2.74 (3H, t), 2.96 (3H, t), 3.26-3.4 (3H, m), 3.62 (2H, d), 3.70 (1H, s), 3.73 (2H, d), 6.25 (1H, s), 6.85 (3H, dd), 7.15 (3H, dd), 7.30 (1H, d), 7.49 (1H, d), 8.32 (1H, s), 10.43 (1H, s), 12.29 (1H, s); m/2׳ . ES+ [M+H]+ = 775.4.
Example 138: 4-Chloro-7-[(37?)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5-fluoro-l-methyl-lZ/-indol-2-yl]piperidin- l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indazole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 260 The title compound was prepared using methodology described in example 123 using intermediate 132a and intermediate 136g to give the title compound in the form of a formate salt (153 mg, 44 %) as a white solid. 1H NMR 5 1.22 (2H, q), 1.64 (4H, dt), 1.80 (2H, d), 1.91 (5H, t), 2.11 (2H, t), 2.24 (2H, d), 2.57-2.82 (7H, m), 2.98 (3H, d), 3.53 (2H, t), 3.63 (2H, d), 3.72 (5H, t), 6.26 (1H, s), 6.89 (3H, dd), 7.18 (2H, d), 7.25 (1H, d), 7.31 (1H, d), 7.49 (1H, d), 10.42 (1H, s), 14.44 (1H, s); m/z; ES+ [M+H]+ = 776.5.
Example 139: 4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5-fluoro-l-methyl-lZ/-indol-2-yl]piperidin- l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl]-lZ/-indazole-3-carbonitrile The title compound was prepared using methodology described in example 123 using intermediate 9g and intermediate 136g to give the title compound in the form of a formate salt (94 mg, 24 %) as a white solid. 1H NMR 5 1.23 (2H, t), 1.56-1.72 (4H, m), 1.80 (2H, d), 1.91 (5H, t), 2.10 (2H, t), 2.24 (2H, d), 2.58-2.83 (7H, m), 2.98 (3H, d), 3.49-3.57 (2H, m), 3.63 (2H, d), 3.71 (5H, d), 6.26 (1H, s), 6.88 (3H, dd), 7.18 (2H, d), 7.(1H, d), 7.31 (1H, d), 7.49 (1H, d), 10.43 (1H, s), 14.45 (1H, s); m/r. ES+ [M+H]+ = 776.4.
Example 140 Intermediate 140a: 7-(4-{4-[4-(Dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl)-4-fluoro-lfl-indazole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 The title compound was prepared using methodology described in intermediate 60d using intermediate 133b and intermediate le to give the title compound (210 mg, 33 %) as a yellow solid. 1H NMR (CDC13) 5 0.(8H, t), 1.28 (1H, s), 1.39-1.47 (4H, m), 1.56-1.62 (4H, m), 1.78 (1H, dtd), 1.91 (2H, d), 2.01 (3H, s), 2.(3H, dt), 2.91 (2H, td), 3.42-3.54 (5H, m), 3.61-3.74 (4H, m), 4.23 (1H, d), 6.87-6.99 (4H, m), 7.14-7.(2H, m); m/z; ES+ [M+H]+ = 562.4.
Example 140: 7-(4-{4-[4-({4-[6-(2,4-Dioxo-l,3-diazinan-l-yl)-l-methyl-lZ/-indol-2-yl]piperidin-l-yl}methyl)piperidin- l-yl]phenyl}piperidin-l-yl)-4-fh1oro-lZ/-indazole-3-carbonitrile 7-(4-[4-|4-(Dibutoxymcthyl)pipcridin-l-yl|phcnyl ;pipcridin-l-yl)-4-nuoro-l//-indazolc-3-carbonitrilc (1mg, 0.18 mmol) was stirred in formic acid (0.5 mL) at 60 °C for 2 h. The reaction was cooled to RT and evaporated to dryness. Intermediate 13c (200 mg, 0.47 mmol) was stirred in formic acid (2 mL) at 40 °C for h. The solvent was evaporated to dryness. The two residues were dissolved in NMP (1.5 mL) and sodium acetate (19.01 mg, 0.23 mmol) was added. The resulting solution was stirred at RT for 16 h. Purification of the reaction mixture by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (41 mg, 23 %) as a white solid. 1H NMR 5 1.24 (2H, s), 1.67 (3H, s), 1.84 (4H, t), 1.94 (4H, s), 2.11 (2H, s), 2.25 (2H, s), 2.57-2.68 (4H, m), 2.69-2.85 (5H, m), 2.95-3.03 (2H, m), 3.56 (2H, s), 3.66 (5H, d), 3.(2H, s), 6.24 (1H, s), 6.91 (4H, d), 7.03 (1H, s), 7.14 (2H, d), 7.36 (1H, s), 7.43 (1H, d), 10.26-10.31 (1H, m); m/z; ES+ [M+H]+ = 742.4.
Example 141: WO 2024/189488 PCT/IB2024/052251 262 7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-2-methyl-lZ/-indol-l-yl]piperidin-l-yl}methyl)piperidin- l-yl]phenyl}piperidin-l-yl)-4-fluoro-lZf-indole-3-carbonitrile A suspension of intermediate 2d (82 mg, 0.19 mmol) and intermediate 114e (100 mg, 0.20 mmol) in NMP (mL) was stirred at RT for 5 mins followed by the addition of sodium triacetoxyborohydride (48 mg, 0.mmol) and was stirred at RT for l h. The mixture was added dropwise to a stirred solution of sat.NaHCO3:water (1:2, 5 mL). The resulting solid was filtered, washing with water and then dried under vacuum at 45 °C to afford crude product. Purification by preparative HPLC (Column A, Eluent A) gave the title compound in the form of a formate salt (83 mg, 58.6 %) as a white solid. 1H NMR 5 1.19 - 1.32 (3H, m), 1.- 1.73 (1H, m), 1.73 - 1.81 (2H, m), 1.86 (4H, s), 1.9-2.04 (2H, m), 2.14 (2H, t), 2.26 (2H, d), 2.38-2.(4H, m), 2.53 - 2.69 (3H, m), 2.7 - 2.83 (4H, m), 3.03 (2H, d), 3.38 (2H, d), 3.67 (2H, d), 3.74 (2H, t), 4.(1H, s), 6.16 (1H, s), 6.83 (1H, dd), 6.87 - 6.96 (4H, m), 7.03 - 7.09 (1H, m), 7.14 (2H, d), 7.48 (1H, d), 8.(1H, s), 10.29 (1H, s), 12.24 (1H, s); m/r. ES+ [M+H]+ = 741.5.
Example 142: 4-Chloro-7-(4-{4-[7-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lLf-indol-l-yl]piperidin-l-yl}methyl)-2- azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl)-lLf-indole-3-carbonitrile Intermediate 129a (80 mg, 0.13 mmol) was stirred in formic acid (1 mL) at 60 °C for 2 h. The solvent was evaporated and diluted with NMP (3 mL). Intermediate 5f (75 mg, 0.16 mmol) and sodium acetate (10.63 mg, 0.13 mmol) was added and stirred at RT for 16 h. The reaction mixture was purified by flash C18-flash chromatography, elution gradient 0 to 50% MeCN in water (0.1% formic acid). Pure fractions were evaporated to dryness to give the title compound in the form of a formate salt (8.5 mg, 8.37 %) as a white solid. 1H NMR 5 1.11 (2H, d), 1.55 (2H, t), 1.85 (5H, s), 1.88 (OH, s), 1.97 (5H, d), 2.15 (2H, d), 2.34 (1H, d), 2.56 (1H, d), 2.64 (2H, d), 2.73-2.84 (4H, m), 2.99 (2H, d), 3.18 (2H, d), 3.43 (3H, d), 3.55 (4H, d), 3.79 (2H, t), 4.74 (1H, d), 6.50 (2H, dd), 6.88 (1H, d), 7.00 (1H, dd), 7.05-7.23 (4H, m), 7.40 (1H, d), 7.62 (1H, dd), 8.33 (1H, d), 10.36 (1H, s), 12.32 (1H, s); m/z; ES+ [M+H]+ = 783.3.
WO 2024/189488 PCT/IB2024/052251 263 Example 143 Intermediate 143a: The title compound was prepared using methodology described in intermediate 11a using 4- (dibutoxymethyl)piperidine and intermediate ic to give the title compound (1.6 g, 37 %) as a brown oil. 1H NMR 5 0.89 (6H, t), 1.33 (6H, m), 1.46-1.52 (5H, m), 1.72 (4H, d), 2.57 (2H, dd), 2.88 (2H, s), 3.35 (3H, s), 3.39 (2H, dt), 3.55 (2H, dt), 3.62 (2H, d), 4.12 (2H, d), 4.18 (1H, d), 5.09 (2H, s), 6.84 (2H, d), 7.05 (2H, d), 7.33-7.43 (5H, m); m/z; ES+ [M+H]+ = 537.5.
Intermediate 143b: 4-(Dibutoxymethyl)-l-[4-(piperidin-4-yl)phenyl]piperidine The title compound was prepared using methodology described in intermediate 41c using benzyl 4-{4-[4- (dibutoxymethyl)piperidin-l-yl]phenyl}piperidine-l-carboxylate to give the title compound (950 mg, 84 %) as a colourless gum. 1H NMR 5 0.87 (6H, t), 0.99-1.55 (13H, m), 1.55-1.75 (5H, m), 2.39 (1H, d), 2.54 (3H, d), 2.97 (2H, d), 3.37 (2H, dt), 3.47-3.59 (3H, m), 3.61 (1H, s), 4.17 (1H, d), 6.77-6.88 (2H, m), 6.97-7.06 (2H, m); m/z; ES+ [M+H]+ = 403.3.
Intermediate 1430: 4-Chloro-7-(4-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidin-l-yl)-lfl-indazole-3-carbonitrile The title compound was prepared using methodology described in intermediate 57b using 4-(dibutoxymethyl)- l-[4-(piperidin-4-yl)phenyl]piperidine and intermediate 9c to give the title compound (220 mg, 39 %) as a yellow solid. 1H NMR 5 0.89 (6H, t), 1.21-1.44 (8H, m), 1.43-1.57 (4H, m), 1.69-1.78 (1H, m), 1.86-2.03 Benzyl 4-{4-[4-(dibutoxymethyl)piperidin-l-yl]phenyl}piperidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 264 (4H, m), 2.53-2.63 (3H, m), 2.82 (2H, t), 3.33-3.45 (4H, m), 3.5-3.62 (2H, m), 3.65 (2H, d), 4.20 (1H, d),6.89 (1H, s), 6.88-7 (2H, m), 7.13 (2H, d), 7.32 (1H, d), 14.67 (1H, s). no mass data Example 143: 4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4- c]pyridin-6-yl]piperazin-l-yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-lZ/-indazole-3-carbonitrile The title compound was prepared using methodology described in example 140 using 4-chloro-7-(4-{4-[4- (dibutoxy methyl )pipe ridin-1-yl Ipheny 1; pipcridin-1 -yl)-1 //-indazolc-3-carbonitrilc and intermediate 30e to give the title compound (16 mg, 9 %) as a white solid. 1H NMR 5 1.23 (2H, q), 1.69 (1H, s), 1.77-2.01 (7H, m), 2.22 (2H, d), 2.31 (1H, dd), 2.42-2.48 (4H, m), 2.57-2.67 (4H, m), 2.76-2.94 (3H, m), 3.62 (8H, d), 3.(3H, s), 4.13 (1H, d), 4.27 (1H, d), 4.96 (1H, dd), 6.48 (1H, s), 6.91 (3H, dd), 7.13 (2H, d), 7.29 (1H, d), 10.(1H, s) one proton exchanged; m z ES+ [M+H]+ = 791.4.
Example 144: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-lZ/-pyrrolo[3,4-c]pyridin-6- yl | piperazin-1-yl ؛ methyl)piperidin-l-yl | phenyl; piperidin-l-yl)-4-tluoro-l//-indazole-3-carbonitrile ^=J0 N O The title compound was prepared using methodology described in example 140 using intermediate 140a and intermediate 30e to give the title compound (18 mg, 16 %) as a white solid. 1H NMR 5 1.25 (2H, q), 1.69 (1H, s), 1.82-1.96 (7H, m), 2.22 (2H, d), 2.24-2.38 (1H, m), 2.45 (4H, t), 2.54-2.69 (5H, m), 2.78 (2H, t), 2.83- 2.96 (1H, m), 3.58-3.68 (7H, m), 3.89 (3H, s), 4.13 (1H, d), 4.27 (1H, d), 4.96 (1H, dd), 6.49 (1H, s), 6.8-6.(3H, m), 7.01 (1H, t), 7.13 (2H, d), 10.92 (1H, s), 14.53 (1H, s); mfc ES+ [M+H]+ = 775.4.
Example 145: 7-(4-2,6)-2]-4 -)؛ 4 -] 4 ؛ -Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l//-isoindol-5-yl|piperazin- 1-yl ؛ methyl)piperidin-l-yl | phenyl{ piperidin-1-yl)-4-tluoro-l//-indazole-3-carbonitrile H _O N. N JO WO 2024/189488 PCT/IB2024/052251 265 The title compound was prepared using methodology described in example 140 using intermediate 140a and intermediate li to give the title compound (20 mg, 18 %) as a white solid. 1H NMR 5 1.24 (3H, tq), 1.69 (1H, d), 1.78-2 (7H, m), 2.23 (2H, d), 2.29-2.45 (1H, m), 2.53 (1H, s), 2.62 (4H, td), 2.79 (2H, dd), 2.91 (1H, ddd), 3.30 (6H, d), 3.55 (2H, d), 3.65 (2H, d), 4.15-4.41 (2H, m), 5.06 (1H, dd), 6.90 (3H, td), 6.98-7.18 (5H, m), 7.53 (1H, d), 10.96 (1H, s), 14.51 (1H, s); m/z; ES־ [M-H]742.2 = ־.
Example 146: 4-Chloro-7-(4-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-n/-indol-l-yl]piperidin-l-yl}methyl)piperidin- The title compound was prepared using methodology described in example 62 using intermediate 143c and intermediate 5f to give the title compound (15 mg, 19 %) as a white solid. 1H NMR 5 1.24 (2H, d), 1.68 (1H, s), 1.81-2.07 (10H, m), 2.23 (4H, dd), 2.6-2.69 (3H, m), 2.72-2.87 (4H, m), 3.02 (2H, d), 3.62 (4H, dd), 3.(2H, t), 4.37-4.41 (1H, m), 6.42 (1H, d), 6.88-7 (4H, m), 7.1-7.19 (3H, m), 7.29 (1H, d), 7.48-7.57 (2H, m), 10.34 (1H, s), 14.55 (1H, s); m/z; ES+ [M+H]+ = 744.4.
Example 147: 7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-lZ/-indol-l-yl]piperidin-l-yl}methyl)piperidin-l- yl]phenyl}piperidin-l-yl)-4-fluoro-lZf-indazole-3-carbonitrile XsC N 0 l-yl]phenyl}piperidin-l-yl)-lZ/-indazole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 266 The title compound was prepared using methodology described in example 62 using intermediate 140a and intermediate 5f to give the title compound (15 mg, 19 %) as a white solid. 1H NMR 5 1.25 (2H, q), 1.69 (1H, s), 1.82-1.88 (4H, m), 1.91-2.09 (6H, m), 2.20 (2H, t), 2.28 (2H, d), 2.55-2.69 (3H, m), 2.74-2.85 (4H, m), 3.03 (2H, d), 3.53 (2H, d), 3.66 (2H, d), 3.79 (2H, t), 4.37-4.42 (1H, m), 6.43 (1H, d), 6.87-7.01 (4H, m), 7.(1H, t), 7.11-7.2 (3H, m), 7.49-7.58 (2H, m), 10.34 (1H, s), 14.55 (1H, s); m/z; ES+ [M+H]+ = 728.4.
Example 148 Intermediate 148a: 7-Chloro-4-methyl-l//-indazole Pd(dppf)C12 (0.632 g, 0.86 mmol) was added to K2CO3 (2.388 g, 17.28 mmol), 4-bromo-7-chloro-l//-indazole (2.0 g, 8.64 mmol) and trimethylboroxine (1.62 g, 12.96 mmol) in l,4-dioxane:water (4:1, 30 mL) under nitrogen. The mixture was stirred at 120 °C for 16 h and then cooled to RT. The reaction mixture was diluted with EtOAc (50 mL) and washed with water (50 mL), NaO solution, dried over MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 20% EtOAc in Et20 to give the title compound (1.3 g, 90 %) as a white solid. 1H NMR 5 2.(3H, s), 6.89 (1H, d), 7.31 (1H, d), 8.23 (1H, d), 13.53 (1H, s); m/r. ES+ [M+H]+ = 167.1.
Intermediate 148b: 7-Chloro-3-iodo-4-methyl-l//-indazole CI The title compound was prepared using methodology described in intermediate 113a using 7-chloro-4-methyl- 1H-indazole to give the title compound (1.9 g, 87 %) as a yellow solid. 1H NMR 5 2.72 (3H, s), 6.83 (1H, dd), 7.31 (1H, d) 1H not observed; m/z; ES+ [M+H]+ = 292.9.
Intermediate 1480: 7-Chloro-4-methyl-l//-indazole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 267 The title compound was prepared using methodology described in intermediate 113b using 7-chloro-3-iodo-4- methyl-!//-indazole to give the title compound (590 mg, 53 %) as a white solid. 1H NMR 5 2.67 (3H, d), 7.(1H, d), 7.51 (1H, d), 14.85 (1H, s); m/r. ES+ [M+H]+ = 192.0.
Intermediate 148d: 7-{4-[4-(Benzyloxy)phenyl]piperidin-l-yl}-4-methyl-lZ/-indazole-3-carbonitrile The title compound was prepared using methodology described in intermediate 23a using 7-chloro-4-methyl- //-indazolc-3-carbo nitrile and intermediate 27b to give the title compound (380 mg, 45 %) as a white solid. 1H NMR 5 1.80 - 2.00 (4H, m), 2.60 (3H, s), 2.59 - 2.66 (1H, m), 2.67 - 2.83 (2H, m), 3.44 - 3.54 (2H, m), 5.07 (2H, s), 6.82 - 6.91 (1H, m), 6.92 - 7.03 (3H, m), 7.16 - 7.25 (2H, m), 7.28 - 7.48 (5H, m), 14.26 (1H, s); m/z; ES+ [M+H]+ = 423.2.
Intermediate 148e: 7-{4-[4-(Benzyloxy)phenyl]piperidin-l-yl}-4-methyl-l-{[2-(trimethylsilyl)ethoxy]methyl}-lZ/-indazole-3- carbonitrile The title compound was prepared using methodology described in intermediate 27d using 7-chloro-4-methyl- 17/-indazole-3-carbonitrile to give the title compound (400 mg, 87 %) as a white solid. 1H NMR 5 -0.12 (9H, s), 0.83 (2H, dt), 1.84 (4H, s), 2.48 - 2.54 (1H, m), 2.63 (3H, s), 2.82 (2H, s), 3.24 (2H, d), 3.66 (2H, t), 5.(2H, d), 6.09 (2H, s), 6.88 - 6.99 (2H, m), 7.10 (1H, d), 7.16 - 7.26 (3H, m), 7.28 - 7.38 (3H, m), 7.39 - 7.(2H, m); m/z; ES+ [M+H]+ = 553.3.
Intermediate 1481: 7-[4-(4-Hydroxyphenyl)piperidin-l-yl]-4-methyl-l-{[2-(trimethylsilyl)ethoxy]methyl}-lZ/-indazole-3- carbonitrile WO 2024/189488 PCT/IB2024/052251 268 The title compound was prepared using methodology described in intermediate 27e using 7-{4-[4- (benzyloxy )pheny !]piperidin-1-yl}-4-methyl-1-{[2-(trimethylsily !)ethoxy ] methyl}-l/7-indazole-3-carbonitrile to give the title compound (280 mg, 96 %) as a yellow solid. 1H NMR 5 -0.08 (9H, s), 0.82 (2H, t), 1.79 - 1.(4H, m), 2.55 - 2.61 (1H, m), 2.65 (3H, s), 2.79 - 2.89 (2H, m), 3.25 (2H, d), 3.68 (2H, t), 6.10 (2H, s), 6.67 - 6.76 (2H, m), 7.06 - 7.15 (3H, m), 7.26 (1H, d), 9.28 (1H, s); m/z; ES+ [M+H]+ = 463.2.
Intermediate 148g: 7-(4-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}piperidin-l-yl)-4-methyl-l-{[2- (trimethylsilyl)ethoxy ]methyl] -l/f-indazole-3-carbonitrile K2CO3 (233 mg, 1.69 mmol) was added to 7-[4-(4-hydroxyphenyl)piperidin-l-yl]-4-methyl-l-{[2- (trimethylsilyl)ethoxy]methyl}-l/7-indazole-3-carbonitrile (260 mg, 0.56 mmol) and 2-(3-bromopropyl)-l,3- dioxolane (219 mg, 1.12 mmol) in MeCN (15 mL). The resulting mixture was stirred at 80 °C for 16 h and then cooled to RT. The solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (0.26 g, %) as a yellow solid. 1H NMR 5 -0.22 (9H, s), 0.64 - 0.83 (2H, m), 1.55 - 1.80 (8H, m), 2.50 - 2.57 (3H, m), 2.70 - 2.77 (3H, m), 3.10 - 3.20 (2H, m), 3.51 - 3.61 (2H, m), 3.63 - 3.72 (2H, m), 3.75 - 3.81 (2H, m), 3.82 - 3.89 (2H, m), 4.73 (1H, t), 5.99 (2H, s), 6.69 - 6.87 (2H, m), 6.94 - 7.05 (1H, m), 7.03 - 7.16 (2H, m), 7.16 (1H, d); m/z; ES+ [M+H]+ = 577.4.
Intermediate 148h: 7-(4-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}piperidin-l-yl)-4-methyl-lZ/-indazole-3-carbonitrile The title compound was prepared using methodology described in intermediate 27g using 7-(4-{4-[3-(l,3- fioxolan-2-yl)propoxy]phenyl}piperidin-1 -yl)-4-methyl-1 -{[2-(trimethylsilyl)ethoxy]methyl} -1 //-indazolc-3 - carbonitrile to give the title compound (120 mg, 67 %) as a white solid. m z ES+ [M+H]+ = 447.2.
Example 148: 7-2,6)-2]-4 -؛ 4 -) 4 -] 4 ؛ -Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-l//-isoindol-5-yl| piperazin-1- yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-lZ/-indazole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 269 The title compound was prepared using methodology described in example 24 using 7-(4-{4-[3-(l,3-dioxolan- 2-yl)propoxy]phenyl}piperidin-l-yl)-4-methyl-l/7-indazole-3-carbonitrile and intermediate 7c to give the title compound (16 mg, 9 %) as a white solid. 1H NMR 5 1.63 (2H, q), 1.76 (2H, t), 1.82 - 2.01 (5H, m), 2.40 (2H, t), 2.58 (1H, s), 2.63 (3H, t), 2.80 (2H, q), 2.83 - 2.96 (2H, m), 3.29 (4H, d), 3.34 (5H, s), 3.51 (2H, d), 3.(3H, d), 4.00 (2H, dt), 4.10 (1H, d), 4.23 (1H, d), 4.92 - 5.01 (1H, m), 6.49 (1H, s), 6.61 (1H, s), 6.85 - 7.(4H, m), 7.21 (2H, dd), 10.91 (1H, s), 14.28 (1H, s); m/r. ES+ [M+H]+ = 745.4.
Example 149 Intermediate 149a: 7-(4-{4-[4-(l,3-Dioxolan-2-yl)piperidin-l-yl]phenyl}piperidin-l-yl)-4-methyl-lZ/-indazole-3-carbonitrile The title compound was prepared using methodology described in intermediate 23a using intermediate 148c and intermediate le to give the title compound (90 mg, 28 %) as a yellow solid. 1H NMR 5 1.30 - 1.48 (2H, m), 1.54 - 1.65 (1H, m), 1.67 - 1.77 (2H, m), 1.83 - 1.89 (2H, m), 1.90 - 2.00 (2H, m), 2.49 - 2.63 (7H, m), 2.73 - 2.82 (1H, m), 3.43 - 3.53 (2H, m), 3.61 - 3.71 (2H, m), 3.71 - 3.92 (4H, m), 4.60 (1H, d), 6.82 - 6.(3H, m), 6.99 (1H, d), 7.11 (2H, d), 14.25 (1H, s); m/z; ES+ [M+H]+ = 472.3.
Example 149: 7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l- yl}methyl)piperidin-l-yl]phenyl}piperidin-l-yl)-4-methyl-lZ/-indazole-3-carbonitrile 7-(4-{4-[4-( 1,3 -Dioxolan-2-y!)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-methyl-1 //-indazolc-3 -carbonitrile (mg, 0.17 mmol) was stirred in formic acid (2 mL) at 60 °C for 3 h. The solvent was evaporated to give a residue.
WO 2024/189488 PCT/IB2024/052251 270 Intermediate 7c (70.7 mg, 0.15 mmol) was also stirred in formic acid (2 mL) at 40 °C for 1 h. The solvent was evaporated to give a residue. The two residues were combined in NMP (2 mL) and stirred at RT for 16 h. The reaction mixture was diluted with DCM and washed with NaHCO3 solution. The organic layer was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 10% MeOH in DCM to give a yellow solid. The yellow solid was purified flash C18-flash chromatography, elution gradient 0 to 100% MeCN in water (0.1% formic acid). Pure fractions were evaporated to dryness to give the title compound in the form of a formate salt (9.3 mg, 3.5 %) as a yellow solid. 1H NMR 5 1.16 - 1.(2H, m), 1.67 - 1.71 (1H, m), 1.77 - 2.02 (7H, m), 2.20 - 2.38 (3H, m), 2.54 (4H, s), 2.56 - 2.68 (6H, m), 2.- 2.82 (2H, m), 2.82 - 2.95 (2H, m), 3.27 - 3.32 (4H, m), 3.47 - 3.54 (2H, m), 3.61 - 3.68 (2H, m), 3.83 (3H, s), 4.10 (1H, d), 4.23 (1H, d), 4.96 (1H, dd), 6.49 (1H, d), 6.61 (1H, s), 6.85 -6.94 (3H, m), 7.00 (1H, d), 7.-7.17(2H,m), 10.91 (1H, s), 14.15 (1H, s); m/z: ES+[M+H]+= 770.5.
Example 150 Intermediate 150a: The title compound was prepared using methodology described in intermediate 60a using 3 -(4- bromophenyl)pyrrolidine and benzyl carbonchloridate to give the title compound (4.4 g, 92 %) as a colourless gum. 1H NMR (CDC13) 5 1.94 - 2.09 (1H, m), 2.27 - 2.35 (1H, m), 3.31 - 3.41 (2H, m), 3.45 - 3.56 (1H, m), 3.68 - 3.72 (1H, m), 3.88 - 3.93 (1H, m), 5.19 (2H, s), 7.08 - 7.16 (2H, m), 7.29 - 7.47 (5H, m), 7.43 - 7.(2H, m); m/z: ES+ [M+H]+ = 360.1.
Intermediate 150b: Benzyl 3-{4-[3-(l,3-dioxolan-2-yl)propoxy]phenyl}pyrrolidine-l-carboxylate RockPhos Pd G3 (0.465 g, 0.56 mmol) was added to benzyl 3 -(4-bromopheny!)pyrrolidine-1 -carboxylate (2.g, 5.55 mmol), 1,3-dioxolane-2-propanol (1.29 g, 8.33 mmol), C52CO3 (3.62 g, 11.10 mmol) and RockPhos (0.260 g, 0.56 mmol) in toluene (30 mL) under nitrogen. The resulting mixture was stirred at 100 °C for 16 h. The reaction was cooled to RT and the solvent was evaporated to dryness to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 40% EtOAc in Et20 to give the title compound (1.0 g, 43.8 %) as a colourless gum. 1H NMR (CDC13) 5 1.82 - 1.93 (3H, m), 1.92 - 2.09 (3H, m), 2.25 - 2.29 (1H, m), 3.31 - 3.44 (2H, m), 3.44 - 3.53 (1H, m), 3.63 - 3.79 (1H, m), 3.82 - 4.07 (6H, m), 4.(1H, t), 5.19 (2H, d), 6.87 (2H, d), 7.15 (2H, d), 7.30 - 7.43 (5H, m); m/z: ES+ [M+H]+ = 412.2.
Benzyl 3-(4-bromophenyl)pyrrolidine-l-carboxylate WO 2024/189488 PCT/IB2024/052251 271 Intermediate 150c: 3-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}pyrrolidine 0V Pd/C (10%, 0.517 g, 0.49 mmol) was added to benzyl 3-{4-[3-(l,3-dioxolan-2-yl)propoxy]phenyl}pyrrolidine- 1-carboxylate (1.0 g, 2.43 mmol) in MeOH (10 mL) under hydrogen. The resulting mixture was stirred at RT for 3 h. The precipitate was collected by filtration, washed with DCM (50 mL) and dried in the vacuum oven to give the title compound (0.630 g, 93 %) as a yellow solid, which was used without further purification. 1H NMR(CDC13) 5 1.19-1.31 (1H, m), 1.74-1.89 (2H, m), 1.84-1.98 (3H, m), 2.02 (1H, d), 2.14-2.31 (1H, m), 2.84 (1H, t), 3.06-3.28 (1H, m), 3.29-3.44 (1H, m), 3.66-4.05 (7H, m), 4.94 (1H, t), 6.78-6.89 (2H, m), 7.1- 7.18 (2H, m); m/z: ES+ [M+H]+ = 278.0.
Intermediates 150d and intermediate 151a The title compound was prepared using methodology described in intermediate 11c using 3-{4-[3-(l,3- dioxolan-2-yl)propoxy]phenyl}pyrrolidine and intermediate 8a to give the title compound as a racemic mixture. The enantiomers were separated by preparative chiral-HPLC on a Column: CHIRALPAKIA-4.6*50mm 3 pm; Flow rate: 1 mL/min; Mobile Phase A: Hex(0.1% DEA), Mobile Phase B: EtOH (1:1); to give, in order of elution, intermediate 150d(isomer 1, 95 mg, 50 %, >99 % ee) and intermediate 151a (isomer 2, 90 mg, 47 %, >99 % ee).
Intermediate 150d: 7-[(3S'*)-3-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}pyrrolidin-l-yl]-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] Intermediate 151a: 7-[(37?*)-3-{4-[3-(l,3-Dioxolan-2-yl)propoxy]phenyl}pyrrolidin-l-yl]-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] Isomer 1 Isomer 2 WO 2024/189488 PCT/IB2024/052251 272 1H NMR 5 1.74-1.8 (9H, m), 2.36 (1H, s), 2.55 (3H, s), 3.56-3.63 (1H, m), 3.69-3.8 (3H, m), 3.87-3.91 (1H, m), 3.93 4.01 (2H, m), 4.85 (1H, t), 6.43 (1H, d), 6.79 (1H, d), 6.89 (2H, d), 7.28 (2H, d), 8.07 (1H, d), 11.(1H, s).
Example 150: 7-{(3،2,6)-2]-4}-4)-4]-3-(*؟-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l- Isomer 1 The title compound was prepared using methodology described in example 24 using intermediate 150d and intermediate li to give the title compound (6 mg, 4 %) as a white solid. 1H NMR 5 1.59-1.64 (2H, m), 1.7- 1.79 (2H, m), 1.9-2.05 (2H, m), 2.31-2.43 (5H, m), 2.55 (4H, s), 2.59 (1H, s), 2.69 (1H, d), 2.88 (1H, d), 3.(5H, d), 3.45 (3H, s), 3.60 (1H, d), 3.71 (1H, s), 3.98 (2H, t), 4.19 (1H, d), 4.32 (1H, d), 5.05 (1H, dd), 6.(1H, d), 6.79 (1H, d), 6.90 (2H, d), 7.05 (2H, d), 7.28 (2H, d), 7.52 (1H, d), 8.08 (1H, d), 10.95 (1H, s), 11.(1H, s); m/z: ES+ [M+H]+ = 700.4.
Example 151: 7-{(37?*)-3-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l- Isomer 2 The title compound was prepared using methodology described in example 24 using intermediate 151a and intermediate li to give the title compound (12 mg, 8 %) as a white solid. 1H NMR 5 1.59-1.64 (2H, m), 1.7- 1.79 (2H, m), 1.9-2.05 (2H, m), 2.31-2.43 (5H, m), 2.55 (4H, s), 2.59 (1H, s), 2.69 (1H, d), 2.88 (1H, d), 3.(5H, d), 3.45 (3H, s), 3.60 (1H, d), 3.71 (1H, s), 3.98 (2H, t), 4.19 (1H, d), 4.32 (1H, d), 5.05 (1H, dd), 6.(1H, d), 6.79 (1H, d), 6.90 (2H, d), 7.05 (2H, d), 7.28 (2H, d), 7.52 (1H, d), 8.08 (1H, d), 10.95 (1H, s), 11.(1H, s); m/z: ES+ [M+H]+ = 700.4.
Example 152 Intermediate 152a: Methyl 4-[4-(dibutoxymethyl)piperidin-l-yl]-2-fh1orobenzoate yl}butoxy)phenyl]pyrrolidin-l-yl}-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] yl}butoxy)phenyl]pyrrolidin-l-yl}-4-methyl-lZ/-indole-3-carbonitrile [absolute stereochemistry not yet confirmed] WO 2024/189488 PCT/IB2024/052251 273 The title compound was prepared using methodology described in intermediate lla using methyl 4-bromo-2- fluorobenzoate and 4-(dibutoxymethy!)piperidine to give the title compound (3.0 g, 35 %) as a pale yellow oil. 1H NMR 5 0.88 (6H, t), 1.21-1.38 (6H, m), 1.48 (4H, m), 1.70 (2H, d), 1.81 (1H, m), 2.77-2.88 (2H, m), 3.(2H, dt), 3.55 (2H, dt), 3.79 (3H, s), 3.94 (2H, d), 4.17 (1H, d), 6.67-6.79 (2H, m), 7.68 (1H, t); m/z: ES+ [M+H]+= 396.1.
Intermediate 152b: 4-[4-(Dibutoxymethyl)piperidin-l-yl]-2-fluorobenzoic acid Methyl 4-[4-(dibutoxymethyl)piperidin-l-yl]-2-fluorobenzoate (900 mg, 2.28 mmol) was added to sodium hydroxide (546 mg, 13.65 mmol) in water (5 mL) and MeOH (5 mL) at 25 °C. The mixture was stirred at °C for 2.5 h. The reaction mixture was cooled to RT and acidified with HC1 (2M), filtered and evaporated to give the title compound (570 mg, 63.3 %) as a white solid which was used without further purification. 1H NMR 5 0.89 (6H, d), 1.23-1.39 (7H, m), 1.48 (5H, dq), 1.66-1.74 (2H, m), 1.81 (1H, dtd), 2.81 (2H, td), 3.52-3.56 (2H, m), 3.92 (2H, d), 4.17 (1H, d), 6.61-6.79 (2H, m), 7.67 (1H, t), 12.36 (1H, s); m/z: ES+ [M+H]+= 382.2.
Intermediate 152c: 4-Chloro-7-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-lZ/-indazole-3-carbonitrile o 'כ N The title compound was prepared using methodology described in intermediate He using intermediate 9c and l,4-dioxa-8-azaspiro[4.5]decane to give the title compound (1.0 g, 53 %) as a yellow solid. 1H NMR 5 1.82- 2.03 (4H, m), 3.15 (4H, t), 4.02 (4H, d), 6.95 (1H, d), 7.34 (1H, dd), 14.67 (1H, s); m/z: ES־ [M-H]317.1 = ־.
Intermediate 152d: 4-Chloro-7-(4-oxopiperidin-l-yl)-lZf-indazole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 274 4-Chloro-7-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-17/-indazole-3-carbonitrile (1.0 g, 3.14 mmol) was added to formic acid (13 mL) and was stirred at 40 °C for 16 h. The reaction was cooled to RT and the solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (0.580 g, 67.5 %) as a brown solid. 1H NMR 2.64 (4H, t), 3.43 (4H, t), 7.01 (1H, d), 7.33 (1H, d), 14.80 (1H, s); m/z: ES+ [M+H]+ = 275.1.
Intermediate 152e: 7-(4-Aminopiperidin-l-yl)-4-chloro-lZf-indazole-3-carbonitrile N Sodium cyanoborohydride (320 mg, 5.10 mmol) was added to ammonium acetate (1.5 g, 20.39 mmol) and 4- chloro-7-(4-oxopiperidin-l-yl)-17/-indazole-3-carbonitrile (700 mg, 2.55 mmol) inMeOH (10 mL). The mixture was stirred at 25 °C for 2 h. The solvent was evaporated to afford crude product. The crude product was purified by flash C18-flash chromatography, elution gradient 0 to 30% MeOH in water (0.2 % HC1) to give the title compound (400 mg, 56.9 %) as a pale yellow solid. 1H NMR 5 1.75-2.1 (3H, m), 2.79 (1H, td), 3.50 (1H, d), 4.27 (6H, s), 6.93 (1H, d), 7.31 (1H, d), 14.82 (1H, s); m/z: ES+ [M+H]+ = 276.2.
Intermediate 152f: 7V-[l-(4-Chloro-3-cyano-lZf-indazol-7-yl)piperidin-4-yl]-4-[4-(dibutoxymethyl)piperidin-l-yl]-2- fluorobenzamide DIPEA (0.190 mL, 1.09 mmol) and HATU (138 mg, 0.36 mmol) were added to 4-[4- (dibutoxymethyl)piperidin-l-yl]-2-fluorobenzoic acid (166 mg, 0.44 mmol) and 7-(4-aminopiperidin-l-yl)-4- chloro-17/-indazole-3-carbonitrile (100 mg, 0.36 mmol) in DMF (2 mL). The resulting mixture was stirred at °C for 1 h. The reaction was cooled to RT and was diluted with EtOAc (15 mL), washed with water (mL), saturated brine (20 mL), dried over Na2SO4, filtered and evaporated to afford crude product. The crude WO 2024/189488 PCT/IB2024/052251 275 product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (110 mg, 47.5 %) as a yellow gum; 1H NMR 5 0.89 (6H, t), 1.33 (6H, dt), 1.43-1.59 (5H, m), 1.(3H, d), 1.81-2.04 (5H, m), 2.85 (3H, dd), 3.45-3.61 (4H, m), 3.8-3.95 (3H, m), 4.14-4.22 (1H, m), 5.77 (1H, s), 6.63-6.84 (2H, m), 6.95 (1H, d), 7.31 (1H, d), 7.51 (1H, t), 7.69-7.9 (1H, m), 14.70 (1H, s); m/z: ES+ [M+H]+= 639.1.
Example 152: /V-[l-(4-Chloro-3-cyano-lZ/-indazol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/- indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl]-2-fluorobenzamide The title compound was prepared using methodology described in example 140 using M[l-(4-chloro-3-cyano- l//-indazol-7-yl)pipcridin-4-yl|-4-|4-(dibutoxymcthyl)pipcridin-l-yl|-2-nuorobcnzamidc and intermediate 5f to give the title compound in the form of a formate salt (28 mg, 25 %) as a white solid. 1H NMR 5 0.86 (1H, d), 1.17 (2H, d), 1.84 (5H, t), 1.99 (6H, d), 2.09-2.29 (4H, m), 2.73-2.89 (5H, m), 3.01 (2H, d), 3.52 (2H, s), 3.78 (2H, t), 3.83-3.99 (3H, m), 4.39 (1H, s), 6.43 (1H, d), 6.77 (2H, dd), 6.90 (1H, d), 6.97 (1H, d), 7.15 (1H, t), 7.28 (1H, d), 7.45-7.63 (3H, m), 7.72-7.92 (1H, m), 10.36 (1H, s)lH not observed; m/z: ES+ [M+H]+ = 805.3.
Example 153 Intermediate 153a: 4-Chloro-7-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in intermediate He using intermediate lb and l,4-dioxa-8-azaspiro[4.5]decane to give the title compound (1.9 g, 46 %) as a white solid. 1H NMR 5 1.(4H, t), 3.05 (4H, dd), 3.93 (4H, s), 6.84 (1H, d), 7.14 (1H, d), 8.33 (1H, d), 12.28 (1H, s); m/z: ES+ [M+H]+ = 318.2.
Intermediate 153b: WO 2024/189488 PCT/IB2024/052251 276 4-Chloro-7-(4-oxopiperidin-l-yl)-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in intermediate 152d using 4-chloro-7-(l,4- dioxa-8-azaspiro[4.5]decan-8-yl)-l/Aindole-3-carbonitrile to give the title compound (1.6 g, 98 %) as a white solid. 1H NMR (CDC13) 5 2.72 (4H, t), 3.41 (4H, t), 6.95 (1H, d), 7.21 (1H, d), 7.84 (1H, d), 9.24 (1H, s); m/z: ES+ [M+H]+ = 274.2.
Intermediate 1530: 4-Chloro-7-[4-(hydroxyimino)piperidin-l-yl]-lZ/-indole-3-carbonitrile Sodium acetate (1.34 g, 16.37 mmol) was added to 4-chloro-7-(4-oxopipcridin-l-yl)-l//-indolc-3-carbonitrilc (1.6 g, 5.85 mmol) and hydroxylammonium chloride solution (1.54 g, 22.21 mmol) inMeOH (25 mL) and was stirred at 25 °C for 16 h. The solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 50% EtOAc in Et20 to give the title compound (1.6 g, 95 %) as a yellow solid. 1H NMR 5 2.48 (1H, d), 2.75 (2H, t), 3.03 (2H, t), 3.10 (2H, t), 3.37 (1H, s), 6.84 (1H, d), 7.15 (1H, d), 8.36 (1H, s), 10.44 (1H, s), 12.36 (1H, s); m/z: ES" [M-H]287.1 = ־.
Intermediate 153d: 7-(4-Aminopiperidin-l-yl)-4-chloro-lZ/-indole-3-carbonitrile LiAlH! (7.18 ml, 17.94 mmol) was added to 4-chloro-7-|4-(hydroxyimino)pipcridin-l-yl|-l//-indolc-3- carbonitrile (1.4 g, 4.85 mmol) in THE (35 mL) and was stirred at 25 °C for 4 h. The reaction mixture was diluted with EtOAc (100 mL), washed with sodium potassium tartrate (150 mL), dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash C18-flash chromatography, elution gradient 0 to 30% MeOH in water (0.1%NH4HCO3). Pure fractions were evaporated to dryness to afford 7-(4-aminopiperidin-l-yl)-4-chloro-lH-indole-3-carbonitrile (0.900 g, 67.6 %) as a yellow solid. 1H NMR 5 1.54 (1H, d), 1.61 (1H, d), 1.82 (2H, t), 2.6-2.82 (3H, m), 3.34 (2H, d), 6.76 (1H, d), 7.09 (1H, d), 8.25 (1H, s); m/z: ES+ [M+H]+= 273.1.
WO 2024/189488 PCT/IB2024/052251 277 Intermediate 153e: /V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-[4-(dibutoxymethyl)piperidin-l-yl]-2- fluorobenzamide HATU (120 mg, 0.31 mmol) was added to intermediate 152b (80 mg, 0.21 mmol), 7-(4-aminopiperidin-l-yl)- 4-chloro-l/Aindole-3-carbonitrile (86 mg, 0.31 mmol) and DIPEA (0.073 mL, 0.42 mmol) in THE (2 mL) and was stirred at RT for 2 h. The mixture was diluted with EtOAc (10 mL), washed with water (10 mL), saturated brine (10 mL) dried over Na2S04, filtered and evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 60% EtOAc in Et20 to give the title compound (100 mg, 74.7 %) as a yellow solid. 1H NMR 5 0.89 (7H, t), 1.19 - 1.36 (20H, m), 1.37 (2H, d), 1.48 (4H, q), 1.71 (2H, d), 1.93 (4H, s), 2.78 (4H, d), 3.15 (1H, dd), 3.41 (1H, s), 3.49 - 3.68 (3H, m), 3.87 (3H, d), 4.(1H, d), 6.67 - 6.90 (3H, m), 7.16 (1H, d), 7.50 (1H, t), 7.80 (1H, s), 8.32 (1H, d), 12.30 (1H, s); m/z: ES+ [M+H]+= 638.0.
Example 153: A-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[5-(2,4-dioxo-l,3 ־diazinan-l-yl)-lZf-indol- l-yl]piperidin-l-yl}methyl)piperidin-l-yl]-2-fluorobenzamide The title compound was prepared using methodology described in example 117 using A-[l-(4-chloro-3-cyano- l/Aindol-7-yl)piperidin-4-yl]-4-[4-(dibutoxymethyl)piperidin-l-yl]-2-fluorobenzamide and intermediate 89c to give the title compound (17 mg, 13 %) as a white solid. 1H NMR 5 1.17 (2H, d), 1.67-1.88 (5H, m), 1.89- 2.08 (6H, m), 2.11-2.31 (4H, m), 2.65-2.87 (6H, m), 3.00 (2H, d), 3.49 (2H, s), 3.78 (2H, t), 3.87 (3H, d), 4.38 (1H, s), 6.42 (1H, d), 6.65-6.84 (3H, m), 6.97 (1H, d), 7.06 (1H, d), 7.15 (1H, t), 7.4-7.62 (3H, m), 7.(1H, d), 8.20 (1H, s), 10.34 (1H, s), 12.32 (1H, s); m/z: ES+ [M+H]+ = 804.5.
Example 154: A-[l-(4-chloro-3-cyano-l~{H}-indol-7-yl)-4-piperidyl]-4-[4-[[4-[4-[(2,6-dioxo-3-piperidyl)carbamoyl]-3- fluoro-phenyl]piperazin-l-yl]methyl]-l-piperidyl]-2-fluoro-benzamide WO 2024/189488 PCT/IB2024/052251 278 The title compound was prepared using methodology described in example 128 using intermediate 153e and intermediate 104c to give the title compound in the form of a formate salt (54 mg, 26 %) as a white solid. 1H NMR 5 1.15 (2H, q), 1.73-2.02 (8H, m), 2.06-2.14 (1H, m), 2.19 (2H, d), 2.47 (4H, t), 2.54 (4H, s), 2.72-2.(5H, m), 3.31-3.4 (3H, m), 3.87 (3H, t), 4.68-4.78 (1H, m), 6.7-6.88 (5H, m), 7.16 (1H, d), 7.50 (1H, t), 7.(1H, t), 7.81 (1H, dd), 8.02-8.09 (1H, m), 8.16 (1H, s), 8.32 (1H, s), 10.86 (1H, s), 12.32 (1H, s); m/z: ES+ [M+H]+ = 824.2.
Example 155: 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo- 3,5,6,7-tetrahydropyrrolo[3,4-f|isoindol-2(lZf)-yl]methyl}piperidin-l-yl)-2-fh1orobenzamide The title compound was prepared using methodology described in example 128 using intermediate 153e and intermediate 75e to give the title compound in the form of a formate salt (34 mg, 23 %) as a white solid. 1H NMR 5 1.21 (3H, d), 1.76 (1H, s), 1.83 (5H, d), 1.94 (2H, s), 2.07 (2H, s), 2.57 (7H, d), 2.85 (5H, dq), 3.(4H, d), 3.97 (4H, s), 5.14 (1H, dd), 6.73 (1H, d), 6.81 (2H, dd), 7.14 (1H, d), 7.51 (1H, t), 7.79 (3H, s), 8.(1H, s), 11.12 (1H, s), 12.31 (1H, s); m/z: ES+ [M+H]+ = 791.3.
Example 156: /V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5-fh1oro- 1-methyl-lZ/-indol-2-yl]piperidin-l-yl}methyl)piperidin-l-yl]-2-fluorobenzamide WO 2024/189488 PCT/IB2024/052251 279 The title compound was prepared using methodology described in example 128 using intermediate 153e and intermediate 136g to give the title compound in the form of a formate salt (18 mg, 10 %) as a white solid. 1H NMR 5 1.15 (2H, dd), 1.65 (2H, dd), 1.75-1.87 (5H, m), 1.9-1.95 (4H, m), 2.01-2.11 (2H, m), 2.19 (2H, d), 2.7-2.87 (7H, m), 2.96 (2H, d), 3.51 (2H, s), 3.67-3.76 (5H, m), 3.8-3.93 (3H, m), 6.26 (1H, s), 6.68-6.(3H, m), 7.04 (1H, d), 7.30 (1H, d), 7.50 (2H, dd), 7.77 (1H, dd), 8.17 (1H, s), 10.41 (1H, s), 12.31 (1H, s); m/z:ES+[M+H]+ = 836.3.
Example 157: The title compound was prepared using methodology described in example 128 using intermediate 153e and intermediate 72b to give the title compound in the form of a formate salt (13 mg, 17 %) as a white solid. 1H NMR 5 1.07-1.31 (2H, m), 1.79 (3H, d), 1.91 (2H, d), 2-2.27 (3H, m), 2.50 (4H, q), 2.56-2.71 (2H, m), 2.78- 3.24 (11H, m), 3.33 (1H, s), 3.34 (1H, s), 3.63 (3H, s), 3.88 (3H, dd), 6.59-7.01 (6H, m), 7.15 (1H, d), 7.(1H, t), 7.78 (1H, dd), 8.31 (1H, s), 11.09 (1H, s), 12.29 (1H, s)lH not observed; m/z: ES+ [M+H]+ = 835.3.
Example 158: 7V-[l-(4-Chloro-3-cyano-lZf-indol-7-yl)piperidin-4-yl]-4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl- lZ/-indol-2-yl]piperidin-l-yl}methyl)piperidin-l-yl]-2-fluorobenzamide 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2- oxo-2,3-dihydro-l/f-benzimidazol-4-yl]piperazin-l-yl}methyl)piperidin-l-yl]-2-fluorobenz amide WO 2024/189488 PCT/IB2024/052251 280 The title compound was prepared using methodology described in example 128 using intermediate 153e and intermediate 13c to give the title compound in the form of a formate salt (22 mg, 8 %) as a white solid. 1H NMR 5 1.17 (2H, p), 1.65 (2H, tt), 1.71-2.03 (9H, m), 2.10 (2H, t), 2.22 (2H, d), 2.69-2.86 (7H, m), 2.98 (2H, d), 3.29-3.37 (2H, m), 3.68 (3H, s), 3.74-3.89 (2H, m), 3.91 (3H, d), 6.23 (1H, s), 6.63-6.86 (2H, m), 6.(1H, d), 6.93 (1H, dd), 7.15 (1H, d), 7.36 (1H, d), 7.43 (1H, d), 7.51 (1H, t), 7.78 (1H, dd), 8.31 (1H, s), 10.(1H, s), 12.31 (1H, s); m/z: ES+ [M+H]+= 818.0.
Example 159: 7V-[l-(4-Chloro-3-cyano-lZf-indol-7-yl)piperidin-4-yl]-4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3- dihydro-lZ/-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]-2-fh1orobenzamide The title compound was prepared using methodology described in example 128 using intermediate 153e and intermediate li to give the title compound in the form of a formate salt (17 mg, 14 %) as a white solid. 1H NMR 5 1.16 (3H, d), 1.7-2.01 (8H, m), 2.20 (2H, d), 2.35 (1H, s), 2.59 (2H, d), 2.80 (5H, s), 3.32 (7H, s), 3.(4H, d), 4.21 (1H, d), 4.33 (1H, d), 5.05 (1H, dd), 6.6-6.93 (3H, m), 7.06 (1H, d), 7.15 (1H, d), 7.51 (2H, dd), 7.78 (1H, d), 8.31 (2H, m), 10.96 (1H, s), 12.37 (1H, s); m/z: ES+ [M+H]+= 820.4.
Example 160: 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l,3 ־diazinan-l-yl)-W/-indol- l-yl]piperidin-l-yl}methyl)piperidin-l-yl]-2-fluorobenzamide WO 2024/189488 PCT/IB2024/052251 281 The title compound was prepared using methodology described in example 117 using intermediate 153e and intermediate 5f to give the title compound in the form of a formate salt (23 mg, 18 %) as a white solid. 1H NMR 5 1.18 (2H, t), 1.65-1.92 (4H, m), 1.9-2.05 (7H, m), 2.1-2.31 (4H, m), 2.79 (6H, dt), 3.01 (2H, d), 3.(2H, s), 3.68-3.85 (2H, m), 3.88 (3H, s), 4.38 (1H, s), 6.42 (1H, d), 6.64-6.88 (3H, m), 6.96 (1H, d), 7.05- 7.35 (2H, m), 7.38-7.58 (3H, m), 7.79 (1H, dd), 8.31 (1H, s), 10.34 (1H, s), 12.30 (1H, s); m/z: ES+ [M+H]+ = 804.4.
Example 161: 7V-[l-(4-Chloro-3-cyano-lZf-indol-7-yl)piperidin-4-yl]-4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3- dioxo-2,3-dihydro-l/f-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]-2-fluorobenz amide The title compound was prepared using methodology described in example 24 using intermediate 153e and intermediate 50b to give the title compound (335 mg, 16 %) as a white solid. 1H NMR 5 1.16 (2H, q), 1.73- 2.04 (7H, m), 1.98-2.09 (1H, m), 2.21 (2H, d), 2.51-2.67 (5H, m), 2.75-3.01 (5H, m), 3.33 (7H, s), 3.88 (3H, dd), 5.11 (1H, dd), 6.67-6.96 (3H, m), 7.15 (1H, d), 7.43-7.66 (2H, m), 7.64-7.9 (2H, m), 8.31 (1H, s), 11.(1H, s), 12.27-12.32 (1H, m); m/z: ES+ [M+H]+ = 852.3.
Example 162 Intermediate 162a: Methyl 2-cyano-4-[4-(dibutoxymethyl)piperidin-l-yl]benzoate WO 2024/189488 PCT/IB2024/052251 282 The title compound was prepared using methodology described in intermediate lla using methyl 4-bromo-2- cyanobenzoate and 4-(dibutoxymethy !)piperidine to give the title compound (1.6g, 69 %) as a white solid. 1H NMR (CDC13) 5 0.95 (5H, t), 1.30 (OH, s), 1.34-1.44 (5H, m), 1.44 (1H, s), 1.59 (4H, dq), 1.90 (3H, q), 2.85- 2.96 (2H, m), 3.45 (2H, dt), 3.65 (2H, dt), 3.93 (5H, d), 4.03 (1H, s), 4.19 (1H, d), 7.01 (1H, dd), 7.16 (1H, d), 7.97 (1H, d); m/z: ES+ [M+H]+ = 403.1.
Intermediate 162b: 2-Cyano-4-[4-(dibutoxymethyl)piperidin-l-yl]benzoic acid Lithium hydroxide (0.268 g, 11.18 mmol) was added to methyl 2-cyano-4-[4-(dibutoxymethyl)piperidin-l- yl]benzoate (1.5 g, 3.73 mmol) in THE (25 mL) and water (25 mL). The resulting solution was stirred at 25 °C for 1 h, followed by addition of HCI (IM, 11.18 mL, 11.18 mmol). The solvent was evaporated to give the title compound (0.90 g, 62.2 %) as a yellow solid which was used in the next step without further purification. 1H NMR 5 1.21 (1H, t), 1.91 (8H, qd), 2.88-2.96 (2H, m), 2.93-3.08 (2H, m), 3.13-3.26 (6H, m), 3.45 (5H, dd), 5.14-5.24 (2H, m), 7.28-7.47 (2H, m), 9.26 (4H, s); m/z: ES+ [M+H]+ = 389.1.
Intermediate 162c: 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-2-cyano-4-[4-(dibutoxymethyl)piperidin-l- yl] benzamide EDC (148 mg, 0.77 mmol) was added to HOBt (118 mg, 0.77 mmol), DIPEA (0.135 mL, 0.77 mmol), 2- cyano-4-[4-(dibutoxymethyl)piperidin-l-yl]benzoic acid (150 mg, 0.39 mmol) and intermediate 153d (1mg, 0.39 mmol) in DMF (2 mL) at 25 °C. The solution was stirred at 25 °C for 2 h and then the reaction mixture was purified by flash C18-flash chromatography, elution gradient 0 to 100% MeCN in water (0.1% NHHCO,) to give the title compound (160 mg, 64.2 %) as a pale yellow solid. 1H NMR 5 0.89 (6H, td), 1.22- 1.47 (8H, m), 1.44-1.54 (4H, m), 1.72 (2H, d), 1.82 (2H, s), 1.89 (1H, d), 1.95 (3H, s), 2.82 (4H, d), 3.35-3.(1H, m), 3.56 (2H, q), 3.94 (3H, d), 4.19 (1H, d), 6.86 (1H, d), 7.12-7.27 (2H, m), 7.33 (1H, d), 7.70 (1H, dd), 8.32 (1H, d), 8.36-8.45 (1H, m), 12.30 (1H, s). no mass ion Intermediate 162d: 7V-[l-(4-Chloro-3-cyano-lZf-indol-7-yl)piperidin-4-yl]-2-cyano-4-(4-formylpiperidin-l-yl)benzamide WO 2024/189488 PCT/IB2024/052251 283 #-[ 1 -(4-Chloro-3 -cy ano-1 //-indol-7-y l )pipcridi n-4-y 11 -2-cyano-4-[4-(dibutoxymethy !)piperidin-1 - yl]benzamide (210 mg, 0.33 mmol) was stirred in formic acid (3 mL) at 60 °C for 1 h. The reaction was cooled to RT and evaporated to dryness to give the title compound (160 mg, 95 %) as a yellow solid which was used without further purification, m/z: ES+ [M+H]+ = 515.2. no nmr data Example 162: 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-2-cyano-4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)- lZf-indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl]benzamide The title compound was prepared using methodology described in example 140 using #-[l-(4-chloro-3-cyano- l/7-indol-7-yl)piperidin-4-yl]-2-cyano-4-(4-formylpiperidin-l-yl)benzamide and intermediate 5f to give the title compound in the form of a formate salt (44 mg, 17 %) as a white solid. 1H NMR 5 1.19 (2H, s), 1.77-2.(10H, m), 2.13-2.36 (5H, m), 2.7-2.86 (6H, m), 2.84-3.04 (2H, m), 3.37 (2H, d), 3.79 (2H, td), 3.94 (3H, s), 4.39 (1H, s), 6.43 (1H, s), 6.86 (1H, dd), 6.98 (1H, s), 7.1-7.2 (2H, m), 7.25 (1H, d), 7.36 (1H, s), 7.47-7.(2H, m), 7.69 (1H, d), 8.32 (1H, d), 8.42 (1H, d), 10.34 (1H, s), 12.31 (1H, s); m/z: ES+ [M+H]+ = 811.4.
Example 163 Intermediate 163a: Methyl 4-[4-(dibutoxymethyl)piperidin-l-yl]-2-fluoro-6-methylbenzoate The title compound was prepared using methodology described in intermediate lla using methyl 4-bromo-2- fluoro-6-methylbenzoate and 4-(dibutoxymethyl)piperidine to give the title compound (2.3 g, 46 %) as a white solid. 1H NMR 5 0.86 (6H, t), 1.2-1.37 (5H, m), 1.39-1.53 (5H, m), 1.72 (3H, dd), 2.31 (3H, s), 2.72 (2H, td), 3.36 (2H, dt), 3.53 (2H, dt), 3.75 (3H, s), 3.85 (2H, d), 4.14 (1H, d), 6.44-6.7 (2H, m); m/z: ES+ [M+H]+ = 410.1.
WO 2024/189488 PCT/IB2024/052251 284 Intermediate 163b: 4-[4-(Dibutoxymethyl)piperidin-l-yl]-2-fluoro-6-methylbenzoic acid The title compound was prepared using methodology described in intermediate 162b using methyl 4-[4- (dibutoxymethyl)piperidin-l-yl]-2-fluoro-6-methylbenzoate to give the title compound (1.6 g, 97 %) as a white solid. 1H NMR 5 0.88 (6H, t), 1.18-1.4 (6H, m), 1.48 (4H, dq), 1.69 (3H, d), 2.29 (3H, s), 2.6-2.73 (2H, m), 3.37 (2H, dt), 3.54 (2H, dt), 3.79 (2H, d), 4.16 (1H, d), 6.43-6.61 (2H, m); m/z: ES+ [M+H]+ = 394.2.
Intermediate 163c: 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-[4-(dibutoxymethyl)piperidin-l-yl]-2-fh1oro-6- methylbenzamide The title compound was prepared using methodology described in intermediate 152f using 4-[4- (dibutoxymethyl)piperidin-l-yl]-2-fluoro-6-methylbenzoic acid and intermediate 153d to give the title compound (180 mg, 55 %) as a yellow gum. m/z: ES+ [M+H]+ = 652.4. no nmr data Example 163: /V-[l-(4-(hloro-3-cyano-l//-indol-7-yl)piperidin-4-yl|-4-[4-(2,4)-4]-4 ؛-dioxo-l,3-diazinan-l-yl)-l//-indol- l-yl]piperidin-l-yl}methyl)piperidin-l-yl]-2-fluoro-6-methylbenz amide The title compound was prepared using methodology described in example 140 using #-[l-(4-chloro-3-cyano- 1//-indol-7-y !)pipe ridin-4-yl|-4-|4-(dibutoxy methyl )pipe ridin-l-yl|-3-fh1oro-5-mcthy !benzamide and intermediate 5f to give the title compound in the form of a formate salt (84 mg, 37 %) as a white solid. 1H NMR 5 1.11-1.26 (2H, m), 1.7-1.89 (5H, m), 1.97 (6H, t), 2.12-2.31 (7H, m), 2.69-2.82 (6H, m), 3.00 (2H, d), 3.39 (2H, s), 3.72-3.83 (4H, m), 3.90 (1H, d), 4.39 (1H, dq), 6.42 (1H, d), 6.53-6.59 (1H, m), 6.63 (1H, d), 6.80 (1H, d), 6.97 (1H, d), 7.06-7.22 (2H, m), 7.47-7.59 (2H, m), 8.27 (1H, s), 8.37 (1H, d), 10.33 (1H, s), 10.35 (1H, s); m/z: ES+ [M+H]+ = 818.3.
Example 164 ,NH 0 WO 2024/189488 PCT/IB2024/052251 285 Intermediate 164a: The title compound was prepared using methodology described in intermediate lla using methyl 4-bromo-3- methylbenzoate and 4-(dibutoxymethyl)piperidine to give the title compound (1.7 g, 33 %) as a yellow gum. 1H NMR 5 0.90 (6H, t), 1.18 (lH,t), 1.33 (3H, ddd), 1.34-1.43 (2H, m), 1.43-1.58 (4H, m), 1.62-1.81 (2H, m), 1.99 (1H, s), 2.26 (3H, s), 2.59 (2H, t), 3.18 (2H, d), 3.41 (2H, dt), 3.57 (2H, dt), 3.80 (3H, s), 4.23 (1H, d), 7.04 (1H, d), 7.69-7.83 (2H, m); m/z: ES+ [M+H]+ = 392.3.
Intermediate 164b: 4-[4-(Dibutoxymethyl)piperidin-l-yl]-3-methylbenzoic acid The title compound was prepared using methodology described in intermediate 162b using methyl 4-[4- (dibutoxymethyl)piperidin-l-yl]-3-methylbenzoate to give the title compound (1.35 g, 82 %) as a black solid. 1H NMR 5 0.72 (6H, t), 1.07-1.25 (6H, m), 1.26-1.39 (4H, m), 1.53 (2H, d), 1.61 (1H, s), 2.07 (3H, s), 2.33- 2.46 (2H, m), 2.96 (2H, d), 3.23 (2H, dt), 3.39 (2H, dt), 4.05 (1H, d), 6.76-6.85 (1H, m), 7.53 (2H, d) (1H not observed); m/z: ES+ [M+H]+ = 378.1.
Intermediate 164c: A,-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl|-4-[4-(dibutoxymethyl)piperidin-l-yl|-3- methylbenzamide The title compound was prepared using methodology described in intermediate 153e using 4-[4- (dibutoxymethyl)piperidin-l-yl]-3-methylbenzoic acid and intermediate 153d to give the title compound (2mg, 65 %) as a yellow gum. 1H NMR 5 0.90 (5H, t), 1.12-1.7 (8H, m), 1.73-2 (2H, m), 2.28 (3H, s), 2.70 (9H, s), 2.92 (OH, s), 3.09-3.17 (2H, m), 3.32 (5H, s), 3.36-3.45 (4H, m), 3.47-3.63 (1H, m), 4.25 (1H, d), 6.(1H, d), 7.02 (1H, d), 7.16 (1H, d), 7.67 (2H, d), 8.19 (1H, d), 8.32 (1H, d), 12.29 (1H, s); m/z: ES+ [M+H]+ = 632.3.
Methyl 4-[4-(dibutoxymethyl)piperidin-l-yl]-3-methylbenzoate WO 2024/189488 PCT/IB2024/052251 286 Example 164: /V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-n/-indol- The title compound was prepared using methodology described in example 140 using #-[l-(4-chloro-3-cyano- l/7-indol-7-yl)piperidin-4-yl]-4-[4-(dibutoxymethyl)piperidin-l-yl]-3-methylbenzamide and intermediate 5f to give the title compound in the form of a formate salt (72 mg, 26 %) as a white solid. 1H NMR 5 1.32 (2H, d), 1.70 (1H, s), 1.8-2.1 (10H, m), 2.19 (2H, t), 2.29 (5H, s), 2.64 (2H, t), 2.77 (4H, t), 3.02 (2H, d), 3.14 (2H, d), 3.3-3.43 (2H, m), 3.78 (2H, t), 3.93 (1H, d), 4.39 (1H, s), 6.42 (1H, d), 6.85 (1H, d), 7.00 (2H, dd), 7.15 (2H, t), 7.45-7.57 (2H, m), 7.68 (2H, d), 8.19 (1H, d), 8.32 (1H, s), 10.33 (1H, s), 12.31 (1H, s); m/z: ES+ [M+H]+ = 800.3.
Example 165 Intermediate 165a: The title compound was prepared using methodology described in intermediate lla using methyl 4-bromo-3- cyanobenzoate and 4-(dibutoxymethyl)piperidine to give the title compound (2.7 g, 55 %) as a pale yellow gum. 1H NMR 5 0.89 (6H, t), 1.3-1.52 (11H, m), 1.79 (3H, d), 2.85-2.98 (2H, m), 3.40 (2H, dt), 3.57 (2H, dt), 3.80 (4H, s), 4.23 (1H, d), 7.17 (1H, d), 7.95-8.1 (2H, m); m/z: ES+ [M+H]+ = 403.1.
Intermediate 165b: 3-Cyano-4-[4-(dibutoxymethyl)piperidin-l-yl]benzoic acid The title compound was prepared using methodology described in intermediate 104b using methyl 3 -cyano-4- [4-(dibutoxymethyl)piperidin-l-y!]benzoate to give the title compound (2.3 g, 88 %) as a white solid. 1H NMR l-yl]piperidin-l-yl}methyl)piperidin-l-yl]-3-methylbenz amide Methyl 3-cyano-4-[4-(dibutoxymethyl)piperidin-l-yl]benzoate WO 2024/189488 PCT/IB2024/052251 287 0.88 (6H, t), 1.28-1.4 (5H, m), 1.42-1.56 (5H, m), 1.77 (3H, d), 2.89 (2H, t), 3.39 (2H, dt), 3.56 (2H, dt), 3.74 (2H, d), 4.23 (1H, d), 7.15 (1H, d), 7.9-8.17 (2H, m), 12.97 (1H, s); m/z: ES+ [M+H]+= 389.1.
Intermediate 165c: /V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-3-cyano-4-[4-(dibutoxymethyl)piperidin-l- yl] benzamide The title compound was prepared using methodology described in intermediate 153e using 3-cyano-4-[4- (dibutoxymethy!)piperidin-1-y!]benzoic acid and intermediate 153d to give the title compound (200 mg, 60 %) as a yellow gum. 1H NMR 5 0.90 (6H, t), 1.27-1.52 (8H, m), 1.71-1.94 (5H, m), 2.70 (14H, s), 3.52-3.77 (3H, m), 3.94 (1H, s), 4.25 (1H, d), 6.86 (1H, d), 7.17 (1H, dd), 8.05 (1H, d), 8.22 (1H, d), 8.26-8.46 (2H, m), 12.30 (1H, s); m/z: ES+ [M+H]+ = 645.2.
Example 165: A,-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl|-3-cyano-4-[4-(2,4)-4]-4 ؛-dioxo-l,3-diazinan-l-yl)- lZf-indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl]benzamide The title compound was prepared using methodology described in example 140 using #-[l-(4-chloro-3-cyano- I //-indol-7-yl)pipcridin-4-yl|-3-cyano-4-|4-(dibuloxymclhyl)pipcridin-l -yl|bcnzamidc and intermediate 5f to give the title compound in the form of a formate salt (69 mg, 30 %) as a white solid. 1H NMR 5 1.33 (2H, t), 1.78 (1H, s), 1.97 (9H, dt), 2.19 (2H, t), 2.29 (2H, d), 2.72-2.86 (4H, m), 2.92 (2H, t), 3.02 (2H, d), 3.40 (2H, d), 3.70 (2H, d), 3.79 (2H, t), 3.94 (1H, s), 4.39 (1H, s), 6.43 (1H, d), 6.84 (1H, d), 6.97 (1H, d), 7.09-7.(3H, m), 7.49-7.56 (2H, m), 8.06 (1H, dd), 8.23 (1H, d), 8.32 (1H, s), 8.39 (1H, d), 10.33 (1H, s), 12.34 (1H, s); m/z: ES+[M+H]+= 811.4.
Example 166 Intermediate 166a: Methyl 5-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)pyridine-2-carboxylate WO 2024/189488 PCT/IB2024/052251 288 The title compound was prepared using methodology described in intermediate 63 a using methyl 5- fluoropyridine-2-carboxylate and l,4-dioxa-8-azaspiro[4.5]decane to give the title compound (2.5 g, 69 %) as a yellow solid. 1H NMR 5 1.63-1.73 (4H, m), 3.44-3.56 (4H, m), 3.79 (3H, s), 3.91 (4H, s), 7.35 (1H, dd), 7.84 (1H, d), 8.38 (1H, d); m/z: ES+ [M+H]+ = 279.0.
Intermediate 166b: 5-(l,4-Dioxa-8-azaspiro[4.5]decan-8-yl)pyridine-2-carboxylic acid LiOH (2.5 g, 106.25 mmol) was added to methyl 5-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)pyridine-2- carboxylate (2.5 g, 10.63 mmol) in THF:water (1:1, 50 mL) at RT and stirred for 1 h. The solvent was removed under reduced pressure to afford and the aqueous was neutralised to pH7 using HCI (2M). The solid was filtered under vacuum to give the title compound (3.00 g, 107 %) which was used without further purification. 1H NMR 5 1.65 (4H, t), 3.35-3.42 (4H, m), 3.88 (4H, s), 7.43 (1H, dd), 7.83 (1H, d), 8.11 (1H, d) 1H not observed; m/z: ES+ [M+H]+ = 265.0.
Intermediate 166c: 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-5-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)pyridine-2- carboxamide Propane phosphonic acid anhydride (50%, 463 mg, 0.73 mmol) was added to 5-(l,4-dioxa-8- azaspiro[4.5]decan-8-yl)pyridine-2-carboxylic acid (144 mg, 0.55 mmol), intermediate 153d (100 mg, 0.mmol) and triethylamine (0.152 mL, 1.09 mmol) in THE (2 mL) and stirred at 40 °C for 2 h. The solvent was removed under reduced pressure afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in Et20 to give the title compound (60.0 mg, 31.6 %) as a brown solid. 1H NMR 5 1.71 (8H, t), 1.9-1.98 (5H, m), 3.44-3.54 (4H, m), 4.23 (1H, t), 6.86 (1H, d), 7.(1H, d), 7.34-7.5 (2H, m), 7.86 (2H, d), 8.27-8.42 (4H, m), 12.32 (1H, s); m/z: ES+ [M+H]+ = 521.0.
Example 166: /V-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl|-5-(4-2,6)-2]-4 ؛-dioxopiperidin-3-yl)-6-fluoro-l,3- dioxo-2,3-dihydro-lZf-isoindol-5-yl]piperazin-l-yl}piperidin-l-yl)pyridine-2-carboxamide WO 2024/189488 PCT/IB2024/052251 289 #-[l-(4-Chloro-3-cyano-l/7-indol-7-yl)piperidin-4-yl]-5-(l,4-dioxa-8-azaspiro[4.5]decan-8-yl)pyridine-2- carboxamide (50 mg, 0.10 mmol) was added to formic acid (1 mL) and stirred at 40 °C for 1 h. The solvent was evaporated to give a residue. Intermediate 50b (53.0 mg, 0.12 mmol) was also added to formic acid (mL) and attired at RT for l h. The solvent was evaporated to give a residue. The two residues were combined inNMP (2 mL) and sodium triacetoxyborohydride (40.7 mg, 0.19 mmol) was added. The mixture was stirred at RT for 16 h. The reaction mixture was purified by flash C18-flash chromatography, elution gradient 5 to 70% MeCN in water (0.1% NHHCO,) to give the title compound (18 mg, 22.8 %) as a yellow solid. 1H NMR 1.54 (3H, d), 1.86-2.09 (7H, m), 2.61 (3H, s), 2.69 (4H, s), 2.76-2.97 (5H, m), 3.25 (4H, s), 3.98 (3H, d), 5.11 (1H, dd), 6.86 (1H, d), 7.16 (1H, d), 7.4-7.49 (2H, m), 7.73 (1H, d), 7.86 (1H, d), 8.27 (1H, d), 8.32 (2H, s), 11.11 (1H, s), 12.33 (1H, s); m/z: ES+ [M+H]+= 821.3.
Example 167: /V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-n/-indol- l-yl]piperidin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide The title compound was prepared using methodology described in example 62 using intermediate 166c and intermediate 5f to give the title compound (16 mg, 8 %) as a white solid. 1H NMR 8 1.24 (3H, s), 1.90 (11H, d), 2.22 (4H, d), 2.69-2.92 (7H, m), 3.01 (2H, d), 3.78 (2H, t), 3.94 (3H, d), 4.39 (1H, s), 6.43 (1H, d), 6.(1H, d), 6.97 (1H, d), 7.15 (2H, t), 7.38-7.47 (1H, m), 7.47-7.59 (2H, m), 7.86 (1H, d), 8.25-8.36 (3H, m), 10.34 (1H, s), 12.32 (1H, s); m/z: ES+ [M+H]+ = 787.4.
Example 168: 2V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3- dihydro-lZf-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide WO 2024/189488 PCT/IB2024/052251 290 The title compound was prepared using methodology described in example 24 using intermediate 166c and intermediate li to give the title compound (62 mg, 17 %) as a white solid. 1H NMR 5 1.21 (3H, d), 1.77-2.(9H, m), 2.23 (2H, d), 2.22-2.43 (1H, m), 2.62 (4H, s), 2.78-2.98 (6H, m), 3.34 (4H, s), 3.93 (3H, d), 4.1-4.(2H, m), 5.06 (1H, dd), 6.86 (1H, d), 7.07 (2H, d), 7.16 (1H, d), 7.36-7.46 (1H, m), 7.53 (1H, d), 7.85 (1H, d), 8.25-8.36 (3H, m), 10.96 (1H, s), 12.32 (1H, s); m/z: ES+ [M+H]+ = 803.3.
Example 169: The title compound was prepared using methodology described in example 24 using intermediate 166c and intermediate 50b to give the title compound (45 mg, 15 %) as a white solid. 1H NMR 5 1.22 (3H, d), 1.84 (3H, d), 1.95 (5H, s), 2.24 (2H, d), 2.55 (6H, s), 2.87 (6H, t), 3.27 (4H, s), 3.93 (3H, d), 5.11 (1H, dd), 6.86 (1H, d), 7.16 (1H, d), 7.36-7.51 (2H, m), 7.74 (1H, d), 7.85 (1H, d), 8.30 (3H, t), 11.12 (1H, s), 12.31 (1H, s); m/z: ES + [M+H]+= 835.4.
Example 170 Intermediate 170a: Methyl 5-[4-(dibutoxymethyl)piperidin-l-yl]pyridine-2-carboxylate The title compound was prepared using methodology described in intermediate 63a using methyl 5- fluoropyridine-2-carboxylate and 4-(dibutoxymethyl)piperidine to give the title compound (3.5 g, 71 %) as a 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fh1oro-l,3- dioxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide WO 2024/189488 PCT/IB2024/052251 291 white solid. 1H NMR 5 0.88 (6H, t), 1.25 (1H, dd), 1.26-1.4 (5H, m), 1.42-1.53 (4H, m), 1.69-1.77 (2H, m), 1.77-1.84 (1H, m), 2.83 (2H, t), 3.34-3.43 (2H, m), 3.5-3.6 (2H, m), 3.79 (3H, s), 3.98 (2H, d), 4.18 (1H, d), 7.31 (1H, dd), 7.84 (1H, d), 8.35 (1H, d); m/z: ES+ [M+H]+ = 379.2.
Intermediate 170b: 5-[4-(Dibutoxymethyl)piperidin-l-yl]pyridine-2-carboxylic acid The title compound was prepared using methodology described in intermediate 104b using methyl 5-[4- (dibutoxymethyl)piperidin-l-yl]pyridine-2-carboxylate to give the title compound (3.2 g, 96 %) as a yellow solid. 1H NMR 5 0.88 (6H, t), 1.21-1.3 (1H, m), 1.26-1.4 (5H, m), 1.48 (4H, dq), 1.73 (2H, d), 1.77-1.84 (1H, m), 2.77-2.88 (2H, m), 3.33-3.43 (2H, m), 3.5-3.6 (2H, m), 3.98 (2H, d), 4.18 (1H, d), 7.32 (1H, dd), 7.(1H, d), 8.33 (1H, d), 12.38 (1H, s); m/z: ES+ [M+H]+ = 365.2.
Intermediate 170c: 2V-[l-(4-Chloro-3-cyano-lZf-indazol-7-yl)piperidin-4-yl]-5-[4-(dibutoxymethyl)piperidin-l-yl]pyridine-2- carboxamide The title compound was prepared using methodology described in intermediate 152f using 5-[4- (dibutoxymethyl)piperidin-l-yl]pyridine-2-carboxylic acid and intermediate 152e to give the title compound (500 mg, 97 %) as a white solid. 1H NMR 5 0.89 (6H, t), 1.2-1.41 (6H, m), 1.37-1.57 (4H, m), 1.75 (2H, d), 1.95 (4H, s), 2.69 (4H, s), 2.84 (3H, s), 3.35-3.46 (2H, m), 3.57 (2H, dt), 3.95 (3H, d), 4.20 (1H, d), 6.94 (1H, dd), 7.01-7.13 (1H, m), 7.40 (1H, dd), 7.85 (1H, d), 8.26-8.35 (2H, m), 14.73 (1H, s); m/z: ES" [M-H]־ = 620.3.
Example 170: 2V-[l-(4-Chloro-3-cyano-lZ/-indazol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/- indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide WO 2024/189488 PCT/IB2024/052251 292 The title compound was prepared using methodology described in example 62 using M[l-(4-chloro-3-cyano- l/7-indazol-7-yl)piperidin-4-yl]-5-[4-(dibutoxymethyl)piperidin-l-yl]pyridine-2-carboxamide and intermediate 5f to give the title compound (5 mg, 4 %) as a white solid. 1H NMR 5 1.22 (3H, d), 1.89 (HH, d), 2.12-2.35 (4H, m), 2.77 (2H, t), 2.91 (4H, s), 3.01 (2H, d), 3.63 (2H, s), 3.78 (2H, t), 3.94 (3H, d), 4.39 (1H, s), 6.42 (1H, d), 6.82 (1H, d), 6.97 (1H, d), 7.05-7.23 (2H, m), 7.42 (1H, dd), 7.47-7.59 (2H, m), 7.86 (1H, d), 8.27-8.37 (2H, m), 10.35 (1H, s); m/z: ES+ [M+H]+ = 788.4.
Example 171 Intermediate 171a: 7-(l,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-4-methyl-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in intermediate 57b using intermediate 8a and l,4-dioxa-8-azaspiro[4.5]decane to give the title compound (729 mg, 77 %) as a white solid. 1H NMR 5 1.89 - 1.99 (4H, m), 2.64 (3H, s), 3.02 - 3.13 (4H, m), 3.98 (4H, s), 6.81 (1H, d), 6.91 (1H, dd), 8.22 (1H, d), 11.(1H, s); m/z: ES+ [M+H]+ = 298.3.
Intermediate 171b: 7-(4-{[(4-Methoxyphenyl)methyl]amino}piperidin-l-yl)-4-methyl-lZ/-indole-3-carbonitrile 7-(l,4-Dioxa-8-azaspiro[4.5]decan-8-yl)-4-methyl-l/7-indole-3-carbonitrile (791 mg, 2.66 mmol) was stirred in formic acid (18 mL, 497.44 mmol) at 60 °C for 4 h. The reaction mixture was evaporated and the residue was suspended in NMP (2 mL) at RT. 4-Methoxybenzylamine (0.695 mL, 5.32 mmol) was added and the mixture was stirred for 5 mins followed by the addition of sodium triacetoxy hydroborate (1.9 g, 9.31 mmol) and was stirred at RT for 2 h. The reaction mixture was diluted with EtOAc (75 mL), washed with water (2x mL), saturated brine (50 mL), dried over a phase separating cartridge and the solvent was evaporated to afford crude product. The crude product was purified by flash silica chromatography, elution gradient 0 to 100% EtOAc in heptane followed by MeOH (10%) in EtOAc to give the title compound (0.743 g, 74.6 %) as a yellow solid. 1H NMR 5 1.9 - 2.01 (6H, m), 2.23 (4H, t), 2.64 (3H, s), 2.93 - 3.04 (1H, m), 3.82 (3H, s), 6.(1H, d), 6.86-6.96 (1H, m), 6.98-7.08 (2H, m), 7.51 (2H, d), 8.11-8.38 (2H, m), 12.04 (1H, s); m/z: ES+ [M+H]+= 375.1.
Intermediate 1710: 7-(4-Aminopiperidin-l-yl)-4-methyl-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 293 7-(4-{[(4-Methoxyphenyl)methyl]amino}piperidin-l-yl)-4-methyl-l/f-indole-3-carbonitrile (743 mg, 1.mmol) was dissolved in ethanol (40 mL), acetic acid (200 pL) and Pd(OH)2/C (20%, 139 mg, 0.20 mmol) was added. The mixture was hydrogenated at atmospheric pressure and RT for 48 h. The mixture was filtered through Celite® and the solvent was evaporated to give the title compound (0.193 g, 38.2 %) as a beige solid. 1H NMR 5 1.53 - 1.68 (2H, m), 1.88 (2H, d), 2.61 - 2.65 (3H, m), 2.66 - 2.75 (2H, m), 3.23 - 3.44 (3H, m), 6.78 (1H, d), 6.90 (1H, dd), 8.18 (1H, s) 3 exchangeable H not observed; m/z: ES+ [M+H]+ = 255.2.
Intermediate 171d: Methyl 5-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]pyridine-2-carboxylate The title compound was prepared using methodology described in intermediate 63a using methyl 5- fluoropyridine-2-carboxylate and 4-( 1,3-dioxolan-2-y!)piperidine to give the title compound (960 mg, 55 %) as a white solid. 1H NMR (CDCL) 5 1.55 (2H, s), 1.82 (1H, tq), 1.88 (2H, d), 2.90 (2H, td), 3.85 - 4.01 (9H, m), 4.69 (1H, d), 7.14 (1H, dd), 7.94 - 8.02 (1H, m), 8.34 (1H, d); m/z: ES+ [M+H]+ = 293.2.
Intermediate 171e: 5-[4-(l,3-Dioxolan-2-yl)piperidin-l-yl]pyridine-2-carboxylic acid LiOH (0.617 g, 14.71 mmol) in water (10 mL) was added to a solution of methyl 5-[4-(l,3-dioxolan-2- y!)piperidin-l-yl]pyridine-2-carboxylate (0.860 g, 2.94 mmol) in THE (10 mL) and MeOH (20 mL). The mixture was stirred at 50 °C for 30 mins and then cooled to RT. The solvent was evaporated and the residue was suspended in water (5 mL) and neutralised with citric acid (IM). The product was extracted with DCM (10 mL) and the solvent was evaporated to give the title compound (0.693 g, 85 %) as a white solid. 1H NMR 1.37 (2H, qd), 1.66 - 1.96 (3H, m), 2.87 (2H, td), 3.72 - 3.94 (4H, m), 4.01 (2H, d), 4.61 (1H, d), 7.34 (1H, dd), 7.84 (1H, d), 8.34 (1H, d); m/z: ES+ [M+H]+ = 279.2.
Intermediate 171f: /V-[l-(3-Cyano-4-methyl-lZ/-indol-7-yl)piperidin-4-yl]-5-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]pyridine-2- carboxamide 0 N■ HO N WO 2024/189488 PCT/IB2024/052251 294 The title compound was prepared using methodology described in intermediate 152f using 7-(4- aminopiperidin-1 -yl)-4-methyl-1 //-indolc-3 -carbonitrile and 5-[4-(l ,3 -dioxolan-2-y!)piperidin-1 -y!]pyridine- 2-carboxylic acid to give the title compound (729 mg, 77 %) as a white solid. 1H NMR 5 1.38 - 1.51 (2H, m), 1.73 - 1.86 (4H, m), 1.96 - 2.07 (4H, m), 2.65 (3H, s), 2.82 - 2.94 (4H, m), 3.34 (1H, s), 3.78 - 3.89 (3H, m), 3.89 - 3.97 (3H, m), 4.04 (2H, s), 6.83 (1H, d), 6.93 (1H, dd), 7.44 - 7.51 (1H, m), 7.90 (1H, d), 8.22 (1H, s), 8.30 (1H, d), 8.35 (1H, s), 11.98 (1H, s); m/z: ES+ [M+H]+= 515.5.
Example 171: /V-[l-(3-Cyano-4-methyl-lZ/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fh1oro-l,3- dioxo-2,3-dihydro-lZ/-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide #-[l-(3-Cyano-4-methyl-l/7-indol-7-yl)piperidin-4-yl]-5-[4-(l,3-dioxolan-2-yl)piperidin-l-yl]pyridine-2- carboxamide (88 mg, 0.17 mmol) and intermediate 50b (87 mg, 0.19 mmol) were heated in formic acid (1 mL, 26.51 mmol) at 60 °C for 2 h and then cooled to RT. The mixture was concentrated and the residue was suspended in NMP (2 mL) at RT. The reaction mixture was stirred for 5 mins followed by addition of sodium triacetoxyhydroborate (91 mg, 0.43 mmol). The suspension was stirred at RT for 2 h. The reaction mixture was purified by flash C18-flash chromatography, elution gradient 5 to 70% MeCN in water (0.1% formic acid) to give the title compound in the form of a formate salt (5.5 mg, 37.4 %) as a yellow solid. 1H NMR 5 1.(3H, d), 1.84 (3H, d), 1.95 (4H, d), 2.04 (1H, dd), 2.25 (2H, d), 2.55 - 2.66 (7H, m), 2.72 - 2.98 (5H, m), 3.(4H, s), 3.93 (3H, d), 5.11 (1H, dd), 6.78 (1H, d), 6.88 (1H, d), 7.36 -7.52 (2H, m), 7.74 (1H, d), 7.85 (1H, d), 8.09 - 8.2 (1H, m), 8.24 (1H, d), 8.30 (1H, d), 11.10 (1H, s) 4H under DMSO; m/z: ES+ [M+H]+ = 815.6.
Example 172: /V-[l-(3-Cyano-4-methyl-n/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3- dihydro-lLf-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide WO 2024/189488 PCT/IB2024/052251 295 The title compound was prepared using methodology described in example 171 using intermediate 17 If and intermediate li to give the title compound in the form of a formate salt (47 mg, 37 %) as a white solid. 1H NMR S 1.19 - 1.38 (3H, m), 1.83 - 1.95 (3H, m), 1.95-2.11 (5H, m), 2.2-2.33 (2H, m), 2.4 - 2.47 (1H, m), 2.61 - 2.71 (4H, m), 2.79 - 3.03 (5H, m), 3.99 (3H, d), 4.27 (1H, d), 4.39 (1H, d), 5.11 (1H, dd), 6.83 (1H, d), 6.93 (1H, d), 7.13 (2H, d), 7.47 (1H, dd), 7.59 (1H, d), 7.91 (1H, d), 8.17 - 8.26 (1H, m), 8.30 (1H, d), 8.(1H, d), 10.99 (1H, s)10H under water and DMSO; m/z: ES+ [M+H]+= 783.8.
Example 173 Intermediate 173a: Methyl 4-[4-(dibutoxymethyl)piperidin-l-yl]benzoate The title compound was prepared using methodology described in intermediate 63a using methyl 4- fluorobenzoate and 4-(dibutoxymethyl)piperidine to give the title compound (2.0 g, 20 %) as a white solid. 1H NMR 5 0.88 (6H, t), 1.18-1.59 (12H, m), 1.75 (3H, t), 2.78 (2H, td), 3.3-3.46 (3H, m), 3.55 (2H, dt), 3.(2H, d), 4.17 (1H, d), 6.93-6.97 (2H, m), 7.74-7.8 (2H, m); m/z: ES+ [M+H]+ = 378.3.
Intermediate 173b: 4-[4-(Dibutoxymethyl)piperidin-l-yl]benzoic acid The title compound was prepared using methodology described in intermediate 104b using methyl 4-[4- (dibutoxymethy!)piperidin-1-y!]benzoate to give the title compound (1.6 g, 83 %) as a white solid. 1H NMR 0.88 (6H, t), 1.15-1.44 (6H, m), 1.4-1.54 (4H, m), 1.75 (3H, t), 2.77 (2H, dd), 3.39 (3H, dt), 3.56 (2H, dt), 3.91 (2H, d), 4.18 (1H, d), 6.86-6.98 (2H, m), 7.69-7.8 (2H, m); m/z: ES+ [M+H]+ = 364.2.
Intermediate 173c: 7V-[l-(4-Chloro-3-cyano-lZf-indol-7-yl)piperidin-4-yl]-4-[4-(dibutoxymethyl)piperidin-l-yl]benzamide WO 2024/189488 PCT/IB2024/052251 296 The title compound was prepared using methodology described in intermediate 152f using 4-[4- (dibutoxymethy!)piperidin-1-y!]benzoic acid and intermediate 153d to give the title compound (170 mg, 66 %) as a yellow gum. 1H NMR 5 0.88 (6H, d), 1.22-1.41 (7H, m), 1.49 (4H, dd), 1.73 (3H, d), 1.93 (4H, d), 2.(3H, p), 3.31-3.43 (5H, m), 3.56 (2H, dt), 3.88 (2H, t), 4.18 (1H, d), 6.85 (1H, d), 6.94 (2H, d), 7.16 (1H, d), 7.77 (2H, d), 8.08 (1H, d), 8.32 (1H, d), 12.22-12.34 (1H, m); m/z: ES+ [M+H]+ = 620.1.
Example 173: /V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/-indol- l-yl]piperidin-l-yl}methyl)piperidin-l-yl]benzamide "؟ HN The title compound was prepared using methodology described in example 142 using #-[l-(4-chloro-3-cyano- l/7-indol-7-yl)piperidin-4-yl]-4-[4-(dibutoxymethyl)piperidin-l-yl]benzamide and intermediate 5f to give the title compound (39 mg, 18 %) as a white solid. 1H NMR 5 1.20 (2H, d), 1.76-2.07 (11H, m), 2.12-2.29 (4H, m), 2.77 (6H, q), 3.00 (2H, d), 3.45 (2H, d), 3.78 (2H, t), 3.86 (2H, d), 3.93 (1H, d), 4.32-4.42 (1H, m), 6.(1H, d), 6.80 (1H, d), 6.96 (3H, dd), 7.09-7.19 (2H, m), 7.48-7.58 (2H, m), 7.77 (2H, d), 8.07 (1H, d), 8.(1H, s), 10.33 (1H, s), 12.29 (1H, s); m/z: ES+ [M+H]+ = 786.4.
Example 174 Intermediate 174a: 4-Chloro-7-(l,4-dioxaspiro[4.5]dec-7-en-8-yl)-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in intermediate 69a using intermediate lb and 8-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-l,4-dioxaspiro[4.5]dec-7-ene to give the title compound (6 g, %) as a yellow solid. 1H NMR 5 1.87 (2H, q), 2.36-2.48 (2H, m), 2.5-2.6 (2H, m), 3.95 (4H, s), 5.89 (1H, td), 7.09 (1H, d), 7.21 (1H, d), 8.35 (1H, s), 12.22 (1H, s); m/z: ES+ [M+H]+ = 315.0.
Intermediate 174b: 4-Chloro-7-(l,4-dioxaspiro[4.5]decan-8-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 297 The title compound was prepared using methodology described in intermediate 60c using 4-chloro-7-(l,4- dioxaspiro[4.5]dec-7-en-8-yl)-17/-indole-3-carbonitrile to give the title compound (5.5 g, 91 %) as a white solid. 1H NMR 5 1.76 (8H, dd), 1.84-1.91 (1H, m), 3.15 (3H, d), 3.95 (1H, s), 7.15 (2H, dt), 8.38 (1H, d), 12.30 (1H, s); m/z: ES+ [M+H]+ = 317.0.
Intermediate 1740: 4-Chloro-7-(4-oxocyclohexyl)-lZ/-indole-3-carbonitrile 4-Chloro-7-(l,4-dioxaspiro[4.5]decan-8-yl)-17/-indole-3-carbonitrile (5.5 g, 17.36 mmol) was stirred in formic acid (40 mL) at 45 °C for 16 h. The reaction was cooled to RT and evaporated to dryness to give the title compound (5.0 g, 106 %) as a brown solid and was used without further purification. 1H NMR 5 1.82-1.(6H, m), 2.13 (1H, s), 2.51 (3H, p), 6.81 (1H, s), 7.07-7.24 (1H, m), 8.42 (1H, s); m/z: ES+ [M+H]+ = 273.0.
Intermediate 174d: 7-(4-Aminocyclohexyl)-4-chloro-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in intermediate 152e using 4-chloro-7-(4- oxocyclohcxyl)-! //-indolc-3-carbo nitrile to give the title compound (3.0 g, 66 %) as a white solid. 1H NMR 1.61 (4H, q), 1.74-2.01 (4H, m), 2.07 (2H, s), 3.09 (2H, s), 7.03-7.22 (2H, m), 8.39 (1H, s) 1H not observed; m/z: ES+ [M+H]+ = 274.0.
Intermediate 174e: 7V-[4-(4-Chloro-3-cyano-lZf-indol-7-yl)cyclohexyl]-4-[4-(dibutoxymethyl)piperidin-l-yl]-2- fluorobenzamide The title compound was prepared using methodology described in intermediate 152f using 7-(4- aminocyclohcxyl)-4-chloro-l//-indolc-3-carbonitrilc and intermediate 152b to give the title compound (2mg, 22 %) as a white solid. 1H NMR 5 0.88 (6H, t), 1.13-1.78 (21H, m), 3.04 (1H, s), 3.26-3.42 (2H, m), 3.5- WO 2024/189488 PCT/IB2024/052251 298 3.58 (2H, m), 3.75-4.03 (5H, m), 4.17 (1H, d), 6.65-6.81 (2H, m), 7.1-7.27 (2H, m), 7.51 (1H, t), 7.68 (1H, dd), 8.39 (1H, d), 12.58 (1H, s); m/z: ES+ [M+H]+ = 637.4.
Example 174: 7V-[4-(4-Chloro-3-cyano-lZ/-indol-7-yl)cyclohexyl]-4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/-indol-l- The title compound was prepared using methodology described in example 142 using #-[4-(4-chloro-3-cyano- l//-indol-7-yl)cyclohcxyl|-4-|4-(dibutoxymcthyl)pipcridin-l-yl|-2-nuorobcnzamidc and intermediate 5f to give the title compound (15 mg, 15 %) as a white solid. 1H NMR 5 1.17 (2H, d), 1.61 (4H, dt), 1.7-1.9 (5H, m), 1.98 (6H, d), 2.20 (4H, dd), 2.72-2.86 (4H, m), 3.01 (3H, t), 3.78 (2H, t), 3.86 (3H, d), 4.32-4.4 (1H, m), 6.42 (1H, d), 6.76 (2H, dd), 6.96 (1H, d), 7.08-7.22 (3H, m), 7.45-7.57 (3H, m), 7.69 (1H, dd), 8.40 (1H, s), 10.32 (1H, s), 12.57 (1H, s); m/z: ES+ [M+H]+ = 803.4.
Example 175 Intermediate 175a: Methyl 4-[4-(dibutoxymethyl)piperidin-l-yl]-2,6-difluorobenzoate The title compound was prepared using methodology described in intermediate 63a using methyl 2,4,6- trifluorobenzoate and 4-(dibutoxymethyl)piperidine to give the title compound (450 mg, 20 %) as a white solid. 1H NMR 5 0.88 (6H, t), 1.14-1.56 (10H, m), 1.58-1.89 (2H, m), 2.08 (1H, s), 2.76-2.9 (2H, m), 3.29- 3.44 (2H, m), 3.55 (2H, dt), 3.77 (3H, s), 3.93 (2H, d), 4.17 (1H, d), 6.64 (2H, d); m/z: ES+ [M+H]+ = 414.1.
Intermediate 175b: 4-[4-(Dibutoxymethyl)piperidin-l-yl]-2,6-difluorobenzoic acid yl]piperidin-l-yl}methyl)piperidin-l-yl]-2-fluorobenzamide WO 2024/189488 PCT/IB2024/052251 299 The title compound was prepared using methodology described in intermediate 104b using methyl 4-[4- (dibutoxymethyl)piperidin-l-yl]-2,6-difluorobenzoate to give the title compound (1.6 g, 83 %) as a white solid. 1H NMR 5 0.88 (6H, td), 1.12-1.59 (10H, m), 1.69 (2H, d), 2.83 (2H, dd), 3.3-3.45 (3H, m), 3.55 (2H, dt), 3.93 (2H, d), 4.17 (1H, d), 6.64 (2H, d) 1H not observed; m/z: ES+ [M+H]+ = 400.0.
Intermediate 1750: 7V-[l-(4-Chloro-3-cyano-lZf-indol-7-yl)piperidin-4-yl]-4-[4-(dibutoxymethyl)piperidin-l-yl]-2,6- difluorobenzamide The title compound was prepared using methodology described in intermediate 153e using 4-[4- (dibutoxymethyl)piperidin-l-yl]-2,6-difluorobenzoic acid and intermediate 153d to give the title compound (100 mg, 40 %) as a white solid. 1H NMR 5 0.89 (6H, t), 1.14-1.76 (12H, m), 1.74-1.95 (5H, m), 2.66-2.(3H, m), 3.24-3.55 (7H, m), 3.84 (3H, d), 4.17 (1H, d), 6.62 (2H, d), 6.84 (1H, d), 7.16 (1H, d), 8.31 (1H, d), 8.47 (1H, d), 12.30 (1H, s); m/z: ES+ [M+H]+ = 654.0.
Example 175: /V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/-indol- l-yl]piperidin-l-yl}methyl)piperidin-l-yl]-2,6-difluorobenzamide The title compound was prepared using methodology described in example 140 using #-[l-(4-chloro-3-cyano- l//-indol-7-y!)piperidin-4-yl|-4-|4-(dibutoxymcthy!)piperidin-l-yl|-2.6-dinuorobcnzamidc and intermediate 5f to give the title compound (55 mg, 43 %) as a white solid. 1H NMR 5 1.14 (2H, d), 1.75-1.88 (5H, m), 1.89-2.1 (6H, m), 2.09-2.25 (4H, m), 2.59-2.87 (6H, m), 2.99 (2H, d), 3.32 (2H, s), 3.74-3.91 (5H, m), 4.(1H, s), 6.42 (1H, d), 6.63 (2H, d), 6.82 (1H, d), 6.96 (1H, d), 7.14 (2H, dt), 7.47-7.57 (2H, m), 8.30 (1H, s), 8.47 (1H, d), 10.32 (1H, s), 12.30 (1H, s); m/z: ES+ [M+H]+ = 822.4.
Example 176 Intermediate 176a: WO 2024/189488 PCT/IB2024/052251 300 Methyl 5-[4-(dibutoxymethyl)piperidin-l-yl]pyrazine-2-carboxylate The title compound was prepared using methodology described in intermediate lla using methyl 5- bromopyrazine-2-carboxylate and 4-(dibutoxymethy!)piperidine to give the title compound (1.0 g, 28 %) as a colourless solid. 1H NMR 5 0.87 (6H, d), 1-1.5 (12H, m), 1.84 (1H, d), 2.96 (3H, t), 3.22-3.45 (5H, m), 3.(3H, dt), 4.55 (1H, s), 8.36 (1H, d), 8.63 (1H, d); m/z: ES+ [M+H]+ = 380.1.
Intermediate 176b: 5-[4-(Dibutoxymethyl)piperidin-l-yl]pyrazine-2-carboxylic acid The title compound was prepared using methodology described in intermediate 104b using methyl 5-[4- (dibutoxymethyl)piperidin-l-yl]pyrazine-2-carboxylate to give the title compound (640 mg, 66 %) as a white solid. 1H NMR 5 0.88 (6H, t), 1.05-1.8 (12H, m), 1.83-1.93 (1H, m), 2.61-3.42 (4H, m), 3.47-4.43 (4H, m), 4.45 (1H, s), 8.18 (1H, s), 8.59 (1H, d) 1H not observed; m/z: ES־ [M-H]364.1 = ־.
Intermediate 176c: 7V-[l-(4-Chloro-3-cyano-lZf-indol-7-yl)piperidin-4-yl]-5-[4-(dibutoxymethyl)piperidin-l-yl]pyrazine-2- carboxamide The title compound was prepared using methodology described in intermediate 153e using 5-[4- (dibutoxymethyl)piperidin-l-yl]pyrazine-2-carboxylic acid and intermediate 153d to give the title compound (300 mg, 88 %) as a colourless gum. 1H NMR 5 0.88 (6H, t), 1.13-1.27 (2H, m), 1.27-1.4 (4H, m), 1.42-1.(4H, m), 1.76 (2H, d), 1.92 (5H, s), 2.89 (8H, s), 3.39 (2H, dt), 3.56 (2H, dt), 3.94 (1H, s), 4.19 (1H, d), 6.(1H, d), 7.15 (1H, d), 8.21 (1H, d), 8.26 (1H, d), 8.31 (1H, s), 8.61 (1H, d), 12.29 (1H, s); m/z: ES+ [M+H]+ = 620.4.
Example 176: /V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-lZ/-indol- l-yl]piperidin-l-yl}methyl)piperidin-l-yl]pyrazine-2-carboxamide O N O N O N■ WO 2024/189488 PCT/IB2024/052251 301 The title compound was prepared using methodology described in example 140 using #-[l-(4-chloro-3-cyano- l//-indol-7-y !)pipe ridin-4-yl|-5-|4-(dibutoxymcthy !)pipe ridin-l-yl|pyrazinc-2-carboxamidc and intermediate 5f to give the title compound (110 mg, 58 %) as a white solid. 1H NMR 5 1.14 (2H, d), 1.79-2.01 (12H, m), 2.21 (4H, dd), 2.78 (4H, dt), 2.83-3.22 (5H, m), 3.78 (2H, t), 3.95 (1H, s), 4.39 (1H, s), 4.48 (2H, d), 6.42 (1H, d), 6.85 (1H, d), 6.96 (1H, d), 7.15 (2H, t), 7.53 (2H, dd), 8.20 (1H, d), 8.29 (2H, d), 8.62 (1H, s), 10.32 (1H, s), 12.30 (1H, s); m/z: ES+ [M+H]+ = 788.4.
Example 177 Intermediate 177a: Methyl 5-[4-(dibutoxymethyl)piperidin-l-yl]pyrimidine-2-carboxylate The title compound was prepared using methodology described in intermediate 63a using methyl 5- fluoropyrimidine-2-carboxylate and 4-(dibutoxymethyl)piperidine to give the title compound (2.7 g, 55 %) as a white solid. 1H NMR (CDCh) 5 0.91 (6H, t), 1.38 (6H, ttd), 1.47-1.63 (4H, m), 1.77-1.93 (2H, m), 1.(1H, d), 2.91 (2H, td), 3.42 (2H, dt), 3.62 (2H, dt), 3.86-3.97 (2H, m), 4.00 (3H, s), 4.17 (1H, d), 8.39 (2H, s); m/z: ES+ [M+H]+ = 380.0.
Intermediate 177b: 5-[4-(Dibutoxymethyl)piperidin-l-yl]pyrimidine-2-carboxylic acid The title compound was prepared using methodology described in intermediate 104b using methyl 5-[4- (dibutoxymethyl)piperidin-l-yl]pyrimidine-2-carboxylate to give the title compound (2.5 g, 96 %) as a white solid. 1H NMR 5 0.88 (6H, t), 1.26-1.38 (5H, m), 1.48 (4H, dq), 1.76 (2H, t), 2.78 (2H, td), 3.39 (2H, dt), 3.(4H, dt), 3.94 (2H, d), 4.19 (1H, d), 8.43 (2H, s) 1H not observed; m/z: ES+ [M+H]+ = 366.1.
WO 2024/189488 PCT/IB2024/052251 302 Intermediate 177c: /V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-5-[4-(dibutoxymethyl)piperidin-l-yl]pyrimidine- 2-carboxamide The title compound was prepared using methodology described in example 166c using 5-[4- (dibutoxymethyl)piperidin-l-yl]pyrimidine-2-carboxylic acid and intermediate 153d to give the title compound (250 mg, 55 %) as a white solid. 1H NMR 5 0.94 (6H, d), 1.29 (4H, d), 1.41-1.84 (18H, m), 1.(2H, d), 2.85 (2H, s), 3.54 (4H, d), 4.12 (2H, d), 5.76 (1H, s), 6.86 (1H, d), 7.16 (1H, d), 8.49 (2H, d), 12.(1H, s); m/z: ES+ [M+H]+ = 622.1.
Example 177: 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-W/-indol- l-yl]piperidin-l-yl}methyl)piperidin-l-yl]pyrimidine-2-carboxamide The title compound was prepared using methodology described in example 140 using #-[l-(4-chloro-3-cyano- l//-indol-7-yl)pipcridin-4-yl|-5-|4-(dibutoxymcthyl)pipcridin-l-yl|pyrimidinc-2-carboxamidc and intermediate 5f to give the title compound (14 mg, 4 %) as a white solid. 1H NMR 5 1.22 (3H, s), 1.89 (11H, d), 2.12-2.29 (4H, m), 2.69-3.07 (9H, m), 3.78 (2H, d), 3.98 (3H, t), 4.38 (1H, s), 6.42 (1H, s), 6.77-7.01 (2H, m), 7.14 (2H, d), 7.52 (2H, d), 8.29 (1H, s), 8.42 (1H, s), 8.54 (2H, s), 10.32 (1H, s), 12.35 (1H, s); m/z: ES+ [M+H]+= 788.3.
Example 178 Intermediate 178a: Methyl 4-[4-(dibutoxymethyl)piperidin-l-yl]-2-methylbenzoate WO 2024/189488 PCT/IB2024/052251 303 The title compound was prepared using methodology described in intermediate 63a using methyl 4-fluoro-2- methylbenzoate and 4-(dibutoxymethyl)piperidine to give the title compound (1.7 g, 36 %) as a white solid. 1H NMR (CDC13) 5 0.93 (6H, t), 1.3-1.65 (10H, m), 1.75-1.91 (3H, m), 2.58 (3H, s), 2.71-2.86 (2H, m), 3.(2H, dt), 3.63 (2H, dt), 3.83 (3H, s), 3.82-3.93 (1H, m), 4.17 (1H, d), 6.70 (2H, d), 7.87 (1H, d); m/z: ES+ [M+H]+= 392.0.
Intermediate 178b: 4-[4-(Dibutoxymethyl)piperidin-l-yl]-2-methylbenzoic acid The title compound was prepared using methodology described in intermediate 104b using methyl 4-[4- (dibutoxymethyl)piperidin-l-yl]-2-methylbenzoate to give the title compound (1.3 g, 79 %) as a white solid.1H NMR (CDC13) 5 0.93 (6H, t), 1.3-1.48 (4H, m), 1.45-1.67 (4H, m), 1.88 (2H, s), 1.99 (3H, s), 2.64 (3H, s), 3.01 (2H, s), 3.45 (2H, dt), 3.66 (2H, dt), 3.85 (2H, d), 4.24 (1H, d), 7.11 (2H, s), 8.05 (1H, d) 1H not observed; m/z: ES+ [M+H]+ = 378.1.
Intermediate 178c: 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-4-[4-(dibutoxymethyl)piperidin-l-yl]-2- methylbenzamide The title compound was prepared using methodology described in example 166c using 4-[4- (dibutoxymethyl)piperidin-l-yl]-2-methylbenzoic acid and intermediate 153d to give the title compound (1mg, 58 %) as a white solid. 1H NMR 5 0.89 (5H, t), 1.33 (6H, dt), 1.49 (4H, p), 1.72 (3H, d), 1.84 (1H, d), 1.92 (4H, s), 2.34 (3H, s), 2.52 (2H, s), 2.65 (2H, t), 2.79 (2H, t), 3.39 (2H, dt), 3.49-3.63 (2H, m), 3.78 (2H, d), 3.88 (1H, s), 4.18 (1H, d), 6.75 (2H, d), 6.85 (1H, d), 7.16 (1H, d), 7.23 (1H, d), 8.05 (1H, d), 8.31 (1H, s), 12.31 (1H, s); m/z: ES+ [M+H]+ = 634.4.
Example 178:7V-[l-(4-Chloro-3-cyano-lZf-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l,3 ־diazinan- 1-yl)-l//-indol-l-yl| piperidin-1-yl ؛methyl)piperidin-l-yl|-2-methylbenz amide WO 2024/189488 PCT/IB2024/052251 304 The title compound was prepared using methodology described in example 140 using #-[l-(4-chloro-3-cyano- l/7-indol-7-yl)piperidin-4-yl]-4-[4-(dibutoxymethyl)piperidin-l-yl]-2-methylbenzamide and intermediate 5f to give the title compound (40 mg, 22 %) as a white solid. 1H NMR 5 1.16-1.26 (2H, m), 1.73 (1H, s), 1.84 (4H, q), 1.96 (6H, td), 2.11-2.28 (4H, m), 2.34 (3H, s), 2.66-2.82 (6H, m), 3.00 (2H, d), 3.37 (2H, s), 3.74-3.(4H, m), 3.88 (1H, s), 4.38 (1H, s), 6.42 (1H, d), 6.76 (2H, d), 6.84 (1H, d), 6.96 (1H, d), 7.15 (2H, dt), 7.(1H, d), 7.52 (2H, dd), 8.04 (1H, d), 8.30 (1H, s), 10.32 (1H, s), 12.31 (1H, s); m/z: ES+ [M+H]+ = 800.0.
Example 179 Intermediate 179a: Methyl 6-[4-(dibutoxymethyl)piperidin-l-yl]pyridazine-3-carboxylate The title compound was prepared using methodology described in intermediate lla using methyl 6- chloropyridazine-3-carboxylate and 4-(dibutoxymethyl)piperidine to give the title compound (6.5g, 59 %) as a white solid. 1H NMR 5 0.88 (6H, t), 1.12-1.26 (2H, m), 1.29-1.4 (4H, m), 1.42-1.55 (4H, m), 1.72-1.8 (2H, m), 1.86-1.98 (1H, m), 2.91-3.03 (2H, m), 3.33-3.44 (2H, m), 3.51-3.61 (2H, m), 3.86 (3H, s), 4.18 (1H, d), 4.54 (2H, d), 7.27 (1H, d), 7.80 (1H, d); m/z: ES+ [M+H]+ = 380.3.
Intermediate 179b: 6-[4-(Dibutoxymethyl)piperidin-l-yl]pyridazine-3-carboxylic acid The title compound was prepared using methodology described in intermediate 104b using methyl 6-[4- (dibutoxymethyl)piperidin-l-yl]pyridazine-3-carboxylate to give the title compound (3.2 g, 51 %) as a yellow solid. 1H NMR 5 0.87 (6H, t), 1.14-1.41 (6H, m), 1.41-1.58 (4H, m), 1.69-1.81 (2H, m), 1.85-1.95 (1H, m), WO 2024/189488 PCT/IB2024/052251 305 2.96 (2H, t), 3.31-3.45 (2H, m), 3.48-3.62 (2H, m), 4.18 (1H, d), 4.53 (2H, d), 7.26 (1H, d), 7.78 (1H, d); m/z: ES+[M+H]+= 366.3.
Intermediate 179c: /V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-6-[4-(dibutoxymethyl)piperidin-l-yl]pyridazine-3- carboxamide The title compound was prepared using methodology described in intermediate 166c using 6-[4- (dibutoxymethyl)piperidin-l-yl]pyridazine-3-carboxylic acid and intermediate 153d to give the title compound (1.0 g, 88 %) as a white solid. 1H NMR 5 0.88 (6H, t), 1.2-1.42 (4H, m), 1.42-1.56 (4H, m), 1.76 (2H, d), 1.(5H, s), 2.01 (1H, d), 2.74 (9H, d), 3.49-3.63 (2H, m), 3.98 (1H, s), 4.19 (1H, d), 4.52 (2H, d), 6.86 (1H, d), 7.16 (1H, d), 7.35 (1H, d), 7.83 (1H, d), 8.32 (1H, d), 8.73 (1H, d), 12.34 (1H, s); m/z: ES+ [M+H]+ = 622.5.
Example 179: 7V-[l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-4-yl]-6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-W/-indol- l-yl]piperidin-l-yl}methyl)piperidin-l-yl]pyridazine-3-carboxamide The title compound was prepared using methodology described in example 140 using #-[l-(4-chloro-3-cyano- l//-indol-7-y !)pipe ridin-4-yl|-6-|4-(dibutoxymcthy !)pipe ridin-l-yl|pyridazinc-3-carboxamidc and intermediate 5f to give the title compound (53 mg, 21 %) as a white solid. 1H NMR 5 1.18 (2H, dd), 1.77-2.(11H, m), 2.21 (4H, dd), 2.50 (4H, q), 2.72-2.86 (4H, m), 3.03 (4H, t), 3.37 (2H, s), 3.78 (2H, t), 3.98 (1H, d), 4.38 (1H, s), 4.50 (2H, d), 6.42 (1H, d), 6.86 (1H, d), 6.96 (1H, d), 7.15 (2H, t), 7.35 (1H, d), 7.48-7.57 (2H, m), 7.83 (1H, d), 8.31 (1H, d), 8.73 (1H, d), 10.33 (1H, s), 12.33 (1H, s); m/z: ES+ [M+H]+ = 788.3.
Example 180 Intermediate 180a: 4-Chloro-7-(l,4-dioxa-7-azaspiro[4.5]decan-7-yl)-lZ/-indole-3-carbonitrile WO 2024/189488 PCT/IB2024/052251 306 The title compound was prepared using methodology described in intermediate He using intermediate lb and l,4-dioxa-7-azaspiro[4.5]decane to give the title compound (1.5 g, 36 %) as a yellow solid. 1H NMR 5 1.(3H, t), 1.91 (2H, tt), 2.97 (2H, s), 3.88-3.91 (5H, m), 6.78 (1H, d), 7.08-7.32 (1H, m), 8.28 (1H, s), 12.(1H, s); m/z: ES+ [M+H]+ = 317.9.
Intermediate 180b: 4-Chloro-7-(3-oxopiperidin-l-yl)-lZf-indole-3-carbonitrile 4-Chloro-7-(l,4-dioxa-7-azaspiro[4.5]decan-7-yl)-l/7-indole-3-carbonitrile (1.5 g, 4.72 mmol) was stirred in formic acid (15 mL) at 40 °C for 16 h. The reaction was then cooled to RT and the solvent was evaporated to dryness to afford the title compound (0.900 g, 69.7 %) as a black gum which was used without further purification. 1H NMR 5 0.66-0.87 (1H, m), 1.36 (1H, d), 2.94-3.08 (2H, m), 3.20 (1H, td), 3.38 (1H, d), 4.(2H, s), 8.15 (2H, s), 8.26 (1H, s), 8.42 (1H, s); m/z: ES+ [M+H]+ = 274.1.
Intermediate 1800: 7-(3-Aminopiperidin-l-yl)-4-chloro-lZ/-indole-3-carbonitrile The title compound was prepared using methodology described in intermediate 152e using 4-chloro-7-(3- oxopiperidin-l-yl)-l/7-indole-3-carbonitrile to give the title compound (600 mg, 74 %) as a white solid. 1H NMR 5 1.71-1.8 (1H, m), 1.77-1.9 (2H, m), 2.42 (1H, q), 2.62 (1H, t), 3.18 (3H, d), 3.23-3.32 (1H, m), 6.(1H, d), 7.11 (1H, d), 8.29 (1H, s) 3H not observed; m/z: ES+ [M+H]+ = 275.2.
Intermediates 180c and 181a WO 2024/189488 PCT/IB2024/052251 307 7-(3-Aminopipcridin-l -yl)-4-chloro-l //-indolc-3-carbonitrilc (150 mg, 0.41 mmol) was added to DIPEA (0.216 mL, 1.23 mmol), HATU (313 mg, 0.82 mmol) and intermediate 170b (113 mg, 0.41 mmol) inDMF (mL) and was stirred at RT for 2 h. The solvent was evaporated to dryness to afford crude product and was purified by flash silica chromatography, elution gradient 0 to 20% EtOAc in Et20 to give the title compound as a racemic mixture. The enantiomers were separated by preparative chiral-HPLC using conditions: CHIRALPAK ID, 2*25 cm, 5 m, Hex:DCM (3:1, 0.5% 2M NH3 -MeOH) and EtOH to give, in order of elution, intermediate 180c(isomer 1, 100 mg, 39 %) and intermediate 181a(isomer 2, 100 mg, 39 %) as yellow solids.
Intermediate 180c: A-[(37?*)-l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-3-yl]-6-[4-(dibutoxymethyl)piperidin-l- yl]pyridine-2-carboxamide [absolute stereochemistry not yet confirmed] 1HNMRS0.88 (6H, t), 1.13-1.56 (10H, m), 1.62 (1H, d), 1.74 (2H, d), 1.94 (3H, d), 2.81 (4H, q), 3.15 (1H, d), 3.31 (1H, s), 3.39 (2H, dt), 3.56 (2H, dt), 3.93 (2H, d), 4.20 (2H, t), 4.42 (OH, s), 6.84 (1H, d), 7.15 (1H, d), 7.38 (1H, dd), 7.83 (1H, d), 8.22-8.38 (3H, m), 12.34 (1H, d); m/z: ES+ [M+H]+ = 621.0; >99% ee.
Intermediate 181a: A-[(3،؟*)-l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-3-yl]-6-[4-(dibutoxymethyl)piperidin-l- yl]pyridine-2-carboxamide [absolute stereochemistry not yet confirmed] Isomer 1 Isomer 2 WO 2024/189488 PCT/IB2024/052251 308 1H NMR 5 0.88 (6H, t), 1.13-1.56 (10H, m), 1.62 (1H, d), 1.74 (2H, d), 1.94 (3H,d),2.81 (4H, q), 3.15 (1H, d), 3.31 (1H, s), 3.39 (2H, dt), 3.56 (2H, dt), 3.93 (2H, d), 4.20 (2H, t), 4.42 (OH, s), 6.84 (1H, d), 7.15 (1H, d), 7.38 (1H, dd), 7.83 (1H, d), 8.22-8.38 (3H, m), 12.34 (1H, d); m/z: ES+ [M+H]+ = 621.0; >99% ee.
Example 180: /V-[(37?*)-l-(4-Chloro-3-cyano-lZ/-indol-7-yl)piperidin-3-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo- 2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 140 using intermediate 180c and intermediate li to give the title compound (40 mg, 31 %) as a white solid. 1H NMR 5 1.19 (2H, d), 1.63 (OH, s), 1.80 (2H, s), 1.83 (2H, s), 1.88 (4H, s), 2.20 (2H, d), 2.36 (1H, d), 2.58 (1H, d), 2.85 (6H, s), 3.15 (1H, s), 3.30 (7H, d), 3.90 (2H, d), 4.20 (2H, d), 4.33 (1H, d), 5.05 (1H, dd), 6.81 (1H, d), 7.05 (2H, d), 7.12 (1H, d), 7.38 (1H, d), 7.52 (1H, d), 7.83 (1H, d), 8.23-8.33 (3H, m), 10.95 (1H, s), 12.35 (1H, s); m/z: ES+ [M+H]+ = 803.4.
Example 181: 7V-[(3،؟*)-l-(4-Chloro-3-cyano-lZZ-indol-7-yl)piperidin-3-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo- 2,3-dihydro-lZZ-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide [absolute stereochemistry not yet confirmed] The title compound was prepared using methodology described in example 140 using intermediate 181a and intermediate li to give the title compound (48 mg, 37 %) as a white solid. 1H NMR 5 1.19 (2H, d), 1.62 (1H, s), 1.81 (4H, d), 1.88 (2H, s), 1.97 (2H, s), 2.20 (2H, d), 2.37 (1H, d), 2.58 (2H, d), 2.83 (5H, t), 3.15 (1H, s), 3.30 (7H, d), 3.90 (2H, d), 4.20 (2H, d), 4.33 (1H, d), 5.05 (1H, dd), 6.82 (1H, d), 7-7.17 (3H, m), 7.35-7.42 WO 2024/189488 PCT/IB2024/052251 309 (1H, m), 7.52 (1H, d), 7.83 (1H, d), 8.23-8.34 (3H, m), 10.95 (1H, s), 12.35 (1H, s); m/z: ES+ [M+H]+ = 803.3.
LNCaP Androgen Receptor Imaging Assay This cell-based imaging assay uses immuno-fluorescence to measure endogenous nuclear AR staining in the prostate cancer cell line LNCaP (expressing AR-full length). The purpose of the assay is to identify compounds that regulate AR protein level according to the protocol laid out in the steps below.All work was performed in a sterile tissue culture hood up to the point of cell fixation. LNCaP cells were cultured at 6-8 xlOA6 per T175 flask and split every 3-4 days. Medium: RPMI (R7638, VWR Sigma) containing 10% FCS and 1% glutamine. Cells were plated in black wall transparent bottom plates at a density of 12,000 cells (CedexTM Cell counter, Beckmann & Coulter), 40pL per well, using a Multidrop (ThermoFisher).Cells were dosed with test compound diluted in DMSO using an Echo 555/655TM (Labeyte) and the final concentration of DMSO in the well was 0.3%. A neutral control (DMSO) and a positive AR degrader control at 3pM (a prior art AR PROTAC) were included. The Echo uses acoustic technology to perform direct microplate-to-microplate transfers of DMSO compound solutions to assay plates. The system can be programmed to transfer volumes as low as 2.5 nL in multiple increments between microplates and in so doing generates a serial dilution of compound in the assay plate which is then back-filled to normalise the DMSO concentration across the dilution range. Compounds were dispensed as a 12 point dose response with indicated concentrations. The plates were incubated at 370C / 5% CO2 for 24h and then fixed and stained as below. 40pL of 8% paraformaldehyde solution (v/v) in phosphate buffered saline (PBS) was added on top of the media already in the well using a Multidrop to fix plates giving a final concentration of 4% PF A (v/v) for 20- minutes (keep in fume hood to minimise PF A exposure). After 20-30 mins, the plates were washed with x PBS using a BioTek washer in a fume hood. A shake out of remaining volume in the well was performed to ensure best removal of remaining PBS. At this plates could be stored in PBS after washing for at least 3 days at 40C, if so, PBS was removed by the BioTek before continuing with the next step.The cells were incubated with a Mouse monoclonal Anti-AR antibody AR441 (DAKO M3562) (1:1000), diluted in modified blocking buffer (PBS+1% BSA+0.1% TritonX); 15 pL / well for 2h at RT. The plates were then washed with 3 x PBS using a BioTek washer. A shake out of remaining volume in the well was performed to ensure best removal of remaining PBS. Cells were then incubated with Goat anti-mouse secondary antibody 488 (Invitrogen A11001) (1:500) and nuclear stain, DRAQ5 (Abeam Abl08410) (1:2000) diluted in modified blocking buffer for 45 mins at room temperature 15 pL / well. Plates are then washed with x PBS using a BioTek washer, without final aspiration, and sealed with black plate seals. Plates could be stored after staining for three days at 4°C before read if required.Plates are read using a Cellomics Cellinsight to measure the Androgen Receptor level in each well. The data is exported into Genedata to perform curve fitting analysis. All data are normalized as % of positive control and the BellFit method automatically determines the correct fit method based on the presence of hook effect, choosing the BellFit when there is a hook and HillFit when there is no hook. Down-regulation of AR is expressed as a DC50 value and determined by calculation of the concentration of compound that is required to give 50% of maximum degradation of AR as per the curve fit for that compound. The maximum degradation WO 2024/189488 PCT/IB2024/052251 310 observed for each compound is expressed as Dmax. The AR degradation data for compounds is shown in the table below and may be a result from a single experiment or an average of two or more experiments.
LNCaP Androgen Receptor L702H Imaging Assay While treatment with AR antagonists has been shown to be of patient benefit, most cancers eventually progress to castration resistant prostate cancer (CRPC). At this stage, anti-androgen therapy is largely ineffective due to AR amplification, overexpression or point mutation. One of the point mutations observed in patient populations is L702H in the AR Ligand Binding Domain. LNCAP cells have been engineered to introduce the mutation L702H into the AR gene using CRISPR/Cas9. The previously described imaging-based AR assay will monitor nuclear AR (L702H) levels in these cells to identify compounds that regulate AR (L702H). Down-regulation of AR (L702H) is expressed as a DC50 value and determined by calculation of the concentration of compound that is required to give 50% of maximum degradation of AR (L702H) as per the curve fit for that compound. The maximum degradation observed for each compound is expressed as Dmax. The AR and AR (L702H) degradation data for compounds is shown in the table below and may be a resultfrom a single experiment or an average of two or more experiments.
Example No. LNCaP AR Degradation DC50 (pM) LNCaP AR Degradation D max (%) LNCaP AR (L702H) Degradation DC50 (pM) LNCaP AR (L702H) Degradation D max (%)0.006 99 0.006 1000.006 96 0.005 1010.018 85 0.017 990.006 96 0.005 1060.008 103 0.012 1100.010 100 0.013 1030.009 98 0.014 1010.029 99 0.103 960.007 105 0.009 1060.007 96 0.005 1030.009 102 0.018 1050.006 95 0.012 970.007 107 0.006 1090.006 107 0.009 1120.009 97 0.024 850.012 77 0.024 840.003 100 0.004 1020.014 93 0.018 960.004 102 0.005 102 WO 2024/189488 PCT/IB2024/052251 311 0.009 94 0.008 1010.008 92 0.007 1030.014 80 0.023 810.012 100 0.057 940.006 100 0.018 830.006 92 0.004 1040.009 92 0.007 1060.014 99 0.027 750.005 96 0.023 830.079 94 0.060 740.025 98 0.083 830.008 94 0.022 880.005 99 0.010 1000.012 97 0.033 900.007 98 0.012 1020.019 84 0.029 910.005 102 0.007 1020.015 90 0.011 1000.009 97 0.012 950.016 88 0.033 990.007 105 0.012 1060.017 98 0.029 950.029 101 0.062 1070.073 94 0.160 970.004 95 0.002 960.003 96 0.006 950.004 101 0.012 980.007 84 0.007 1000.057 97 0.359 990.033 91 0.045 970.137 98 0.769 940.037 101 0.071 960.062 93 0.052 970.030 99 0.078 1030.036 77 0.052 970.033 99 0.034 1030.061 101 0.357 940.018 87 0.031 790.013 96 0.114 78 WO 2024/189488 PCT/IB2024/052251 312 59 0.051 88 0.047 950.005 93 0.023 570.006 94 0.025 650.007 99 0.080 710.006 94 0.016 630.005 83 0.008 560.009 96 0.798 780.010 97 0.022 940.004 98 0.014 870.006 97 0.021 840.009 92 0.005 940.009 97 0.009 1010.007 84 0.007 940.014 91 0.021 920.007 93 0.013 900.008 93 0.021 700.062 68 0.068 830.018 92 0.038 1040.014 79 0.067 691.37 70 3.1 1000.009 92 0.021 790.038 64 3.1 100>3 - 3.1 1000.031 90 0.022 913.1 100 >3 -0.022 99 0.012 1030.004 98 0.017 830.015 94 0.014 990.005 95 0.008 940.013 96 0.021 990.421 70 0.056 970.281 87 0.164 1010.023 100 0.010 993.1 100 3.1 1000.020 87 0.011 95>3 - - -0.010 54 >3 -0.031 54 0.012 95>3 - >3 - WO 2024/189488 PCT/IB2024/052251 313 98 0.090 40 0.015 83>3 - 3.1 100100 0.029 101 0.449 89101 0.006 97 0.015 87102 0.052 86 0.044 106103 0.008 85 0.007 107104 0.013 98 0.046 97105 0.061 89 0.049 95106 0.022 97 0.050 93107 0.006 93 0.300 107108 0.007 104 0.034 102109 0.005 97 0.010 96110 0.006 88 0.005 97ill 0.004 99 0.005 106112 >3 - 0.017 87113 0.019 92 0.036 76114 0.019 101 0.031 101115 0.014 99 0.013 102116 0.011 103 0.023 97117 0.017 89 0.363 84118 0.024 92 2.3 100119 0.006 99 0.014 103120 0.013 101 0.040 90121 0.018 81 3.1 98122 0.093 85 0.067 75123 0.014 95 0.018 104124 0.003 95 0.009 93125 0.004 102 0.009 93126 0.004 98 0.002 107127 0.004 100 0.004 110128 0.026 102 0.061 103129 0.020 95 0.029 99130 0.031 99 0.042 78131 0.017 105 0.041 94132 0.006 98 0.005 115133 0.004 103 0.008 97134 0.005 106 0.022 94135 0.024 105 0.081 91136 0.010 104 0.014 108 WO 2024/189488 PCT/IB2024/052251 314 137 0.010 105 0.020 109138 0.008 104 0.006 108139 0.010 105 0.016 107140 0.007 88 0.014 56141 0.021 95 0.023 105142 0.025 106 0.045 109143 0.037 101 0.067 104144 0.021 97 0.095 75145 0.009 98 0.040 70146 0.027 100 0.038 102147 0.006 102 0.038 96148 0.020 99 0.052 89149 0.020 96 0.060 91150 0.014 82 0.893 50151 0.018 67 0.497 42152 0.002 105 0.002 108153 0.002 109 0.003 114154 0.004 81 0.009 79155 0.004 80 0.017 82156 0.005 104 0.010 105157 0.003 97 0.004 96158 0.001 104 0.007 107159 0.002 101 0.003 106160 0.001 104 0.004 105161 0.007 95 0.020 98162 0.001 106 0.001 110163 0.001 107 0.002 113164 0.002 108 0.002 114165 0.002 106 0.002 115166 0.004 85 0.037 92167 0.001 101 0.002 100168 0.001 87 0.002 96169 0.005 86 0.023 94170 0.001 100 0.002 101171 0.005 96 0.036 85172 0.001 94 0.004 94173 0.001 102 0.002 109174 0.003 106 0.013 104175 0.001 107 0.001 109 WO 2024/189488 PCT/IB2024/052251 315 176 0.001 104 0.003 102177 0.002 107 0.015 40178 0.002 106 0.002 107179 0.001 103 0.001 108180 0.003 94 0.002 88181 0.004 95 0.009 95 WO 2024/189488 PCT/IB2024/052251 316 STATEMENTS 1. A compound of Formula (I): (1)or a pharmaceutically acceptable salt thereof, wherein: X1 is CH or N; p where:is 0, 1 or 2; each R1 is a substituent on any C atom and is independently selected from F, Cl, Ci-salkyl and C1-zalkoxy, wherein said C1-salkyl and C!.3alkoxy may be independently optionally substituted by one or more F; RN is selected from H and Me; n is 0, 1 or 2; m is 0 or 1;Q1when n & mare both other than 0, Q2 when n & mare both 0, Q2 iswhen n is 0 or 1, Q3when n is 2 and Q2 is N, Q3when n is 2 and Q2 is CH, Q3 is R2aand R2b is CH or N;is CH or N;CH;is CH;is CH;CHorO;are substituents on the same or different C atoms other than at Q1 or Q2, each independently selected from H, F and C!.3alkyl, or R2a & R2btogether form a -(CH2)r- group where ris 1, 2 orך•Q4 R4 יל ­is a single bond or -NR4C(=O) ;is H or Me;0, 1 or 2 of Y1, Y2, Y3, Y4 & Y5 each R3 is/are N, and are otherwise C;is a substituent on any C atom at Y1, Y2, Y3, Y4 & Y5,and is independently selected from F, Cl, CN, C!.3alkyl and C!.3alkoxy, wherein said C!.3alkyl and C!.3alkoxy may be independently optionally substituted by one or more F; WO 2024/189488 PCT/IB2024/052251 317 q is 0, 1 or 2;wherein Linkeris attached at any available C atom at Y4 & Y5; Linker is a saturated or a partially or fully unsaturated frameworkcomprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a’ and ‘b’ and a length of from 5 to 26 atoms between ‘a’ and ‘b’; wherein said framework may include one or more straight and/or branched chains and/or rings and is optionally substituted on any available C atom(s) by one or more F; and W is an E3 ubiquitin ligase cereblon binder unit. 2. The compound of Formula(1), or pharmaceutically acceptable salt thereof, according to statement wherein the Linkeris a saturated or partially unsaturated framework. 3. The compound of Formula (I),or pharmaceutically acceptable salt thereof, according to statement I orstatement 2 wherein the Linkercomprises C and H atoms and at least two heteroatoms. 4. The compound of Formula (I),or pharmaceutically acceptable salt thereof, according to statement I or statement 2 wherein the Linkercomprises C and H atoms and at least one nitrogen heteroatom in the form of a secondary or tertiary amine.
. The compound of Formula (I),or pharmaceutically acceptable salt thereof, according to statement I or statement 2 wherein the Linkerincludes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group having from 4 to 12 ring atoms, or a A4-CH2-CH2-A2 unit where A1 and A2 are each independently selected from N and O. 6. The compound of Formula (I),or pharmaceutically acceptable salt thereof, according to any one of statements 1 to 5 wherein the Linkerhas the Formula: a’ -Q*-Q*-QC b’ wherein: ‘a ’and ‘b’represent the end points of attachment;QA is -G-QH- or -G-(C1.5alkylene)-;QB is a direct bond, -QB1-QB2-QB3- or 0ן.י,alkylene optionally substituted by one or more F (e.g. 1 or 2); where:QB1 & QB3 each independently represent a direct bond or C!.2alkylene;QB2 is QH, -O-CH2CH2-O-, -O- or -N(RJ)- where RJ is H or C1-3alkyl;Qc is -QH-G- or -(C1.5alkylene)-G-;each G is independently a direct bond, -CH2-, -0-, -C(=O)- or -N(RG)- where RG is H or C1-3alkyl; WO 2024/189488 PCT/IB2024/052251 318 each QH is independently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;where the values of QA, QBand Qcare selected so that the Linkerdoes not contain any N-N or N-O bonds. 7. The compound of Formula(1), or pharmaceutically acceptable salt thereof, according to statement wherein QB is a direct bond, -CH2- or -CH2CH2-. 8. The compound of Formula (I),or pharmaceutically acceptable salt thereof, according to statement 6 or statement 7 wherein Qc is -QH-G- or -(C1.2alkylene)-G-. 9. The compound of Formula (I),or pharmaceutically acceptable salt thereof, according to any one of statements 6 to 8, wherein each QH is independently selected from piperazin- 1,4-diyl, azetidin-1,3-diyl, piperidin-1,4-diyl, l,4-diazepan-l,4-diyl, 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin-1,3- diyl, 3,9-diazaspiro[5.5]undecan-3,9-diyl, 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl, 1,3,3a,4,6,6a- hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3.6-dihydro-2//-pyridin- 1,4-diyl, morpholin-2,3-diyl, 2- azaspiro[3.5]nonan-2,7-diyl and 9-azaspiro[5.5]undecan-3,9-diyl.
. The compound of Formula (I),or pharmaceutically acceptable salt thereof, according to any one of statements 1 to 9, wherein the Linkeris selected from any of Linkers1 to 58 as shown in the description. 11. A PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la) : (la) where R1, p, X1, RN, n, m, R2a , R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qare as defined in statement 1. 12. The PROTAC compound or a pharmaceutically acceptable salt thereof, according to statement 11, containing an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la)of Formula (lb): WO 2024/189488 PCT/IB2024/052251 319 (1b) where:QA is -G-QH- or -G-(C1.5alkylene)-;G is a direct bond, -CH2-, -0-, -C(=O)- or -N(RG)- where RG is H or C!.3alkyl; andQH is a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group. 13. The PROTAC compound or a pharmaceutically acceptable salt thereof, according to statement 12, containing an E3 ubiquitin ligase cereblon binder unit and an AR binding unit of Formula (la)of Formula (Ic): (ic) where:QB is a direct bond, -QB1-QB2-QB3- or C!.3alkylene optionally substituted by one or more F (e.g. 1 or 2); where:QB1 & QB3 each independently represent a direct bond or C!.2alkylene; q62 ؛s qh -0-CHCH-o- -0- or -N(RJ)- where RJ is H or C!.3alkyl;and each QH is independently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;where the values of QA and QB are selected so that Formula (Ic)does not contain any N-N or N-O bonds. 14. The PROTAC compound or a pharmaceutically acceptable salt thereof, according to statement 12 orstatement 13, where: WO 2024/189488 PCT/IB2024/052251 320 QA is -Ga-Qha - or -GA-(C1-531kylene)- where:GA is selected from a direct bond, -CH2-, -C(=O)-, -0- or -N(RG)-;RG is H or Ci.galkyl; andQI,A is a 4 to 11-membered nitrogen-containing saturated heterocyclic group.
. A compound of Formula (II): (11) or a salt thereof, wherein:QA is -G-QH- or -G-(C1.5alkylene)-;G is a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)- where RG is H or C!.3alkyl;QH is a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;QD is a direct bond or C!.2alkylene optionally substituted by one or more F (for example 1 or 2 F); and(i) RL1 & RL2 together form "=O" and RL3 is H or C!.6alkoxy;(ii) RL1 & RL2 are each independently C!-6alkoxy, and RL3 is H;(iii) RL1 & RL2 together form -O-(CH2)k-O- where k is 2 or 3, and RL3 is H; or(iv) RL1 is OH or LG1 where LG1 is a leaving group, and RL2 & RL3 are both H;where when QD is a direct bond and QA is -G-QH-, the value of QH is selected so that QD connects to a C atom of QH;and R1, p, X1, RN, n, m, R2a, R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3 and q are as defined instatement 1. 16. The compound of Formula (II)or a salt thereof, according to statement 15, wherein LG1is selected from Cl, Br, 1, trifluoromethanesulfonate and C1-7hydrocarbylsulfonate. 17. A compound of Formula (IV): WO 2024/189488 PCT/IB2024/052251 321 or a salt thereof, wherein:J is H or PG2 where PG2 is a nitrogen protecting group (for example a ter/-butoxy carbonyl group);QA is -G-QH- or -G-(C1.5alkylene)-;G is a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)- where RG is H or Ci.galkyl;QB is a direct bond, -QB1-QB2-QB3- or C!.3alkylene optionally substituted by one or more F (e.g. 1 or 2); where:QB1 & QB3 each independently represent a direct bond or C!.2alkylene;QB2 is QH, -0-CHCH-o- -0- or -N(RJ)- where RJ is H or C!.3alkyl;and each QH(including the "QH Ring "attached to J)is independently a 4-12-membered nitrogen- containing saturated or partially unsaturated heterocyclic group;where the values of QA, QBand QH Ringare selected so that Formula (IV)does not contain any N-N or N-O bonds; and R1, p, X1, RN, n, m, R2a , R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qare as defined in statement 1. 18. The compound of Formula (IV),or a salt thereof, as statemented in statement 17, wherein PG2is C1-6alkoxy carbonyl.
(V) or a salt thereof, wherein: Xxis selected from:(i)(ii)N substituted by Jwhere Jis H or PG3where PG3is a protecting group; andC substituted by oxo, or by RU1and Ru2;where RU1and Ru2are each C!.6alkoxy;or RU1and Ru2together represent -O-(CH2)U-O- where uis 2 or 3; (IV) 19. A compound of Formula (V): WO 2024/189488 PCT/IB2024/052251 322 Gis a direct bond, -CH2-, -C(=O)-, -0-, or -N(RG)-where RGis H or Ci.galkyl; QH Ringis a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group; where the values of Gand QH Ringare selected so that Formula (V)does not contain any N-N or N-O bonds; and R1, p, X1, RN, n, m, R2a , R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qare as defined in statement 1.
. The compound of Formula (V),or a salt thereof, according to statement 19, wherein PG3isC1-6alkoxy carbonyl. 21. The compound of Formula (I),or a pharmaceutically acceptable salt thereof, according to any one ofstatements 1 to 10, wherein Wis W1which is: -Z-(R')hwhere Z is: wherein: 0, 1 or 2 of XA, XB, Xc , XD, XE & XF 1 0fXG, XH&XJ 0fXG, XH&XJ 0fXG, XH&XJ each Ra wherein the Linker represents a single covalent bond or a double covalent bond;is/are N, where XE & XEare not both N, and are otherwise C;is C(O);is N-(2,6-dioxopiperidin-3-yl) (Y); andis selected from C(RT)2, -CH2CH2-, C(O), N(C!.3alkyl), -0- and -N=, wherein each RT is selected from H, F, Me or together with the carbon of C(RT)2 forms a cycloprop-1,1-diyl group;where XG, XH & XJare selected such that there are not two C(O) groups present at adjacent positions, and that the N-(2,6-dioxopiperidin-3-yl) is not at an adjacent position to either N(C!.3alkyl) or O;is independently a substituent on any available C atom at XA, XB, Xcor XDselected from F, Cl, C!.3alkyl, C!.3alkoxy wherein said C!.3alkyl and C!.3alkoxy is independently optionally substituted by one or more F;is 0, 1 or 2; andis attached to any C atom at XA, XB, Xcor XD. h WO 2024/189488 PCT/IB2024/052251 323 22. The compound of Formula(1), or a pharmaceutically acceptable salt thereof, according to statement where each RAis a substituent on any available C at XA, XB, Xcor XDselected from F, CI and C!.3alkoxy optionally substituted by one or more F. 23. The compound of Formula(1), or a pharmaceutically acceptable salt thereof, according to statement or statement 22 where XG-XH-XJis:(i) XG-NY-C(O) where XG is -CH2-, -CH2CH2-, =N- or C(O);(ii) XG-C(O)-NY where XG is -0- or N(C!.3alkyl); or(iii) C(O)-NY-CH2. 24. The compound of Formula (I),or a pharmaceutically acceptable salt thereof, according to any one of statements 21 to 23 where -Z-(RA)htogether represent any of the groups 1 to 21 or 27 as shown in the description.
. The compound of Formula (I),or a pharmaceutically acceptable salt thereof, according to any one of YN statements 1 to 10, wherein Wis W2which is ZAis: wherein: 1 of XA2, XB2, Xc2 & XD2represents a single covalent bond or a double covalent bond; is C and covalently bound to YN;0, 1 or 2 of XA2, XB2, Xc2, XD2, XE2 & XF2 is/are N,where XE2 & XE2 are not both N, and are 1 0r2 0fXG2, XH2&XJ2 each Raa otherwise C;is/are N; and are otherwise C;is a substituent on any available C or N atom of Z - in each case independently selected from RAAI optionally substituted by one or more RAA2: where RAA is further selected from RAA2 when RAA is a substituent on an available C atom of ZA; WO 2024/189488 PCT/IB2024/052251 324 each Raa1 is independently C!.4alkyl, C2-3alkenyl, C2-3alkynyl, C1-3alkoxyC1-3alkyl, carboxyC!.3alkyl, C5-7carbocyclyl or a 4-membered heterocyclyl;each RAA2 is independently selected from F, Cl, Br, CN, NH2, C!.3alkyl, O(C!.3alkyl), NH(C!.3alkyl) and N(C!.3alkyl)2; wherein said C!.3alkyls are optionally substituted by one or more F; V is 0, 1 or 2; yN is 2,4-dioxohexahydropyrimidin-1-yl. 26. The compound or salt thereof according to statement 25, whereinof XA2 & XB2 is C and covalently bound to Y and the other of XA2 & XB2 is C;or 1 of Xc2 & XD2 is N and is/are otherwise C;0fXG2&XJ2 is N and the other of XG2 & XJ2 is C; andXH2 XE2 & XF2are all C. 27. The compound or salt thereof according to statement 25, wherein Wis W2-1 wherein:XK and XL are either N-linker and CH, N-linker and CMe or NMe and C-linkerrespectively;0fXMandX° is C-2,4-dioxohexahydropyrimidin-l-yl (YN);or 1 of XM and XN is C-F;XNmay be N if XM is not C-F;the remainder of XN, XM and X°Xpare CH;is CH or CMe. 28. The compound or salt thereof according to statement 27, wherein Wrepresents any of the groups 22 toor 29 or 31 shown below: WO 2024/189488 PCT/IB2024/052251 325 29. The compound of Formula(1), or a pharmaceutically acceptable salt thereof, according to any one of statements 1 to 10, wherein Wis W3which is: -ZB where ZBis: XE3 is selected from C(=0) and CRE1RE2, where RE1 and RE2 areindependendently selected from the group consisting of H and C!. alkyl, or RE1 and RE2 taken together with the carbons to be they are attached form a C3-6 cycloalkane ring; Y is N-(2,6-dioxopiperidin-3-yl);All of XA3, XB3, Xc3and XD3 are C;one pair of XA3and XB3, XB3and Xc3and Xc3and XD3form a five or six membered fully unsaturated or partially unsaturated N containg heterocylic ring, which is attached to the ‘b’ end of the Linkervia a N atom;the others of XA3, XB3, Xc3and XD3 bear a group RB,where each RBis selected from H, F, Cl, C!.3alkyl and C1-3 alkoxy.
. The compound or salt thereof according to statement 29, wherein XB3and Xc3form a five membered partially unsaturated N containg heterocylic ring, which is attached to the ‘b’ end of the Linkervia a N atom.
WO 2024/189488 PCT/IB2024/052251 326 31. The compound or salt thereof according to either statement 29 or statement 30, wherein Wrepresents group 28 shown below: 32. The compound of Formula(1), or a pharmaceutically acceptable salt thereof, according to any one of statements 1 to 10, wherein Wis W3which is: - Zc where Zcis: one of XB4and Xc4 one of XA4, XB4, Xc4 , XD4 and XE4 one or two of XA4, XB4, Xc4 , XD4 and XE4 the remainder of XA4, XB4, Xc4 , XD4 and XE4 is C-C(=O)-NH-Y;may be C-F; or may be N;are CH. 33. The compound or salt thereof according to statement 31, wherein Xc4 is C-C(=O)-NH-Y and none of XA4, xB4, Xc4 , XD4 and XE4are N. 34. The compound or salt thereof according to either statement 31 or statement 32, wherein W represents group 30 shown below: . The compound or salt thereof, according to any preceding statement wherein RNis H, and pis 0 or 1, R1is selected from Cl, F and Me, and R1,if present, is bound para to Q1.
F HN.
WO 2024/189488 PCT/IB2024/052251 327 36. The compound or salt thereof, according to any preceding statement wherein X1is CH. 37. The compound or salt thereof, according to any preceding statement wherein X1is N. 38. The compound or salt thereof, according to any preceding statement wherein:(a) nis 0 and mis 1; or(b) nis 1 and mis 1; or(c) nis 2 and mis 0. 39. The compound or salt thereof, according to any preceding statement wherein Q1 is N, Q2 is CH and Q3is CH. 40. The compound or salt thereof, according to any one of statements 1 to 37 wherein Q1 is N, Q2 is CH and Q3 is CH, and nand mare 1 and 1 or 2 and 0 respectively.41. The compound or salt thereof, according to any preceding statement wherein R2aand R2bare both H. 42. The compound or salt thereof, according to any preceding statement wherein:(a) Q4 is a single bond; or(b) Q4 is a NR4C(=O) and R4 is H. 43. The compound or salt thereof according to any preceding statement wherein Y1, Y2, Y3, Y4 & Y5are respectively selected from (C, C, C, C, C), (N, C, C, C, C), (C, N, C, C, C), (N, C, C, N, C), (N, N, C, C, C), (N, C, N, C, C), (C, N, C, N, C) and (C, N, N, C, C).44. The compound or salt thereof according to any preceding statement wherein Y1, Y2, Y3, Y4 & Y5are respectively selected from (C, C, C, C, C), (N, C, C, C, C) and (N, N, C, C, C). 45. The compound or salt thereof according to any preceding statement wherein Y1, Y2, Y3, Y4 & Y5are all 46. The compound or salt thereof according to any preceding statement wherein qis 0, 1 or 2 and R3(when present) is a substituent on any C atom at Y1, Y2, Y3, Y4 & Y5selected from F, CN and methyl. 47. The compound or salt thereof according to any preceding statement wherein qis 0 or 1 and R3(whenpresent) is a substituent on any C atom at Y1, Y2, Y3, Y4 & Y5which is F. 48. The compound or salt thereof according to any preceding statement wherein Linkeris attached at Y5. 40 49. The compound or salt thereof according to any one of statements 1 to 34, wherein: WO 2024/189488 PCT/IB2024/052251 328 X1is CH; Pis 1; RNis H; nis 1; mis 1; R2aand R2bare both H;Q2 is CH; Q3 is CH;Q4 is a single bond; Y1, Y2, Y3and Y4are all CH; Y5is C and has the Linkerattached; qis 0.50. The compound or salt thereof according to any one of statements 1 to 34, wherein: X1is N; Pis 1; RNis H; nis 2; mis 0; R2aand R2bare both H;Q4 is a single bond; Y1, Y2, Y3and Y4are all CH; Y5is C and has the Linkerattached; qis 0.51. The compound or salt thereof according to any one of statements 1 to 34, wherein: X1is CH; Pis 1; RNis H; nis 1; mis 0; R2aand R2bare both H;Q4 is a single bond; Y1, Y2, Y3and Y4are all CH; Y5is C and has the Linkerattached; qis 0. 52. A pharmaceutical composition, which comprises a compound of Formula(I) or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof according to one of statements 1-14 0r21-51, in association with a pharmaceutically acceptable excipient.
WO 2024/189488 PCT/IB2024/052251 329 53. A pharmaceutical composition, which comprises a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in the treatment of cancer. 54. A pharmaceutical composition, which comprises a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in the treatment of a solid tumour. 55. A pharmaceutical composition, which comprises a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in the treatment of an AR-sensitive tumour type. 56. A pharmaceutical composition, which comprises a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in the treatment of tumour types that harbour one or more mutated forms of the androgen receptor. 57. A pharmaceutical composition, which comprises a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in the treatment of prostate cancer. 58. A pharmaceutical composition, which comprises a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in the treatment of castrate-resistant prostate cancer. 59. A pharmaceutical composition, which comprises a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in the treatment of metastatic castrate-resistant prostate cancer. 60. A pharmaceutical composition, which comprises a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in the treatment of AR-mutated cancer. 61. The compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable saltthereof, according to any one of statements 1 -14 or 21 -51, for use as a medicament.
WO 2024/189488 PCT/IB2024/052251 330 62. The compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in therapy. 63. The compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for use in a method of treatment of the human or animal body by therapy. 64. The compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in the production of an anti- proliferative effect in a warm-blooded animal such as man. 65. Use of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for the manufacture of a medicament for the production of an anti-proliferative effect in a warm-blooded animal such as man. 66. A method for producing an anti-proliferative effect in a warm-blooded animal, such as man, in need of such effect, which comprises administering to said animal an effective amount of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51. 67. A compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease. 68. Use of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease. 69. A method for producing an anti-invasive effect by the containment and/or treatment of solid tumour disease, in a warm-blooded animal, such as man, in need of such effect, which comprises administering to said animal an effective amount of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51. 70. A compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for use in the prevention or treatment of cancer.
WO 2024/189488 PCT/IB2024/052251 331 71. Use of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for the manufacture of a medicament for the prevention or treatment of cancer. 72. A method for the prevention or treatment of cancer in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51. 73. A compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for use in the prevention or treatment of solid tumour(s). 74. Use of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51 for the manufacture of a medicament for the prevention or treatment of solid tumour(s). 75. A method for the prevention or treatment of solid tumour(s) in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51. 76. A compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for use in the prevention or treatment of tumour types that are sensitive to degradation of androgen receptors. 77. Use of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for the manufacture of a medicament for the prevention or treatment of those tumour types that are sensitive to degradation of androgen receptors. 78. A method for the prevention or treatment of those tumour types that are sensitive to degradation ofandrogen receptors in a warm-blooded animal, such as man, in need of such treatment, which comprises administering to said animal an effective amount of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-5151.
WO 2024/189488 PCT/IB2024/052251 332 79. A compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for use in providing a degrading effect on androgen receptors in a warm-blooded animal such as man. 80. Use of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for the manufacture of a medicament for providing a degrading effect on androgen receptors in a warm-blooded animal such as man. 81. A method for providing a degrading effect on androgen receptors in a warm-blooded animal, such as man, in need of such effect, which comprises administering to said animal an effective amount of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51. 82. A compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for use in providing a selective degrading effect on androgen receptors in a warm-blooded animal such as man. 83. Use of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for the manufacture of a medicament for providing a selective degrading effect on androgen receptors in a warm-blooded animal such as man. 84. A method for providing a selective degrading effect on androgen receptors in a warm-blooded animal, such as man, in need of such effect, which comprises administering an effective amount of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51. 85. A compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for use in the treatment of tumour types that harbour androgen receptor mutations. 86. Use of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for the manufacture of a medicament for the prevention or treatment of those tumour types that harbour androgen receptor mutations. 87. A method for the prevention or treatment of those tumour types that harbour androgen receptor mutations in a warm-blooded animal, such as man, in need of such prevention or treatment, which comprises administering to said animal an effective amount of a compound of Formula (I)or WO 2024/189488 PCT/IB2024/052251 333 PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51. 88. A compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51, for use in the treatment of prostate cancer(for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC)). 89. Use of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1 -14 or 21 -51, for the manufacture of a medicament for the treatment of prostate cancer (for example castrate-resistant prostate cancer (CRPC), for examplemetastatic CRPC). 90. A method for treating prostate cancer (for example castrate-resistant prostate cancer (CRPC), for example metastatic CRPC) in a warm-blooded animal, such as man, in need of such treatment, whichcomprises administering to said animal an effective amount of a compound of Formula (I)orPROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of statements 1-14 or 21-51.

Claims (25)

WO 2024/189488 PCT/IB2024/052251 334 CLAIMS
1. A compound of Formula (I): (1)or a pharmaceutically acceptable salt thereof, wherein: X1 is CH or N; p where:is 0, 1 or 2; each R1 is a substituent on any C atom and is independently selected from F, Cl, Ci-salkyl and C1-zalkoxy, wherein said C1-salkyl and C!.3alkoxy may be independently optionally substituted by one or more F; RN is selected from H and Me; n is 0, 1 or 2; m is 0 or 1;Q1when n & mare both other than 0, Q2 when n & mare both 0, Q2 iswhen n is 0 or 1, Q3when n is 2 and Q2 is N, Q3when n is 2 and Q2 is CH, Q3 is R2aand R2b is CH or N;is CH or N;CH;is CH;is CH;CHorO;are substituents on the same or different C atoms other than at Q1 or Q2, each independently selected from H, F and C!.3alkyl, or R2a & R2btogether form a -(CH2)r- group where ris 1, 2 orך•Q4 R4 יל ­is a single bond or -NR4C(=O) ;is H or Me;0, 1 or 2 of Y1, Y2, Y3, Y4 & Y5 each R3 is/are N, and are otherwise C;is a substituent on any C atom at Y1, Y2, Y3, Y4 & Y5,and is independently selected from F, Cl, CN, C!.3alkyl and C!.3alkoxy, wherein said C!.3alkyl and C!.3alkoxy may be independently optionally substituted by one or more F; WO 2024/189488 PCT/IB2024/052251 335 q is 0, 1 or 2;wherein Linkeris attached at any available C atom at Y4 & Y5; Linker is a saturated or a partially or fully unsaturated frameworkcomprising C and H atoms and at least one heteroatom, wherein said framework has end points of attachment ‘a ’ and ‘b’ and a length of from 5 to 26 atoms between ‘a ’ and ‘b’; wherein said framework may include one or more straight and/or branched chains and/or rings and is optionally substituted on any available C atom(s) by one or more F; and W is an E3 ubiquitin ligase cereblon binder unit.
2. The compound of Formula(1), or pharmaceutically acceptable salt thereof, according to claim I or claim 2 wherein the Linkeris a saturated or partially unsaturated framework and:(a) comprises C and H atoms and at least two heteroatoms; or(b) comprises C and H atoms and at least one nitrogen heteroatom in the form of a secondary or tertiary amine; or(c) includes at least one nitrogen-containing saturated or partially unsaturated heterocyclic group having from 4 to 12 ring atoms, or a A -CH2-CH2-A2 unit where A1 and A2 are each independently selected from N and O.
3. The compound of Formula (I),or pharmaceutically acceptable salt thereof, according to either claim 1or claim 2 wherein the Linkerhas the Formula: a ’ -QA-QB-QC-‘b’ wherein: ‘a’and ‘b’represent the end points of attachment;QA is -G-QH- or -G-(C1.5alkylene)-;QB is a direct bond, -QB1-QB2-QB3- or 0ן.י,alkylene optionally substituted by one or more F (e.g. 1 or 2); where:QB1 & QB3 each independently represent a direct bond or C!.2alkylene;QB2 is QH, -O-CH2CH2-O-, -O- or -N(RJ)- where RJ is H or C1-3alkyl;Qc is -QH-G- or -(C1.5alkylene)-G-;each G is independently a direct bond, -CH2-, -0-, -C(=O)- or -N(RG)- where RG is H or C1-3alkyl; each QH is independently a 4-12-membered nitrogen-containing saturated or partially unsaturated heterocyclic group;where the values of QA, QBand Qcare selected so that the Linkerdoes not contain any N-N or N-O bonds.
4. The compound of Formula (I),or pharmaceutically acceptable salt thereof, according to claim 3wherein:(a) QB is a direct bond, -CH2- or -CH2CH2-; and/or WO 2024/189488 PCT/IB2024/052251 336 (b) Qc is -QH-G- or -(C1-2alkylene)-G-; and/or(c) each QH is independently selected from piperazin-1,4-diyl, azetidin- 1,3-diyl, piperidin- 1,4-diyl, 1,4- diazepan-l,4-diyl, 12-oxa-3,9-diazaspiro[5.6]dodecan-3,9-diyl, pyrrolidin-l,3-diyl, 3,9- diazaspiro[5.5]undecan-3,9-diyl, 2,5-diazabicyclo[2.2.1]heptan-2,5-diyl, 1,3,3a, 4,6,6a- hexahydropyrrolo[3,4-c]pyrrol-2,5-diyl, 3.6-dihydro-2//-pyridin-1.4-diyl. morpholin-2,3-diyl, 2- azaspiro[3.5]nonan-2,7-diyl and 9-azaspiro[5.5]undecan-3,9-diyl.
5. A PROTAC compound or a pharmaceutically acceptable salt thereof, containing an E3 ubiquitin ligasecereblon binder unit and an AR binding unit of Formula (la): (la) where R1, p, X1, RN, n, m, R2a, R2b, Q1, Q2, Q3, Q4, Y1, Y2, Y3, Y4, Y5, R3and qare as defined in claim 1.
6. The compound of Formula (I),or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 4, wherein Wis W2which isZAis: wherein: represents a single covalent bond or a double covalent bond;of XA2, XB2, Xc2 & XD2 is C and covalently bound to YN; 0, 1 or 2 of XA2, XB2, Xc2, XD2, XE2 & XF2 is/are N,where XE2 & XE2are not both N, and areotherwise C; WO 2024/189488 PCT/IB2024/052251 337 1 0r2 0fXG2, XH2&XJeach Raais/are N; and are otherwise C;is a substituent on any available C or N atom of Z - in each case independently selected from RAAI optionally substituted by one or more RAA2: where RAA is further selected from RAA2 when RAA is a substituent on an available C atom of ZA;each Raa1 is independently C!.4alkyl, C2-3alkenyl, C2-3alkynyl, C!.3alkoxyC1-3alkyl, carboxyC!.3alkyl, C5-7carbocyclyl or a 4-membered heterocyclyl;each RAA2 is independently selected from F, Cl, Br, CN, NH2, C!.3alkyl, O(C!.3alkyl), NH(C!.3alkyl) and N(C!-3alkyl)2; wherein said C!.3alkyls are optionally substituted by one or more F; V is 0, 1 or 2; yN is 2,4-dioxohexahydropyrimidin-1-yl.
7. The compound or pharmaceutically acceptable salt thereof according to claim 6, wherein of XA2 & XB2 is C and covalently bound to Y and the other of XA2 & XB2 is C;or 1 of Xc2 & XD2 is N and is/are otherwise C;0fXG2&XJ2 is N and the other of XG2 & XJ2 is C; andXH2 XE2 & XF2are all C.
8. The compound or pharmaceutically acceptable salt thereof according to claim 6, wherein Wis W2-1 wherein:XK and XL respectively;0fXMandX°or 1 of XM and XNXNthe remainder of XN, XM and X°Xp are either N-linker and CH, N-linker and CMe or NMe and C-linker is C-2,4-dioxohexahydropyrimidin-l-yl (YN);is C-F;may be N if XM is not C-F;are CH; andis CH or CMe.
9. The compound of Formula(1), or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 4, wherein Wis W1which is: -Z~(RA)h where Z is: WO 2024/189488 PCT/IB2024/052251 338 wherein: 0, 1 or 2 of XA, XB, Xc, XD, XE & XF 1 0fXG, XH&XJ 0fXG, XH&XJ 0fXG, XH&XJ each Ra h wherein the Linker represents a single covalent bond or a double covalent bond;is/are N, where XE & XEare not both N, and are otherwise C;is C(O);is N-(2,6-dioxopiperidin-3-yl) (Y); andis selected from C(RT)2, -CH2CH2-, C(O), N(C!.',alkyl). -0- and -N=, wherein each RT is selected from H, F, Me or together with the carbon of C(RT)2 forms a cycloprop- 1,1-diyl group;where XG, XH & XJare selected such that there are not two C(O) groups present at adjacent positions, and that the N-(2,6-dioxopiperidin-3-yl) is not at an adjacent position to either N(C!.3alkyl) or O;is independently a substituent on any available C atom at XA, XB, Xcor XDselected from F, Cl, C!.3alkyl, C!.3alkoxy wherein said C!.3alkyl and C!.3alkoxy is independently optionally substituted by one or more F;is 0, 1 or 2; andis attached to any C atom at XA, XB, Xcor XD.
10. The compound of Formula(I), or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 4, wherein Wis W3which is: -ZB where ZBis: WO 2024/189488 PCT/IB2024/052251 339 XE3 is selected from C(=0) and CRE1RE2, where RE1 and RE2 areindependendently selected from the group consisting of H and C!. alkyl, or RE1 and RE2 taken together with the carbons to be they are attached form a C3-6 cycloalkane ring; Y is N-(2,6-dioxopiperidin-3-yl);All of XA3, XB3, Xc3and XD3 are C;one pair of XA3and XB3, XB3and Xc3and Xc3and XD3form a five or six membered fully unsaturated or partially unsaturated N containg heterocylic ring, which is attached to the ‘b’ end of the Linkervia a N atom;the others of XA3, XB3, Xc3and XD3bear a group RB,where each RBis selected from H, F, Cl, C!.alkyl and C1-3 alkoxy.
11. The compound or pharmaceutically acceptable salt thereof, according to any preceding claim wherein RNis H, and pis 0 or 1, R1is selected from Cl, F and Me, and R1,if present, is bound para to Q1.
12. The compound or pharmaceutically acceptable salt thereof, according to any preceding claim wherein X1is N.
13. The compound or pharmaceutically acceptable salt thereof, according to any one of claims 1 to wherein Q1 is N, Q2 is CH and Q3 is CH, and nand mare 1 and 1 or 2 and 0 respectively.
14. The compound or pharmaceutically acceptable salt thereof, according to any preceding claim wherein R2aand R2bare both H.
15. The compound or pharmaceutically acceptable salt thereof, according to any preceding claim wherein: (a) Q4 is a single bond; or(b) Q4 is a NR4C(=O) and R4 is H.
16. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein Y1, Y2, Y3, Y4 & Y5are all C.
17. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein q is 0 or 1 and R3(when present) is a substituent on any C atom at Y1, Y2, Y3, Y4 & Y5which is F.
18. The compound or pharmaceutically acceptable salt thereof according to any preceding claim wherein Linkeris attached at Y5.
19. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 34, wherein: WO 2024/189488 PCT/IB2024/052251 340 X1is N; Pis 1; RNis H; nis 2; mis 0; R2aand R2bare both H;Q4 is a single bond; Y1, Y2, Y3and Y4are all CH; Y5is C and has the Linkerattached; and qis 0.
20. The compound according to claim I, selected from:4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/f-isoindol-5-yl]piperazin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/7-isoindol-5-yl]piperazin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro-1 //-indolc-3-carbonitrilc:7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/7-isoindol-5-yl]piperazin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro-1 //-indolc-3-carbonitrilc:7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/7-isoindol-5-yl]piperazin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro-1 //-indolc-3-carbonitrilc:4-Chloro-7-(4-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]pipe ridin-1-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl|phcny !;pipe ridin-l-yl)-4-nuoro-l//-indolc-3-carbonitrilc:4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-l/7-isoindol-5- y !]piperazin- 1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 //-i ndolc-3 -carbonitrile;7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl|phcny !]pipe ridin-l-yl)-4-mcthyl-l//-indolc-3-carbonitrilc:4-Chloro-7-[(3S)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indazolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/7-isoindol-5-y !]piperazin- 1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl] -1 //-i ndazolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-l/7-isoindol-5-y !]piperazin- 1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l/7-indol-2-yl]piperidin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l/7-indol-2-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indazolc-3 -carbonitrile; WO 2024/189488 PCT/IB2024/052251 342 4-Chloro-7-[4-(4-{4-[(4-{2-[(37?*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-177- pynolo [3,4-c]py ridin-6-y 1 }piperazin- 1 -y!)methyl]piperidin- 1 -y 1 }pheny !)piperidin-1 -y 1] -I //-i ndo lc-3 - carbonitrile;4-Chloro-7-[4-(4-{4-[(4-{2-[(3S'*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-177- pynolo [3,4-c]py ridin-6-y 1 }piperazin- 1 -y!)methyl]piperidin- 1 -y 1 }pheny!)piperidin-1 -y 1] -I //-i ndo lc-3 - carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177-pynolo[3,4-c]pyridin- 6-yl|pipcrazin-l-yl]mcthyl)pipcridin-l-yl|phcnyl]pipcridin-l-yl)-4-nuoro-l//-indolc-3-carbonitrilc:4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pynolo[3,4-c]pyridin-6-y!]piperazin- 1 -yl}methyl)piperidin-l-y!]pheny!}piperidin- 1 -yl]-I //-i ndolc-3- carbonitrile;4-Chloro-7-[(3S)-3-(4-{4-[(4-{2-[(37?*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-177- pynolo [3,4-c]py ridin-6-y 1 }piperazin- 1 -y!)methyl]piperidin- 1 -y 1 }pheny!)piperidin-1 -y 1] -I //-i ndo lc-3 - carbonitrile;4-Chloro-7-[(3S)-3-(4-{4-[(4-{2-[(3S'*)-2,6-dioxopiperidin-3-yl]-4-methoxy-3-oxo-2,3-dihydro-177- pynolo [3,4-c]py ridin-6-y 1 }piperazin- 1 -y!)methyl]piperidin- 1 -y 1 }pheny!)piperidin-1 -y 1] -I //-i ndo lc-3 - carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-177-isoindol-5-y !]piperazin-1 -yl}methy !)piperidin-1 -yl] -2-fluorophenyl}piperidin-1 -y l)-4-mcthy l-1 //-i ndolc-3 -carbonitrile;7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl] -2-fluorophenyl}piperidin-1 -yl)-4-methyl-1 //-i ndolc-3 -carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l,3-dioxo-2,3-dihydro-177-isoindol-5- y !]piperazin-1 -yl}methy !)piperidin-1 -yl] -2-fluorophenyl}piperidin-1 -y l)-4-mcthy l-1 //-i ndolc-3 -carbonitrile;7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-l-yl}-4-fluoro-177-indole-3-carbonitrile;4-Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin--yl}butoxy )pheny !]piperidin-1 -yl}-1 //-indo lc-3 -carbonitrile;4-CI1loro-7-2.4)-4|-4 -؛ 4 -) 4 -| 4 ؛ -dioxo-l.3-diazinan-l-yl)-l//-indol-l-yl|pipcridin-l-y 1 }butoxy)pheny!]piperidin-1 -y 1}-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(37?)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pynolo[3,4-c]pyridin-6-y!]piperazin- 1 -yl}methyl)piperidin-l-y!]pheny!}piperidin- 1 -yl]-1 //-indolc-3- carbonitrile;7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-7-methoxy-l,3-dioxo-2,3-dihydro-177-isoindol-5- yl]piperazin-l-yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-l/7-indole-3-carbonitrile;4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l,3-dioxo-2,3-dihydro-177-isoindol- 5-yl]piperazin-l -yl}methyl)piperidin-l -yl]phenyl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-177-isoindol-5- yl]piperazin-l-yl}butoxy)phenyl]piperidin-l-yl}-4-methyl-l/7-indole-3-carbonitrile;4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-177-isoindol-5- y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 //-i ndolc-3 -carbonitrile; WO 2024/189488 PCT/IB2024/052251 343 7-(4-f4-|4-(f4-|2-(2.6-Dioxopipcridin-3-yl)-6-fh1oro-1.3-dioxo-2.3-dihydro-l//-isoindol-5- y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-4-fluoro-1 //-indolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-177- isoindol-5-y!]piperazin- 1 -y 1 }methy!)piperidin- 1 -y!]phenyl}piperidin-1 -y 1] -1 //-i ndo lc-3-carbonitrile;4-Chloro-7-[(37?)-3-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-l,3-dioxo-2,3-dihydro-177- isoindol-5-y!]piperazin- 1 -y 1 }methy!)piperidin- 1 -y!]phenyl}piperidin-1 -y 1] -1 //-i ndo lc-3-carbonitrile;4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l,3-dioxo-2,3-dihydro-177-isoindol-5- y !]piperazin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 //-i ndolc-3 -carbonitrile;7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l,3-dioxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl]butoxy)phcnyl|pipcridin-l-yl]-4-1ncthyl-l//-indolc-3-carbonitrilc:7-{4-[4-(4-{4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l-y 1 }butoxy)pheny!]piperidin-1 -y 1}-1 //-i ndo lc-3 -carbonitrile;7-{4-[4-(4-{4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-y 1 }butoxy )pheny !]piperidin-1 -y 1} -1 //-i ndo lc-3 -carbonitrile;7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl|phcny !]pipe ridin-l-yl)-l//-indolc-3-carbonitrilc:4-Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-177-isoindol-5- y !]piperazin- 1 -yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177-pynolo[3,4- c]pyridin-6-y !]piperazin- 1 -yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -y 1)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]pyridazin-3 -yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin- -yl }methy !)piperidin-1 -y l]py ridazin-3 -y 1 }piperidin-1 -y1)-1 //-i ndo lc-3 -carbonitrile ;4-Chloro-7-[(37?*)-3-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(3S'*)-3-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]pyridin-2-yl}piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]pipe ridin-1- yl}methy !)piperidin-1 -yl]pyrazin-2-yl}piperidin- 1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin- -yl}methy !)piperidin-1 -yl]pyrazin-2-yl}piperidin- 1 -yl)-1H-indole-3-carbonitrile;7-[4-(4-{4-[(4-{[l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazol-4- y 1] methyl }piperazin- 1 -y !)methy !]piperidin-1 -y 1 }pheny !)piperidin-1 -yl] -4-methy 1-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[4-(4-{4-[(4-{[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177- benzimidazol-4-y 1] methyl }piperazin- 1 -y !)methy !]piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 - carbonitrile; WO 2024/189488 PCT/IB2024/052251 344 7-[4-(4-{4-[(4-{[l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazol-4- y 1] methyl }piperazin- 1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -yl] -4-fluoro - l/7-indole-3 -carbonitrile;4-Chloro-7-(4-{4-[4-({4-[l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazol- 4-yl]piperazin-l -yl}methyl)piperidin-l -yl]phenyl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-(4-{4-[(4-{ [l-(2,6-dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177- benzimidazol-4-y 1] methyl }piperazin- 1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -y 1] -1 //-i ndo lc-3 - carbonitrile;7-[(3S)-3-(4-{4-[(4-{ [l-(2,6-Dioxopiperidin-3-yl)-3-methyl-2-oxo-2,3-dihydro-177-benzimidazol-4- y 1] methyl }piperazin- 1 -y !)methyl] piperidin-1 -y 1 }pheny !)piperidin-1 -yl] -4-fluoro -1 //-i ndo lc-3 -carbonitrile;4-Chloro-7-{4-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f] isoindol-2( l//)-yl] methyl }piperidin-1-y !)pheny !]piperidin-1-yl}-l/7-indole-3-carbonitrile;4-Chloro-7-{(3S)-3-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4-f] isoindol-2( l//)-yl] methyl }piperidin-1-y !)pheny !]piperidin-1-yl}-l/7-indazole-3-carbonitrile;4-Chloro-7-{(3S)-3-[4-(4-{[6-(2,6-dioxopiperidin-3-yl)-5,7-dioxo-3,5,6,7-tetrahydropyrrolo[3,4- f] isoindol-2( l//)-yl] methyl }piperidin-1-y !)pheny !]piperidin-1-yl}-l/7-indole-3-carbonitrile;7-{(37?*)-l-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl]butoxy)phcnyl|pipcridin-3-yl]-4-mcthyl-l//-indolc-3-carbonitrilc:7-{(3S'*)-l-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-l/7-indole-3-carbonitrile;7-{(37?*)-l-[3-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-l/7-indole-3-carbonitrile;7-{(3S'*)-l-[3-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}butoxy)phenyl]piperidin-3-yl}-4-methyl-l/7-indole-3-carbonitrile;7-[(37?*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}methy !)piperidin-1 -yl]phenyl}pipe ridin-3 -yl] -4-methyl- 1 //-indo lc-3-carbo nitrile:7-[(3S'*)-l-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}methy !)piperidin-1 -yl]phenyl}pipe ridin-3 -yl] -4-methyl-1 //-indo lc-3-carbo nitrile:4-Chloro-7-(4-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-l/7-indol-2-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indo lc-3 -carbonitrile;4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin- -yl}methy !)piperidine-1 -carbony !]pheny !}piperidin-1 -yl)-1 //-indo lc-3-carbo nitrile:4-Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-17/-pyrrolo[3,4- c]pyridin-6-y !]piperazin-1 -yl}piperidin-l -y !)pheny !]piperidin-1 -yl}-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{4-[4-(2-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pyrrolo [3,4-c]pyridin-6-y !]piperazin- 1 -yl}ethyl)piperidin-l -yl]phenyl}piperidin-1 -y 1)-1 //-indo lc-3 - carbonitrile;4-Chloro-7-(4-{4-[4-(3-{4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177- pyrrolo [3,4-c]pyridin-6-y !]piperazin- 1 -yl}propy !)piperidin-1-y !]phenyl }piperidin-1 -yl)-1 //-i ndolc-3 - carbonitrile; WO 2024/189488 PCT/IB2024/052251 346 7-[4-(4-{[4-({l-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperidin-4- yl}methyl)piperazin-l-yl]methyl}phenyl)piperidin-l-yl]-4-fluoro-177-indole-3-carbonitrile;4-Chloro-7-(4-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]pyridin-3 -yl}piperidin-1 -yl)-I //-i ndolc-3 -carbonitrile;4-Chloro-7-(4-{6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin--y 1 }methy !)piperidin-1 -y 1] py ridin-3 -y 1 }piperidin-1 -y1)-I //-i ndo lc-3 -carbonitrile ;4-Chloro-7-{4-[4-(4-{4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin--y 1 }piperidin-1 -y!)phenyl]piperidin-1 -y 1} -I //-i ndo lc-3 -carbonitrile ;4-Chloro-7-[4-(4-{4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl][l,d'-bipiperidin]-!'-y 1 }pheny !)piperidin-1 -y 1] -I //-i ndo lc-3 -carbonitrile;4-chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-7-methoxy-l-oxo-2,3-dihydro-lH-isoindol-5-y !]piperazin- 1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 -methyl- lH-indole-3 -carbonitrile;4-Chloro-7-(4-{3-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin- -yl}methy!)piperidin- 1 -y !]phenyl }piperidin-1 -yl)-1 //-indolc-3-carbonitrile;4-Chloro-7-[(3S)-3-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-2-methyl-l/7-indol-l-yl]piperidin-l- yl}methy!)piperidin- 1 -yl]phenyl}piperidin-1 -yl]-1 //-indolc-3-carbonitrile;4-Chloro-7-[(3S'*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l- yl}methy!)piperidin- 1 -yl]pyridin-3-yl}piperidin-1 -yl]-1 //-indolc-3-carbonitrile;4-Chloro-7-[(37?*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3־diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy!)piperidin- 1 -yl]pyridin-3-yl}piperidin-1 -yl]-1 //-indolc-3-carbonitrile;4-Chloro-7-|(2,S*)-2-f4-|4-(f4-|4-(2.4-dioxo-l.3-diazinan-l-yl)-l//-indol-l-yl|pipcridin-l-yl}methy!)piperidin- 1 -yl]phenyl}morpholin-4-yl] -1 //-indolc-3-carbonitrile;4-Chloro-7-[(27?*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3־diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy!)piperidin- 1 -yl]phenyl}morpholin-4-yl]-1 //-indolc-3-carbonitrile;4-Chloro-7-[(2S'*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy!)piperidin- 1 -yl]phenyl}morpholin-4-yl]-I //-indazolc-3-carbonitrile;4-Chloro-7-[(27?*)-2-{4-[4-({4-[4-(2,4-dioxo-l,3־diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy!)piperidin- 1 -yl]phenyl}morpholin-4-yl]-I //-indazolc-3-carbonitrile;4-Chloro-7-[(37?*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3־diazinan-l-yl)-l/7-indol-l-yl]piperidin-l- yl}methy!)piperidin- 1 -yl]pyridazin-3-yl}piperidin- 1 -yl]-1 //-indolc-3-carbonitrile;4-Chloro-7-[(3S'*)-3-{6-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l- yl}methy!)piperidin- 1 -yl]pyridazin-3-yl}piperidin- 1 -yl]-1 //-indolc-3-carbonitrile;4-Chloro-7-(4-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-2-methyl-l/7-indol-l-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-(4-{2-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin- -yl }methy !)piperidin-1 -y 1] py rimidin-5 -y 1 }piperidin-1 -y!)-1 //-i ndo lc-3 -carbonitrile ;4-Chloro-7-(4-{2-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l/7-indol-l-yl]piperidin-l-yl}methy !)piperidin-1 -yl]pyrimidin-5-yl}piperidin-1 -yl)-1 //-i ndolc-3 -carbonitrile;7-(4-{4-[(27?)-2-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}methyl)morpholin-4-yl]phenyl}piperidin-1 -yl)-4-fluoro-1 //-i ndo lc-3 -carbonitrile; WO 2024/189488 PCT/IB2024/052251 347 4-Chloro-7-(4-{4-[(27?)-2-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5- yl|pipcrazin-l-yl]mcthyl)morpholin-4-yl|phcny !]pipe ridin-l-yl)-l//-indolc-3-carbonitrilc:7-(4-{4-[7-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l- yl}methyl)-2-azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl)-4-fluoro-177-indole-3-carbonitrile;4-Chloro-7-(4-{4-[7-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin--yl}methyl)-2-azaspiro [3.5]nonan-2-yl]phenyl}piperidin- 1 -yl)-1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(3S)-3-{4-[7-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-y !]piperazin- 1 -yl}methyl)-2-azaspiro [3.5]nonan-2-yl]phenyl}piperidin- 1 -yl]-1 //-i ndolc-3-carbo nitrile:4-Chloro-7-[(3S)-3-{4-[7-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]piperidin-l-yl}methyl)- 2-azaspiro [3.5]nonan-2-y !]phenyl }piperidin-1 -yl] -1 //-i ndolc-3 -carbonitrile;4-Chloro-7-[(37?)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-l-methyl-17/-indol-2-yl]piperidin-l- yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indazolc-3 -carbonitrile;7-[(3S)-3-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -4-fluoro-1 //-indazolc-3-carbo nitrile:7-[(3S)-3-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]piperidin-l-yl}methyl)piperidin--yl]phenyl}piperidin-1 -yl] -4-fluoro-1 //-indazolc-3-carbonitri 1c:7-(4-{4-[7-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]piperidin-l-yl}methyl)-2- azaspiro[3.5]nonan-2-yl]phenyl}piperidin-l-yl)-4-fluoro-177-indole-3-carbonitrile;4-Chloro-7-[(37?)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5-fluoro-l-methyl-17/-indol-2-y !]piperidin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indolc-3-carbonitri 1c:4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5-fluoro-l-methyl-17/-indol-2-y !]piperidin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indolc-3-carbonitri 1c:4-Chloro-7-[(37?)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5-fluoro-l-methyl-17/-indol-2-y !]piperidin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indazolc-3-carbo nitri 1c:4-Chloro-7-[(3S)-3-{4-[4-({4-[6-(2,4-dioxo-l,3-diazinan-l-yl)-5-fluoro-l-methyl-17/-indol-2-y !]piperidin-1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl] -1 //-indazolc-3-carbo nitri 1c:7-(4-{4-[4-({4-[6-(2,4-Dioxo-l,3-diazinan-l-yl)-l-methyl-17/-indol-2-yl]pipe ridin-1-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro-1 //-indazolc-3-carbo nitrile:7-(4-{4-[4-({4-[4-(2,4-Dioxo-l,3-diazinan-l-yl)-2-methyl-17/-indol-l-yl]pipe ridin-1-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro-1 //-indolc-3-carbonitrilc:4-Chloro-7-(4-{4-[7-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]piperidin-l-yl}methyl)-2- azaspiro [3.5]nonan-2-yl]phenyl}piperidin- 1 -yl)-1 //-indolc-3 -carbonitrile;4-Chloro-7-(4-{4-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177-pynolo[3,4- c]pyridin-6-y !]piperazin- 1 -yl}methy !)piperidin-1 -yl]phenyl}piperidin-l -yl)-1 //-indazolc-3 -carbonitrile;7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-4-methoxy-3-oxo-2,3-dihydro-177-pynolo[3,4-c]pyridin-6-yl|pipcrazin-l-yl]mcthyl)pipcridin-l-yl|phcnyl]pipcridin-l-yl)-4-nuoro-l//-indazolc-3-carbonitrilc:7-(4-{4-[4-({4-[2-(2,6-Dioxopiperidin-3-yl)-l-oxo-2,3-dihydro-177-isoindol-5-yl]piperazin-l-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-4-fluoro-1 //-indazolc-3-carbo nitrile:4-Chloro-7-(4-{4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-17/-indol-l-yl]pipe ridin-1-yl}methy !)piperidin-1 -yl]phenyl}piperidin-1 -yl)-1 //-indazolc-3 -carbonitrile; u Ph 00 00 o £ momomomocm cm co co WO 2024/189488 PCT/IB2024/052251 349 A-[l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//- indol-1 -y !]piperidin-1 -y 1 }methy !)piperidin-1 -y l]py ridine-2-carboxamide ;#-[ 1-(4-Chloro-3-cyano-177-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)- 1-oxo-2,3 -dihydro- 177-isoindol-5-y !]piperazin- 1 -yl}methy !)piperidin-1 -yl]pyridine-2-carboxamide;#-[ 1-(4-Chloro-3-cyano-177-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6- fluoro-l,3-dioxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide;#-[l-(4-Chloro-3-cyano-177-indazol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)- !//-indol-1 -y !]piperidin-1 -yl}methy !)piperidin- l-yl]pyridine-2-carboxamide;A-[l-(3-Cyano-4-methyl-l//-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6- fluoro-l,3-dioxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide;A-[l-(3-Cyano-4-methyl-l//-indol-7-yl)piperidin-4-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l-oxo-2,3 -dihydro- 177-isoindol-5-y !]piperazin- 1 -yl}methy !)piperidin-1 -yl]pyridine-2-carboxamide;#-[ 1-(4-Chloro-3-cyano-177-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l ,3-diazinan- 1-yl)-1/7- indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y !]benzamide ;#-[4-(4-Chloro-3-cyano-l//-indol-7-yl)cyclohexyl]-4-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//- indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y 1] -2-fluorobenzamide ;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l ,3-diazinan- 1-yl)-1//- indol-1 -y !]piperidin-1 -yl}methy !)piperidin- 1-yl] -2,6-difluorobenzamide;#-[l-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//- indol-l-yl]piperidin-l-yl}methyl)piperidin-l-yl]pyrazine-2-carboxamide;#-[l-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-5-[4-({4-[4-(2,4-dioxo-l,3-diazinan-l-yl)-l//- indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y l]py rimidine-2-carboxamide ;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-4-[4-({4-[4-(2,4-dioxo-l ,3-diazinan- 1-yl)-1//- indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y 1] -2-methy !benzamide ;#-[ 1-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-4-yl]-6-[4-({4-[4-(2,4-dioxo-l ,3-diazinan- 1-yl)-1//- indol-1 -y !]piperidin-1 -yl }methy !)piperidin-1 -y l]py ridazine-3 -carboxamide ;A-[(3R*)-l-(4-Chloro-3-cyano-l//-indol-7-yl)piperidin-3-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l- oxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide; and#-[(3>S'*)-l-(4-Chloro-3-cyano-17/-indol-7-yl)piperidin-3-yl]-5-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-l- oxo-2,3-dihydro-l//-isoindol-5-yl]piperazin-l-yl}methyl)piperidin-l-yl]pyridine-2-carboxamide;or pharmaceutically acceptable salts thereof.
21. A pharmaceutical composition, which comprises a compound of Formula(I) or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof according to one of claims 1-20, in association with a pharmaceutically acceptable excipient.
22. The compound of Formula(I) or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of claims 1-20, for use in a method of treatment of the human or animal body by therapy. WO 2024/189488 PCT/IB2024/052251 350
23. A compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of claims 1-20, for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease. 5
24. Use of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable saltthereof, according to any one of claims 1-20, for the manufacture of a medicament for use as an anti- invasive agent in the containment and/or treatment of solid tumour disease.
25. A method for producing an anti-invasive effect by the containment and/or treatment of solid tumourdisease, in a warm-blooded animal, such as man, in need of such effect, which comprises administeringto said animal an effective amount of a compound of Formula (I)or PROTAC of Formula (la),or a pharmaceutically acceptable salt thereof, according to any one of claims 1-20.
IL323195A 2023-03-10 2025-09-07 Bifunctional compounds capable of degrading androgen receptors IL323195A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363489528P 2023-03-10 2023-03-10
PCT/IB2024/052251 WO2024189488A1 (en) 2023-03-10 2024-03-08 Bifunctional compounds capable of degrading androgen receptors

Publications (1)

Publication Number Publication Date
IL323195A true IL323195A (en) 2025-11-01

Family

ID=90364229

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323195A IL323195A (en) 2023-03-10 2025-09-07 Bifunctional compounds capable of degrading androgen receptors

Country Status (16)

Country Link
EP (1) EP4676922A1 (en)
JP (1) JP2026510359A (en)
KR (1) KR20250154418A (en)
CN (1) CN120835881A (en)
AR (1) AR132085A1 (en)
AU (1) AU2024235906A1 (en)
CL (1) CL2025002736A1 (en)
CO (1) CO2025013819A2 (en)
CR (1) CR20250426A (en)
DO (1) DOP2025000220A (en)
IL (1) IL323195A (en)
MX (1) MX2025010560A (en)
PE (1) PE20252537A1 (en)
TW (1) TW202502749A (en)
UY (1) UY40670A (en)
WO (1) WO2024189488A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250197411A1 (en) 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs
WO2026120044A1 (en) * 2024-12-04 2026-06-11 Astrazeneca Ab Smarca2 degraders and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3526202T1 (en) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3795570B1 (en) * 2019-09-23 2022-02-23 Accutar Biotechnology Inc. Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof
WO2021061644A1 (en) * 2019-09-23 2021-04-01 Accutar Biotechnology Inc. Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
WO2021231927A1 (en) * 2020-05-14 2021-11-18 The Regents Of The University Of Michigan Androgen receptor protein degraders with a tricyclic cereblon ligand

Also Published As

Publication number Publication date
KR20250154418A (en) 2025-10-28
MX2025010560A (en) 2025-10-01
TW202502749A (en) 2025-01-16
DOP2025000220A (en) 2025-10-31
UY40670A (en) 2024-09-13
CL2025002736A1 (en) 2026-01-02
AU2024235906A1 (en) 2025-10-30
EP4676922A1 (en) 2026-01-14
PE20252537A1 (en) 2025-10-27
CR20250426A (en) 2025-11-21
CO2025013819A2 (en) 2025-10-20
AR132085A1 (en) 2025-05-21
JP2026510359A (en) 2026-04-02
WO2024189488A1 (en) 2024-09-19
CN120835881A (en) 2025-10-24

Similar Documents

Publication Publication Date Title
AU2019237329B2 (en) Substituted imidazolidin-2-one derivatives as PRMT5 inhibitors
CN108135168B (en) CCR2 modulators
US11976071B2 (en) Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases
AU2019251151A1 (en) Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
AU2013337086B2 (en) 2-aminopyridine compounds
EP2858994A1 (en) Pyrazolopyrimidone and pyrazolopyridone inhibitors of tankyrase
TWI823932B (en) Triazolopyrimidine compounds and their use in treating cancer
AU2019379213B2 (en) Six-membered fused with six-membered heterocyclic compound and uses thereof serving as protein receptor kinase inhibitor
TWI802604B (en) PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF
CN113423708A (en) Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists
EP4362939A1 (en) Bifunctional compounds that degrade alk and uses thereof
CA3226796A1 (en) Novel parp7 inhibitor and use thereof
KR102359707B1 (en) Aminopyridine derivatives and their use as selective alk-2 inhibitors
KR20250154418A (en) Bifunctional compounds capable of degrading androgen receptors
WO2023139199A1 (en) Compounds and their use in treating cancer
WO2016130444A1 (en) Inhibitors of the renal outer medullary potassium channel
WO2025163390A2 (en) Heterobifunctional compounds for the degradation of hpk1
TW202500141A (en) Isoxazolidines as ripk1 inhibitors and use thereof
KR20230153959A (en) Pim kinase inhibitors and methods of their use
CN121293199A (en) Tyrosine kinase 2 degradation compounds and their uses
CN117886814A (en) PD-1/PD-L1 small molecule inhibitors and their applications in medicine
EA046513B1 (en) SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS
HK1193807A (en) Pyrazolo[3,4-c]pyridine compounds and methods of use